Apoptosis-inducing medications for treating cancer and immune and autoimmune diseases

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to compounds, which possess an inhibiting activity with respect to anti-apoptotic Bcl-2 proteins. The invention also relates to a pharmaceutical composition, containing the said compounds, and to a method of treating urinary bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukaemia, colorectal cancer, oesophageal cancer, hepatocellular cancer, lymphoblast leukosis, follicular lymphoma, lymphoid malignant diseases of a T-cell or B-cell origin, melanoma, myelogenous leukaemia, myeloma, oral cavity cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small-cell lung cancer or spleen cancer.

EFFECT: obtaining the compounds, possessing the inhibiting activity with respect to anti-apoptotic Bcl-2 proteins.

4 cl, 5 tbl, 405 ex

 

The present application is a partial continuation of Patent application U.S. serial No. 12/787682, filed may 26, 2010, which claims priority relative to Prior patent application U.S. serial No. 61/181203, filed may 26, 2009, which are both incorporated by reference in their entirety.

The technical field to which the invention relates

The present invention relates to compounds that inhibit the activity of Bcl-2 anti-apofaticheski proteins, to compositions containing such compounds, and to methods of treating diseases during which is expressed anti-ipoptions Bcl-2 proteins.

Background of the invention

Anti-ipoptions Bcl-2 proteins associated with a number of diseases. Therefore, in therapeutics there is a need for compounds that inhibit the activity of anti-apofaticheski Bcl-2 proteins.

The over-expression of Bcl-2 proteins correlates with resistance to chimiotherapie, clinical outcome, disease progression, overall prognosis or a combination of the above factors in various cancers and disorders of the immune system.

The involvement of Bcl-2 proteins in bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, impalla�wide leukemia, follicular lymphoma, lymphoid malignant disease of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer, cancer of the spleen and similar diseases are described in co-owned PCT application US 2004/36770, published as WO 2005/049593, and PCT US 2004/037911, published as WO 2005/049594.

The involvement of Bcl-2 proteins in immune and autoimmune diseases is described in Current Allergy and Asthma Reports 2003, 3, 378-384; British Journal of Haematology 2000, 110(3), 584-90; Blood 2000, 95(4), 1283-92; and New England Journal of Medicine 2004, 351(14), 1409-1418. The involvement of Bcl-2 proteins in arthritis are disclosed in co-owned Provisional Patent Application U.S. serial No. 60/988479. The involvement of Bcl-2 proteins in graft rejection, bone marrow are disclosed in co-owned Provisional Patent Application U.S. serial No. 11/941196.

Summary of the invention

One embodiment of the present invention, therefore, pertains to compounds or therapeutically acceptable salts, which are useful as inhibitors of anti-apofaticheski Bcl-2 proteins, where the compounds have the formula (I)

where

A1represents N or C(A2);

A2ameri� a H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A;

B1represents H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2 N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A;

D1represents H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2,N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A;

E1represents H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1 , C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2,N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A; and

Y1represents H, CN, NO2, C(O)OH, F, Cl, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R17, OR17, C(O)R17, C(O)OR17, SR17, SO2R17NH2, NHR17N(R17)2, NHC(O)R17, C(O)NH2, C(O)NHR17, C(O)N(R17)2, NHS(O)R17or NHSO2R17; or

E1and Y1together with the atoms to which they are linked, represent a benzene, naftilan, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

A2B1and D1have the independence�IMO selected values H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2,N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A; or

Y1and B1together with the atoms to which they are linked, represent a benzene, naftilan, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

A2, D1and E1have independently selected values H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2 , NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2,N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A; or

A2and B1together with the atoms to which they are linked, represent a benzene, naftilan, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

D1E1and Y1have independently selected values H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1 )2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A; or

A2and D1together with the atoms to which they are linked, represent a benzene, naphthalene, heteroaryl, cycloalkane, cycloalkene, geteroseksualen or geteroseksualen; and

B1E1and Y1have independently selected values H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R 1, F, Cl, Br, I, CN, NO2,N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A;

G1represents H or C(O)OR;

R represents alkyl;

R1is an R2, R3, R4or R5;

R1Ais cycloalkyl, cycloalkenyl or cycloalkenyl;

R2represents phenyl, which is neskondensirovannyh or fused with R2A; R2Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R3is heteroaryl, which is neskondensirovannyh or fused with R3A; R3Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R4is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R4A; R4Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R5represents alkyl, alkenyl or alkinyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R6, NC(R6A)(R6B), R7, OR7, SR7, S(O)R , SO2R7, NHR7N(R7)2, C(O)R7, C(O)NH2,C(O)NHR7, C(O)N(R7)2, NHC(O)R7, NR7C(O)R7, NHSO2R7, NHC(O)OR7, SO2NH2, SO2NHR7, SO2N(R7)2, NHC(O)NH2, NHC(O)NHR7, NHC(O)CH(CH3)NHC(O)CH(CH3NH2, NHC(O)CH(CH3)NHC(O)CH(CH3)NHR7, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;

R6represents C2-C5-spiralcell, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, CF2CF3, F, Cl, Br, I, NH2NH(CH3) or N(CH3)2Deputy;

R6Aand R6Brepresent independently selected alkyl, or together with the N atom to which they are linked, represent R6C;

R6Cis aziridine-1-yl, azetidin-1-yl, pyrrolidin-1-yl or piperidine-1-yl, each of which contains a single CH2group which is unsubstituted or substituted by O, C(O), CNOH, CNOCH3S , S(O), SO2or NH;

R7is an R8, R9, R10or R11;

R8represents phenyl, which is neskondensirovannyh or fused with R8A; R8Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

<> R9is heteroaryl, which is neskondensirovannyh or fused with R9A; R9Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R10is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R10A; R10Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R11represents alkyl, alkenyl or alkinyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12NH2, NHR12N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R12)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH 3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R12is an R13, R14, R15or R16;

R13represents phenyl, which is neskondensirovannyh or fused with R13A; R13Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R14is heteroaryl, which is neskondensirovannyh or fused with R14A; R14Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R15is cycloalkane, cycloalkene, geteroseksualen or geteroseksualen, each of which is neskondensirovannyh or fused with R15A; R15Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R16represents alkyl, alkenyl or alkinyl;

R17is an R18, R19, R20or R21;

R18represents phenyl, which is neskondensirovannyh or fused with R18A; R18Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R19is the FDS�th heteroaryl, which is neskondensirovannyh or fused with R19A; R19Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R20is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen each of which is neskondensirovannyh or fused with R20A; R20Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R21represents alkyl, alkenyl or alkinyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R22, OR22, SR22, S(O)R22, SO2R22, C(O)R22, CO(O)R22, OC(O)R22, OC(O)OR22NH2, NHR22N(R22)2, NHC(O)R22, NR22C(O)R22, NHS(O)2R22, NR22S(O)2R22, NHC(O)OR22, NR22C(O)OR22, NHC(O)NH2, NHC(O)NHR22, NHC(O)N(R22)2, NR22C(O)NHR22, NR22C(O)N(R22)2, C(O)NH2, C(O)NHR22, C(O)N(R22)2, C(O)NHOH, C(O)NHOR22, C(O)NHSO2R22, C(O)NR22SO2R22, SO2NH2, SO2NHR22, SO2N(R22)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR22, C(N)N(R22)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2,CF 3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R22is an R23, R24or R25;

R23represents phenyl, which is neskondensirovannyh or fused with R23A; R23Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R24is heteroaryl, which is neskondensirovannyh or fused with R24A; R24Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R25is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R25A; R25Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

Z1is an R26or R27;

Z2is an R28, R29or R30;

Z1Aand Z2Aboth absent or are taken together with the formation of CH2, CH2CH2or Z12A;

Z12Arepresents C2-C6-alkylene containing one or two CH2groups, substituted NH, N(CH3), S, S(O) or SO2;

L1is an R37, OR3737, S(O)R37, SO2R37, C(O)R37, CO(O)R37, OC(O)R37, OC(O)OR37, NHR37, C(O)NH, C(O)NR37, C(O)NHOR37, C(O)NHSO2R37, SO2NH, SO2NHR37, C(N)NH or C(N)NHR37;

R26represents a phenylene, which is neskondensirovannyh or fused with R26A; R26Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R27is heteroaryl, which is neskondensirovannyh or fused with R27A; R27Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R28represents a phenylene, which is neskondensirovannyh or fused with R28A; R28Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R29is heteroaryl, which is neskondensirovannyh or fused with R29A; R29Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R30is cycloalkyl, cycloalkenyl, heteroseksualci or geterotsiklicheskie, each of which is neskondensirovannyh or fused with R30A; R30Arepresents a benzene, heteroaryl, cycloalkane, cycloalkene, geteroseksualen or geteroseksualen;

R37represents a bond, or R37A;

R37Ais alkylen, albaniles, or akinyan, each of which is unsubstituted or substituted with one or two or three independently selected R37B, OR37B, SR37B, S(O)R37B, SO2R37B, C(O)R37B, CO(O)R37B, OC(O)R37B, OC(O)OR37BNH2, NHR37BN(R37B)2, NHC(O)R37B, NR37BC(O)R37B, NHS(O)2R37B, NR37BS(O)2R37B, NHC(O)OR37B, NR37BC(O)OR37B, NHC(O)NH2, NHC(O)NHR37B, NHC(O)N(R37B)2, NR37BC(O)NHR37B, NR37BC(O)N(R37B)2, C(O)NH2, C(O)NHR37B, C(O)N(R37B)2, C(O)NHOH, C(O)NHOR37B, C(O)NHSO2R37B, C(O)NR37BSO2R37B, SO2NH2, SO2NHR37B, SO2N(R37B)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR37B, C(N)N(R37B)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br and I substituents;

R37Brepresents alkyl, alkenyl, alkynyl or R37C;

R37Crepresents phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen;

Z3is an R38, R39or R ;

R38represents phenyl, which is neskondensirovannyh or fused with R38A; R38Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R39is heteroaryl, which is neskondensirovannyh or fused with R39A; R39Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R40is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R40A; R40Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

where the group represented as R26and R27,are substituted (i.e., if Z1Aand Z2Aare absent) or further substituted (i.e., if Z1Aand Z2Apresent, the substituents R41, OR41, SR41, S(O)R41, SO2R41, C(O)R41, CO(O)R41, OC(O)R41, OC(O)OR41, NHR41N(R41)2, NHC(O)R41, NR41C(O)R41, NHS(O)2R41, NR41S(O)2R41, NHC(O)OR41, NR41C(O)OR41, NHC(O)NHR41, NHC(O)N(R41)2, NR41C(O)NHR41, NR41C(O)N(R41)2, C(O)NHR41, C(O)N(R41)2, C(O)NHOR41, C(O)NHSO2R41, C(O)NR41SO2R41, SO2NHR41, SO2N(R41)2, C(N)NHR41or C(N)N(R41)2;

R41is heteroaryl, which is fused with R43A; R43Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; which is neskondensirovannyh or condensed with benzene, heteroatom or R43B; R43Bis cycloalkane, cycloalkene, geteroseksualen or geteroseksualen;

where the cyclic groups represented as E1and Y1however, Y1and B1however, A2and B1however, A2andD1together, R1A, R2, R2A, R3, R3A, R4, R4A, R6, R6C, R8, R8A, R9, R9A, R10, R10A, R13, R13A, R14, R14A, R15, R15A, R18, R18A, R19, R19A, R20, R20A, R23, R23A, R24, R24A, R25, R25A, R26, R26A, R27, R27A, R28, R28A, R29, R29A, R30, R30A, R37B, R38, R38A, R39, R39A, R40and R40Athat are independently unsubstituted, having additional substitution, sameshe�governmental or optionally substituted by one or two or three or four or five independently selected substituents R 57A, R57, OR57, SR57, S(O)R57, SO2R57, C(O)R57, CO(O)R57, OC(O)R57, OC(O)OR57NH2, NHR57N(R57)2, NHC(O)R57, NR57C(O)R57, NHS(O)2R57, NR57S(O)2R57, NHC(O)OR57, NR57C(O)OR57, NHC(O)NH2, NHC(O)NHR57, NHC(O)N(R57)2, NR57C(O)NHR57, NR57C(O)N(R57)2, C(O)NH2, C(O)NHR57, C(O)N(R57)2, C(O)NHOH, C(O)NHOR57, C(O)NHSO2R57, C(O)NR57SO2R57, SO2NH2, SO2NHR57, SO2N(R57)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR57, C(N)N(R57)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R57Ais spiralcell or spiroheterocyclic;

R57is an R58, R59, R60or R61;

R58represents phenyl, which is neskondensirovannyh or fused with R58A; R58Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R59is heteroaryl, which is neskondensirovannyh or fused with R59A; R59Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or GE�erotikseiten;

R60is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R60A; R60Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R61represents alkyl, alkenyl or alkinyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R62, OR62, SR62, S(O)R62, SO2R62, C(O)R62, CO(O)R62, OC(O)R62, OC(O)OR62NH2, NHR62N(R62)2, NHC(O)R62, NR62C(O)R62, NHS(O)2R62, NR62S(O)2R62, NHC(O)OR62, NR62C(O)OR62, NHC(O)NH2, NHC(O)NHR62, NHC(O)N(R62)2, NR62C(O)NHR62, NR62C(O)N(R62)2, C(O)NH2, C(O)NHR62, C(O)N(R62)2, C(O)NHOH, C(O)NHOR62, C(O)NHSO2R62, C(O)NR62SO2R62, SO2NH2, SO2NHR62, SO2N(R62)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR62, C(N)N(R62)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R62is an R63, R64, R65or R66;

R63represents Fe�Il, which is neskondensirovannyh or fused with R63A; R63Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R64is heteroaryl, which is neskondensirovannyh or fused with R64A; R64Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R65is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R65A; R65Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R66represents alkyl, alkenyl or alkinyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R67, OR67, SR67, S(O)R67, SO2R67, C(O)R67, CO(O)R67, OC(O)R67, OC(O)OR67NH2, NHR67N(R67)2, NHC(O)R67, NR67C(O)R67, NHS(O)2R67, NR67S(O)2R67, NHC(O)OR67, NR67C(O)OR67, NHC(O)NH2, NHC(O)NHR67, NHC(O)N(R67)2, NR67C(O)NHR67, NR67C(O)N(R67)2, C(O)NH2, C(O)NHR67, C(O)N(R67)2, C(O)NHOH, C(O)NHOR 67, C(O)NHSO2R67, C(O)NR67SO2R67, SO2NH2, SO2NHR67, SO2N(R67)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR67, C(N)N(R67)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R67represents alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen;

where the cyclic groups represented as R57A, R58, R59, R60, R63, R64, R65and R67,are unsubstituted or substituted with one or two or three or four independently selected substituents R68, OR68, SR68, S(O)R68, SO2R68, C(O)R68, CO(O)R68, OC(O)R68, OC(O)OR68NH2, NHR68N(R68)2, NHC(O)R68, NR68C(O)R68, NHS(O)2R68, NR68S(O)2R68, NHC(O)OR68, NR68C(O)OR68, NHC(O)NH2, NHC(O)NHR68, NHC(O)N(R68)2, NR68C(O)NHR68, NR68C(O)N(R68)2, C(O)NH2, C(O)NHR68, C(O)N(R68)2, C(O)NHOH, C(O)NHOR68, C(O)NHSO2R68, C(O)NR68SO2R68, SO2NH2, SO2NHR68, SO2N(R68)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR68, C(N)N(R68)2, CNOH, CNOCH3 ,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R68is an R69, R70, R71or R72;

R69represents phenyl, which is neskondensirovannyh or fused with R69A; R69Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R70is heteroaryl, which is neskondensirovannyh or fused with R70A; R70Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R71is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R71A; R71Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R72represents alkyl, alkenyl or alkinyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R73, OR73, SR73, S(O)R73, SO2R73, C(O)R73, CO(O)R73, OC(O)R73, OC(O)OR73NH2, NHR73N(R73)2, NHC(O)R73, NR73C(O)R73, NHS(O)2R73, NR73 S(O)2R73, NHC(O)OR73, NR73C(O)OR73, NHC(O)NH2, NHC(O)NHR73, NHC(O)N(R73)2, NR73C(O)NHR73, NR73C(O)N(R73)2, C(O)NH2, C(O)NHR73, C(O)N(R73)2, C(O)NHOH, C(O)NHOR73, C(O)NHSO2R73, C(O)NR73SO2R73, SO2NH2, SO2NHR73, SO2N(R73)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR73, C(N)N(R73)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R73represents alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen; and

where the group represented as R69, R70and R71,are unsubstituted or substituted with one or two or three or four independently selected substituents of NH2, C(O)NH2, C(O)NHOH, SO2NH2, CF3,CF2CF3,C(O)H, C(O)OH, C(N)NH2, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I.

Another embodiment of the present invention relates to compounds or therapeutically acceptable salts, which are useful as inhibitors of anti-apofaticheski Bcl-2 proteins, where the compounds have the formula (II)

or a therapeutically acceptable salt of such a compound, where

R100has the meaning specified for substituents on R26;

n is 0, 1, 2 or 3;

A1represents N or C(A2);

A2represents H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A;

B1represents H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR 1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A;

D1represents H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2,N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A;

E1represents H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2,N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A; and

Y1represents H, CN, NO2, C(O)OH, F, Cl, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R17, OR17, C(O)R17, C(O)OR17, SR17, SO2R17NH2, NHR17N(R17)2, NHC(O)R17, C(O)NH2, C(O)NHR17, C(O)N(R17)2, NHS(O)R17or NHSO2/sub> R17; or

E1and Y1together with the atoms to which they are linked, represent a benzene, naftilan, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

A2B1and D1have independently selected values H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2,N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A; or

Y1and B1together with the atoms to which they are linked, represent a benzene, naftilan, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

A2, D1and E1have �ezavisimo selected values H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2,N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A; or

A2and B1together with the atoms to which they are linked, represent a benzene, naftilan, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

D1E1and Y1have independently selected values H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2 , NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A; or

A2and D1together with the atoms to which they are linked, represent a benzene, naphthalene, heteroaryl, cycloalkane, cycloalkene, geteroseksualen or geteroseksualen; and

B1E1and Y1have independently selected values H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1) 2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2,N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A;

R1is an R2, R3, R4or R5;

R1Ais cycloalkyl, cycloalkenyl or cycloalkenyl;

R2represents phenyl, which is neskondensirovannyh or fused with R2A; R2Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R3is heteroaryl, which is neskondensirovannyh or fused with R3A; R3Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R4is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R4A; R4Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R5represents alkyl, alkenyl or alkinyl, each of which� is unsubstituted or substituted with one or two or three independently selected substituents R 6, NC(R6A)(R6B), R7, OR7, SR7, S(O)R7, SO2R7, NHR7N(R7)2, C(O)R7, C(O)NH2,C(O)NHR7, C(O)N(R7)2, NHC(O)R7, NR7C(O)R7, NHSO2R7, NHC(O)OR7, SO2NH2, SO2NHR7, SO2N(R7)2, NHC(O)NH2, NHC(O)NHR7, NHC(O)CH(CH3)NHC(O)CH(CH3NH2, NHC(O)CH(CH3)NHC(O)CH(CH3)NHR7, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;

R6represents C2-C5-spiralcell, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, CF2CF3, F, Cl, Br, I, NH2NH(CH3) or N(CH3)2Deputy;

R6Aand R6Brepresent independently selected alkyl, or together with the N atom to which they are linked, represent R6C;

R6Cis aziridine-1-yl, azetidin-1-yl, pyrrolidin-1-yl or piperidine-1-yl, each of which contains a single CH2group which is unsubstituted or substituted by O, C(O), CNOH, CNOCH3S , S(O), SO2or NH;

R7is an R8, R9, R10or R11;

R8represents phenyl, which is neskondensirovannyh or fused with R8A; R8Arepresents a benzene, heteroaryl, �cloaken, cycloalken, geteroseksualen or geteroseksualen;

R9is heteroaryl, which is neskondensirovannyh or fused with R9A; R9Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R10is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R10A; R10Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R11represents alkyl, alkenyl or alkinyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12NH2, NHR12N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R12)2, C(O)H, C()OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R12is an R13, R14, R15or R16;

R13represents phenyl, which is neskondensirovannyh or fused with R13A; R13Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R14is heteroaryl, which is neskondensirovannyh or fused with R14A; R14Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R15is cycloalkane, cycloalkene, geteroseksualen or geteroseksualen, each of which is neskondensirovannyh or fused with R15A; R15Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R16represents alkyl, alkenyl or alkinyl;

R17is an R18, R19, R20or R21;

R18represents phenyl, which is neskondensirovannyh or fused with R18A; R18Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, heterocyclic�n or geteroseksualen;

R19is heteroaryl, which is neskondensirovannyh or fused with R19A; R19Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R20is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R20A; R20Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R21represents alkyl, alkenyl or alkinyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R22, OR22, SR22, S(O)R22, SO2R22, C(O)R22, CO(O)R22, OC(O)R22, OC(O)OR22NH2, NHR22N(R22)2, NHC(O)R22, NR22C(O)R22, NHS(O)2R22, NR22S(O)2R22, NHC(O)OR22, NR22C(O)OR22, NHC(O)NH2, NHC(O)NHR22, NHC(O)N(R22)2, NR22C(O)NHR22, NR22C(O)N(R22)2, C(O)NH2, C(O)NHR22, C(O)N(R22)2, C(O)NHOH, C(O)NHOR22, C(O)NHSO2R22, C(O)NR22SO2R22, SO2NH2, SO2NHR22, SO2N(R22)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR22, C(N)N(R22)2, COH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R22is an R23, R24or R25;

R23represents phenyl, which is neskondensirovannyh or fused with R23A; R23Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R24is heteroaryl, which is neskondensirovannyh or fused with R24A; R24Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R25is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R25A; R25Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

Z2is an R28, R29or R30;

L1is an R37, OR37, SR37, S(O)R37, SO2R37, C(O)R37, CO(O)R37, OC(O)R37, OC(O)OR37, NHR37, C(O)NH, C(O)NR37, C(O)NHOR37, C(O)NHSO2R37, SO2NH, SO2NHR37, C(N)NH or C(N)NHR37;

R28represents a phenylene, which is some�generowanym or fused with R 28A; R28Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R29is heteroaryl, which is neskondensirovannyh or fused with R29A; R29Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R30is cycloalkyl, cycloalkenyl, heteroseksualci or geterotsiklicheskie, each of which is neskondensirovannyh or fused with R30A; R30Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R37represents a bond, or R37A;

R37Ais alkylen, albaniles or akinyan, each of which is unsubstituted or substituted with one or two or three independently selected R37B, OR37B, SR37B, S(O)R37B, SO2R37B, C(O)R37B, CO(O)R37B, OC(O)R37B, OC(O)OR37BNH2, NHR37BN(R37B)2, NHC(O)R37B, NR37BC(O)R37B, NHS(O)2R37B, NR37BS(O)2R37B, NHC(O)OR37B, NR37BC(O)OR37B, NHC(O)NH2, NHC(O)NHR37B, NHC(O)N(R37B)2, NR37BC(O)NHR37B, NR37BC(O)N(R37B)2, C(O)NH2, C(O)NHR37B, C(O)N(R37B)2C()NHOH, C(O)NHOR37B, C(O)NHSO2R37B, C(O)NR37BSO2R37B, SO2NH2, SO2NHR37B, SO2N(R37B)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR37B, C(N)N(R37B)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br and I substituents;

R37Brepresents alkyl, alkenyl, alkynyl or R37C;

R37Crepresents phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen;

Z3is an R38, R39or R40;

R38represents phenyl, which is neskondensirovannyh or fused with R38A; R38Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R39is heteroaryl, which is neskondensirovannyh or fused with R39A; R39Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R40is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R40A; R40Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or heterocy�louken;

where the cyclic groups represented as E1and Y1however, Y1and B1however, A2and B1however, A2andD1together, R1A, R2, R2A, R3, R3A, R4, R4A, R6, R6C, R8, R8A, R9, R9A, R10, R10A, R13, R13A, R14, R14A, R15, R15A, R18, R18A, R19, R19A, R20, R20A, R23, R23A, R24, R24A, R25, R25A, R26, R26A, R27, R27A, R28, R28A, R29, R29A, R30, R30A, R37B, R38, R38A, R39, R39A, R40and R40Athat are independently unsubstituted, having additional substitution, substituted or further substituted by one or two or three or four or five independently selected substituents R57A, R57, OR57, SR57, S(O)R57, SO2R57, C(O)R57, CO(O)R57, OC(O)R57, OC(O)OR57NH2, NHR57N(R57)2, NHC(O)R57, NR57C(O)R57, NHS(O)2R57, NR57S(O)2R57, NHC(O)OR57, NR57C(O)OR57, NHC(O)NH2, NHC(O)NHR57, NHC(O)N(R57)2, NR57C(O)NHR57, NR57C(O)N(R57)2, C(O)NH2, C(O)NHR57, C(O)N(R57)2, C(O)NHOH, C(O)NHOR57 , C(O)NHSO2R57, C(O)NR57SO2R57, SO2NH2, SO2NHR57, SO2N(R57)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR57, C(N)N(R57)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R57Ais spiralcell or heterosporous;

R57is an R58, R59, R60or R61;

R58represents phenyl, which is neskondensirovannyh or fused with R58A; R58Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R59is heteroaryl, which is neskondensirovannyh or fused with R59A; R59Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R60is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R60A; R60Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R61represents alkyl, alkenyl or alkinyl, each of which is unsubstituted or substituted with one or two or t�time, independently selected substituents R 62, OR62, SR62, S(O)R62, SO2R62, C(O)R62, CO(O)R62, OC(O)R62, OC(O)OR62NH2, NHR62N(R62)2, NHC(O)R62, NR62C(O)R62, NHS(O)2R62, NR62S(O)2R62, NHC(O)OR62, NR62C(O)OR62, NHC(O)NH2, NHC(O)NHR62, NHC(O)N(R62)2, NR62C(O)NHR62, NR62C(O)N(R62)2, C(O)NH2, C(O)NHR62, C(O)N(R62)2, C(O)NHOH, C(O)NHOR62, C(O)NHSO2R62, C(O)NR62SO2R62, SO2NH2, SO2NHR62, SO2N(R62)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR62, C(N)N(R62)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R62is an R63, R64, R65or R66;

R63represents phenyl, which is neskondensirovannyh or fused with R63A; R63Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R64is heteroaryl, which is neskondensirovannyh or fused with R64A; R64Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R65is cycloalkyl, cycloalkenyl, GE�erotically or geteroseksualen, each of which is neskondensirovannyh or fused with R65A; R65Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R66represents alkyl, alkenyl or alkinyl, each of which is unsubstituted or substituted with one or two or three independently selected R67, OR67, SR67, S(O)R67, SO2R67, C(O)R67, CO(O)R67, OC(O)R67, OC(O)OR67NH2, NHR67N(R67)2, NHC(O)R67, NR67C(O)R67, NHS(O)2R67, NR67S(O)2R67, NHC(O)OR67, NR67C(O)OR67, NHC(O)NH2, NHC(O)NHR67, NHC(O)N(R67)2, NR67C(O)NHR67, NR67C(O)N(R67)2, C(O)NH2, C(O)NHR67, C(O)N(R67)2, C(O)NHOH, C(O)NHOR67, C(O)NHSO2R67, C(O)NR67SO2R67, SO2NH2, SO2NHR67, SO2N(R67)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR67, C(N)N(R67)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I substituents;

R67represents alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen;

where the cyclic groups represented by R57A, R58, R59/sup> , R60, R63, R64, R65and R67,are unsubstituted or substituted with one or two or three or four independently selected substituents R68, OR68, SR68, S(O)R68, SO2R68, C(O)R68, CO(O)R68, OC(O)R68, OC(O)OR68NH2, NHR68N(R68)2, NHC(O)R68, NR68C(O)R68, NHS(O)2R68, NR68S(O)2R68, NHC(O)OR68, NR68C(O)OR68, NHC(O)NH2, NHC(O)NHR68, NHC(O)N(R68)2, NR68C(O)NHR68, NR68C(O)N(R68)2, C(O)NH2, C(O)NHR68, C(O)N(R68)2, C(O)NHOH, C(O)NHOR68, C(O)NHSO2R68, C(O)NR68SO2R68, SO2NH2, SO2NHR68, SO2N(R68)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR68, C(N)N(R68)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R68is an R69, R70, R71or R72;

R69represents phenyl, which is neskondensirovannyh or fused with R69A; R69Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R70is heteroaryl, which is neskondensirovannyh or fused with R70A; 70Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R71is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R71A; R71Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R72represents alkyl, alkenyl or alkinyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R73, OR73, SR73, S(O)R73, SO2R73, C(O)R73, CO(O)R73, OC(O)R73, OC(O)OR73NH2, NHR73N(R73)2, NHC(O)R73, NR73C(O)R73, NHS(O)2R73, NR73S(O)2R73, NHC(O)OR73, NR73C(O)OR73, NHC(O)NH2, NHC(O)NHR73, NHC(O)N(R73)2, NR73C(O)NHR73, NR73C(O)N(R73)2, C(O)NH2, C(O)NHR73, C(O)N(R73)2, C(O)NHOH, C(O)NHOR73, C(O)NHSO2R73, C(O)NR73SO2R73, SO2NH2, SO2NHR73, SO2N(R73)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR73, C(N)N(R73)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

p> R73represents alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen; and

where the group represented as R69, R70and R71,are unsubstituted or substituted with one or two or three or four independently selected substituents of NH2, C(O)NH2, C(O)NHOH, SO2NH2, CF3,CF2CF3,C(O)H, C(O)OH, C(N)NH2, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I.

Another variant of implementation relates to compounds of formula (I), where A1represents N or C(A2); A2represents H; and G1represents H.

Another variant of implementation relates to compounds of formula (I), where A1represents N or C(A2); A2represents H; G1represents H; and B1represents NHR1.

Another variant of implementation relates to compounds of formula (I), where A1represents N or C(A2); A2represents H; G1represents H; B1represents NHR1; and D1represents H.

Another variant of implementation relates to compounds of formula (I), where A1represents N or C(A2); A2performance�possessing a H; G1represents H; B1represents NHR1; D1represents H; and E1represents H.

Another variant of implementation relates to compounds of formula (I), where A1represents N or C(A2); A2represents H; G1represents H; B1represents NHR1; D1represents H; E1represents H; and Y1is a NO2.

Another variant of implementation relates to compounds having formula (I) or formula (II), which represent

4-{4-[(4'-chloro-1,1'-biphenyl-2-yl)methyl]piperazine-1-yl}-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chloro-1,1'-biphenyl-2-yl)methyl]piperazine-1-yl}-N-({4-[(3-morpholine-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-demerol-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahy�ro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methylpiperazin-1-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-methoxyethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxane-2-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3R)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-(2-naphthylmethyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridi�-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-methoxyethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-({4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1,4-dioxane-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(2,2,2-trifluoroethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3,3,3-cryptochromes)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2S)-1,4-dioxane-2-ylethoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2R)-1,4-dioxane-2-ylethoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(1,4-dioxane-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxane-2-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-neran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[3-(aminocarbonyl)-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-{[4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-(trifluoromethyl)phenyl]sulfonyl}benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-({4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide;

TRANS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-CL�henyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(1-demerol-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

5-({[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]amino}sulfonyl)-2-(tetrahydro-2H-Piran-4-ylethoxy)nicotinamide;

N-({5-bromo-6-[(1-demerol-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-demerol-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(1,4-dioxane-2-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[5-bromo-6-(1,4-dioxane-2-ylethoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2,2-dimethylether-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-5-cyano-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1-acetylpiperidine-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({2-chloro-5-fluoro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-morpholine-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(2-morpholine-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[2-(2-methoxyethoxy)ethyl]sulfonyl}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[2-(2-methoxyethoxy)ethyl]sulfonyl}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)oxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-bromo-6-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-harfe�yl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-cyanoethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-{[4-({4-[bis(cyclopropylmethyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1-demerol-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(morpholine-3-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-methylpiperazin-1-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-albut-2-inyl)oxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-ethinyl-6-(tetrahydro-2H-Piran-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-oxo-3,4-dihydroquinazolin-6-yl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

tert-butyl 3-{[4-({[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-ylox�)benzoyl]amino}sulfonyl)-2-nitrophenoxy]methyl}morpholine-4-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(morpholine-3-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[1-(methyl-sulfonyl)piperidine-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1,1-dissidocerida-2H-thiopyran-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-chloro-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[1-(2,2,2-trifluoroethyl)piperidine-4-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)oxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-isopropyl-6-(tetrahydro-2H-Piran-4-illcox�)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-5-fluoro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

and their therapeutically acceptable salts, and metabolites.

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[2-fluoro-1-(permitil)ethyl]piperidine-4-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[1-(2,2-deflorati)piperidine-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclopropylidene-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1-the morpholine-4-illlogical)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(dicyclopropyl)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)Bentham�d;

4-(4-{[2-(4-chlorophenyl)-6,6-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-bromo-6-[(4-ethylmorpholine-3-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-ethylmorpholine-3-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(4-tetrahydro-2H-Piran-4-Immortalis-3-yl)methoxy]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-tetrahydro-2H-Piran-4-reparacin-3-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(tetrahydro-2H-Piran-4-ylmethyl)amino]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1,1-diocletianopolis-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(4-aminotetraline-2H-Piran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(4-morpholine-4-illlogical)amino]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-cyano-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1S,3R)-3-morpholine-4-enciclopedic]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1R,3S)-3-morpholine-4-enciclopedic]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(morpholine-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydrofuran-3-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[CIS-3-Porterage-2H-Piran-4-yl]piperidine-4-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-and�)-N-({3-nitro-4-[(1-tetrahydro-2H-Piran-4-ilization-3-yl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydrofuran-3-ilization-3-yl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3R)-1-tetrahydro-2H-Piran-4-imperiality-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)-N-(4-((TRANS-4-hydroxycyclohexyl)methoxy)-3-nitrophenyloctyl)benzamide;

2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)-N-(4-((CIS-4-methoxycyclohexyl)methoxy)-3-nitrophenyloctyl)benzamide;

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(cyclopropylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(tetrahydro-2H-Piran-4-ylamino)cyclohexyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-({5-bromo-6-[(4-morpholine-4-illcl�hexyl)oxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxycyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

tert-butyl 4-{[4-({[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]amino}sulfonyl)-2-nitrophenoxy]methyl}-4-foreperiod-1-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-foreperiod-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(4-tetrahydro-2H-Piran-4-reparacin-1-yl)cyclohexyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[2-fluoro-1-(permitil)ethyl]piperidine-4-yl}methoxy)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3R)-1-tetrahydro-2H-Piran-4-imperiality-3-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(2,2-dimethylether-2H-Piran-4-yl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)Bentham�d;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-tetrahydro-2H-Piran-4-imperiality-3-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-(2,2-dimethylether-2H-Piran-4-yl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(2-methoxyethyl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(4-acetylmorpholine-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[TRANS-4-(permitil)-1-oxetan-3-imperiality-3-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-Porterage-2H-Piran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4 dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-oxetan-3-reparacin-4-yl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclobutylmethyl-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[1-(2,2-dimethylether-2H-Piran-4-yl)piperidine-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-cyclopropylidene-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydrofuran-3-reparacin-4-yl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-cyclopropylidene-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3S)-1-tetrahydro-2H-Piran-4-imperiality-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-hydroxy-2,2-dimethylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(methyl-sulfonyl)piperidine-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(1-acetylpiperidine-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(methyl-sulfonyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-3,3-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[2-fluoro-1-(permitil)ethyl]azetidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(methyl-sulfonyl)pyrrolidin-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(1-acetylpyrrolidine-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(3R)-1-acetylpyrrolidine-3-yl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazin�-1-yl)-N-({4-[(3-methoxy-2,2-dimethylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1R,3R)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1S,3S)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1S,3R)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1R,3S)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-2-oxopiperidin-3-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[({1-[2-fluoro-1-(permitil)ethyl]azetidin-3-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(1-oxetan-3-ilization-3-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}p�perazine-1-yl)-N-[(3-nitro-4-{[(1-oxetan-3-reparacin-4-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1-cyclopropylidene-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(2-fluoroethyl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(2,2-deflorati)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-oxetan-3-reparacin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(2S)-4,4-debtor-1-oxetan-3-imperiality-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(4-tetrahydro-2H-Piran-4-Immortalis-3-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyclobutylmethyl-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclo�CEN-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(4-tetrahydrofuran-3-Immortalis-3-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[({1-[2-fluoro-1-(permitil)ethyl]piperidine-4-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclopropyl-4-foreperiod-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[3-(triptoreline)benzyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-methoxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(deformedarse)benzyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxaspiro[4.5]Dec-8-ylamino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-[(4-{[4-(acetylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclo�COP-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(2,2-deflorati)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-(2-fluoroethyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-(2,2-deflorati)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(2-fluoroethyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-oxetan-3-imperiality-3-yl]methoxy}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-hydroxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-hydroxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[3-(deformedarse)benzo�l]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[CIS-3-morpholine-4-enciclopedic]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(methyl-sulfonyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclopropylidene-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-oxetan-3-reparacin-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-tetrahydro-2H-Piran-4-reparacin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-tetrahydrofuran-3-reparacin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-fluoro-1-(methyl-sulfonyl)piperidine-4-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3R)-1-oxetan-3-imperiality-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-hydroxycyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[3-(dimethylamino)propoxy]benzyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(2-the morpholine-4-ylethoxy)benzyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(E)-4-hydroxy-1-adamantyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(Z)-4-hydroxy-1-adamantyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1S,4S)-bicyclo[2.2.1]hept-5-ene-2-ylethoxy]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-methyl-5-oxopyrrolidin-3-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1R,4,5 R,6S)-5,6-dihydroxybutyl[2.2.1]hept-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1R,4R,5S,6R)-5,6-dihydroxybutyl[2.2.1]hept-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3-oxocyclohexyl)methoxy]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1,3-Dien-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({(3R)-1-[2-fluoro-1-(permitil)ethyl]pyrrolidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[6-[(4-Porterage-2H-Piran-4-yl)methoxy]-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3S)-1-oxetan-3-imperiality-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-N-({5-chloro-6-[(4-metacritical�KSIL)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-oxetan-3-imperiality-3-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[({4-[2-(2-methoxyethoxy)ethyl]morpholine-2-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(cyanomethyl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(N,N-dimethylglycine)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

(2-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}morpholine-4-yl)acetic acid;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[4-(oxetan-3-yl)morpholine-2-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyclopropylmethyl-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex�-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-(methyl-sulfonyl)-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methyltetrahydro-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

ethyl 4-(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)piperazine-1-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[4-(morpholine-4-yl)piperidine-1-yl]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3R)-1-(oxetan-3-yl)pyrrolidin-3-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]amino}-3-[(trifluoromethyl)sulfonyl]phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-isopropylpiperazine-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1-tert-butylpiperazine-4-yl)amino]-3-nitro�enyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(2-methoxyethyl)piperidine-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(cyanomethyl)piperidine-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-demerol-4-yl)methoxy]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]amino}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

tert-butyl 4-[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]piperazine-1-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-(pendaftar-λ6-sulfanyl)-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxytyramine-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]oxy}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(oxetan-3-yl)piperazine-1-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(tetrahydro-2H-Piran-4-yl)piperazine-1-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3R)-tetrahydrofuran-3-ylamino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4,4-diverticulosis)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1-tert-butylpiperazine-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-({[4-(oxetan-3-yl)morpholine-2-yl]methyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(4-Porterage-2H-Piran-4-yl)methyl]amino}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(1-cyclopropylidene�in-4-yl)amino]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2S)-4-(cyanomethyl)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2S)-4-(N,N-dimethylglycine)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2R)-4-(cyanomethyl)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2R)-4-(N,N-dimethylglycine)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-fluoro-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[3-hydroxy-2-(gidroximetil)-2-methylpropoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dim�testicles-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(1,3-ditropan-2-yl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(cyanomethyl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({(3R)-1-[2-(2-methoxyethoxy)ethyl]pyrrolidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(N,N-dimethylglycine)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[1-(oxetan-3-yl)azetidin-3-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(cyanomethyl)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2R)-4-(N,N-dimethylglycine)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2S)-4-(N,N-dimethylglycine)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(N,N-dimethyl�ITIL)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(2,2-deflorati)pyrrolidin-3-yl]oxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(cyanomethyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-methoxypiperidine-1-yl}-N-({5-chloro-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-methoxypiperidine-1-yl}-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-(1,3-ditropan-2-yl)-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-(1,3-ditropan-2-yl)-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]und�C-8-EN-8-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4-fluoro-1-demerol-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(N,N-dimethylphenyl)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-foreperiod-1-yl}-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-foreperiod-1-yl}-N-({5-chloro-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-({4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-(trifluoromethyl)phenyl}sulfonyl)benzamide;

N-[(5-chloro-6-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]oxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[2-(tetrahydrofuran-3-yloxy)ethoxy]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperaz�n-1-yl)-N-[(4-{[(TRANS-4-cyanocyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[2-(tetrahydro-2H-Piran-4-yl)ethoxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(3-FuelMAX)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(2,2-deflorati)pyrrolidin-3-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(1,3-ditropan-2-yl)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-fluoro-1-demerol-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-ene-yl]methyl}piperazine-1-yl)-N-{[3-cyano-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(2,2-deflorati)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4,4-diverticulosis)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[6-{[1-(1,3-ditropan-2-yl)-4-foreperiod-4-yl]methoxy}-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-chloro-6-[2-(tetrahydrofuran-2-yl)ethoxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}-3-methylpiperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[3-(cyclopropylamino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[5-chloro-6-(2-methoxyethoxy)pyridin-3-and�]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-fluoro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(methoxyacetyl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(N,N-dimethylglycine)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohexyl]methyl}piperidine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-{[6-(tetrahydro-2H-Piran-4-ylethoxy)-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}benzamide;

N-({5-chloro-6-[(TRANS-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-cyano-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}Pieper�Zin-1-yl)-N-({6-[(TRANS-4-methoxycyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({6-[(CIS-4-methoxycyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4,4-debtor-1-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperidine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[TRANS-4-(morpholine-4-yl)cyclohexyl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[the cyclopropyl(1,3-thiazol-5-ylmethyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(TRANS-4-hydroxycyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-chloro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-(trifluoromethyl)phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethyl�ilogix-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[the cyclopropyl(2,2,2-trifluoroethyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(oxetan-3-yl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3,5-debtor-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[the cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(1-methyl-L-shed)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3,4-debtor-5-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2S)-4-cyclopropylmethyl-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperidine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}PIP�ridin-1-yl)-N-{[3-chloro-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

methyl 2-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}morpholine-4-carboxylate;

2-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(methyl-sulfonyl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclobutyl(cyclopropyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-diverticulosis-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-chloro-4-(tetrahydrofuran-3-ylethoxy)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-diverticulosis-1-EN-1-yl]methyl�}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[9-(4-chlorophenyl)-3-(oxetan-3-yl)-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2R)-4-cyclopropylmethyl-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2S)-4-cyclopropylmethyl-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[5-chloro-6-({4-[cyclopropyl(oxetan-3-yl)amino]cyclohexyl}methoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyclopropylmethyl-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-cyclopropylmethyl-2-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[(4-cyclopropylmethyl-2-yl)methyl]amino}�enyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

2-{[(2-chloro-4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}phenyl)amino]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

(2S)-2-{[(3-chloro-5-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}pyridin-2-yl)oxy]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

N-[(5-chloro-6-{[(4-cyclopropylmethyl-2-yl)methyl]amino}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

2-{[(3-chloro-5-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}pyridin-2-yl)amino]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(CIS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(1R,2R,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridin-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(2-cyanoethyl)(cyclopropyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(1R,2S,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(CIS-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(3,3-giftability-1-yl)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-�ENT-6-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(CIS-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(2,2-diversicolor)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(CIS-1-fluoro-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-(2-oxaspiro[3.5]non-7-ylethoxy)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-bis(permitil)cyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-cyclopropylmethyl-2-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(TRANS-1-fluoro-4-hydroxy-4-methyl�illogical)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(CIS-1-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-cyano-4-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-ethyl-4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(CIS-4-ethyl-4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5-(methoxymethyl)-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(2S)-4-(oxetan-3-yl)morpholine-2-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-CL�henyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(2-cyanoethyl)(cyclopropyl)amino]-1-forcelogix}methoxy)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-nitro-6-[(tetrahydro-2H-Piran-4-ylmethyl)amino]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(2-oxaspiro[3.5]non-7-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyano-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)amino}Metreveli;

{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)amino}methyl butyrate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-{[3-(tetrahydro-2H-Piran-4-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-6-yl]sulfonyl}benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(6-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-5-nitropyridine-3-yl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(chlorphenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(5-cyano-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)morpholine-4-carboxamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(methoxymethyl)cyclohexyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(5-chloro-6-{[1-(1,3-- thiazol-2-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(6-{[(CIS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-5-nitropyridine-3-yl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

methyl TRANS-4-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}cyclohexanecarboxylate;

TRANS-4-{[(4-{[4-(4-{[2-(4-chlorophenyl)4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}cyclohexanecarbonyl acid;

N-(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)-4-cyanopiperidine-1-carboxamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[CIS-4-(methoxymethyl)cyclohexyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[TRANS-4-(methoxymethyl)cyclohexyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-{[1-(tetrahydro-2H-Piran-4-ylmethyl)-1H-benzotriazole-5-yl]sulfonyl}benzamide;

N-({5-chloro-6-[(2-oxo-1-ox-3-azaspiro[4.5]Dec-8-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)-4-methoxypiperidine-1-carboxamide;

N-({5-chloro-6-[(2-methyl-4,5,6,7-tetrahydro-1,3-benzothiazol-5-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1st�-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-{[1-(tetrahydro-2H-Piran-4-ylmethyl)-1H-imidazo[2,3-b]pyridin-5-yl]sulfonyl}benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-chloro-1-(tetrahydro-2H-Piran-4-ylmethyl)-1H-imidazo[2,3-b]pyridin-5-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4-(methoxymethyl)-4-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[4,4-bis(gidroximetil)cyclohexyl]methoxy}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-(2-chloro-4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}phenyl)-4-methoxypiperidine-1-carboxamide;

N-(2-chloro-4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}phenyl)-4-cyanopiperidine-1-carboxamide;

N-(2-chloro-4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}phenyl)-4-hydroxy-4-demerol-1-carboxamide;

N-(2-chloro-4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}phenyl)-4-(methoxymethyl)piperidine-1-carboxamide;

N-[(5-chloro-6-{[(5r,8r)-2-oxo-1-ox-3-azaspiro[4.5]Dec-8-yl]methoxy}�of iridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(5s,8s)-2-oxo-1-ox-3-azaspiro[4.5]Dec-8-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-(2-chloro-4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}phenyl)-4-(morpholine-4-yl)piperidine-1-carboxamide;

N-[(5-chloro-6-{[TRANS-4-hydroxy-4-(methoxymethyl)cyclohexyl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[CIS-4-hydroxy-4-(gidroximetil)cyclohexyl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[TRANS-4-hydroxy-4-(gidroximetil)cyclohexyl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)cyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)Benza�ID;

4-(4-chlorophenyl)-1-methyl-3-[(4-{4-[({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)carbamoyl]-3-(1H-imidazo[2,3-b]pyridine-5-yloxy)phenyl}piperazine-1-yl)methyl]cyclohex-3-ene-1-carboxylic acid;

N-[(5-chloro-6-{[1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; and their therapeutically acceptable salts, and metabolites.

Another variant of implementation refers to the connection 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide derivative; or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection of the TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide derivative; or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection of the CSA-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide derivative; or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection of the TRANS-4-(-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide derivative; or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide derivative; or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide derivative; or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(CIS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide derivative; or its pharmaceutically acceptable salt.

Another variant of implementation relates to the compound N-[(5-chloro-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide derivative; or its pharmaceutically acceptable salt.

Another variant of implementation relates to the compound N-({5-bromo-6-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorp�Neal)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide derivative; or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(methyl-sulfonyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide derivative; or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[the cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide derivative; or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection 4-(4-{[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide derivative; or its pharmaceutically acceptable salt.

Another variant of implementation relates to compounds having formula (I) or formula (II), which represent 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(methyl-sulfonyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)su�hanil]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[the cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; or a pharmaceutically acceptable salt of such a compound.

Another variant of implementation relates to compounds having formula (I) or formula (II), which are N-[(5-chloro-6-{[1-(cyanomethyl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[the cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide derivative; or a pharmaceutically acceptable salt of such a compound.

Another variant of implementation relates to compounds having formula (I) or formula (II), which represent 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(CIS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide derivative; or pharmaceutically acceptable salt of such an a� connection.

Another variant of implementation refers to the connection 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[the cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide derivative; or its pharmaceutically acceptable salt.

Another variant of implementation relates to compounds having formula (I) or formula (II), which represent 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3R)-1-tetrahydro-2H-Piran-4-imperiality-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide derivative; or a pharmaceutically acceptable salt of such a compound.

Another variant of implementation relates to compounds having formula (I) or formula (II), which represent 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxane-2-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-bromo-6-[(1-tetrahydro-2H-Piran-4-and�piperidine-4-yl)amino]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(4-aminotetraline-2H-Piran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3R)-1-tetrahydro-2H-Piran-4-imperiality-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(methyl-sulfonyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxytyramine-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(cyanomethyl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[the cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(1R,2S,4R,5R)-5-hydroxy-5-me�albicilla[2.2.1]hept-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(6-{[(CIS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-5-nitropyridine-3-yl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide derivative; or a pharmaceutically acceptable salt of such a compound.

Another variant of implementation relates to the compound N-[(5-chloro-6-{[1-(cyanomethyl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide derivative; or its pharmaceutically acceptable salt.

Another variant of implementation relates to compounds having formula (I) or formula (II), which are N-[(4-{[(4-aminotetraline-2H-Piran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxytyramine-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide derivative; or a pharmaceutically acceptable salt of such a compound.

Another variant of implementation refers to the connection 4-(4-{[2-(4-harfe�yl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxytyramine-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide derivative; or its pharmaceutically acceptable salt.

Another variant of implementation relates to compositions for treating bladder cancer, brain cancer, breast cancer, cancer of the bone marrow, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignant diseases of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or cancer of the spleen, where the specified composition includes excipient and a therapeutically effective amount of a compound of formula (I) or formula (II).

Another variant of implementation relates to a method for treating bladder cancer, brain cancer, breast cancer, cancer of the bone marrow, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignant diseases of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-mackleton�th lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or cancer of the spleen in a patient, wherein said method comprises administering to the patient a therapeutically effective amount of a compound of formula (I) or formula (II).

Another variant of implementation relates to a method for treating bladder cancer, brain cancer, breast cancer, cancer of the bone marrow, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignant diseases of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or cancer of the spleen in a patient, wherein said method comprises administering to the patient a therapeutically effective amount of a compound of formula (I) or formula (II) and a therapeutically effective amount of one additional therapeutic agent or more additional therapeutic agents.

Detailed description of the invention

Different groups are represented in the present application identifiers (�andmainly letters with numerical and/or alphabetic indices) and may have specific implementation.

It should be clear that the appropriate valences are maintained for all groups, and combinations thereof, monovalent groups containing more than one atom are listed in order from left to right and are attached at their left ends, and that divalent groups are also listed in order from left to right.

Also it should be clear that a particular variant of implementation of some variable in the present application may be the same or different from another specific embodiment having the same identifier.

The term "alkenyl" as used in this application, means linear or branched hydrocarbon chain containing from 2 to 10 carbon atoms and containing at least one carbon-carbon double bond. The term “Cx-Cythe alkenyl” means linear or branched hydrocarbon chain containing at least one carbon-carbon double bond containing carbon atoms in an amount of from x to y. The term “C3-C6the alkenyl” means an alkenyl group containing 3-6 carbon atoms. Representative examples alkenyl include, but are not limited to, buta-2,3-dienyl, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-1-heptanol and 3-decenyl.

The term "albaniles" means a divalent group of obrazovan�Yu from linear or branched hydrocarbon chain, containing from 2 to 4 carbon atoms, and contains at least one carbon-carbon double bond. The term “Cx-Cyalbaniles” means a divalent group formed from a linear or branched hydrocarbon chain containing at least one carbon-carbon double bond and containing carbon atoms in an amount of from x to y. Representative examples of Alcanena include, but are not limited to, -CH=CH - and-CH2CH=CH-.

The term "alkyl" as used in this application, means a linear or branched saturated hydrocarbon chain containing from 1 to 10 carbon atoms. The term “CX-Cyalkyl” means linear or branched saturated hydrocarbon chain containing carbon atoms in an amount of from x to y. For example, “C1-C6alkyl” means linear or branched saturated hydrocarbon chain containing from 2 to 6 carbon atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-etylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl and n-decyl.

The term "alkylene" means a divalent group formed from a linear or branched saturated hydrocarbon chain containing �t 1 to 10 carbon atoms, for example, from 1 to 4 carbon atoms. The term “CX-Cyalkylene” means a divalent group formed from a linear or branched saturated hydrocarbon chain containing carbon atoms in an amount of from x to y. For example, “C2-C6alkylene” means a linear or branched saturated hydrocarbon chain containing from 2 to 6 carbon atoms. Representative examples of alkylene include, but are not limited to, -CH2-, -CH2CH2-, -CH2CH2CH2-, -CH2CH2CH2CH2- and-CH2CH(CH3)CH2-.

The term "alkynyl" as used in this application, means linear or branched hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond. The term “Cx-Cyalkynyl” means linear or branched hydrocarbon group containing carbon atoms in an amount of from x to y. For example, “C3-C6alkynyl” means linear or branched hydrocarbon group containing from 3 to 6 carbon atoms and containing at least one carbon-carbon triple bond. Representative examples of alkynyl include, but are not limited to, acetylenyl, 1-PROPYNYL, 2-PROPYNYL, 3-butynyl, 2-pentenyl and 1-butynyl.

The term "akinyan" used�used in the present application, means a divalent radical formed from linear or branched hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond.

The term "aryl" as used in this application, means phenyl.

The term "cyclic group" as used in this application, means benzene, phenyl, phenylene, cycloalkane, cycloalkyl, cycloalkene, cycloalken, cycloalkenyl, cycloalkenyl, cycloalkyl, cycloalkenyl, cycloalkenyl, heteroaryl, heteroaryl, heteroseksualci, geteroseksualen, heteroseksualci, geteroseksualen and spiralcell.

The term "cycloalkyl" or cycloalkyl" or “cycloalkane” as used in this application, means a monocyclic or associated bridge connection hydrocarbon ring system. The monocyclic cycloalkyl represents a carbocyclic ring system containing three to ten carbon atoms, zero heteroatoms and zero double bonds. Examples of monocyclic ring systems include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. Monocyclic ring may contain one or two alkilinity bridge, each of which consists of one, two or three carbon atoms, each links two non-adjacent carbon atoms of the ring system. Repre�entative examples of such related bridging communication cycloalkyl ring systems include, but not limited to, bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, bicyclo[4.2.1]nonane, tricyclo[3.3.1.03,7]nonane (octahydro-2,5-methanoindene or noradsanta) and tricyclo[3.3.1.13,7]Dean (adamantane). Monocyclic and associated bridging the communication cycloalkyl can be attached to the original molecular group via any suitable replacement for the atom contained in the ring system.

The term "cycloalkenyl" or "cycloalkenyl" or “cycloalkene” as used in this application, means a monocyclic or associated bridge connection hydrocarbon ring system. Monocyclic cycloalkenyl contains from four to ten carbon atoms and zero heteroatoms. Four-membered ring systems have one double bond, the five - or six-membered ring system containing one or two double bonds, seven - or eight-membered ring systems have one, two or three double bonds, and nine - or ten-membered ring containing one, two, three or four double bonds. Representative examples of monocyclic cycloalkenyl groups include, but are not limited to, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctanol. Monocyclic cycloalkenyl ring may contain one or two alkyl�new bridge each of which consists of one, two or three carbon atoms, each links two non-adjacent carbon atoms of the ring system. Representative examples of associated bridging communication cycloalkenyl groups include, but are not limited to, 4,5,6,7-tetrahydro-3aH-indene, octahydronaphthalene and 1,6-dihydro-pentalene. Monocyclic and associated bridging communication cycloalkenyl can be attached to the original molecular group via any suitable replacement for the atom, which is contained within the ring systems.

The term "cycloalkyl" or "cycloalkenyl" or "cycloalkenyl" as used in this application, means a monocyclic or associated bridge connection hydrocarbon ring system. The monocyclic cycloalkenyl contains eight or more carbon atoms, zero heteroatoms and one or more triple bonds. Monocyclic cycloalkenyl ring may contain one or two alkilinity bridge, each of which consists of one, two or three carbon atoms, each links two non-adjacent carbon atoms of the ring system. Monocyclic and associated bridging the communication cycloalkenyl can be attached to the original molecular group via any suitable replacement for the atom, which is contained within the ring systems.

The term "heteroaryl" or "heteroaryl" or "g�teroare", used in this application, means a five-membered or six-membered aromatic ring containing at least one carbon atom and one or more independently selected nitrogen atoms, oxygen or sulfur. Heteroarenes of the present invention are connected through any adjacent atoms in the ring, provided that these are appropriate valence. Representative examples of heteroaryl include, but are not limited to, furanyl (including, but not limited to, furan-2-yl), imidazolyl (including, but not limited to, 1H-imidazol-1-yl), isoxazolyl, isothiazolin, oxadiazolyl, 1,3-oxazolyl, pyridinyl (e.g., pyridin-4-yl, pyridin-2-yl, pyridin-3-yl), pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, tetrazolyl, thiadiazolyl, 1,3-thiazolyl, thienyl (including, but not limited to, Thien-2-yl, Tien-3-yl), triazolyl and triazinyl.

The term "geteroseksualen" or "heteroseksualci" or "heteroseksualci" as used in this application, means a monocyclic or associated bridge connection three-, four-, five-, six-, seven - or eight-membered ring containing at least one heteroatom, independently selected from the group including O, N and S, and zero double bonds. Monocyclic and associated bridging communication geteroseksualen linked to the original molecular group through any �odpadami to replace the carbon atom or any suitable for substitution of the nitrogen atom, which is contained in the ring. The heteroatoms nitrogen and sulfur in the heterocyclic ring can optionally be oxidized, and the nitrogen atoms can optionally be quartersawn. Representative examples geterotsiklicheskikh groups include, but are not limited to, morpholinyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, DIOXOLANYL, tetrahydrofuranyl, thiomorpholine, 1,4-dioxane, tetrahydrofuranyl, tetrahydropyranyl, oxetanyl, piperazinyl, imidazolidinyl ureido, azetidin, azepane, aziridine, diazepan, dithiolane, dithienyl, isoxazolidine, isothiazolinones, oxadiazolidine, oxazolidinyl, pyrazolidine, tetrahydrothieno, thiadiazolidine, diazolidinyl, thiomorpholine, tritional and tritional.

The term "geteroseksualen" or "heteroseksualci," or "heterocyclisation" as used in this application, means a monocyclic or associated bridge connection three-, four-, five-, six-, seven - or eight-membered ring containing at least one heteroatom, independently selected from the group comprising O, N and S, and one or more double bonds. Monocyclic and associated bridging communication geteroseksualen linked to the original molecular group via any suitable for substitution of the carbon atom or any suitable for substitution of the nitrogen atom contained within the rings. G�teratoma of nitrogen and sulfur in the heterocyclic ring can optionally be oxidized, and the nitrogen atoms can optionally be quartersawn. Representative examples geterotsiklicheskikh groups include, but are not limited to, 1,4,5,6-tetrahydropyridine, 1,2,3,6-tetrahydropyridine, dihydropyran, imidazolyl, isothiazolin, oxadiazolyl, isoxazolyl, oxazolyl, pyranyl, pyrazolyl, pyrrolyl, thiadiazolyl, thiazolyl and tiopronin.

The term "phenyl" as used in this application, means a monovalent radical formed by removal of a hydrogen atom from benzene.

The term "phenylene" as used in this application, means a divalent radical formed by removing a hydrogen atom from the phenyl.

The term "spirooli" as used in this application, means alkylene, both ends of which are attached to the same carbon atom, and examples include the C2-spiralcell, C3-spiralcell, C4-spiralcell, C5-spiralcell, C6-spiralcell, C7-spiralcell, C8-spiralcell, C9-spiralcell and such.

The term "spirolaterals" as used in this application, means spiralcell containing one or two CH2group substituted with independently selected O, C(O), CNOH, CNOCH3S , S(O), SO2or NH and one or two CH groups which are unsubstituted or substituted N.

The term "spiroheterocyclic" as used in N.�standing application means serialkey containing one or two CH2group substituted with independently selected O, C(O), CNOH, CNOCH3S , S(O), SO2or NH and one or two CH groups which are unsubstituted or substituted N, and also means serialkey containing one or two CH2groups which are unsubstituted or substituted with independently selected O, C(O), CNOH, CNOCH3S , S(O), SO2or NH and one or two CH groups that are substituted N.

The term "C2-C5-spiralcell" as used in this application, means C2-spiralcell, C3-spiralcell, C4-spiralcell and C5--spiralcell.

The term "C2-spiralcell” as used in this application, means et-1,2-ilen, both ends of which replace hydrogen atoms of the same CH2group.

The term "C3-spiralcell,” as used in this application, means prop-1,3-ilen, both ends of which replace hydrogen atoms of the same CH2group.

The term "C4-spiralcell” as used in this application, means a buta-1,4-ilen, both ends of which replace hydrogen atoms of the same CH2group.

The term "C5-spiralcell” as used in this application, means pent-1,5-ilen, both ends of which replace hydrogen atoms of the same CH2group.

The term "C6-spiralcell” as used in the infusion�her request, means hex-1,6-ilen, both ends of which replace hydrogen atoms of the same CH2group.

The term "NH protective group" as used in this application, means trichlorocyanuric, tribromoethanol, benzyloxycarbonyl, para-nitrobenzenesulfonyl, ortho-bromobenzyloxycarbonyl, chloroacetyl, dichloroacetyl, trichloroacetyl, triptorelin, phenylacetyl, formyl, acetyl, benzoyl, tert-aryloxyalkyl, tert-butoxycarbonyl, para-methoxybenzeneboronic, 3,4-dimethoxybenzyl-oxycarbonyl, 4-(phenylazo)benzyloxycarbonyl, 2-furfuryl-oxycarbonyl, diphenylcarbinol, 1,1-DIMETHYLPROPANE-carbonyl, isopropoxycarbonyl, phthaloyl, succinyl, alanyl, leucyl, 1-adamantanecarbonyl, 8-hinolincarbonova, benzyl, diphenylmethyl, triphenylmethyl, 2-nitrophenylthio, methanesulfonyl, para-toluensulfonyl, N,N-dimethylaminomethylene, benzylidene, 2-hydroxybenzylidene, 2-hydroxy-5-chlorobenzylidene, 2-hydroxy-1-naphthyl-methylene, 3-hydroxy-4-pyridylmethylene, cyclohexylidene, 2-ethoxycarbonylmethylene, 2-ethoxycarbonylmethylene, 2-acetylcyclohexanone, 3,3-dimethyl-5-axillo-hexylidene, diphenylphosphoryl, dibenzoyltartaric, 5-methyl-2-oxo-2H-1,3-dioxol-4-yl-methyl, trimethylsilyl, triethylsilyl and triphenylsilanol.

The term "C(O)OH protective group" as used in this application, means methyl, ethyl, n-propyl,�propyl, 1,1-dimethylpropyl, n-butyl, tert-butyl, phenyl, naphthyl, benzyl, diphenylmethyl, triphenylmethyl, para-nitrobenzyl, para-methoxybenzyl, bis(para-methoxyphenyl)methyl, acetylethyl, benzoylmethyl, para-nitrobenzoyl, para-bromobenzoyl, para-methanesulfonylaminoethyl, 2-tetrahydropyranyl, 2-tetrahydrofuranyl, 2,2,2-trichloro-ethyl, 2-(trimethylsilyl)ethyl, acetoxymethyl, propionyloxy, pivaloyloxymethyl, phthalimidomethyl, Succinimidyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxymethyl, methoxyethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, benzyloxyethyl, methylthiomethyl, 2-methylthioethyl, phenylthiomethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, diethylenediamine, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, diphenylmethyl and tert-butylmethylether.

The term "OH or SH protective group" as used in this application, means benzyloxycarbonyl, 4-nitrobenzenesulfonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxy, 3,4-dimethoxyphenylacetone, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, 1,1-dimethyldioxirane, isopropoxycarbonyl, isobutylacetate, diphenylcarbinol, 2,2,2-trichlorocyanuric, 2,2,2-tribromoethanol, 2-(trimethylsilyl)ethoxycarbonyl, 2-(phenylsulfonyl)is�dicarbonyl, 2-(triphenylphosphonio)ethoxycarbonyl, 2-furfurylalcohol, 1-adamantanecarbonyl, vinyloxycarbonyl, allyloxycarbonyl, S-benzyltoluene, 4-ethoxy-1-naphthaleneboronic, 8-hinolincarbonova, acetyl, formyl, chloroacetyl, dichloroacetyl, trichloroacetyl, triptorelin, methoxyacetyl, phenoxyacetyl, pivaloyl, benzoyl, methyl, tert-butyl, 2,2,2-trichlorethyl, 2-trimethylsilylmethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl (phenylmethyl), para-methoxybenzyl, 3,4-dimethoxybenzyl, diphenylmethyl, triphenylmethyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydropyranyl, methoxymethyl, methylthiomethyl, benzoyloxymethyl, 2-methoxyethoxymethyl, 2,2,2-trichloro-ethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, 1-ethoxyethyl, methanesulfonyl, para-toluensulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, diethylenediamine, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, diphenylmethyl and tert-butylmethylether.

Connection

Geometric isomers may exist in the compounds of the present invention. Compounds of the present invention may contain carbon-carbon double bond or carbon-nitrogen double bond in E or Z konfiguracji, where the term “E” means higher order substituents on opposite sides of the carbon-carbon or carbon-nitrogen double bond, and the termi� “Z” means higher order substituents on the same side of the carbon-carbon or carbon-nitrogen double bond, as determined in accordance with the rules of assigning priority Cahn-Ingold-Prelog. Compounds of the present invention may also exist as mixtures of E and Z isomers. Substituents around cycloalkyl or heteroseksualci listed as being in CIS or TRANS to konfiguracji. In addition, the invention includes various isomers and mixtures thereof, formed as a result of the arrangement of substituents around a ring of Adamantine system. Two Deputy around one ring of Adamantine ring system is designated as being of Z or E relative konfiguracji. For examples, see C. D. Jones, M. Kaselj, R. N. Salvatore, W. J. le Noble J. Org. Chem. 1998, 63, 2758-2760.

Compounds of the present invention may contain asimmetricheskii substituted carbon atoms in the R or S configuratie where the terms "R" and "S" have the meanings defined in IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, pure Appl. Chem. (1976) 45, 13-10. Compounds containing asimmetricheskii substituted carbon atoms with equal amounts of R and S configurations are racemic at these carbon atoms. Atoms with an excess of one configuratie relative to another, is attributed to konfiguracija present in greater amount, preferably in excess of about 85% -90%, more preferably an excess of about 95% -99%, and still more preferably an excess greater than about 99%. The relevant�but the present invention includes racemic mixtures, relative and absolute stereoisomers and mixtures of relative and absolute stereoisomers.

Isotopically enriched or labeled compounds

Compounds of the present invention can exist in isotope-labeled or enriched form containing one or more atoms having an atomic mass or mass number different from the atomic mass or mass number most commonly found in nature. The isotopes may be radioactive or non-radioactive. Isotopes of atoms such as hydrogen, carbon, phosphorus, sulfur, fluorine, chlorine, and iodine include, but are not limited to,2H,3H,13C,14C,15N,18O,32P,35S,18F,36Cl and125I. Compounds that contain other isotopes of these and/or other atoms, are covered by the scope of the present invention.

In another embodiment of the isotope-labeled compounds contain isotopes of deuterium (2H), tritium (3(H) or14C. Isotopically-labeled compounds of the present invention can be obtained by methods well known to the ordinary skilled specialists in this field. Such isotope-labeled compounds of the easy way can be obtained by carrying out procedures disclosed in the Examples described in the present for�VKE, and Schemes, by replacing the unlabeled reagent readily available isotope-labeled reagent. In some cases, the compounds can be processed isotope-labeled reagents to replace the normal atom with its isotope, for example, hydrogen may be replaced by deuterium by exposure to deuterium acids, such as D2SO4/D2O. In addition to the above, relevant procedures and intermediates are disclosed, for instance, in Lizondo, J et al., Drugs Fut, 21(11), 1116 (1996); Brickner, S J et al., J Med Chem, 39(3), 673 (1996); Mallesham, B et al., Org Lett, 5(7), 963 (2003); Publications PCT WO1997010223, WO2005099353, WO1995007271, WO2006008754; U.S. Patents№№ 7538189; 7534814; 7531685; 7528131; 7521421; 7514068; 7511013; and United States Patent application№№ 20090137457; 20090131485; 20090131363; 20090118238; 20090111840; 20090105338; 20090105307; 20090105147; 20090093422; 20090088416; and 20090082471, and such methods are included in this application by reference.

Isotope-labeled compounds of the present invention can be used as standards to determine the effectiveness of inhibitors of Bcl-2 in the analysis of binding. Containing the isotope compounds used in pharmaceutical research to determine the in vivo metabolic pathway connections through the study of the mechanism of action and metabolic pathway unlabeled isotope of the parent compound (Blake et al. J. Pharm. Sci. 64, 3, 367-391 (1975)). Such metabolic studies are important in the development without�ACLs effective therapeutic agents because either in vivo active compound administered to the patient, or the metabolites formed from the parent compound, are toxic or carcinogenic (Foster et al., Advances in Drug Research Vol. 14, pp. 2-36, Academic press, London, 1985; Kato et al., J. Labelled Comp. Radiopharmaceut., 36(10):927-932 (1995); Kushner et al., Can. J. Physiol. Pharmacol., 77, 79-88 (1999).

Besides containing non-radioactive isotope of drugs, such as deuterated drugs called “heavy drugs”, can be used for the treatment of diseases and conditions associated with Bcl-2 activity. The amount of the isotope present in the mix, above the quantity that is usually present in nature, is called enrichment. Examples of enrichment include from about 0,5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 21, 25, 29, 33, 37, 42, 46, 50, 54, 58, 63, 67, 71, 75, 79, 84, 88, 92, 96, to about 100 mol %. Substitution of up to about 15% of normal heavy atom isotope is carried out and maintained during the period of time from several days to weeks in mammals, including rodents and dogs, with minimal observed adverse effects (Czajka D M and Finkel A J, Ann. N. Y. Acad. Sci. 1960 84: 770; Thomson J F, Ann. New York Acad. Sci 1960 84: 736; Czakja D M et al., Am. J. Physiol. 1961 201: 357). It was found that the abrupt substitution with deuterium up to 15% -23% in bodily fluids does not cause toxicity (Blagojevic N et al. "Dosimetry &Treatment Planning for Neutron Capture Therapy", Zaenhof R, Solares G and Harling O Eds. 1994. Advanced Medical Publishing, Madison Wis. pp.125-134; Diabetes Metab. 23: 251 (1997)).

The drug labeling with a stable isotope can alter its physicochemical properties such as pKa and lipid solubility. These effects and alterations can affect the pharmacodynamic response of a molecule of the drug, if the isotopic substitution affects a region involved in the interaction of ligand-receptor. Although some of the physical properties of a stable isotope-labeled molecule are different from the properties of the unlabeled molecules, chemical and biological properties remain the same, with one important exception: because of the higher mass of the heavy isotope, any bond involving the heavy isotope and another atom will be stronger than the same bond between the light isotope and that atom. Accordingly, the incorporation of an isotope at a site of metabolism or enzymatic transformation will slow these reactions potentially altering the pharmacokinetic profile or efficacy compared to do not contain the isotope connection.

Suitable groups for A1B1, D1E1G1, Y1, L1, Z1A, Z2A, Z1, Z2and Z3in the compounds of formula (I) are independently selected. Described embodiments of the present invention can be combined. So�combination I provided and covered by the scope of the present invention. For example, it is envisaged that embodiments of any of A1B1, D1E1G1, Y1, L1, Z1A, Z2A, Z1, Z2and Z3can be combined with the variants of implementation, defined for any other of A1B1, D1E1G1, Y1, L1, Z1A, Z2A, Z1, Z2and Z3.

One embodiment of the present invention, therefore, pertains to compounds or therapeutically acceptable salts, which are useful as inhibitors of anti-apofaticheski Bcl-2 proteins, where the compounds have the formula (I)

where

A1represents N or C(A2);

A2represents H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, (O)NHSO 2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A;

B1represents H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A;

D1represents H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1 , NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2,N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A;

E1represents H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2 NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2,N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A; and

Y1represents H, CN, NO2, C(O)OH, F, Cl, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R17, OR17, C(O)R17, C(O)OR17, SR17, SO2R17NH2, NHR17N(R17)2, NHC(O)R17, C(O)NH2, C(O)NHR17, C(O)N(R17)2, NHS(O)R17or NHSO2R17; or

E1and Y1together with the atoms to which they are linked, represent a benzene, naftilan, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

A2B1and D1have independently selected values H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2,N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A; or

Y1and B1together with the atoms to which they are linked, represent a benzene, naftilan, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

A2, D1and E1have independently selected values H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2,N3OH, C(O)H, CHNOH, CH(NOCH3), CF3 , C(O)OH, C(O)NH2or C(O)OR1A; or

A2and B1together with the atoms to which they are linked, represent a benzene, naftilan, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

D1E1and Y1have independently selected values H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A; or

A2and D1together with the atoms to which they are linked, represent a benzene, naphthalene, heteroaryl, cycloalkane, cycloalkene, geteroseksualen or geteroseksualen; and

B1E1and Y 1have independently selected values H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2,N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A;

G1represents H or C(O)OR;

R represents alkyl;

R1is an R2, R3, R4or R5;

R1Ais cycloalkyl, cycloalkenyl or cycloalkenyl;

R2represents phenyl, which is neskondensirovannyh or fused with R2A; R2Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R3is heteroaryl, which is neskondensirovannyh or fused with R3A; R3Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R4is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R4A; R4Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R5represents alkyl, alkenyl or alkinyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R6, NC(R6A)(R6B), R7, OR7, SR7, S(O)R7, SO2R7, NHR7N(R7)2, C(O)R7, C(O)NH2,C(O)NHR7, C(O)N(R7)2, NHC(O)R7, NR7C(O)R7, NHSO2R7, NHC(O)OR7, SO2NH2, SO2NHR7, SO2N(R7)2, NHC(O)NH2, NHC(O)NHR7, NHC(O)CH(CH3)NHC(O)CH(CH3NH2, NHC(O)CH(CH3)NHC(O)CH(CH3)NHR7, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;

R6represents C2-C5-spiralcell, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF 3, CF2CF3, F, Cl, Br, I, NH2NH(CH3) or N(CH3)2;

R6Aand R6Brepresent independently selected alkyl, or together with the N atom to which they are linked, represent R6C;

R6Cis aziridine-1-yl, azetidin-1-yl, pyrrolidin-1-yl or piperidine-1-yl, each of which contains a single CH2group which is unsubstituted or substituted by O, C(O), CNOH, CNOCH3S , S(O), SO2or NH;

R7is an R8, R9, R10or R11;

R8represents phenyl, which is neskondensirovannyh or fused with R8A; R8Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R9is heteroaryl, which is neskondensirovannyh or fused with R9A; R9Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R10is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R10A; R10Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R11represents alkyl, Alchemilla alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12NH2, NHR12N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R12)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R12is an R13, R14, R15or R16;

R13represents phenyl, which is neskondensirovannyh or fused with R13A; R13Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R14is heteroaryl, which is neskondensirovannyh or fused with R14A; R14Arepresents a benzene, heteroaryl, cyclo�of lcan, cycloalken, geteroseksualen or geteroseksualen;

R15is cycloalkane, cycloalkene, geteroseksualen or geteroseksualen, each of which is neskondensirovannyh or fused with R15A; R15Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R16represents alkyl, alkenyl or alkinyl;

R17is an R18, R19, R20or R21;

R18represents phenyl, which is neskondensirovannyh or fused with R18A; R18Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R19is heteroaryl, which is neskondensirovannyh or fused with R19A; R19Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R20is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R20A; R20Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R21represents alkyl, alkenyl or alkinyl, each of which is n�substituted or substituted by one or two or three independently selected substituents R 22, OR22, SR22, S(O)R22, SO2R22, C(O)R22, CO(O)R22, OC(O)R22, OC(O)OR22NH2, NHR22N(R22)2, NHC(O)R22, NR22C(O)R22, NHS(O)2R22, NR22S(O)2R22, NHC(O)OR22, NR22C(O)OR22, NHC(O)NH2, NHC(O)NHR22, NHC(O)N(R22)2, NR22C(O)NHR22, NR22C(O)N(R22)2, C(O)NH2, C(O)NHR22, C(O)N(R22)2, C(O)NHOH, C(O)NHOR22, C(O)NHSO2R22, C(O)NR22SO2R22, SO2NH2, SO2NHR22, SO2N(R22)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR22, C(N)N(R22)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R22is an R23, R24or R25;

R23represents phenyl, which is neskondensirovannyh or fused with R23A; R23Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R24is heteroaryl, which is neskondensirovannyh or fused with R24A; R24Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R25is cycloalkyl, cycloalkenyl, heterocycle�lkyl or geteroseksualen, each of which is neskondensirovannyh or fused with R25A; R25Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

Z1is an R26or R27;

Z2is an R28, R29or R30;

Z1Aand Z2Aboth absent or are taken together with the formation of CH2, CH2CH2or Z12A;

Z12Arepresents C2-C6-alkylene containing one or two CH2groups, substituted NH, N(CH3), S, S(O) or SO2;

L1is an R37, OR37, SR37, S(O)R37, SO2R37, C(O)R37, CO(O)R37, OC(O)R37, OC(O)OR37, NHR37, C(O)NH, C(O)NR37, C(O)NHOR37, C(O)NHSO2R37, SO2NH, SO2NHR37, C(N)NH or C(N)NHR37;

R26represents a phenylene, which is neskondensirovannyh or fused with R26A; R26Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R27is heteroaryl, which is neskondensirovannyh or fused with R27A; R27Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R28performance�possessing a phenylene, which is neskondensirovannyh or fused with R28A; R28Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R29is heteroaryl, which is neskondensirovannyh or fused with R29A; R29Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R30is cycloalkyl, cycloalkenyl, heteroseksualci or geterotsiklicheskie, each of which is neskondensirovannyh or fused with R30A; R30Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R37represents a bond, or R37A;

R37Ais alkylen, albaniles or akinyan, each of which is unsubstituted or substituted with one or two or three independently selected R37B, OR37B, SR37B, S(O)R37B, SO2R37B, C(O)R37B, CO(O)R37B, OC(O)R37B, OC(O)OR37BNH2, NHR37BN(R37B)2, NHC(O)R37B, NR37BC(O)R37B, NHS(O)2R37B, NR37BS(O)2R37B, NHC(O)OR37B, NR37BC(O)OR37B, NHC(O)NH2, NHC(O)NHR37B, NHC(O)N(R37B)2, NR37BC(O)NHR37B, NR37BC(O)N(R37B/sup> )2, C(O)NH2, C(O)NHR37B, C(O)N(R37B)2, C(O)NHOH, C(O)NHOR37B, C(O)NHSO2R37B, C(O)NR37BSO2R37B, SO2NH2, SO2NHR37B, SO2N(R37B)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR37B, C(N)N(R37B)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br and I substituents;

R37Brepresents alkyl, alkenyl, alkynyl or R37C;

R37Crepresents phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen;

Z3is an R38, R39or R40;

R38represents phenyl, which is neskondensirovannyh or fused with R38A; R38Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R39is heteroaryl, which is neskondensirovannyh or fused with R39A; R39Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R40is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R40A; R40Arepresents a benzene, Goethe�Aaren, cycloalkane, cycloalkene, geteroseksualen or geteroseksualen;

where the group represented as R26and R27,are substituted (i.e., if Z1Aand Z2Aare absent) or further substituted (i.e., if Z1Aand Z2Apresent, the substituents R41, OR41, SR41, S(O)R41, SO2R41, C(O)R41, CO(O)R41, OC(O)R41, OC(O)OR41, NHR41N(R41)2, NHC(O)R41, NR41C(O)R41, NHS(O)2R41, NR41S(O)2R41, NHC(O)OR41, NR41C(O)OR41, NHC(O)NHR41, NHC(O)N(R41)2, NR41C(O)NHR41, NR41C(O)N(R41)2, C(O)NHR41, C(O)N(R41)2, C(O)NHOR41, C(O)NHSO2R41, C(O)NR41SO2R41, SO2NHR41, SO2N(R41)2, C(N)NHR41or C(N)N(R41)2;

R41is heteroaryl, which is fused with R43A; R43Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; which is neskondensirovannyh or condensed with benzene, heteroatom or R43B; R43Bis cycloalkane, cycloalkene, geteroseksualen or geteroseksualen;

where the cyclic groups represented as E1and Y1however, Y1and B1however, A2� B 1however, A2andD1together, R1A, R2, R2A, R3, R3A, R4, R4A, R6, R6C, R8, R8A, R9, R9A, R10, R10A, R13, R13A, R14, R14A, R15, R15A, R18, R18A, R19, R19A, R20, R20A, R23, R23A, R24, R24A, R25, R25A, R26, R26A, R27, R27A, R28, R28A, R29, R29A, R30, R30A, R37B, R38, R38A, R39, R39A, R40and R40Athat are independently unsubstituted, having additional substitution, substituted or further substituted by one or two or three or four or five independently selected substituents R57A, R57, OR57, SR57, S(O)R57, SO2R57, C(O)R57, CO(O)R57, OC(O)R57, OC(O)OR57NH2, NHR57N(R57)2, NHC(O)R57, NR57C(O)R57, NHS(O)2R57, NR57S(O)2R57, NHC(O)OR57, NR57C(O)OR57, NHC(O)NH2, NHC(O)NHR57, NHC(O)N(R57)2, NR57C(O)NHR57, NR57C(O)N(R57)2, C(O)NH2, C(O)NHR57, C(O)N(R57)2, C(O)NHOH, C(O)NHOR57, C(O)NHSO2R57, C(O)NR57SO2R57, SO2NH2, SO2NHR57, SO2N(R57) , C(O)H, C(O)OH, C(N)NH2, C(N)NHR57, C(N)N(R57)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R57Ais spiralcell or spiroheterocyclic;

R57is an R58, R59, R60or R61;

R58represents phenyl, which is neskondensirovannyh or fused with R58A; R58Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R59is heteroaryl, which is neskondensirovannyh or fused with R59A; R59Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R60is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R60A; R60Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R61represents alkyl, alkenyl or alkinyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R62, OR62, SR62, S(O)R62, SO2R62, C(O)R62, CO(OR 62, OC(O)R62, OC(O)OR62NH2, NHR62N(R62)2, NHC(O)R62, NR62C(O)R62, NHS(O)2R62, NR62S(O)2R62, NHC(O)OR62, NR62C(O)OR62, NHC(O)NH2, NHC(O)NHR62, NHC(O)N(R62)2, NR62C(O)NHR62, NR62C(O)N(R62)2, C(O)NH2, C(O)NHR62, C(O)N(R62)2, C(O)NHOH, C(O)NHOR62, C(O)NHSO2R62, C(O)NR62SO2R62, SO2NH2, SO2NHR62, SO2N(R62)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR62, C(N)N(R62)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R62is an R63, R64, R65or R66;

R63represents phenyl, which is neskondensirovannyh or fused with R63A; R63Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R64is heteroaryl, which is neskondensirovannyh or fused with R64A; R64Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R65is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is nakonde�dened-contribution or fused with R 65A; R65Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R66represents alkyl, alkenyl or alkinyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R67, OR67, SR67, S(O)R67, SO2R67, C(O)R67, CO(O)R67, OC(O)R67, OC(O)OR67NH2, NHR67N(R67)2, NHC(O)R67, NR67C(O)R67, NHS(O)2R67, NR67S(O)2R67, NHC(O)OR67, NR67C(O)OR67, NHC(O)NH2, NHC(O)NHR67, NHC(O)N(R67)2, NR67C(O)NHR67, NR67C(O)N(R67)2, C(O)NH2, C(O)NHR67, C(O)N(R67)2, C(O)NHOH, C(O)NHOR67, C(O)NHSO2R67, C(O)NR67SO2R67, SO2NH2, SO2NHR67, SO2N(R67)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR67, C(N)N(R67)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R67represents alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen;

where the cyclic groups represented as R57A, R58, R59, R60, R63, R64, R65and R67,are�Xia unsubstituted or substituted with one or two or three or four independently selected substituents R 68, OR68, SR68, S(O)R68, SO2R68, C(O)R68, CO(O)R68, OC(O)R68, OC(O)OR68NH2, NHR68N(R68)2, NHC(O)R68, NR68C(O)R68, NHS(O)2R68, NR68S(O)2R68, NHC(O)OR68, NR68C(O)OR68, NHC(O)NH2, NHC(O)NHR68, NHC(O)N(R68)2, NR68C(O)NHR68, NR68C(O)N(R68)2, C(O)NH2, C(O)NHR68, C(O)N(R68)2, C(O)NHOH, C(O)NHOR68, C(O)NHSO2R68, C(O)NR68SO2R68, SO2NH2, SO2NHR68, SO2N(R68)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR68, C(N)N(R68)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R68is an R69, R70, R71or R72;

R69represents phenyl, which is neskondensirovannyh or fused with R69A; R69Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R70is heteroaryl, which is neskondensirovannyh or fused with R70A; R70Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R71is cycloalkyl, cycloalkenyl, GE�erotically or geteroseksualen, each of which is neskondensirovannyh or fused with R71A; R71Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R72represents alkyl, alkenyl or alkinyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R73, OR73, SR73, S(O)R73, SO2R73, C(O)R73, CO(O)R73, OC(O)R73, OC(O)OR73NH2, NHR73N(R73)2, NHC(O)R73, NR73C(O)R73, NHS(O)2R73, NR73S(O)2R73, NHC(O)OR73, NR73C(O)OR73, NHC(O)NH2, NHC(O)NHR73, NHC(O)N(R73)2, NR73C(O)NHR73, NR73C(O)N(R73)2, C(O)NH2, C(O)NHR73, C(O)N(R73)2, C(O)NHOH, C(O)NHOR73, C(O)NHSO2R73, C(O)NR73SO2R73, SO2NH2, SO2NHR73, SO2N(R73)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR73, C(N)N(R73)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R73represents alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen; and

where the group represented as R69, R70and R71, are unsubstituted or substituted with one or two or three or four independently selected substituents of NH2, C(O)NH2, C(O)NHOH, SO2NH2, CF3,CF2CF3,C(O)H, C(O)OH, C(N)NH2, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I.

Another embodiment of the present invention relates to compounds of formula (I), where

A1represents N or C(A2);

A2represents H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A

B1represents H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A;

D1represents H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R 1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2,N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A;

E1represents H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2,N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A; and

Y1represents H, CN, NO2, C(O)OH, F, Cl, Br, I, CF 3, OCF3, CF2CF3, OCF2CF3, R17, OR17, C(O)R17, C(O)OR17, SR17, SO2R17NH2, NHR17N(R17)2, NHC(O)R17, C(O)NH2, C(O)NHR17, C(O)N(R17)2, NHS(O)R17or NHSO2R17; or

E1and Y1together with the atoms to which they are linked, represent a benzene, naftilan, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

A2B1and D1have independently selected values H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2,N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)H, C(O)NH2or C(O)OR1A; or

Y1and B1together with the atoms to which they are linked, represent a benzene, naftilan, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

A2, D1and E1have independently selected values H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2,N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A; or

A2and B1together with the atoms to which they are linked, represent a benzene, naftilan, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

D1E1 1have independently selected values H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A; or

A2and D1together with the atoms to which they are linked, represent a benzene, naphthalene, heteroaryl, cycloalkane, cycloalkene, geteroseksualen or geteroseksualen; and

B1E1and Y1have independently selected values H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR , NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2,N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A;

G1represents H or C(O)OR;

R represents alkyl;

R1is an R2, R3, R4or R5;

R1Ais cycloalkyl, cycloalkenyl or cycloalkenyl;

R2represents phenyl, which is neskondensirovannyh or fused with R2A; R2Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R3is heteroaryl, which is neskondensirovannyh or fused with R3A; R3Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R4performance�possessing cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R4A; R4Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R5represents alkyl, alkenyl or alkinyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R6, NC(R6A)(R6B), R7, OR7, SR7, S(O)R7, SO2R7, NHR7N(R7)2, C(O)R7, C(O)NH2,C(O)NHR7, C(O)N(R7)2, NHC(O)R7, NR7C(O)R7, NHSO2R7, NHC(O)OR7, SO2NH2, SO2NHR7, SO2N(R7)2, NHC(O)NH2, NHC(O)NHR7, NHC(O)CH(CH3)NHC(O)CH(CH3NH2, NHC(O)CH(CH3)NHC(O)CH(CH3)NHR7, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;

R6represents C2-C5-spiralcell, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, CF2CF3, F, Cl, Br, I, NH2NH(CH3) or N(CH3)2;

R6Aand R6Brepresent independently selected alkyl, or together with the N atom to which they are linked, represent R6C;

R6Cis aziridine-1-�l, azetidin-1-yl, pyrrolidin-1-yl or piperidine-1-yl, each of which contains a single CH2group which is unsubstituted or substituted by O, C(O), CNOH, CNOCH3S , S(O), SO2or NH;

R7is an R8, R9, R10or R11;

R8represents phenyl, which is neskondensirovannyh or fused with R8A; R8Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R9is heteroaryl, which is neskondensirovannyh or fused with R9A; R9Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R10is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R10A; R10Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R11represents alkyl, alkenyl or alkinyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12NH2, NHR12N(R12 )2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R12)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R12is an R13, R14, R15or R16;

R13represents phenyl, which is neskondensirovannyh or fused with R13A; R13Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R14is heteroaryl, which is neskondensirovannyh or fused with R14A; R14Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R15is cycloalkane, cycloalkene, geteroseksualen or geteroseksualen, each of which is neskondensirovannyh or fused with R15A; R15Ais �Wallpaper benzene, heteroaryl, cycloalkane, cycloalkene, geteroseksualen or geteroseksualen;

R16represents alkyl, alkenyl or alkinyl;

R17is an R18, R19, R20or R21;

R18represents phenyl, which is neskondensirovannyh or fused with R18A; R18Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R19is heteroaryl, which is neskondensirovannyh or fused with R19A; R19Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R20is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R20A; R20Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R21represents alkyl, alkenyl or alkinyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R22, OR22, SR22, S(O)R22, SO2R22, C(O)R22, CO(O)R22, OC(O)R22, OC(O)OR22NH2, NHR22N(R22)2, NHC(O)R22, NR22C(O)R 22, NHS(O)2R22, NR22S(O)2R22, NHC(O)OR22, NR22C(O)OR22, NHC(O)NH2, NHC(O)NHR22, NHC(O)N(R22)2, NR22C(O)NHR22, NR22C(O)N(R22)2, C(O)NH2, C(O)NHR22, C(O)N(R22)2, C(O)NHOH, C(O)NHOR22, C(O)NHSO2R22, C(O)NR22SO2R22, SO2NH2, SO2NHR22, SO2N(R22)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR22, C(N)N(R22)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R22is an R23, R24or R25;

R23represents phenyl, which is neskondensirovannyh or fused with R23A; R23Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R24is heteroaryl, which is neskondensirovannyh or fused with R24A; R24Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R25is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R25A; R25Arepresents a benzene, heteroaryl, cycloalkyl, cyclo�of lcen, geteroseksualen or geteroseksualen;

Z1is an R26or R27;

Z2is an R28, R29or R30;

Z1Aand Z2Aboth absent or are taken together with the formation of CH2, CH2CH2or Z12A;

Z12Arepresents C2-C6-alkylene containing one or two CH2groups, substituted NH, N(CH3), S, S(O) or SO2Deputy;

L1is an R37, OR37, SR37, S(O)R37, SO2R37, C(O)R37, CO(O)R37, OC(O)R37, OC(O)OR37, NHR37, C(O)NH, C(O)NR37, C(O)NHOR37, C(O)NHSO2R37, SO2NH, SO2NHR37, C(N)NH or C(N)NHR37;

R26represents a phenylene, which is neskondensirovannyh or fused with R26A; R26Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R27is heteroaryl, which is neskondensirovannyh or fused with R27A; R27Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R28represents a phenylene, which is neskondensirovannyh or fused with R28A; R28Arepresents a benzene, heteroaro�, cycloalkane, cycloalkene, geteroseksualen or geteroseksualen;

R29is heteroaryl, which is neskondensirovannyh or fused with R29A; R29Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R30is cycloalkyl, cycloalkenyl, heteroseksualci or geterotsiklicheskie, each of which is neskondensirovannyh or fused with R30A; R30Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R37represents a bond, or R37A;

R37Ais alkylen, albaniles or akinyan, each of which is unsubstituted or substituted with one or two or three independently selected R37B, OR37B, SR37B, S(O)R37B, SO2R37B, C(O)R37B, CO(O)R37B, OC(O)R37B, OC(O)OR37BNH2, NHR37BN(R37B)2, NHC(O)R37B, NR37BC(O)R37B, NHS(O)2R37B, NR37BS(O)2R37B, NHC(O)OR37B, NR37BC(O)OR37B, NHC(O)NH2, NHC(O)NHR37B, NHC(O)N(R37B)2, NR37BC(O)NHR37B, NR37BC(O)N(R37B)2, C(O)NH2, C(O)NHR37B, C(O)N(R37B)2, C(O)NHOH, C(O)NHOR37B, C(O)NHSO2R37B, C(O)NR37BSO 2R37B, SO2NH2, SO2NHR37B, SO2N(R37B)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR37B, C(N)N(R37B)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br and I substituents;

R37Brepresents alkyl, alkenyl, alkynyl or R37C;

R37Crepresents phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen;

Z3is an R38, R39or R40;

R38represents phenyl, which is neskondensirovannyh or fused with R38A; R38Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R39is heteroaryl, which is neskondensirovannyh or fused with R39A; R39Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R40is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R40A; R40Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

where the group represented as R26 27,are substituted (i.e., if Z1Aand Z2Aare absent) or further substituted (i.e., if Z1Aand Z2Apresent, the substituents R41, OR41, SR41, S(O)R41, SO2R41, C(O)R41, CO(O)R41, OC(O)R41, OC(O)OR41, NHR41N(R41)2, NHC(O)R41, NR41C(O)R41, NHS(O)2R41, NR41S(O)2R41, NHC(O)OR41, NR41C(O)OR41, NHC(O)NHR41, NHC(O)N(R41)2, NR41C(O)NHR41, NR41C(O)N(R41)2, C(O)NHR41, C(O)N(R41)2, C(O)NHOR41, C(O)NHSO2R41, C(O)NR41SO2R41, SO2NHR41, SO2N(R41)2, C(N)NHR41or C(N)N(R41)2;

R41is heteroaryl, which is fused with R43A; R43Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; which is neskondensirovannyh;

where the cyclic groups represented as E1and Y1however, Y1and B1however, A2and B1however, A2andD1together, R1A, R2, R2A, R3, R3A, R4, R4A, R6, R6C, R8, R8A, R9, R9A, R10, R10A, R13, R13A, R14, R14A, R15, R15A, R18, R 18A, R19, R19A, R20, R20A, R23, R23A, R24, R24A, R25, R25A, R26, R26A, R27, R27A, R28, R28A, R29, R29A, R30, R30A, R37B, R38, R38A, R39, R39A, R40and R40Athat are independently unsubstituted, having additional substitution, substituted or further substituted by one or two or three or four or five independently selected substituents R57A, R57, OR57, SR57, S(O)R57, SO2R57, C(O)R57, CO(O)R57, OC(O)R57, OC(O)OR57NH2, NHR57N(R57)2, NHC(O)R57, NR57C(O)R57, NHS(O)2R57, NR57S(O)2R57, NHC(O)OR57, NR57C(O)OR57, NHC(O)NH2, NHC(O)NHR57, NHC(O)N(R57)2, NR57C(O)NHR57, NR57C(O)N(R57)2, C(O)NH2, C(O)NHR57, C(O)N(R57)2, C(O)NHOH, C(O)NHOR57, C(O)NHSO2R57, C(O)NR57SO2R57, SO2NH2, SO2NHR57, SO2N(R57)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR57, C(N)N(R57)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R57Ais spiralcell or spiroheterocyclic;

R57before�provide an R 58, R59, R60or R61;

R58represents phenyl, which is neskondensirovannyh or fused with R58A; R58Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R59is heteroaryl, which is neskondensirovannyh or fused with R59A; R59Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R60is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R60A; R60Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R61represents alkyl, alkenyl or alkinyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R62, OR62, SR62, S(O)R62, SO2R62, C(O)R62, CO(O)R62, OC(O)R62, OC(O)OR62NH2, NHR62N(R62)2, NHC(O)R62, NR62C(O)R62, NHS(O)2R62, NR62S(O)2R62, NHC(O)OR62, NR62C(O)OR62, NHC(O)NH2, NHC(O)NHR62, NHC(O)N(R62)2, NR62C(O)NHR62, NR62(O)N(R 62)2, C(O)NH2, C(O)NHR62, C(O)N(R62)2, C(O)NHOH, C(O)NHOR62, C(O)NHSO2R62, C(O)NR62SO2R62, SO2NH2, SO2NHR62, SO2N(R62)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR62, C(N)N(R62)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R62is an R63, R64, R65or R66;

R63represents phenyl, which is neskondensirovannyh or fused with R63A; R63Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R64is heteroaryl, which is neskondensirovannyh or fused with R64A; R64Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R65is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R65A; R65Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R66represents alkyl, alkenyl or alkinyl, each of which is unsubstituted or substituted by one or �two or three independently selected substituents R 67, OR67, SR67, S(O)R67, SO2R67, C(O)R67, CO(O)R67, OC(O)R67, OC(O)OR67NH2, NHR67N(R67)2, NHC(O)R67, NR67C(O)R67, NHS(O)2R67, NR67S(O)2R67, NHC(O)OR67, NR67C(O)OR67, NHC(O)NH2, NHC(O)NHR67, NHC(O)N(R67)2, NR67C(O)NHR67, NR67C(O)N(R67)2, C(O)NH2, C(O)NHR67, C(O)N(R67)2, C(O)NHOH, C(O)NHOR67, C(O)NHSO2R67, C(O)NR67SO2R67, SO2NH2, SO2NHR67, SO2N(R67)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR67, C(N)N(R67)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R67represents alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen;

where the cyclic groups represented as R57A, R58, R59, R60, R63, R64, R65and R67,are unsubstituted or substituted with one or two or three or four independently selected substituents R68, OR68, SR68, S(O)R68, SO2R68, C(O)R68, CO(O)R68, OC(O)R68, OC(O)OR68NH2, NHR68N(R68)2, NHC(O)R68, NR68C(O)R68, NHS(O)2 R68, NR68S(O)2R68, NHC(O)OR68, NR68C(O)OR68, NHC(O)NH2, NHC(O)NHR68, NHC(O)N(R68)2, NR68C(O)NHR68, NR68C(O)N(R68)2, C(O)NH2, C(O)NHR68, C(O)N(R68)2, C(O)NHOH, C(O)NHOR68, C(O)NHSO2R68, C(O)NR68SO2R68, SO2NH2, SO2NHR68, SO2N(R68)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR68, C(N)N(R68)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R68is an R69, R70, R71or R72;

R69represents phenyl, which is neskondensirovannyh or fused with R69A; R69Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R70is heteroaryl, which is neskondensirovannyh or fused with R70A; R70Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R71is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R71A; R71Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, g�tereticaulis or geteroseksualen;

R72represents alkyl, alkenyl or alkinyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R73, OR73, SR73, S(O)R73, SO2R73, C(O)R73, CO(O)R73, OC(O)R73, OC(O)OR73NH2, NHR73N(R73)2, NHC(O)R73, NR73C(O)R73, NHS(O)2R73, NR73S(O)2R73, NHC(O)OR73, NR73C(O)OR73, NHC(O)NH2, NHC(O)NHR73, NHC(O)N(R73)2, NR73C(O)NHR73, NR73C(O)N(R73)2, C(O)NH2, C(O)NHR73, C(O)N(R73)2, C(O)NHOH, C(O)NHOR73, C(O)NHSO2R73, C(O)NR73SO2R73, SO2NH2, SO2NHR73, SO2N(R73)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR73, C(N)N(R73)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R73represents alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen; and

where the group represented as R69, R70and R71,are unsubstituted or substituted with one or two or three or four independently selected substituents of NH2, C(O)NH2, C(O)NHOH, SO2NH2, CF3,CF2CF 3,C(O)H, C(O)OH, C(N)NH2, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I.

Another embodiment of the present invention relates to compounds of formula (I), where

A1represents N or C(A2);

A2represents H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A;

B1represents H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2 , NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A;

D1represents H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)NR 1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2,N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A;

E1represents H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2,N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A; and

Y1represents H, CN, NO2, C(O)OH, F, Cl, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R17, OR17, C(O)R17, C(O)OR17, SR17, SO2R17NH2, NHR17N(R17)2, NHC(O)R17, C(O)NH , C(O)NHR17, C(O)N(R17)2, NHS(O)R17or NHSO2R17; or

E1and Y1together with the atoms to which they are linked, represent a benzene, naftilan, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

A2B1and D1have independently selected values H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2,N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A; or

Y1and B1together with the atoms to which they are linked, represent a benzene, naftilan, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen and�and geteroseksualen; and

A2, D1and E1have independently selected values H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2,N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A; or

A2and B1together with the atoms to which they are linked, represent a benzene, naftilan, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

D1E1and Y1have independently selected values H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(OR 1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A; or

A2and D1together with the atoms to which they are linked, represent a benzene, naphthalene, heteroaryl, cycloalkane, cycloalkene, geteroseksualen or geteroseksualen; and

B1E1and Y1have independently selected values H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1 , NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2, NHSO2NHR1, NHSO2N(CH3)R1N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2,N3OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2or C(O)OR1A;

G1represents H or C(O)OR;

R represents alkyl;

R1is an R2, R3, R4or R5;

R1Ais cycloalkyl, cycloalkenyl or cycloalkenyl;

R2represents phenyl, which is neskondensirovannyh or fused with R2A; R2Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R3is heteroaryl, which is neskondensirovannyh or fused with R3A; R3Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R4is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R4A; R4Arepresents a benzene, heteroa�Yong, cycloalkane, cycloalkene, geteroseksualen or geteroseksualen;

R5represents alkyl, alkenyl or alkinyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R6, NC(R6A)(R6B), R7, OR7, SR7, S(O)R7, SO2R7, NHR7N(R7)2, C(O)R7, C(O)NH2,C(O)NHR7, C(O)N(R7)2, NHC(O)R7, NR7C(O)R7, NHSO2R7, NHC(O)OR7, SO2NH2, SO2NHR7, SO2N(R7)2, NHC(O)NH2, NHC(O)NHR7, NHC(O)CH(CH3)NHC(O)CH(CH3NH2, NHC(O)CH(CH3)NHC(O)CH(CH3)NHR7, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;

R6represents C2-C5-spiralcell, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, CF2CF3, F, Cl, Br, I, NH2NH(CH3) or N(CH3)2Deputy;

R6Aand R6Brepresent independently selected alkyl, or together with the N atom to which they are linked, represent R6C;

R6Cis aziridine-1-yl, azetidin-1-yl, pyrrolidin-1-yl or piperidine-1-yl, each of which contains a single CH2group which is unsubstituted or substituted by O, C(O), CNOH, CNOCH3S , S(O), SOsub> 2or NH;

R7is an R8, R9, R10or R11;

R8represents phenyl, which is neskondensirovannyh or fused with R8A; R8Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R9is heteroaryl, which is neskondensirovannyh or fused with R9A; R9Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R10is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R10A; R10Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R11represents alkyl, alkenyl or alkinyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12NH2, NHR12N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12 )2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R12)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R12is an R13, R14, R15or R16;

R13represents phenyl, which is neskondensirovannyh or fused with R13A; R13Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R14is heteroaryl, which is neskondensirovannyh or fused with R14A; R14Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R15is cycloalkane, cycloalkene, geteroseksualen or geteroseksualen, each of which is neskondensirovannyh or fused with R15A; R15Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R16represents alkyl, alkenyl or alkinyl;

R17performance�ulation of an R 18, R19, R20or R21;

R18represents phenyl, which is neskondensirovannyh or fused with R18A; R18Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R19is heteroaryl, which is neskondensirovannyh or fused with R19A; R19Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R20is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen each of which is neskondensirovannyh or fused with R20A; R20Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R21represents alkyl, alkenyl or alkinyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R22, OR22, SR22, S(O)R22, SO2R22, C(O)R22, CO(O)R22, OC(O)R22, OC(O)OR22NH2, NHR22N(R22)2, NHC(O)R22, NR22C(O)R22, NHS(O)2R22, NR22S(O)2R22, NHC(O)OR22, NR22C(O)OR22, NHC(O)NH2, NHC(O)NHR22, NHC(O)N(R22)2, NR22C(O)NHR22, NR22CO)N(R 22)2, C(O)NH2, C(O)NHR22, C(O)N(R22)2, C(O)NHOH, C(O)NHOR22, C(O)NHSO2R22, C(O)NR22SO2R22, SO2NH2, SO2NHR22, SO2N(R22)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR22, C(N)N(R22)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R22is an R23, R24or R25;

R23represents phenyl, which is neskondensirovannyh or fused with R23A; R23Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R24is heteroaryl, which is neskondensirovannyh or fused with R24A; R24Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R25is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R25A; R25Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

Z1is an R26or R27;

Z2is an R28, R29or R30;

Z1A 2Aboth absent or are taken together with the formation of CH2, CH2CH2or Z12A;

Z12Arepresents C2-C6-alkylene containing one or two CH2groups, substituted NH, N(CH3), S, S(O) or SO2Deputy;

L1is an R37, OR37, SR37, S(O)R37, SO2R37, C(O)R37, CO(O)R37, OC(O)R37, OC(O)OR37, NHR37, C(O)NH, C(O)NR37, C(O)NHOR37, C(O)NHSO2R37, SO2NH, SO2NHR37, C(N)NH or C(N)NHR37;

R26represents a phenylene, which is neskondensirovannyh or fused with R26A; R26Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R27is heteroaryl, which is neskondensirovannyh or fused with R27A; R27Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R28represents a phenylene, which is neskondensirovannyh or fused with R28A; R28Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R29is heteroaryl, which is neskondensirovannyh or fused with R29A;R 29Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R30is cycloalkyl, cycloalkenyl, heteroseksualci or geterotsiklicheskie, each of which is neskondensirovannyh or fused with R30A; R30Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R37represents a bond, or R37A;

R37Ais alkylen, albaniles or akinyan, each of which is unsubstituted or substituted with one or two or three independently selected R37B, OR37B, SR37B, S(O)R37B, SO2R37B, C(O)R37B, CO(O)R37B, OC(O)R37B, OC(O)OR37BNH2, NHR37BN(R37B)2, NHC(O)R37B, NR37BC(O)R37B, NHS(O)2R37B, NR37BS(O)2R37B, NHC(O)OR37B, NR37BC(O)OR37B, NHC(O)NH2, NHC(O)NHR37B, NHC(O)N(R37B)2, NR37BC(O)NHR37B, NR37BC(O)N(R37B)2, C(O)NH2, C(O)NHR37B, C(O)N(R37B)2, C(O)NHOH, C(O)NHOR37B, C(O)NHSO2R37B, C(O)NR37BSO2R37B, SO2NH2, SO2NHR37B, SO2N(R37B)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR37B, C(N)N(R37B)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2 , CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br and I substituents;

R37Brepresents alkyl, alkenyl, alkynyl or R37C;

R37Crepresents phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen;

Z3is an R38, R39or R40;

R38represents phenyl, which is neskondensirovannyh or fused with R38A; R38Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R39is heteroaryl, which is neskondensirovannyh or fused with R39A; R39Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R40is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R40A; R40Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

where the group represented as R26and R27,are substituted (i.e., if Z1Aand Z2Aare absent) or further substituted (i.e., if Z1Aand Z2Apresent, the substituents R41,OR 41, SR41, S(O)R41, SO2R41, C(O)R41, CO(O)R41, OC(O)R41, OC(O)OR41, NHR41N(R41)2, NHC(O)R41, NR41C(O)R41, NHS(O)2R41, NR41S(O)2R41, NHC(O)OR41, NR41C(O)OR41, NHC(O)NHR41, NHC(O)N(R41)2, NR41C(O)NHR41, NR41C(O)N(R41)2, C(O)NHR41, C(O)N(R41)2, C(O)NHOR41, C(O)NHSO2R41, C(O)NR41SO2R41, SO2NHR41, SO2N(R41)2, C(N)NHR41or C(N)N(R41)2;

R41is heteroaryl, which is fused with R43A; R43Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; which is condensed with benzene, heteroatom or R43B; R43Bis cycloalkane, cycloalkene, geteroseksualen or geteroseksualen;

where the cyclic groups represented by E1and Y1however, Y1and B1however, A2and B1however, A2and D1together, R1A, R2, R2A, R3, R3A, R4, R4A, R6, R6C, R8, R8A, R9, R9A, R10, R10A, R13, R13A, R14, R14A, R15, R15A, R18, R18A, R19, R19A, R20, R20A, R23, R23A, R2 , R24A, R25, R25A, R26, R26A, R27, R27A, R28, R28A, R29, R29A, R30, R30A, R37B, R38, R38A, R39, R39A, R40and R40Athat are independently unsubstituted, having additional substitution, substituted or further substituted by one or two or three or four or five independently selected substituents R57A, R57, OR57, SR57, S(O)R57, SO2R57, C(O)R57, CO(O)R57, OC(O)R57, OC(O)OR57NH2, NHR57N(R57)2, NHC(O)R57, NR57C(O)R57, NHS(O)2R57, NR57S(O)2R57, NHC(O)OR57, NR57C(O)OR57, NHC(O)NH2, NHC(O)NHR57, NHC(O)N(R57)2, NR57C(O)NHR57, NR57C(O)N(R57)2, C(O)NH2, C(O)NHR57, C(O)N(R57)2, C(O)NHOH, C(O)NHOR57, C(O)NHSO2R57, C(O)NR57SO2R57, SO2NH2, SO2NHR57, SO2N(R57)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR57, C(N)N(R57)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R57Ais spiralcell or spiroheterocyclic;

R57is an R58, R59, R60or R61;

R58before�offers a phenyl, which is neskondensirovannyh or fused with R58A; R58Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R59is heteroaryl, which is neskondensirovannyh or fused with R59A; R59Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R60is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R60A; R60Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R61represents alkyl, alkenyl or alkinyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R62, OR62, SR62, S(O)R62, SO2R62, C(O)R62, CO(O)R62, OC(O)R62, OC(O)OR62NH2, NHR62N(R62)2, NHC(O)R62, NR62C(O)R62, NHS(O)2R62, NR62S(O)2R62, NHC(O)OR62, NR62C(O)OR62, NHC(O)NH2, NHC(O)NHR62, NHC(O)N(R62)2, NR62C(O)NHR62, NR62C(O)N(R62)2, C(O)NH2, C(O)NHR62, C(O)N(R62)2, C(O)NHOH, C(O)NHOR 62, C(O)NHSO2R62, C(O)NR62SO2R62, SO2NH2, SO2NHR62, SO2N(R62)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR62, C(N)N(R62)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R62is an R63, R64, R65or R66;

R63represents phenyl, which is neskondensirovannyh or fused with R63A; R63Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R64is heteroaryl, which is neskondensirovannyh or fused with R64A; R64Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R65is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R65A; R65Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R66represents alkyl, alkenyl or alkinyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R67, OR67, R 67, S(O)R67, SO2R67, C(O)R67, CO(O)R67, OC(O)R67, OC(O)OR67NH2, NHR67N(R67)2, NHC(O)R67, NR67C(O)R67, NHS(O)2R67, NR67S(O)2R67, NHC(O)OR67, NR67C(O)OR67, NHC(O)NH2, NHC(O)NHR67, NHC(O)N(R67)2, NR67C(O)NHR67, NR67C(O)N(R67)2, C(O)NH2, C(O)NHR67, C(O)N(R67)2, C(O)NHOH, C(O)NHOR67, C(O)NHSO2R67, C(O)NR67SO2R67, SO2NH2, SO2NHR67, SO2N(R67)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR67, C(N)N(R67)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R67represents alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen;

where the cyclic groups represented as R57A, R58, R59, R60, R63, R64, R65and R67,are unsubstituted or substituted with one or two or three or four independently selected substituents R68, OR68, SR68, S(O)R68, SO2R68, C(O)R68, CO(O)R68, OC(O)R68, OC(O)OR68NH2, NHR68N(R68)2, NHC(O)R68, NR68C(O)R68, NHS(O)2R68, NR68 S(O)2R68, NHC(O)OR68, NR68C(O)OR68, NHC(O)NH2, NHC(O)NHR68, NHC(O)N(R68)2, NR68C(O)NHR68, NR68C(O)N(R68)2, C(O)NH2, C(O)NHR68, C(O)N(R68)2, C(O)NHOH, C(O)NHOR68, C(O)NHSO2R68, C(O)NR68SO2R68, SO2NH2, SO2NHR68, SO2N(R68)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR68, C(N)N(R68)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R68is an R69, R70, R71or R72;

R69represents phenyl, which is neskondensirovannyh or fused with R69A; R69Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R70is heteroaryl, which is neskondensirovannyh or fused with R70A; R70Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R71is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is neskondensirovannyh or fused with R71A; R71Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen Il� geteroseksualen;

R72represents alkyl, alkenyl or alkinyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R73, OR73, SR73, S(O)R73, SO2R73, C(O)R73, CO(O)R73, OC(O)R73, OC(O)OR73NH2, NHR73N(R73)2, NHC(O)R73, NR73C(O)R73, NHS(O)2R73, NR73S(O)2R73, NHC(O)OR73, NR73C(O)OR73, NHC(O)NH2, NHC(O)NHR73, NHC(O)N(R73)2, NR73C(O)NHR73, NR73C(O)N(R73)2, C(O)NH2, C(O)NHR73, C(O)N(R73)2, C(O)NHOH, C(O)NHOR73, C(O)NHSO2R73, C(O)NR73SO2R73, SO2NH2, SO2NHR73, SO2N(R73)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR73, C(N)N(R73)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R73represents alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen; and

where the group represented as R69, R70and R71,are unsubstituted or substituted with one or two or three or four independently selected substituents of NH2, C(O)NH2, C(O)NHOH, SO2NH2, CF3,CF2CF 3,C(O)H, C(O)OH, C(N)NH2, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I.

In one embodiment of formula (I), A1represents N; and G1represents H. In another embodiment of formula (I), A1is C(A2); and G1represents H. In another embodiment of formula (I), A1is C(A2); A2represents H, F, Cl, Br or I; and G1represents H. In another embodiment of formula (I), A1is C(A2); A2represents H; and G1represents H.

In one embodiment of formula (I), B1is an R1, OR1, NHR1, NHC(O)R1, F, Cl, Br or I. In another embodiment of formula (I), A1is C(A2); A2represents H; B1represents NHR1; and G1represents H. In another embodiment of formula (I), A1is C(A2); A2represents H; B1represents OR1; and G1represents H. In another embodiment of formula (I), A1is C(A2); A2represents H; B1represents Cl; and G1the performance�t H. a In another embodiment of formula (I), A1is C(A2); A2represents H; B1is an R1; and G1represents H. In another embodiment of formula (I), A1represents N; B1represents NHR1; and G1represents H. In another embodiment of formula (I), A1represents N; B1represents OR1; and G1represents H. In another embodiment of formula (I), A1represents N; B1represents Cl; and G1represents H. In another embodiment of formula (I), A1represents N; B1is an R1; and G1represents H.

In one embodiment of formula (I), D1represents H or Cl. In another embodiment of formula (I), A1is C(A2); A2represents H; B1represents NHR1; D1represents H; and G1represents H. In another embodiment of formula (I), A1is C(A2); A2represents H; B1represents NHR1; D1represents Cl; and G1represents H. In another embodiment of formula (I), A1 is C(A 2); A2represents H; B1represents OR1; D1represents H; and G1represents H. In another embodiment of formula (I), A1is C(A2); A2represents H; B1represents Cl; D1represents H; and G1represents H. In another embodiment of formula (I), A1is C(A2); A2represents H; B1is an R1; D1represents H; and G1represents H. In another embodiment of formula (I), A1represents N; B1represents NHR1; D1represents H; and G1represents H. In another embodiment of formula (I), A1represents N; B1represents NHR1; D1represents Cl; and G1represents H. In another embodiment of formula (I), A1represents N; B1represents OR1; D1represents H; and G1represents H. In another embodiment of formula (I), A1represents N; B1represents Cl; D1represents H; and G1represents H. In another embodiment of formula (I), A1is�Oh N; B1is an R1; D1represents H; and G1represents H.

In one embodiment of formula (I), E1represents H. In another embodiment of formula (I), A1is C(A2); A2represents H; B1represents NHR1; D1represents H; E1represents H; and G1represents H. In another embodiment of formula (I), A1is C(A2); A2represents H; B1represents NHR1; E1represents H; D1represents Cl; and G1represents H. In another embodiment of formula (I), A1is C(A2); A2represents H; B1represents OR1; D1represents H; E1represents H; and G1represents H. In another embodiment of formula (I), A1is C(A2); A2represents H; B1represents Cl; D1represents H; E1represents H; and G1represents H. In another embodiment of formula (I), A1is C(A2); A2represents H; B1is an R1; D1submitted�is H; E1represents H; and G1represents H. In another embodiment of formula (I), A1represents N; B1represents NHR1; D1represents H; E1represents H; and G1represents H. In another embodiment of formula (I), A1represents N; B1represents NHR1; E1represents H; D1represents Cl; and G1represents H. In another embodiment of formula (I), A1represents N; B1represents OR1; D1represents H; E1represents H; and G1represents H. In another embodiment of formula (I), A1represents N; B1represents Cl; D1represents H; E1represents H; and G1represents H. In another embodiment of formula (I), A1represents N; B1is an R1; D1represents H; E1represents H; and G1represents H.

In one embodiment of formula (I), Y1represents H, CN, NO2, F, Cl, Br, I, CF3, R17, OR17, SR17, SO2R17or C(O)NH2. In another embodiment of formula (I), Y1isone H. In another embodiment of formula (I), Y1represents CN. In another embodiment of formula (I), Y1represents F, Cl, Br or I. In another embodiment of formula (I), Y1is a CF3. In another embodiment of formula (I), Y1represents SR17. In another embodiment of formula (I), Y1represents OR17. In another embodiment of formula (I), Y1is a NO2. In another embodiment of formula (I), Y1is a SO2R17; where R17has the meaning specified in the present application. In another embodiment of formula (I), Y1is a SO2R17; where R17represents alkyl. In another embodiment of formula (I), Y1is an R17; where R17is alkynyl. In another embodiment of formula (I), A1is C(A2); A2represents H; B1represents NHR1; D1represents H; E1represents H; G1represents H; and Y1is a NO2or SO2R17; where R17represents an alkyl or alkynyl. In another embodiment of formula (I), A1the performance�t a C(A 2); A2represents H; B1represents NHR1; D1represents H; E1represents H; G1represents H; and Y1is a NO2. In another embodiment of formula (I), A1is C(A2); A2represents H; B1represents NHR1; D1represents H; E1represents H; G1represents H; and Y1is a SO2R17; where R17represents alkyl, substituted with three F. In another embodiment of formula (I), A1represents N; B1represents NHR1; D1represents H; E1represents H; G1represents H; and Y1is a NO2or SO2R17; where R17represents an alkyl or alkynyl. In another embodiment of formula (I), A1represents N; B1represents NHR1; D1represents H; E1represents H; G1represents H; and Y1is a NO2. In another embodiment of formula (I), A1represents N; B1represents NHR1; D1represents H; E1represents H; G1is a fun� H; and Y1is a SO2R17; where R17represents aalkyl, substituted with three F.

In one embodiment of formula (I), G1represents H; A1represents N or C(A2); and A2represents H. In another embodiment of formula (I), G1represents H; A1represents N or C(A2); A2represents H; and B1represents NHR1. In another embodiment of formula (I), G1represents H; A1represents N or C(A2); A2represents H; B1represents NHR1; and D1represents H. In another embodiment of formula (I), G1represents H; A1represents N or C(A2); A2represents H; B1represents NHR1; D1represents H; and E1represents H. In another embodiment of formula (I), G1represents H; A1represents N or C(A2); A2represents H; B1represents NHR1; D1represents H; E1represents H; and Y1is a NO2.

In one embodiment of formula (I), Y1and B1together with the atoms to which they related�Ana, represent benzene. In another embodiment of formula (I), Y1and B1together with the atoms to which they are linked, represent heteroaryl. In another embodiment of formula (I), A1is C(A2); A2G1E1and D1independently selected from H; and Y1and B1together with the atoms to which they are linked, represent a benzene. In another embodiment of formula (I), A1is C(A2); A2G1E1and D1independently selected from H; and Y1and B1together with the atoms to which they are linked, represent heteroaryl.

In one embodiment of formula (I), R1is an R4or R5. In one embodiment of formula (I), R1is an R4. In one embodiment of formula (I), R1is an R5. In one embodiment of formula (I), R1is an R4; and R4is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen. In one embodiment of formula (I), R1is an R4; and R4is cycloalkyl or heteroseksualci. In one embodiment of formula (I), R1is an R4; and R4PR�dstanley cycloalkyl. In one embodiment of formula (I), R1is an R4; and R4is heteroseksualci.

In one embodiment of formula (I), R1is an R4; and R4is cycloalkyl; where R4is unsubstituted or substituted as defined in this application. In another embodiment of formula (I), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is substituted as defined in this application. In another embodiment of formula (I), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is substituted with R57or N(R57)2Deputy. In another embodiment of formula (I), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57Deputy; and R57is an R60. In another embodiment of formula (I), R1is an R4; R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57Deputy; R57is an R ; and R60is heteroseksualci. In another embodiment of formula (I), R1is an R4; R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57Deputy; R57is an R60; R60is heteroseksualci; where geteroseksualnoe ring is morpholinyl. In another embodiment of formula (I), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring substituted N(R57)2Deputy. In another embodiment of formula (I), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with N(R57)2Deputy. In another embodiment of formula (I), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with N(R57)2Deputy; R57is an R61; and R61represents alkyl, which is unsubstituted or substituted with R62Deputy. In another embodiment, the OSU�of estline of formula (I), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57Deputy; R57is an R61; and R61represents alkyl, which is unsubstituted or substituted with R62Deputy; R62is an R65; and R65is cycloalkyl. In another embodiment of formula (I), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57Deputy; R57is an R61; and R61represents alkyl which is substituted by R62Deputy; R62is an R65; and R65represents cyclopropyl.

In one embodiment of formula (I), R1is an R4; and R4is heteroseksualci; where R4is unsubstituted or substituted as defined in this application. In another embodiment of formula (I), R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring is substituted as defined in this application. In each�m an embodiment, the formula (I), R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring is substituted with R57Deputy. In another embodiment of formula (I), R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where geteroseksualnoe ring is substituted with R57Deputy; and R57is an R60or R61. In another embodiment of formula (I), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring is substituted with R57Deputy; R57is an R60or R61; R60is heteroseksualci; and R61represents alkyl. In another embodiment of formula (I), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring is substituted with R57Deputy; R57is an R60; R60is heteroseksualci; where heterocycle�lcil is tetrahydropyranyl. In another embodiment of formula (I), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring is substituted with R57Deputy; R57is an R61; R61represents alkyl; and the alkyl is methyl. In another embodiment of formula (I), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted with C(O)OR57Deputy; R57is an R61; R61represents alkyl; and the alkyl is methyl.

In one embodiment of formula (I), R1is an R5; and R5represents alkyl, which is unsubstituted or substituted. In one embodiment of formula (I), R1is an R5; and R5represents alkyl, which is unsubstituted or substituted with R7, OR7, OH, CN or F Deputy. In another embodiment of formula (I), R1is an R5; and R5represents alkyl which is substituted by R , OR7, NHR7or N(R7)2Deputy.

In one embodiment of formula (I), R7is an R8, R9, R10or R11which are unsubstituted or substituted as defined in this application. In another embodiment of formula (I), R7is an R8which is unsubstituted or substituted as defined in this application. In another embodiment of formula (I), R7is an R9which is unsubstituted or substituted as defined in this application. In another embodiment of formula (I), R7is an R10which is unsubstituted or substituted as defined in this application. In another embodiment of formula (I), R7is an R11which is unsubstituted or substituted as defined in this application.

In one embodiment of formula (I), R8represents phenyl, which is unsubstituted or substituted as defined in this application.

In one embodiment of formula (I), R9is heteroaryl, which is unsubstituted or substituted as defined in this application. In another embodiment of formula (I), R9is furanyl; which �is unsubstituted or substituted, as defined in the present application. In another embodiment of formula (I), R9is furanyl; which is unsubstituted.

In one embodiment of formula (I), R10is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, which are unsubstituted or substituted as defined in this application. In another embodiment of formula (I), R10is heteroseksualci, which is unsubstituted or substituted as defined in this application. In another embodiment of formula (I), R10is tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, dioxane, oxetanyl, piperidinyl or pyrrolidinyl, which are unsubstituted or substituted as defined in this application. In another embodiment of formula (I), R10is tetrahydropyranyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (I), R10is morpholinyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (I), R10is cycloalkyl, which is unsubstituted or substituted as defined in this application. In another vari�NTE implementation of the formula (I), R10is cycloalkyl, which is unsubstituted or substituted as defined in this application. In another embodiment of formula (I), R10represents cyclohexyl, cyclopropyl, cyclobutyl or bicyclo[2.2.1]heptenyl, which is unsubstituted or substituted as defined in this application. In another embodiment of formula (I), R10is heteroseksualci which is fused with R10A; and R10Ais heteroaryl. In another embodiment of formula (I), R10is a 5,6,7,8-tetrahydroimidazo[1,2-a]pyridinyl.

In one embodiment of formula (I), R11represents alkyl, alkenyl or alkynyl, which are unsubstituted or substituted as defined in this application. In another embodiment of formula (I), R11represents alkyl. In another embodiment of formula (I), R11is methyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (I), R11represents alkyl; which is substituted as defined in this application. In another embodiment of formula (I), R11represents alkyl; which is substituted with R12, OR12or CF3co�Telem. In another embodiment of formula (I), R11represents alkyl; which is substituted OR12Deputy, R12is an R16; and R16represents alkyl. In another embodiment of formula (I), R11represents alkyl; which is substituted with CF3Deputy. In another embodiment of formula (I), R11represents alkyl; which is substituted with R12Deputy; R12is an R14; and R14is heteroaryl.

In one embodiment of formula (I), A1represents N or C(A2);

A2represents H, F, Br, I or Cl;

B1is an R1, OR1, NHR1, NHC(O)R1, F, Br, I or Cl;

D1represents H, F, Br, I or Cl;

E1represents H; and

Y1represents H, CN, NO2,F, Cl, Br, I, CF3, R17, OR17, SR17, SO2R17or C(O)NH2; or

Y1and B1together with the atoms to which they are linked, represent a benzene, heteroaryl or heteroseksualci; and

A2, D1and E1independently selected from H;

G1represents H or C(O)OR;

R represents alkyl;

R1is an R4or R5;

R4is cycloalkyl or GE�erotically;

R5represents an alkyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R7, OR7, NHR7N(R7)2, CN, OH, F, Cl, Br or I;

R7is an R8, R9, R10or R11;

R8represents phenyl;

R9is heteroaryl;

R10is cycloalkyl, cycloalkenyl or geteroseksualen; each of which is neskondensirovannyh or fused with R10A, R10Ais heteroaryl;

R11represents alkyl each of which is unsubstituted or substituted with one or two or three independently selected substituents R12, OR12or CF3;

R12is an R14or R16;

R14is heteroaryl;

R16represents alkyl;

R17is an R21;

R21represents an alkyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R22, F, Cl, Br or I;

R22is an R25;

R25is heteroseksualci;

Z1is an R26;

Z2performance�possessing an R 30;

Z1Aand Z2Aboth are absent;

L1is an R37;

R26represents a phenylene;

R30is geteroseksualen;

R37is an R37A;

R37Ais alkylen;

Z3is an R38or R40;

R38represents phenyl;

R40is cycloalkyl, cycloalkenyl or geteroseksualen;

where the group represented as R26substituted OR41Deputy;

R41is heteroaryl, which is fused with R43A; R43Ais heteroaryl; which is neskondensirovannyh or fused with benzene;

where the cyclic groups represented by Y1and B1together, R4, R8, R10, R10A, R25, R30, R38and R40that are independently unsubstituted, having additional substitution, substituted or further substituted by one or two or three or four or five independently selected substituents R57A, R57, OR57, SO2R57, C(O)R57, CO(O)R57,C(O)N(R57)2NH2, NHR57N(R57)2, NHC(O)R57, NHS(O)2R57, C(O)OH, OH, CN, (O), F, Cl, Br or I;

R57Ais spiralcell �whether spiroheterocyclic;

R57is an R58, R59, R60or R61;

R58represents phenyl;

R59is heteroaryl;

R60is cycloalkyl or heteroseksualci;

R61represents alkyl, which is unsubstituted or substituted with one or two or three independently selected substituents R62, OR62N(R62)2, C(O)OH, OH, CN, F, Cl, Br or I;

R62is an R65or R66;

R65is cycloalkyl or heteroseksualci;

R66represents alkyl, which is unsubstituted or substituted OR67Deputy;

R67represents alkyl;

where the cyclic groups represented as R57A, R58and R60are unsubstituted or substituted with one or two or three or four independently selected substituents R68, (O), F, Cl, Br or I;

R68is an R71or R72;

R71is heteroseksualci; and

R72represents alkyl, which is unsubstituted or substituted with one or two F.

Another variant of implementation relates to compounds having formula (I), which represent

4-{4-[(4'-chloro-1,1'-biphenyl-2-yl)methyl]piperazine-1-yl}-N-({3-nitro-4-[(tetrahydro�-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chloro-1,1'-biphenyl-2-yl)methyl]piperazine-1-yl}-N-({4-[(3-morpholine-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-demerol-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methylpiperazin-1-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

2-(9H-carbazole-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-demerol-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide;

2-(9H-carbazole-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3-pyrrolidin-1-ylpropyl)amino]phenyl}sulfonyl)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridi�-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-methoxyethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxane-2-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3R)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-(2-naphthylmethyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-methoxyethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-({4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-[(Tr�permitil)sulfonyl]phenyl}sulfonyl)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1,4-dioxane-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(2,2,2-trifluoroethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3,3,3-cryptochromes)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2S)-1,4-dioxane-2-ylethoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2R)-1,4-dioxane-2-ylethoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(1,4-dioxane-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]�of iridin-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxane-2-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[3-(aminocarbonyl)-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-{[4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-(trifluoromethyl)phenyl]sulfonyl}benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-({4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide;

TRANS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(1-demerol-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

5-({[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]amino}sulfonyl)-2-(tetrahydro-2H-Piran-4-ylethoxy)nicotinamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-demerol-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(1,4-dioxane-2-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[5-bromo-6-(1,4-dioxane-2-ylethoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2,2-dimethylether-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-5-cyano-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1-acetylpiperidine-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({2-chloro-5-fluoro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-morpholine-4-ylpropyl)amine�]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(2-morpholine-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[2-(2-methoxyethoxy)ethyl]sulfonyl}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[2-(2-methoxyethoxy)ethyl]sulfonyl}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)oxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-bromo-6-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-cyanoethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-�cyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-{[4-({4-[bis(cyclopropylmethyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1-demerol-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(morpholine-3-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-methylpiperazin-1-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-albut-2-inyl)oxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-ethinyl-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-oxo-3,4-dihydroquinazolin-6-yl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-any�Ravenel}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

tert-butyl 3-{[4-({[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]amino}sulfonyl)-2-nitrophenoxy]methyl}morpholine-4-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(morpholine-3-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[1-(methyl-sulfonyl)piperidine-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1,1-dissidocerida-2H-thiopyran-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-chloro-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[1-(2,2,2-trifluoroethyl)piperidine-4-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)oxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-isopropyl-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-5-fluoro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

and their therapeutically acceptable salts, and metabolites.

4-(4-{[2-(4-chlorophenyl)-4,4-di�ethylcyclohexyl-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[2-fluoro-1-(permitil)ethyl]piperidine-4-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[1-(2,2-deflorati)piperidine-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclopropylidene-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1-the morpholine-4-illlogical)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(dicyclopropyl)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-6,6-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-bromo-6-[(4-ethylmorpholine-3-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)N-({4-[(4-ethylmorpholine-3-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(4-tetrahydro-2H-Piran-4-Immortalis-3-yl)methoxy]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-tetrahydro-2H-Piran-4-reparacin-3-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(tetrahydro-2H-Piran-4-ylmethyl)amino]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1,1-diocletianopolis-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(4-aminotetraline-2H-Piran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(4-morpholine-4-illlogical)amino]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-cyano-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-ene-yl]methyl}piperazine-1-yl)-N-[(4-{[(1S,3R)-3-morpholine-4-enciclopedic]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1R,3S)-3-morpholine-4-enciclopedic]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(morpholine-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydrofuran-3-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[CIS-3-Porterage-2H-Piran-4-yl]piperidine-4-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydro-2H-Piran-4-ilization-3-yl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydrofuran-3-ilization-3-yl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3R)-1-tetrahydro-2H-Piran-4-imperiality-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-ene-1-�l]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)-N-(4-((TRANS-4-hydroxycyclohexyl)methoxy)-3-nitrophenyloctyl)benzamide;

2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)-N-(4-((CIS-4-methoxycyclohexyl)methoxy)-3-nitrophenyloctyl)benzamide;

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(cyclopropylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(tetrahydro-2H-Piran-4-ylamino)cyclohexyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-({5-bromo-6-[(4-morpholine-4-illlogical)oxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxycyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

tert-butyl 4-{[4-({[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]amino}sulfonyl)-2-nitrophenoxy]methyl}-4-foreperiod-1-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclo�COP-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-foreperiod-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(4-tetrahydro-2H-Piran-4-reparacin-1-yl)cyclohexyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[2-fluoro-1-(permitil)ethyl]piperidine-4-yl}methoxy)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3R)-1-tetrahydro-2H-Piran-4-imperiality-3-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(2,2-dimethylether-2H-Piran-4-yl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-tetrahydro-2H-Piran-4-imperiality-3-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-(2,2-dimethylether-2H-Piran-4-yl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]PI�idin-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(2-methoxyethyl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(4-acetylmorpholine-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[TRANS-4-(permitil)-1-oxetan-3-imperiality-3-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-Porterage-2H-Piran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-oxetan-3-reparacin-4-yl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclobutylmethyl-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[1-(2,2-dimethylether-2H-Piran-4-yl)piperidine-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex--EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-cyclopropylidene-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydrofuran-3-reparacin-4-yl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-cyclopropylidene-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3S)-1-tetrahydro-2H-Piran-4-imperiality-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-hydroxy-2,2-dimethylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(methyl-sulfonyl)piperidine-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(1-acetylpiperidine-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(methyl-sulfonyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-3,3-dimethylcyclohex-1-EN-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[2-fluoro-1-(permitil)ethyl]azetidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(methyl-sulfonyl)pyrrolidin-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(1-acetylpyrrolidine-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(3R)-1-acetylpyrrolidine-3-yl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-methoxy-2,2-dimethylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1R,3R)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1S,3S)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazin�-1-yl)-N-{[4-({[(1S,3R)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1R,3S)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-2-oxopiperidin-3-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[({1-[2-fluoro-1-(permitil)ethyl]azetidin-3-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(1-oxetan-3-ilization-3-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(1-oxetan-3-reparacin-4-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1-cyclopropylidene-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(2-fluoroethyl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}PI�erasin-1-yl)-N-{[4-({[4-(2,2-deflorati)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-oxetan-3-reparacin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(2S)-4,4-debtor-1-oxetan-3-imperiality-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(4-tetrahydro-2H-Piran-4-Immortalis-3-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyclobutylmethyl-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(4-tetrahydrofuran-3-Immortalis-3-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[({1-[2-fluoro-1-(permitil)ethyl]piperidine-4-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclopropyl-4-foreperiod-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorine�enyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[3-(triptoreline)benzyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-methoxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(deformedarse)benzyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxaspiro[4.5]Dec-8-ylamino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-[(4-{[4-(acetylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(2,2-deflorati)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-(2-fluoroethyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-(2,2-deflorati)pyrrolidin-3-�l]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(2-fluoroethyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-oxetan-3-imperiality-3-yl]methoxy}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-hydroxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-hydroxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[3-(deformedarse)benzyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[CIS-3-morpholine-4-enciclopedic]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(methyl-sulfonyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclopropyl�uridin-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-oxetan-3-reparacin-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-tetrahydro-2H-Piran-4-reparacin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-tetrahydrofuran-3-reparacin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-fluoro-1-(methyl-sulfonyl)piperidine-4-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3R)-1-oxetan-3-imperiality-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-hydroxycyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[3-(dimethylamino)propoxy]benzyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-DIMET�cyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(2-the morpholine-4-ylethoxy)benzyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(E)-4-hydroxy-1-adamantyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(Z)-4-hydroxy-1-adamantyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1S,4S)-bicyclo[2.2.1]hept-5-ene-2-ylethoxy]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-methyl-5-oxopyrrolidin-3-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1R,4R,5R,6S)-5,6-dihydroxybutyl[2.2.1]hept-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1R,4R,5S,6R)-5,6-dihydroxybutyl[2.2.1]hept-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3-oxocyclohexyl)methoxy]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1,3-Dien-1-yl]methyl}Pipa�Azin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({(3R)-1-[2-fluoro-1-(permitil)ethyl]pyrrolidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[6-[(4-Porterage-2H-Piran-4-yl)methoxy]-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3S)-1-oxetan-3-imperiality-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-oxetan-3-imperiality-3-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[({4-[2-(2-methoxyethoxy)ethyl]morpholine-2-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4 dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(cyanomethyl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(N,N-dimethylglycine)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

(2-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}morpholine-4-yl)acetic acid;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[4-(oxetan-3-yl)morpholine-2-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyclopropylmethyl-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-(methyl-sulfonyl)-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methyltetrahydro-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

ethyl 4-(4-{[4-(4-{[2-(4-chlorp�Neal)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)piperazine-1-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[4-(morpholine-4-yl)piperidine-1-yl]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3R)-1-(oxetan-3-yl)pyrrolidin-3-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]amino}-3-[(trifluoromethyl)sulfonyl]phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-isopropylpiperazine-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1-tert-butylpiperazine-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(2-methoxyethyl)piperidine-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(cyanomethyl)piperidine-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}�piperazin-1-yl)-N-({4-[(4-fluoro-1-demerol-4-yl)methoxy]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]amino}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

tert-butyl 4-[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]piperazine-1-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-(pendaftar-λ6-sulfanyl)-4- [(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxytyramine-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]oxy}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(oxetan-3-yl)piperazine-1-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(tetrahydro-2H-Piran-4-yl)piperazine-1-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-harfe�yl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3R)-tetrahydrofuran-3-ylamino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4,4-diverticulosis)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1-tert-butylpiperazine-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-({[4-(oxetan-3-yl)morpholine-2-yl]methyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(4-Porterage-2H-Piran-4-yl)methyl]amino}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(1-cyclopropylidene-4-yl)amino]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2S)-4-(cyanomethyl)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2S)-4-(N,N-dimethylglycine)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-[(2R)-4-(cyanomethyl)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2R)-4-(N,N-dimethylglycine)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-fluoro-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[3-hydroxy-2-(gidroximetil)-2-methylpropoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(1,3-ditropan-2-yl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(cyanomethyl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({(3R)-1-[2-(2-methoxyethoxy)ethyl]pyrrolidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-�emailregex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(N,N-dimethylglycine)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[1-(oxetan-3-yl)azetidin-3-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(cyanomethyl)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2R)-4-(N,N-dimethylglycine)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2S)-4-(N,N-dimethylglycine)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(N,N-dimethylglycine)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(2,2-deflorati)pyrrolidin-3-yl]oxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(cyanomethyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chlorobiphenyl-2-yl)methyl]4-methoxypiperidine-1-yl}-N-({5-chloro-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-methoxypiperidine-1-yl}-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-(1,3-ditropan-2-yl)-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-(1,3-ditropan-2-yl)-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4-fluoro-1-demerol-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(N,N-dimethylphenyl)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-glorvigen�-2-yl)methyl]-4-foreperiod-1-yl}-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-foreperiod-1-yl}-N-({5-chloro-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-({4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-(trifluoromethyl)phenyl}sulfonyl)benzamide;

N-[(5-chloro-6-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]oxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[2-(tetrahydrofuran-3-yloxy)ethoxy]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-cyanocyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[2-(tetrahydro-2H-Piran-4-yl)ethoxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]�ethyl}piperazine-1-yl)-N-{[4-(3-FuelMAX)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(2,2-deflorati)pyrrolidin-3-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(1,3-ditropan-2-yl)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-fluoro-1-demerol-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-cyano-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(2,2-deflorati)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4,4-diverticles�KSIL)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[6-{[1-(1,3-ditropan-2-yl)-4-foreperiod-4-yl]methoxy}-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-chloro-6-[2-(tetrahydrofuran-2-yl)ethoxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}-3-methylpiperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[3-(cyclopropylamino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[5-chloro-6-(2-methoxyethoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-fluoro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(methoxyacetyl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(N,N-dimethylglycine)piperidine-4-yl]methoxy}phenyl)Sul�o'neill]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohexyl]methyl}piperidine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-{[6-(tetrahydro-2H-Piran-4-ylethoxy)-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}benzamide;

N-({5-chloro-6-[(TRANS-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-cyano-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({6-[(TRANS-4-methoxycyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({6-[(CIS-4-methoxycyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4,4-debtor-1-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperidine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[TRANS-4-(Mohali�-4-yl)cyclohexyl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[the cyclopropyl(1,3-thiazol-5-ylmethyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(TRANS-4-hydroxycyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-chloro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-(trifluoromethyl)phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[the cyclopropyl(2,2,2-trifluoroethyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(oxetan-3-yl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3,5-debtor-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[the cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(1-methyl-L-shed)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3,4-debtor-5-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2S)-4-cyclopropylmethyl-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperidine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperidine-1-yl)-N-{[3-chloro-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

methyl 2-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}morpholine-4-carboxylate;

2-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}Pipa�Azin-1-yl)-N-{[4-({[4-(methyl-sulfonyl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclobutyl(cyclopropyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-diverticulosis-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-chloro-4-(tetrahydrofuran-3-ylethoxy)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-diverticulosis-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[9-(4-chlorophenyl)-3-(oxetan-3-yl)-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2R)-4-cyclopropylmethyl-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}�piperazin-1-yl)-N-{[4-({[(2S)-4-cyclopropylmethyl-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[5-chloro-6-({4-[cyclopropyl(oxetan-3-yl)amino]cyclohexyl}methoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyclopropylmethyl-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-cyclopropylmethyl-2-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[(4-cyclopropylmethyl-2-yl)methyl]amino}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

2-{[(2-chloro-4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}phenyl)amino]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

(2S)-2-{[(3-chloro-5-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}pyridin-2-yl)oxy]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

N-[(5-chloro-6-{[(4-cyclopropylmethyl-2-yl)meth�l]amino}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

2-{[(3-chloro-5-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}pyridin-2-yl)amino]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(CIS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(1R,2R,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(2-cyanoethyl)(cyclopropyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-and�oxy)benzamide;

N-[(5-chloro-6-{[(1R,2S,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(CIS-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(3,3-giftability-1-yl)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(CIS-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(2,2-diversicolor)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({-chloro-6-[(CIS-1-fluoro-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-(2-oxaspiro[3.5]non-7-ylethoxy)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-bis(permitil)cyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-cyclopropylmethyl-2-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(TRANS-1-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(CIS-1-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-cyano-4-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimetallic�ohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-ethyl-4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(CIS-4-ethyl-4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5-(methoxymethyl)-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(2S)-4-(oxetan-3-yl)morpholine-2-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(2-cyanoethyl)(cyclopropyl)amino]-1-forcelogix}methoxy)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-nitro-6-[(tetrahydro-2H-Piran-4-ylmethyl)amino]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(2-oxaspiro[3.5]non-7-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-44-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyano-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)amino}Metreveli;

{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)amino}methylbutyrate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-{[3-(tetrahydro-2H-Piran-4-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-6-yl]sulfonyl}benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(6-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-5-nitropyridine-3-yl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(5-cyano-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)morpholine-4-carboxamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(methoxymethyl)cyclohexyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-x�arvanil)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(5-chloro-6-{[1-(1,3-- thiazol-2-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(6-{[(CIS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-5-nitropyridine-3-yl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

methyl TRANS-4-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}cyclohexanecarboxylate;

TRANS-4-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}cyclohexanecarbonyl acid;

N-(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)-4-cyanopiperidine-1-carboxamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[CIS-4-(methoxymethyl)cyclohexyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-x�arvanil)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[TRANS-4-(methoxymethyl)cyclohexyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-{[1-(tetrahydro-2H-Piran-4-ylmethyl)-1H-benzotriazole-5-yl]sulfonyl}benzamide;

N-({5-chloro-6-[(2-oxo-1-ox-3-azaspiro[4.5]Dec-8-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)-4-methoxypiperidine-1-carboxamide;

N-({5-chloro-6-[(2-methyl-4,5,6,7-tetrahydro-1,3-benzothiazol-5-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-{[1-(tetrahydro-2H-Piran-4-ylmethyl)-1H-imidazo[2,3-b]pyridin-5-yl]sulfonyl}benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-chloro-1-(tetrahydro-2H-Piran-4-ylmethyl)-1H-imidazo[2,3-b]pyridin-5-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4-(methoxymethyl)-4-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[4,4-bis(gidroximetil)C�clohessy]methoxy}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-(2-chloro-4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}phenyl)-4-methoxypiperidine-1-carboxamide;

N-(2-chloro-4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}phenyl)-4-cyanopiperidine-1-carboxamide;

N-(2-chloro-4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}phenyl)-4-hydroxy-4-demerol-1-carboxamide;

N-(2-chloro-4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}phenyl)-4-(methoxymethyl)piperidine-1-carboxamide;

N-[(5-chloro-6-{[(5r,8r)-2-oxo-1-ox-3-azaspiro[4.5]Dec-8-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(5s,8s)-2-oxo-1-ox-3-azaspiro[4.5]Dec-8-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-(2-chloro-4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}phenyl)-4-(morpholine-4-yl)piperidine-1-carboxamide;

N-[(5-chloro-6-{[TRANS-4-hydroxy-4-(methoxymethyl)cyclohexyl�]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[CIS-4-hydroxy-4-(gidroximetil)cyclohexyl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[TRANS-4-hydroxy-4-(gidroximetil)cyclohexyl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)cyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-chlorophenyl)-1-methyl-3-[(4-{4-[({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)carbamoyl]-3-(1H-imidazo[2,3-b]pyridine-5-yloxy)phenyl}piperazine-1-yl)methyl]cyclohex-3-ene-1-carboxylic acid;

N-[(5-chloro-6-{[1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; and their therapeutically acceptable salts, and metabolites.

Another variant of implementation relates to 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(Tetra�Idro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; and its therapeutically acceptable salts, and metabolites.

Another variant of implementation refers to the TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; and therapeutically acceptable salts, and metabolites.

Another variant of implementation relates to CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; and therapeutically acceptable salts, and metabolites.

Another variant of implementation refers to the TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; and therapeutically acceptable salts, and metabolites.

Another variant of implementation relates to 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; and therapeutically acceptable salts, and metabolites.

Another variant of implementation refers to the connection constituting N-[(5-chloro-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulph�Neal]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection representing a 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection representing a 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(CIS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection representing a 4-[4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}(2H8)piperazine-1-yl]-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection, representing N-({5-bromo-6-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection representing a 4-(4-{[-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(methyl-sulfonyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection representing a 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[the cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection representing a 4-(4-{[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; or its pharmaceutically acceptable salt.

Another variant of implementation relates to compounds having formula (I) or formula (II), which represent 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(methyl-sulfonyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[the cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; Il� their pharmaceutically acceptable salts.

Another variant of implementation relates to compounds having formula (I) or formula (II), which are N-[(5-chloro-6-{[1-(cyanomethyl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[the cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; or their pharmaceutically acceptable salts.

Another variant of implementation relates to compounds having formula (I) or formula (II), which represent 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(CIS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide or a pharmaceutically acceptable salt of such a compound.

Another variant of implementation refers to the connection representing a 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[the cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridin-yloxy)benzamide; or its pharmaceutically acceptable salt.

Another variant of implementation relates to compounds having formula (I) or formula (II), which represent 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3R)-1-tetrahydro-2H-Piran-4-imperiality-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; or their pharmaceutically acceptable salts.

Another variant of implementation relates to compounds having formula (I) or formula (II), which represent 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxane-2-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-bromo-6-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(4-aminotetraline-2H-Piran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethyl�ilogix-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3R)-1-tetrahydro-2H-Piran-4-imperiality-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(methyl-sulfonyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxytyramine-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(cyanomethyl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[the cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(1R,2S,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorphen�)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(6-{[(CIS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-5-nitropyridine-3-yl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; or their pharmaceutically acceptable salts.

Another variant of implementation refers to the connection constituting N-[(5-chloro-6-{[1-(cyanomethyl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; or its pharmaceutically acceptable salt.

Another variant of implementation relates to compounds having formula (I) or formula (II), which are N-[(4-{[(4-aminotetraline-2H-Piran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxytyramine-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide; or their pharmaceutically acceptable salts.

Another variant of implementation refers to the connection representing a 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxytyramine-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide, or its Pharma�automatically acceptable salt.

In another aspect, the present invention provides compounds of formula (II)

and their therapeutically acceptable salts, and metabolites,

where A1B1, D1E1, Y1, Z2, L1and Z3have the meanings given in this application for Formula (II); n is 0, 1, 2 or 3; indicating the number of substituents in Z1; and R100has the meaning specified for substituents on R26.

In one embodiment of formula (II), n has a value of 0 or 1. In another embodiment of formula (II), n has the value 0.

In one embodiment of formula (II), A1represents N. In another embodiment of formula (II), A1is C(A2). In another embodiment of formula (II), A1is C(A2); and A2represents H, F, Cl, Br or I. In another embodiment of formula (II), A1is C(A2); and A2represents H.

In one embodiment of formula (II), B1is an R1, OR1, NHR1, NHC(O)R1, F, Cl, Br or I. In another embodiment of formula (II), A1is C(A2); A2represents H; and B1represents NHR1. In another embodiment of the form�s (II), A1is C(A2); A2represents H; and B1represents OR1. In another embodiment of formula (II), A1is C(A2); A2represents H; and B1represents Cl. In another embodiment of formula (II), A1is C(A2); A2represents H; and B1is an R1. In another embodiment of formula (II), A1represents N; and B1represents NHR1. In another embodiment of formula (II), A1represents N; and B1represents OR1. In another embodiment of formula (II), A1represents N; and B1represents Cl. In another embodiment of formula (II), A1represents N; and B1is an R1.

In one embodiment of formula (II), D1represents H or Cl. In another embodiment of formula (II), A1is C(A2); A2represents H; B1represents NHR1; and D1represents H. In another embodiment of formula (II), A1is C(A2); A2represents H; B1represents NHR1; and D1represents Cl. In �another embodiment of formula (II), A1is C(A2); A2represents H; B1represents OR1; and D1represents H. In another embodiment of formula (II), A1is C(A2); A2represents H; B1represents Cl; and D1represents H. In another embodiment of formula (II), A1is C(A2); A2represents H; B1is an R1; and D1represents H. In another embodiment of formula (II), A1represents N; B1represents NHR1; and D1represents H. In another embodiment of formula (II), A1represents N; B1represents NHR1; and D1represents Cl. In another embodiment of formula (II), A1represents N; B1represents OR1; and D1represents H. In another embodiment of formula (II), A1represents N; B1represents Cl; and D1represents H. In another embodiment of formula (II), A1represents N; B1is an R1; and D1represents H.

In one embodiment of formula (II), E1represents H. In another embodiment, the OS�implementation of the formula (II), A1is C(A2); A2represents H; B1represents NHR1; D1represents H; and E1represents H. In another embodiment of formula (II), A1is C(A2); A2represents H; B1represents NHR1; E1represents H; and D1represents Cl. In another embodiment of formula (II), A1is C(A2); A2represents H; B1represents OR1; D1represents H; and E1represents H. In another embodiment of formula (II), A1is C(A2); A2represents H; B1represents Cl; D1represents H; and E1represents H. In another embodiment of formula (II), A1is C(A2); A2represents H; B1is an R1; D1represents H; and E1represents H. In another embodiment of formula (II), A1represents N; B1represents NHR1; D1represents H; and E1represents H. In another embodiment of formula (II), A1represents N; B1represents NHR1; E1 represents H; and D1represents Cl. In another embodiment of formula (II), A1represents N; B1represents OR1; D1represents H; and E1represents H. In another embodiment of formula (II), A1represents N; B1represents Cl; D1represents H; and E1represents H. In another embodiment of formula (II), A1represents N; B1is an R1; D1represents H; and E1represents H.

In one embodiment of formula (II), Y1represents H, CN, NO2, F, Cl, Br, I, CF3, R17, OR17, SR17, SO2R17or C(O)NH2. In another embodiment of formula (II), Y1represents H. In another embodiment of formula (II), Y1represents CN. In another embodiment of formula (II), Y1represents F, Cl, Br or I. In another embodiment of formula (II), Y1is a CF3. In another embodiment of formula (II), Y1represents SR17. In another embodiment of formula (II), Y1represents OR17. In another embodiment of formula (II), Y1is a NO2. In other� embodiment of formula (II), Y1is a SO2R17; where R17has the meaning specified in the present application. In another embodiment of formula (II), Y1is a SO2R17; where R17represents alkyl. In another embodiment of formula (II), Y1is an R17; where R17is alkynyl. In another embodiment of formula (II), A1is C(A2); A2represents H; B1represents NHR1; D1represents H; E1represents H; and Y1is a NO2or SO2R17; where R17represents an alkyl or alkynyl. In another embodiment of formula (II), A1is C(A2); A2represents H; B1represents NHR1; D1represents H; E1represents H; and Y1is a NO2. In another embodiment of formula (II), A1is C(A2); A2represents H; B1represents NHR1; D1represents H; E1represents H; and Y1is a SO2R17; where R17represents alkyl, substituted with three F. In another embodiment of formula (II), A1 represents N; B1represents NHR1; D1represents H; E1represents H; and Y1is a NO2or SO2R17; where R17represents an alkyl or alkynyl. In another embodiment of formula (II), A1represents N; B1represents NHR1; D1represents H; E1represents H; and Y1is a NO2. In another embodiment of formula (II), A1represents N; B1represents NHR1; D1represents H; E1represents H; and Y1is a SO2R17; where R17represents alkyl, substituted with three F.

In one embodiment of formula (II), Y1and B1together with the atoms to which they are linked, represent a benzene. In another embodiment of formula (II), Y1and B1together with the atoms to which they are linked, represent heteroaryl. In another embodiment of formula (II), A1is C(A2); A2E1and D1independently selected from H; and Y1and B1together with the atoms to which they are linked, represent a benzene. In another embodiment of formula (II), A1is C(A2); A2 E1and D1independently selected from H; and Y1and B1together with the atoms to which they are linked, represent heteroaryl.

In one embodiment of formula (II), R1is an R4or R5. In one embodiment of formula (II), R1is an R4. In one embodiment of formula (II), R1is an R5. In one embodiment of formula (II), R1is an R4; and R4is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen. In one embodiment of formula (II), R1is an R4; and R4is cycloalkyl or heteroseksualci. In one embodiment of formula (II), R1is an R4; and R4is cycloalkyl. In one embodiment of formula (II), R1is an R4; and R4is heteroseksualci.

In one embodiment of formula (II), R1is an R4; and R4is cycloalkyl; where R4is unsubstituted or substituted as defined in this application. In another embodiment of formula (II), R1is an R4; and R4is cycloalkyl; DG� cycloalkyl ring is substituted, as defined in the present application. In another embodiment of formula (II), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is substituted with R57or N(R57)2Deputy. In another embodiment of formula (II), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57Deputy; and R57is an R60. In another embodiment of formula (II), R1is an R4; R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57Deputy; R57is an R60; and R60is heteroseksualci. In another embodiment of formula (II), R1is an R4; R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57Deputy; R57is an R60; R60is heteroseksualci; where geteroseksualnoe ring is morpholinyl. In another embodiment of formula (II), R1performance�ulation of an R 4; and R4is cycloalkyl; where cycloalkyl ring substituted N(R57)2Deputy. In another embodiment of formula (II), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with N(R57)2Deputy. In another embodiment of formula (II), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with N(R57)2Deputy; R57is an R61; and R61represents alkyl, which is unsubstituted or substituted with R62Deputy. In another embodiment of formula (II), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57Deputy; R57is an R61; and R61represents alkyl, which is unsubstituted or substituted with R62Deputy; R62is an R65; and R65is cycloalkyl. In another embodiment of formula (II), R1is an R ; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57Deputy; R57is an R61; and R61represents alkyl which is substituted by R62Deputy; R62is an R65; and R65represents cyclopropyl.

In one embodiment of formula (II), R1is an R4; and R4is heteroseksualci; where R4is unsubstituted or substituted as defined in this application. In another embodiment of formula (II), R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring is substituted as defined in this application. In another embodiment of formula (II), R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring is substituted with R57Deputy. In another embodiment of formula (II), R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where geteroseksualnoe ring is substituted with R57Deputy; and R57is an R60/sup> or R61. In another embodiment of formula (II), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring is substituted with R57Deputy; R57is an R60or R61; R60is heteroseksualci; and R61represents alkyl. In another embodiment of formula (II), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring is substituted with R57Deputy; R57is an R60; R60is heteroseksualci; where heteroseksualci is tetrahydropyranyl. In another embodiment of formula (II), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring is substituted with R57Deputy; R57is an R61; R61represents alkyl; and the alkyl is methyl. In another embodiment is�the implementation of the formula (II), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted with C(O)OR57Deputy; R57is an R61; R61represents alkyl; and the alkyl is methyl.

In one embodiment of formula (II), R1is an R5; and R5represents alkyl, which is unsubstituted or substituted. In one embodiment of formula (II), R1is an R5; and R5represents alkyl, which is unsubstituted or substituted with R7, OR7, OH, CN or F Deputy. In another embodiment of formula (II), R1is an R5; and R5represents alkyl which is substituted by R7, OR7, NHR7or N(R7)2Deputy.

In one embodiment of formula (II), R7is an R8, R9, R10or R11which are unsubstituted or substituted as defined in this application. In another embodiment of formula (II), R7is an R8which is unsubstituted or substituted as defined in this application. In another embodiment, the implementation�of tvline of formula (II), R7is an R9which is unsubstituted or substituted as defined in this application. In another embodiment of formula (II), R7is an R10which is unsubstituted or substituted as defined in this application. In another embodiment of formula (II), R7is an R11which is unsubstituted or substituted as defined in this application.

In one embodiment of formula (II), R8represents phenyl, which is unsubstituted or substituted as defined in this application.

In one embodiment of formula (II), R9is heteroaryl, which is unsubstituted or substituted as defined in this application. In another embodiment of formula (II), R9is furanyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (II), R9is furanyl; which is unsubstituted.

In one embodiment of formula (II), R10is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, which are unsubstituted or substituted as defined in this application. In another embodiment of formula (II), R 10is heteroseksualci, which is unsubstituted or substituted as defined in this application. In another embodiment of formula (II), R10is tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, dioxane, oxetanyl, piperidinyl or pyrrolidinyl; which are unsubstituted or substituted as defined in this application. In another embodiment of formula (II), R10is tetrahydropyranyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (II), R10is morpholinyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (II), R10is cycloalkyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (II), R10is cycloalkyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (II), R10represents cyclohexyl, cyclopropyl, cyclobutyl or bicyclo[2.2.1]heptenyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (II), R10is heteroseksualci; which is fused with R10A; and R10Ais heteroaryl. In another embodiment of formula (II), R10is a 5,6,7,8-tetrahydroimidazo[1,2-a]pyridinyl.

In one embodiment of formula (II), R11represents alkyl, alkenyl or alkynyl, which are unsubstituted or substituted as defined in this application. In another embodiment of formula (II), R11represents alkyl. In another embodiment of formula (II), R11is methyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (II), R11represents alkyl; which is substituted as defined in this application. In another embodiment of formula (II), R11represents alkyl; which is substituted with R12, OR12or CF3Deputy. In another embodiment of formula (II), R11represents alkyl; which is substituted OR12Deputy; R12is an R16; and R16represents alkyl. In another embodiment of formula (II), R11represents alkyl; which is substituted with CF3Deputy. In another embodiment of formula (II), R11represents alkyl; which is substituted with R2 Deputy; R12is an R14; and R14is heteroaryl.

In one embodiment of formula (II),

n has a value of 0;

A1represents N or C(A2);

A2represents H, F, Br, I or Cl;

B1is an R1, OR1, NHR1, NHC(O)R1, F, Br, I or Cl;

D1represents H, F, Br, I or Cl;

E1represents H; and

Y1represents H, CN, NO2,F, Cl, Br, I, CF3, R17, OR17, SR17, SO2R17or C(O)NH2; or

Y1and B1together with the atoms to which they are linked, represent a benzene, heteroaryl or heteroseksualci; and

A2, D1and E1independently selected from H;

R1is an R4or R5;

R4is cycloalkyl or heteroseksualci;

R5represents an alkyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R7, OR7, NHR7N(R7)2, CN, OH, F, Cl, Br or I;

R7is an R8, R9, R10or R11;

R8represents phenyl;

R9is heteroaryl;

R10is cycloalkyl, cycloalken�l or heteroseksualci; each of which is neskondensirovannyh or fused with R10A, R10Ais heteroaryl;

R11represents alkyl each of which is unsubstituted or substituted with one or two or three independently selected substituents R12, OR12or CF3;

R12is an R14or R16;

R14is heteroaryl;

R16represents alkyl;

R17is an R21;

R21represents an alkyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R22, F, Cl, Br or I;

R22is an R25;

R25is heteroseksualci;

Z2is an R30;

Z1Aand Z2Aboth are absent;

L1is an R37;

R30is geteroseksualen;

R37is an R37A;

R37Ais alkylen;

Z3is an R38or R40;

R38represents phenyl;

R40is cycloalkyl, cycloalkenyl or geteroseksualen;

where the cyclic groups represented by Y1and B1together, R4, R8, R10, R10A, R25, R30, R38and R40that are independently unsubstituted, having additional substitution, substituted or further substituted by one or two or three or four or five independently selected substituents R57A, R57, OR57, SO2R57, C(O)R57, CO(O)R57, C(O)N(R57)2NH2, NHR57N(R57)2, NHC(O)R57, NHS(O)2R57, C(O)OH, OH, CN, (O), F, Cl, Br or I;

R57Ais spiralcell or spiroheterocyclic;

R57is an R58, R60or R61;

R58represents phenyl;

R60is cycloalkyl or heteroseksualci;

R61represents alkyl, which is unsubstituted or substituted with one or two or three independently selected substituents R62, OR62N(R62)2, C(O)OH, OH, CN, F, Cl, Br or I;

R62is an R65or R66;

R65is cycloalkyl or heteroseksualci;

R66represents alkyl, which is unsubstituted or substituted OR67Deputy;

R67represents alkyl;

where the cyclic groups represented as R57A, R58and R60are unsubstituted or substituted with one or two or t�time or four independently selected substituents R 68, (O), F, Cl, Br or I;

R68is an R71or R72;

R71is heteroseksualci; and

R72represents alkyl, which is unsubstituted or substituted with one or two F.

Another variant of implementation relates to compounds having formula (II), which represent

4-{4-[(4'-chloro-1,1'-biphenyl-2-yl)methyl]piperazine-1-yl}-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chloro-1,1'-biphenyl-2-yl)methyl]piperazine-1-yl}-N-({4-[(3-morpholine-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-demerol-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methylpiperazin-1-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridi�-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-methoxyethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxane-2-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3R)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-(2-naphthylmethyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-methoxyethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-Pirro�[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-({4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1,4-dioxane-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(2,2,2-trifluoroethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3,3,3-cryptochromes)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2S)-1,4-dioxane-2-ylethoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2R)-1,4-dioxane-2-ylethoxy]-3-nitrophenyl}su�honil)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(1,4-dioxane-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxane-2-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[3-(aminocarbonyl)-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-4-(4-{[2-(4-x�arvanil)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-{[4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-(trifluoromethyl)phenyl]sulfonyl}benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-({4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide;

TRANS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(1-demerol-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

p> 5-({[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]amino}sulfonyl)-2-(tetrahydro-2H-Piran-4-ylethoxy)nicotinamide;

N-({5-bromo-6-[(1-demerol-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-demerol-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(1,4-dioxane-2-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[5-bromo-6-(1,4-dioxane-2-ylethoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2,2-dimethylether-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-5-cyano-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1-acetylpiperidine-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-ene-1-�l]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({2-chloro-5-fluoro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-morpholine-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(2-morpholine-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[2-(2-methoxyethoxy)ethyl]sulfonyl}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[2-(2-methoxyethoxy)ethyl]sulfonyl}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)oxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-bromo-6-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-harfe�yl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-cyanoethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-{[4-({4-[bis(cyclopropylmethyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1-demerol-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(morpholine-3-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-methylpiperazin-1-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-albut-2-inyl)oxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-ethinyl-6-(tetrahydro-2H-Piran-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-oxo-3,4-dihydroquinazolin-6-yl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

tert-butyl 3-{[4-({[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-ylox�)benzoyl]amino}sulfonyl)-2-nitrophenoxy]methyl}morpholine-4-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(morpholine-3-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[1-(methyl-sulfonyl)piperidine-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1,1-dissidocerida-2H-thiopyran-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-chloro-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[1-(2,2,2-trifluoroethyl)piperidine-4-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)oxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-isopropyl-6-(tetrahydro-2H-Piran-4-illcox�)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-5-fluoro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

and their therapeutically acceptable salts, and metabolites.

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[2-fluoro-1-(permitil)ethyl]piperidine-4-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[1-(2,2-deflorati)piperidine-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclopropylidene-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1-the morpholine-4-illlogical)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(dicyclopropyl)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)Bentham�d;

4-(4-{[2-(4-chlorophenyl)-6,6-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-bromo-6-[(4-ethylmorpholine-3-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-ethylmorpholine-3-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(4-tetrahydro-2H-Piran-4-Immortalis-3-yl)methoxy]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-tetrahydro-2H-Piran-4-reparacin-3-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(tetrahydro-2H-Piran-4-ylmethyl)amino]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1,1-diocletianopolis-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(4-aminotetraline-2H-Piran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(4-morpholine-4-illlogical)amino]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-cyano-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1S,3R)-3-morpholine-4-enciclopedic]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1R,3S)-3-morpholine-4-enciclopedic]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(morpholine-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydrofuran-3-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[CIS-3-Porterage-2H-Piran-4-yl]piperidine-4-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-and�)-N-({3-nitro-4-[(1-tetrahydro-2H-Piran-4-ilization-3-yl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydrofuran-3-ilization-3-yl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3R)-1-tetrahydro-2H-Piran-4-imperiality-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)-N-(4-((TRANS-4-hydroxycyclohexyl)methoxy)-3-nitrophenyloctyl)benzamide;

2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)-N-(4-((CIS-4-methoxycyclohexyl)methoxy)-3-nitrophenyloctyl)benzamide;

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(cyclopropylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(tetrahydro-2H-Piran-4-ylamino)cyclohexyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-({5-bromo-6-[(4-morpholine-4-illcl�hexyl)oxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxycyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

tert-butyl 4-{[4-({[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]amino}sulfonyl)-2-nitrophenoxy]methyl}-4-foreperiod-1-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-foreperiod-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(4-tetrahydro-2H-Piran-4-reparacin-1-yl)cyclohexyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[2-fluoro-1-(permitil)ethyl]piperidine-4-yl}methoxy)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3R)-1-tetrahydro-2H-Piran-4-imperiality-3-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(2,2-dimethylether-2H-Piran-4-yl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)Bentham�d;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-tetrahydro-2H-Piran-4-imperiality-3-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-(2,2-dimethylether-2H-Piran-4-yl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(2-methoxyethyl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(4-acetylmorpholine-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[TRANS-4-(permitil)-1-oxetan-3-imperiality-3-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-Porterage-2H-Piran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4 dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-oxetan-3-reparacin-4-yl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclobutylmethyl-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[1-(2,2-dimethylether-2H-Piran-4-yl)piperidine-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-cyclopropylidene-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydrofuran-3-reparacin-4-yl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-cyclopropylidene-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3S)-1-tetrahydro-2H-Piran-4-imperiality-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-hydroxy-2,2-dimethylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(methyl-sulfonyl)piperidine-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(1-acetylpiperidine-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(methyl-sulfonyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-3,3-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[2-fluoro-1-(permitil)ethyl]azetidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(methyl-sulfonyl)pyrrolidin-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(1-acetylpyrrolidine-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(3R)-1-acetylpyrrolidine-3-yl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazin�-1-yl)-N-({4-[(3-methoxy-2,2-dimethylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1R,3R)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1S,3S)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1S,3R)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1R,3S)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-2-oxopiperidin-3-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[({1-[2-fluoro-1-(permitil)ethyl]azetidin-3-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(1-oxetan-3-ilization-3-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}p�perazine-1-yl)-N-[(3-nitro-4-{[(1-oxetan-3-reparacin-4-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1-cyclopropylidene-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(2-fluoroethyl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(2,2-deflorati)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-oxetan-3-reparacin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(2S)-4,4-debtor-1-oxetan-3-imperiality-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(4-tetrahydro-2H-Piran-4-Immortalis-3-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyclobutylmethyl-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclo�CEN-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(4-tetrahydrofuran-3-Immortalis-3-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[({1-[2-fluoro-1-(permitil)ethyl]piperidine-4-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclopropyl-4-foreperiod-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[3-(triptoreline)benzyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-methoxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(deformedarse)benzyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxaspiro[4.5]Dec-8-ylamino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-[(4-{[4-(acetylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclo�COP-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(2,2-deflorati)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-(2-fluoroethyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-(2,2-deflorati)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(2-fluoroethyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-oxetan-3-imperiality-3-yl]methoxy}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-hydroxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-hydroxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[3-(deformedarse)benzo�l]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[CIS-3-morpholine-4-enciclopedic]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(methyl-sulfonyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclopropylidene-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-oxetan-3-reparacin-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-tetrahydro-2H-Piran-4-reparacin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-tetrahydrofuran-3-reparacin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-fluoro-1-(methyl-sulfonyl)piperidine-4-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3R)-1-oxetan-3-imperiality-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-hydroxycyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[3-(dimethylamino)propoxy]benzyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(2-the morpholine-4-ylethoxy)benzyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(E)-4-hydroxy-1-adamantyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(Z)-4-hydroxy-1-adamantyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1S,4S)-bicyclo[2.2.1]hept-5-ene-2-ylethoxy]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-methyl-5-oxopyrrolidin-3-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1R,4,5 R,6S)-5,6-dihydroxybutyl[2.2.1]hept-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1R,4R,5S,6R)-5,6-dihydroxybutyl[2.2.1]hept-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3-oxocyclohexyl)methoxy]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1,3-Dien-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({(3R)-1-[2-fluoro-1-(permitil)ethyl]pyrrolidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[6-[(4-Porterage-2H-Piran-4-yl)methoxy]-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3S)-1-oxetan-3-imperiality-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-N-({5-chloro-6-[(4-metacritical�KSIL)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-oxetan-3-imperiality-3-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[({4-[2-(2-methoxyethoxy)ethyl]morpholine-2-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(cyanomethyl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(N,N-dimethylglycine)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

(2-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}morpholine-4-yl)acetic acid;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[4-(oxetan-3-yl)morpholine-2-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyclopropylmethyl-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex�-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-(methyl-sulfonyl)-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methyltetrahydro-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

ethyl 4-(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)piperazine-1-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[4-(morpholine-4-yl)piperidine-1-yl]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3R)-1-(oxetan-3-yl)pyrrolidin-3-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]amino}-3-[(trifluoromethyl)sulfonyl]phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-isopropylpiperazine-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1-tert-butylpiperazine-4-yl)amino]-3-nitro�enyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(2-methoxyethyl)piperidine-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(cyanomethyl)piperidine-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-demerol-4-yl)methoxy]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]amino}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

tert-butyl 4-[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]piperazine-1-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-(pendaftar-λ6-sulfanyl)-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxytyramine-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]oxy}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(oxetan-3-yl)piperazine-1-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(tetrahydro-2H-Piran-4-yl)piperazine-1-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3R)-tetrahydrofuran-3-ylamino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4,4-diverticulosis)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1-tert-butylpiperazine-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-({[4-(oxetan-3-yl)morpholine-2-yl]methyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(4-Porterage-2H-Piran-4-yl)methyl]amino}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(1-cyclopropylidene�in-4-yl)amino]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2S)-4-(cyanomethyl)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2S)-4-(N,N-dimethylglycine)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2R)-4-(cyanomethyl)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2R)-4-(N,N-dimethylglycine)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-fluoro-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[3-hydroxy-2-(gidroximetil)-2-methylpropoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dim�testicles-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(1,3-ditropan-2-yl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(cyanomethyl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({(3R)-1-[2-(2-methoxyethoxy)ethyl]pyrrolidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(N,N-dimethylglycine)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[1-(oxetan-3-yl)azetidin-3-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(cyanomethyl)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2R)-4-(N,N-dimethylglycine)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2S)-4-(N,N-dimethylglycine)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(N,N-dimethyl�ITIL)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(2,2-deflorati)pyrrolidin-3-yl]oxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(cyanomethyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-methoxypiperidine-1-yl}-N-({5-chloro-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-methoxypiperidine-1-yl}-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-(1,3-ditropan-2-yl)-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-(1,3-ditropan-2-yl)-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]und�C-8-EN-8-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4-fluoro-1-demerol-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(N,N-dimethylphenyl)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-foreperiod-1-yl}-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-foreperiod-1-yl}-N-({5-chloro-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-({4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-(trifluoromethyl)phenyl}sulfonyl)benzamide;

N-[(5-chloro-6-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]oxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[2-(tetrahydrofuran-3-yloxy)ethoxy]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperaz�n-1-yl)-N-[(4-{[(TRANS-4-cyanocyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[2-(tetrahydro-2H-Piran-4-yl)ethoxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(3-FuelMAX)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(2,2-deflorati)pyrrolidin-3-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(1,3-ditropan-2-yl)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-fluoro-1-demerol-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-ene-yl]methyl}piperazine-1-yl)-N-{[3-cyano-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(2,2-deflorati)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4,4-diverticulosis)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[6-{[1-(1,3-ditropan-2-yl)-4-foreperiod-4-yl]methoxy}-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-chloro-6-[2-(tetrahydrofuran-2-yl)ethoxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}-3-methylpiperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[3-(cyclopropylamino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[5-chloro-6-(2-methoxyethoxy)pyridin-3-and�]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-fluoro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(methoxyacetyl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(N,N-dimethylglycine)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohexyl]methyl}piperidine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-{[6-(tetrahydro-2H-Piran-4-ylethoxy)-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}benzamide;

N-({5-chloro-6-[(TRANS-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-cyano-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}Pieper�Zin-1-yl)-N-({6-[(TRANS-4-methoxycyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({6-[(CIS-4-methoxycyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4,4-debtor-1-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperidine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[TRANS-4-(morpholine-4-yl)cyclohexyl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[the cyclopropyl(1,3-thiazol-5-ylmethyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(TRANS-4-hydroxycyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-chloro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-(trifluoromethyl)phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethyl�ilogix-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[the cyclopropyl(2,2,2-trifluoroethyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(oxetan-3-yl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3,5-debtor-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[the cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(1-methyl-L-shed)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3,4-debtor-5-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2S)-4-cyclopropylmethyl-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperidine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}PIP�ridin-1-yl)-N-{[3-chloro-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

methyl 2-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}morpholine-4-carboxylate;

2-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(methyl-sulfonyl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclobutyl(cyclopropyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-diverticulosis-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-chloro-4-(tetrahydrofuran-3-ylethoxy)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-diverticulosis-1-EN-1-yl]methyl�}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[9-(4-chlorophenyl)-3-(oxetan-3-yl)-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2R)-4-cyclopropylmethyl-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2S)-4-cyclopropylmethyl-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[5-chloro-6-({4-[cyclopropyl(oxetan-3-yl)amino]cyclohexyl}methoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyclopropylmethyl-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-cyclopropylmethyl-2-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[(4-cyclopropylmethyl-2-yl)methyl]amino}�enyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

2-{[(2-chloro-4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}phenyl)amino]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

(2S)-2-{[(3-chloro-5-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}pyridin-2-yl)oxy]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

N-[(5-chloro-6-{[(4-cyclopropylmethyl-2-yl)methyl]amino}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

2-{[(3-chloro-5-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}pyridin-2-yl)amino]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(CIS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(1R,2R,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridin-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(2-cyanoethyl)(cyclopropyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(1R,2S,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(CIS-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(3,3-giftability-1-yl)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-�ENT-6-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(CIS-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(2,2-diversicolor)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(CIS-1-fluoro-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-(2-oxaspiro[3.5]non-7-ylethoxy)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-bis(permitil)cyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-cyclopropylmethyl-2-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(TRANS-1-fluoro-4-hydroxy-4-methyl�illogical)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(CIS-1-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-cyano-4-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-ethyl-4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(CIS-4-ethyl-4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5-(methoxymethyl)-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(2S)-4-(oxetan-3-yl)morpholine-2-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-CL�henyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(2-cyanoethyl)(cyclopropyl)amino]-1-forcelogix}methoxy)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-nitro-6-[(tetrahydro-2H-Piran-4-ylmethyl)amino]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(2-oxaspiro[3.5]non-7-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyano-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-{[3-(tetrahydro-2H-Piran-4-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-6-yl]sulfonyl}benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(6-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-5-nitropyridine-3-yl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(5-cyano-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)morpholine-4-carboxamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]�ethyl}piperazine-1-yl)-N-{[4-({[4-(methoxymethyl)cyclohexyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(5-chloro-6-{[1-(1,3-- thiazol-2-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(6-{[(CIS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-5-nitropyridine-3-yl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

methyl TRANS-4-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}cyclohexanecarboxylate;

TRANS-4-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}cyclohexanecarbonyl acid;

N-(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)-4-cyanopiperidine-1-carboxamide;

4-(4-{[2-(4-Chloe�phenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[CIS-4-(methoxymethyl)cyclohexyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[TRANS-4-(methoxymethyl)cyclohexyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-{[1-(tetrahydro-2H-Piran-4-ylmethyl)-1H-benzotriazole-5-yl]sulfonyl}benzamide;

N-({5-chloro-6-[(2-oxo-1-ox-3-azaspiro[4.5]Dec-8-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)-4-methoxypiperidine-1-carboxamide;

N-({5-chloro-6-[(2-methyl-4,5,6,7-tetrahydro-1,3-benzothiazol-5-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-{[1-(tetrahydro-2H-Piran-4-ylmethyl)-1H-imidazo[2,3-b]pyridin-5-yl]sulfonyl}benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-chloro-1-(tetrahydro-2H-Piran-4-ylmethyl)-1H-imidazo[2,3-b]pyridin-5-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4-(methoxy�ethyl)-4-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[4,4-bis(gidroximetil)cyclohexyl]methoxy}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-(2-chloro-4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}phenyl)-4-methoxypiperidine-1-carboxamide;

N-(2-chloro-4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}phenyl)-4-cyanopiperidine-1-carboxamide;

N-(2-chloro-4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}phenyl)-4-hydroxy-4-demerol-1-carboxamide;

N-(2-chloro-4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}phenyl)-4-(methoxymethyl)piperidine-1-carboxamide;

N-[(5-chloro-6-{[(5r,8r)-2-oxo-1-ox-3-azaspiro[4.5]Dec-8-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(5s,8s)-2-oxo-1-ox-3-azaspiro[4.5]Dec-8-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-(2-chloro-4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-�n-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}phenyl)-4-(morpholine-4-yl)piperidine-1-carboxamide;

N-[(5-chloro-6-{[TRANS-4-hydroxy-4-(methoxymethyl)cyclohexyl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[CIS-4-hydroxy-4-(gidroximetil)cyclohexyl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[TRANS-4-hydroxy-4-(gidroximetil)cyclohexyl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)cyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-chlorophenyl)-1-methyl-3-[(4-{4-[({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)carbamoyl]-3-(1H-imidazo[2,3-b]pyridine-5-yloxy)phenyl}piperazine-1-yl)methyl]cyclohex-3-ene-1-carboxylic acid;

N-[(5-chloro-6-{[1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-and�oxy)benzamide; and their therapeutically acceptable salts, and metabolites.

In another aspect, the present invention provides compounds of formula (III)

and their therapeutically acceptable salts, and metabolites,

where A1B1, D1E1and Y1have the meanings given in this application for Formula (I); R100has the meaning specified for substituents on R26; n is 0, 1, 2 or 3; R101has the meaning specified for substituents on R30; p has the value 0, 1, 2, 3, 4, 5 or 6; R102has the meaning specified for substituents on R40; q has a value of 0, 1, 2, 3, 4, 5 or 6; R103has the meaning specified for substituents on R58; and r is 0, 1, 2, 3, or 4.

In one embodiment of formula (III), n, p, r and q each have a value of 0.

In one embodiment of formula (III), A1represents N. In another embodiment of formula (III), A1is C(A2). In another embodiment of formula (III), A1is C(A2); and A2represents H, F, Cl, Br or I. In another embodiment of formula (III), A1is C(A2); and A2represents H.

In one embodiment of formula (III), B1is an R1, OR1, NHRsup> 1, NHC(O)R1, F, Cl, Br or I. In another embodiment of formula (III), A1is C(A2); A2represents H; and B1represents NHR1. In another embodiment of formula (III), A1is C(A2); A2represents H; and B1represents OR1. In another embodiment of formula (III), A1is C(A2); A2represents H; and B1represents Cl. In another embodiment of formula (III), A1is C(A2); A2represents H; and B1is an R1. In another embodiment of formula (III), A1represents N; and B1represents NHR1. In another embodiment of formula (III), A1represents N; and B1represents OR1. In another embodiment of formula (III), A1represents N; and B1represents Cl. In another embodiment of formula (III), A1represents N; and B1is an R1.

In one embodiment of formula (III), D1represents H or Cl. In another embodiment of formula (III), A1is C(A2); A2represents H; B1is�Oh NHR 1; and D1represents H. In another embodiment of formula (III), A1is C(A2); A2represents H; B1represents NHR1; and D1represents Cl. In another embodiment of formula (III), A1is C(A2); A2represents H; B1represents OR1; and D1represents H. In another embodiment of formula (III), A1is C(A2); A2represents H; B1represents Cl; and D1represents H. In another embodiment of formula (III), A1is C(A2); A2represents H; B1is an R1; and D1represents H. In another embodiment of formula (III), A1represents N; B1represents NHR1; and D1represents H. In another embodiment of formula (III), A1represents N; B1represents NHR1; and D1represents Cl. In another embodiment of formula (III), A1represents N; B1represents OR1; and D1represents H. In another embodiment of formula (III), A1represents N; B1represents Cl; and D 1represents H. In another embodiment of formula (III), A1represents N; B1is an R1; and D1represents H.

In one embodiment of formula (III), E1represents H. In another embodiment of formula (III), A1is C(A2); A2represents H; B1represents NHR1; D1represents H; and E1represents H. In another embodiment of formula (III), A1is C(A2); A2represents H; B1represents NHR1; E1represents H; and D1represents Cl. In another embodiment of formula (III), A1is C(A2); A2represents H; B1represents OR1; D1represents H; and E1represents H. In another embodiment of formula (III), A1is C(A2); A2represents H; B1represents Cl; D1represents H; and E1represents H. In another embodiment of formula (III), A1is C(A2); A2represents H; B1is an R1; D1represents H; and E1represents . In another embodiment of formula (III), A1represents N; B1represents NHR1; D1represents H; and E1represents H. In another embodiment of formula (III), A1represents N; B1represents NHR1; E1represents H; and D1represents Cl. In another embodiment of formula (III), A1represents N; B1represents OR1; D1represents H; and E1represents H. In another embodiment of formula (III), A1represents N; B1represents Cl; D1represents H; and E1represents H. In another embodiment of formula (III), A1represents N; B1is an R1; D1represents H; and E1represents H.

In one embodiment of formula (III), Y1represents H, CN, NO2, F, Cl, Br, I, CF3, R17, OR17, SR17, SO2R17or C(O)NH2. In another embodiment of formula (III), Y1represents H. In another embodiment of formula (III), Y1represents CN. In another embodiment of formula (III), Y1represents F, Cl, Br or I. In another embodiment of the forms�crystals (III), Y1is a CF3. In another embodiment of formula (III), Y1represents SR17. In another embodiment of formula (III), Y1represents OR17. In another embodiment of formula (III), Y1is a NO2. In another embodiment of formula (III), Y1is a SO2R17; where R17has the meaning specified in the present application. In another embodiment of formula (III), Y1is a SO2R17; where R17represents alkyl. In another embodiment of formula (III), Y1is an R17; where R17is alkynyl. In another embodiment of formula (III), A1is C(A2); A2represents H; B1represents NHR1; D1represents H; E1represents H; and Y1is a NO2or SO2R17; where R17represents an alkyl or alkynyl. In another embodiment of formula (III), A1is C(A2); A2represents H; B1represents NHR1; D1represents H; E1represents H; and Y1is a NO2. In another embodiment, the implementation of f�of rmula (III), A1is C(A2); A2represents H; B1represents NHR1; D1represents H; E1represents H; and Y1is a SO2R17; where R17represents alkyl, substituted with three F. In another embodiment of formula (III), A1represents N; B1represents NHR1; D1represents H; E1represents H; and Y1is a NO2or SO2R17; where R17represents an alkyl or alkynyl. In another embodiment of formula (III), A1represents N; B1represents NHR1; D1represents H; E1represents H; and Y1is a NO2. In another embodiment of formula (III), A1represents N; B1represents NHR1; D1represents H; E1represents H; and Y1is a SO2R17; where R17represents alkyl, substituted with three F.

In one embodiment of formula (III), Y1and B1together with the atoms to which they are linked, represent a benzene. In another embodiment of formula (III), Y1and B1together with the atoms to which they are linked, represent �Wallpaper heteroaro. In another embodiment of formula (III), A1is C(A2); A2E1and D1independently selected from H; and Y1and B1together with the atoms to which they are linked, represent a benzene. In another embodiment of formula (III), A1is C(A2); A2E1and D1independently selected from H; and Y1and B1together with the atoms to which they are linked, represent heteroaryl.

In one embodiment of formula (III), R1is an R4or R5. In one embodiment of formula (III), R1is an R4. In one embodiment of formula (III), R1is an R5. In one embodiment of formula (III), R1is an R4; and R4is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen. In one embodiment of formula (III), R1is an R4; and R4is cycloalkyl or heteroseksualci. In one embodiment of formula (III), R1is an R4; and R4is cycloalkyl. In one embodiment of formula (III), R1is an R4; and R4is heteroseksualci.

In one VA�iante implementation of the formula (III), R1is an R4; and R4is cycloalkyl; where R4is unsubstituted or substituted as defined in this application. In another embodiment of formula (III), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is substituted as defined in this application. In another embodiment of formula (III), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is substituted with R57or N(R57)2Deputy. In another embodiment of formula (III), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57Deputy; and R57is an R60. In another embodiment of formula (III), R1is an R4; R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57Deputy; R57is an R60; and R60is heteroseksualci. In another embodiment of formula (III), R1is an R4; R4is a cyclo�lkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57Deputy; R57is an R60; R60is heteroseksualci; where geteroseksualnoe ring is morpholinyl. In another embodiment of formula (III), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring substituted N(R57)2Deputy. In another embodiment of formula (III), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with N(R57)2Deputy. In another embodiment of formula (III), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with N(R57)2Deputy; R57is an R61; and R61represents alkyl, which is unsubstituted or substituted with R62Deputy. In another embodiment of formula (III), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where the CEC�hexylene ring is substituted with R 57Deputy; R57is an R61; and R61represents alkyl, which is unsubstituted or substituted with R62Deputy; R62is an R65; and R65is cycloalkyl. In another embodiment of formula (III), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57Deputy; R57is an R61; and R61represents alkyl which is substituted by R62Deputy; R62is an R65; and R65represents cyclopropyl.

In one embodiment of formula (III), R1is an R4; and R4is heteroseksualci; where R4is unsubstituted or substituted as defined in this application. In another embodiment of formula (III), R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring is substituted as defined in this application. In another embodiment of formula (III), R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring is substituted with R57the Deputy�the Titel. In another embodiment of formula (III), R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where geteroseksualnoe ring is substituted with R57Deputy; and R57is an R60or R61. In another embodiment of formula (III), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring is substituted with R57Deputy; R57is an R60or R61; R60is heteroseksualci; and R61represents alkyl. In another embodiment of formula (III), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring is substituted with R57Deputy; R57is an R60; R60is heteroseksualci; where heteroseksualci is tetrahydropyranyl. In another embodiment of formula (III), R1is an R4; R4ameri� heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring is substituted with R57Deputy; R57is an R61; R61represents alkyl; and the alkyl is methyl. In another embodiment of formula (III), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted with C(O)OR57Deputy; R57is an R61; R61represents alkyl; and the alkyl is methyl.

In one embodiment of formula (III), R1is an R5; and R5represents alkyl, which is unsubstituted or substituted. In one embodiment of formula (III), R1is an R5; and R5represents alkyl, which is unsubstituted or substituted with R7, OR7, OH, CN or F Deputy. In another embodiment of formula (III), R1is an R5; and R5represents alkyl which is substituted by R7, OR7, NHR7or N(R7)2Deputy.

In one embodiment of formula (III), R7performance�ulation of an R 8, R9, R10or R11which are unsubstituted or substituted as defined in this application. In another embodiment of formula (III), R7is an R8which is unsubstituted or substituted as defined in this application. In another embodiment of formula (III), R7is an R9which is unsubstituted or substituted as defined in this application. In another embodiment of formula (III), R7is an R10which is unsubstituted or substituted as defined in this application. In another embodiment of formula (III), R7is an R11which is unsubstituted or substituted as defined in this application.

In one embodiment of formula (III), R8represents phenyl, which is unsubstituted or substituted as defined in this application.

In one embodiment of formula (III), R9is heteroaryl, which is unsubstituted or substituted as defined in this application. In another embodiment of formula (III), R9is furanyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (III), R9pre�represents furanyl; which is unsubstituted.

In one embodiment of formula (III), R10is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen; which are unsubstituted or substituted as defined in this application. In another embodiment of formula (III), R10is heteroseksualci; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (III), R10is tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, dioxane, oxetanyl, piperidinyl or pyrrolidinyl; which are unsubstituted or substituted as defined in this application. In another embodiment of formula (III), R10is tetrahydropyranyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (III), R10is morpholinyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (III), R10is cycloalkyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (III), R10is cycloalkyl; which is unsubstituted or W�substituted, as defined in the present application. In another embodiment of formula (III), R10represents cyclohexyl, cyclopropyl, cyclobutyl or bicyclo[2.2.1]heptenyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (III), R10is heteroseksualci which is fused with R10A; and R10Ais heteroaryl. In another embodiment of formula (III), R10is a 5,6,7,8-tetrahydroimidazo[1,2-a]pyridinyl.

In one embodiment of formula (III), R11represents alkyl, alkenyl or alkynyl; which are unsubstituted or substituted as defined in this application. In another embodiment of formula (III), R11represents alkyl. In another embodiment of formula (III), R11is methyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (III), R11represents alkyl; which is substituted as defined in this application. In another embodiment of formula (III), R11represents alkyl; which is substituted with R12, OR12or CF3Deputy. In another embodiment of formula (III), R11is with�fight alkyl; which is substituted OR12Deputy; R12is an R16; and R16represents alkyl. In another embodiment of formula (III), R11represents alkyl; which is substituted with CF3Deputy. In another embodiment of formula (III), R11represents alkyl; which is substituted with R12Deputy; R12is an R14; and R14is heteroaryl.

In one embodiment of formula (III),

n, p, r and q each have a value of 0;

A1represents N or C(A2);

A2represents H, F, Br, I or Cl;

B1is an R1, OR1, NHR1, NHC(O)R1, F, Br, I or Cl;

D1represents H, F, Br, I or Cl;

E1represents H; and

Y1represents H, CN, NO2, F, Cl, Br, I, CF3, R17, OR17, SR17, SO2R17or C(O)NH2; or

Y1and B1together with the atoms to which they are linked, represent a benzene, heteroaryl or heteroseksualci; and

A2, D1and E1independently selected from H;

R1is an R4or R5;

R4is cycloalkyl or heteroseksualci;

R5represents an alkyl or alkynyl, each of which is nezameshchenny� or substituted with one or two or three independently selected substituents R 7, OR7, NHR7N(R7)2, CN, OH, F, Cl, Br or I;

R7is an R8, R9, R10or R11;

R8represents phenyl;

R9is heteroaryl;

R10is cycloalkyl, cycloalkenyl or geteroseksualen; each of which is neskondensirovannyh or fused with R10A, R10Ais heteroaryl;

R11represents alkyl each of which is unsubstituted or substituted with one or two or three independently selected substituents R12, OR12or CF3;

R12is an R14or R16;

R14is heteroaryl;

R16represents alkyl;

R17is an R21;

R21represents an alkyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R22, F, Cl, Br or I;

R22is an R25;

R25is heteroseksualci;

where the cyclic groups represented by Y1and B1together, R4, R8, R10, R10Aand R25that are independently unsubstituted, having additional substitution, substituted or additionally sameshe�governmental one or two or three or four or five independently selected substituents R 57A, R57, OR57, SO2R57, C(O)R57, CO(O)R57, C(O)N(R57)2NH2, NHR57N(R57)2, NHC(O)R57, NHS(O)2R57, C(O)OH, OH, CN, (O), F, Cl, Br or I;

R57Ais spiralcell or spiroheterocyclic;

R57is an R58, R60or R61;

R58represents phenyl;

R60is cycloalkyl or heteroseksualci;

R61represents alkyl, which is unsubstituted or substituted with one or two or three independently selected substituents R62, OR62N(R62)2, C(O)OH, OH, CN, F, Cl, Br or I;

R62is an R65or R66;

R65is cycloalkyl or heteroseksualci;

R66represents alkyl, which is unsubstituted or substituted OR67Deputy;

R67represents alkyl;

where the cyclic groups represented as R57A, R58and R60are unsubstituted or substituted with one or two or three or four independently selected substituents R68, (O), F, Cl, Br or I;

R68is an R71or R72;

R71is heteroseksualci; and

R72represents alkyl, which is unsubstituted or sameshe� one or two F.

Another variant of implementation relates to compounds having the formula (III), which represent

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-demerol-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methylpiperazin-1-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-methoxyethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)Besame�;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxane-2-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3R)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-(2-naphthylmethyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-methoxyethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-({4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1,4-dioxane-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(2,2,2-trifluoroethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3,3,3-cryptochromes)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2S)-1,4-dioxane-2-ylethoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2R)-1,4-dioxane-2-ylethoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[3-(aminocarbonyl)-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex�-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

5-({[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]amino}sulfonyl)-2-(tetrahydro-2H-Piran-4-ylethoxy)nicotinamide;

N-({5-bromo-6-[(1-demerol-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-demerol-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(1,4-dioxane-2-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[5-bromo-6-(1,4-dioxane-2-ylethoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2,2-dimethylether-2H-Piran-4-yl)m�methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-5-cyano-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1-acetylpiperidine-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({2-chloro-5-fluoro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-morpholine-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(2-morpholine-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[2-(2-methoxyethoxy)ethyl]sulfonyl}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[2-(2-methoxyethoxy)ethylsulfanyl}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)oxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-bromo-6-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-cyanoethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[4-({4-[bis(cyclopropylmethyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1-demerol-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(morpholine-3-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-albut-2-inyl)oxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-ethinyl-6-(tetrahydro-H-PYRAN-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-oxo-3,4-dihydroquinazolin-6-yl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

tert-butyl 3-{[4-({[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]amino}sulfonyl)-2-nitrophenoxy]methyl}morpholine-4-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(morpholine-3-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[1-(methyl-sulfonyl)piperidine-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1,1-dissidocerida-2H-thiopyran-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-chloro-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[1-(2,2,2-trifluoroethyl)piperidine-4-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)oxy]PIR�DIN-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-isopropyl-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-5-fluoro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[2-fluoro-1-(permitil)ethyl]piperidine-4-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[1-(2,2-deflorati)piperidine-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclopropylidene-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1-the morpholine-4-illlogical)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]IU�yl}piperazine-1-yl)-N-[(4-{[4-(dicyclopropyl)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-bromo-6-[(4-ethylmorpholine-3-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-ethylmorpholine-3-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(4-tetrahydro-2H-Piran-4-Immortalis-3-yl)methoxy]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-tetrahydro-2H-Piran-4-reparacin-3-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(tetrahydro-2H-Piran-4-ylmethyl)amino]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1,1-diocletianopolis-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(4-aminotetraline-2H-Piran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}Pipa�Azin-1-yl)-N-({5-cyano-6-[(4-morpholine-4-illlogical)amino]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-cyano-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1S,3R)-3-morpholine-4-enciclopedic]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1R,3S)-3-morpholine-4-enciclopedic]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(morpholine-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydrofuran-3-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[CIS-3-Porterage-2H-Piran-4-yl]piperidine-4-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydro-2H-Piran-4-ilization-3-yl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)--({3-nitro-4-[(1-tetrahydrofuran-3-ilization-3-yl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3R)-1-tetrahydro-2H-Piran-4-imperiality-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)-N-(4-((TRANS-4-hydroxycyclohexyl)methoxy)-3-nitrophenyloctyl)benzamide;

2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)-N-(4-((CIS-4-methoxycyclohexyl)methoxy)-3-nitrophenyloctyl)benzamide;

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(cyclopropylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(tetrahydro-2H-Piran-4-ylamino)cyclohexyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-({5-bromo-6-[(4-morpholine-4-illlogical)oxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxycyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

tert-butyl 4-{[4-({[4-(4-{[2-(4-chlorophenyl)-4,-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]amino}sulfonyl)-2-nitrophenoxy]methyl}-4-foreperiod-1-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-foreperiod-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(4-tetrahydro-2H-Piran-4-reparacin-1-yl)cyclohexyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[2-fluoro-1-(permitil)ethyl]piperidine-4-yl}methoxy)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3R)-1-tetrahydro-2H-Piran-4-imperiality-3-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(2,2-dimethylether-2H-Piran-4-yl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-tetrahydro-2H-Piran-4-imperiality-3-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-(2,2-dimethylether-2H-Piran-4-yl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridi�-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(2-methoxyethyl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(4-acetylmorpholine-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[TRANS-4-(permitil)-1-oxetan-3-imperiality-3-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-Porterage-2H-Piran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-oxetan-3-reparacin-4-yl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclobutylmethyl-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazin�-1-yl)-N-[(4-{[1-(2,2-dimethylether-2H-Piran-4-yl)piperidine-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-cyclopropylidene-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydrofuran-3-reparacin-4-yl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-cyclopropylidene-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3S)-1-tetrahydro-2H-Piran-4-imperiality-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-hydroxy-2,2-dimethylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(methyl-sulfonyl)piperidine-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(1-acetylpiperidine-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]�ethyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(methyl-sulfonyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[2-fluoro-1-(permitil)ethyl]azetidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(methyl-sulfonyl)pyrrolidin-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(1-acetylpyrrolidine-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(3R)-1-acetylpyrrolidine-3-yl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-methoxy-2,2-dimethylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1R,3R)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1S,3S)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazin�-1-yl)-N-{[4-({[(1S,3R)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1R,3S)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-2-oxopiperidin-3-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[({1-[2-fluoro-1-(permitil)ethyl]azetidin-3-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(1-oxetan-3-ilization-3-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(1-oxetan-3-reparacin-4-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1-cyclopropylidene-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(2-fluoroethyl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}PI�erasin-1-yl)-N-{[4-({[4-(2,2-deflorati)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-oxetan-3-reparacin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(2S)-4,4-debtor-1-oxetan-3-imperiality-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(4-tetrahydro-2H-Piran-4-Immortalis-3-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyclobutylmethyl-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(4-tetrahydrofuran-3-Immortalis-3-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[({1-[2-fluoro-1-(permitil)ethyl]piperidine-4-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclopropyl-4-foreperiod-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorine�enyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[3-(triptoreline)benzyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-methoxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(deformedarse)benzyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxaspiro[4.5]Dec-8-ylamino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-[(4-{[4-(acetylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(2,2-deflorati)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-(2-fluoroethyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-(2,2-deflorati)pyrrolidin-3-�l]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(2-fluoroethyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-oxetan-3-imperiality-3-yl]methoxy}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-hydroxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-hydroxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[3-(deformedarse)benzyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[CIS-3-morpholine-4-enciclopedic]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(methyl-sulfonyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclopropyl�uridin-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-oxetan-3-reparacin-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-tetrahydro-2H-Piran-4-reparacin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-tetrahydrofuran-3-reparacin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-fluoro-1-(methyl-sulfonyl)piperidine-4-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3R)-1-oxetan-3-imperiality-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-hydroxycyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[3-(dimethylamino)propoxy]benzyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-DIMET�cyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(2-the morpholine-4-ylethoxy)benzyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(E)-4-hydroxy-1-adamantyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(Z)-4-hydroxy-1-adamantyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1S,4S)-bicyclo[2.2.1]hept-5-ene-2-ylethoxy]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-methyl-5-oxopyrrolidin-3-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1R,4R,5R,6S)-5,6-dihydroxybutyl[2.2.1]hept-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1R,4R,5S,6R)-5,6-dihydroxybutyl[2.2.1]hept-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3-oxocyclohexyl)methoxy]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazin�-1-yl)-N-{[4-({(3R)-1-[2-fluoro-1-(permitil)ethyl]pyrrolidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[6-[(4-Porterage-2H-Piran-4-yl)methoxy]-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3S)-1-oxetan-3-imperiality-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-oxetan-3-imperiality-3-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[({4-[2-(2-methoxyethoxy)ethyl]morpholine-2-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(cyanomethyl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethyl�logex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(N,N-dimethylglycine)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

(2-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}morpholine-4-yl)acetic acid;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[4-(oxetan-3-yl)morpholine-2-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyclopropylmethyl-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-(methyl-sulfonyl)-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methyltetrahydro-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

ethyl 4-(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)piperazine-1-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[4-(morpholine-4-yl)piperidine-1-yl]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3R)-1-(oxetan-3-yl)pyrrolidin-3-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]amino}-3-[(trifluoromethyl)sulfonyl]phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-isopropylpiperazine-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1-tert-butylpiperazine-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(2-methoxyethyl)piperidine-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(cyanomethyl)piperidine-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-demerol-4-yl)methoxy]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(1,3-debtor�opan-2-yl)pyrrolidin-3-yl]amino}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

tert-butyl 4-[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]piperazine-1-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-(pendaftar-λ6-sulfanyl)-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxytyramine-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]oxy}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(oxetan-3-yl)piperazine-1-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(tetrahydro-2H-Piran-4-yl)piperazine-1-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3R)-tetrahydrofuran-3-ylamino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex�-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4,4-diverticulosis)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1-tert-butylpiperazine-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-({[4-(oxetan-3-yl)morpholine-2-yl]methyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(4-Porterage-2H-Piran-4-yl)methyl]amino}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(1-cyclopropylidene-4-yl)amino]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2S)-4-(cyanomethyl)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2S)-4-(N,N-dimethylglycine)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2R)-4-(cyanomethyl)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-(5-chloro-6-{[(2R)-4-(N,N-dimethylglycine)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-fluoro-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[3-hydroxy-2-(gidroximetil)-2-methylpropoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(1,3-ditropan-2-yl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(cyanomethyl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({(3R)-1-[2-(2-methoxyethoxy)ethyl]pyrrolidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(N,N-dimethylglycine)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dime�icicles-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[1-(oxetan-3-yl)azetidin-3-yl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(cyanomethyl)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2R)-4-(N,N-dimethylglycine)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2S)-4-(N,N-dimethylglycine)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(N,N-dimethylglycine)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(2,2-deflorati)pyrrolidin-3-yl]oxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(cyanomethyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4-fluoro-1-demerol-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(N,N-dimethy�glycyl)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]oxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[2-(tetrahydrofuran-3-yloxy)ethoxy]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-cyanocyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[2-(tetrahydro-2H-Piran-4-yl)ethoxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(3-FuelMAX)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(2,2-deflorati)pyrrolidin-3-yl]methoxy}Piri�in-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(1,3-ditropan-2-yl)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-fluoro-1-demerol-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-cyano-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(2,2-deflorati)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4,4-diverticulosis)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[6-{[1-(1,3-ditropan-2-yl)-4-foreperiod-4-yl]methoxy}-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-DIMET�cyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-chloro-6-[2-(tetrahydrofuran-2-yl)ethoxy]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[3-(cyclopropylamino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[5-chloro-6-(2-methoxyethoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-fluoro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(methoxyacetyl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(N,N-dimethylglycine)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-{[6-(tetrahydro-2H-Piran-4-ylethoxy)-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}benzamide;

N-({5-chloro-6-[(TRANS-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-cyano--[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({6-[(TRANS-4-methoxycyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({6-[(CIS-4-methoxycyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[TRANS-4-(morpholine-4-yl)cyclohexyl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[the cyclopropyl(1,3-thiazol-5-ylmethyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(TRANS-4-hydroxycyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-chloro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-(trifluoromethyl)phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-di�ethylcyclohexyl-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[the cyclopropyl(2,2,2-trifluoroethyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(oxetan-3-yl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3,5-debtor-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[the cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(1-methyl-L-shed)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3,4-debtor-5-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2S)-4-cyclopropylmethyl-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

methyl 2-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}morpholine-4-carboxylate;

2-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-ene-1-�l]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(methyl-sulfonyl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclobutyl(cyclopropyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-chloro-4-(tetrahydrofuran-3-ylethoxy)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2R)-4-cyclopropylmethyl-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2S)-4-cyclopropylmethyl-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[5-chloro-6-({4-[cyclopropyl(oxetan-3-yl)amino]cyclohexyl}methoxypyridine-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyclopropylmethyl-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-cyclopropylmethyl-2-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[(4-cyclopropylmethyl-2-yl)methyl]amino}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

2-{[(2-chloro-4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}phenyl)amino]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

(2S)-2-{[(3-chloro-5-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}pyridin-2-yl)oxy]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

N-[(5-chloro-6-{[(4-cyclopropylmethyl-2-yl)methyl]amino}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

2-{[(3-chloro-5-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}pyridin-2-yl)amino]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethyl�ilogix-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(CIS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(1R,2R,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(2-cyanoethyl)(cyclopropyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(1R,2S,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(CIS-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-ylo�si)benzamide;

N-[(5-chloro-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(3,3-giftability-1-yl)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(CIS-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(2,2-diversicolor)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(CIS-1-fluoro-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-(2-oxaspiro[3.5]non-7-ylethoxy)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethyl�ilogix-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-cyclopropylmethyl-2-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(TRANS-1-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(CIS-1-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-cyano-4-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-ethyl-4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(CIS-4-ethyl-4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(2S)-4-(oxetan-3-yl)morpholine-2-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(2-cyanoethyl)(cyclopropyl)amino]-1-forcelogix}methoxy)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-nitro-6-[(tetrahydro-2H-Piran-4-ylmethyl)amino]pyridin-3-yl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(2-oxaspiro[3.5]non-7-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyano-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-{[3-(tetrahydro-2H-Piran-4-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-6-yl]sulfonyl}benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(6-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-5-nitropyridine-3-yl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(5-cyano-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-(4-{[4-(4-{[2(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)morpholine-4-carboxamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(methoxymethyl)cyclohexyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(5-chloro-6-{[1-(1,3-- thiazol-2-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(6-{[(CIS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-5-nitropyridine-3-yl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

methyl TRANS-4-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}cyclohexanecarboxylate;

TRANS-4-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}cyclohexanecarbonyl acid;

N-(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)-4-cyanopiperidine-1-carboxamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[CIS-4-(methoxymethyl)cyclohexyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-�emailregex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[TRANS-4-(methoxymethyl)cyclohexyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-{[1-(tetrahydro-2H-Piran-4-ylmethyl)-1H-benzotriazole-5-yl]sulfonyl}benzamide;

N-({5-chloro-6-[(2-oxo-1-ox-3-azaspiro[4.5]Dec-8-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)-4-methoxypiperidine-1-carboxamide;

N-({5-chloro-6-[(2-methyl-4,5,6,7-tetrahydro-1,3-benzothiazol-5-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-{[1-(tetrahydro-2H-Piran-4-ylmethyl)-1H-imidazo[2,3-b]pyridin-5-yl]sulfonyl}benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-chloro-1-(tetrahydro-2H-Piran-4-ylmethyl)-1H-imidazo[2,3-b]pyridin-5-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[4,4-bis(gidroximetil)cyclohexyl]methoxy}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-(2-chloro-4-{[4-(4-{[2-(4-chlorophenyl)-4,4-di�ethylcyclohexyl-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}phenyl)-4-methoxypiperidine-1-carboxamide;

N-(2-chloro-4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}phenyl)-4-cyanopiperidine-1-carboxamide;

N-(2-chloro-4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}phenyl)-4-hydroxy-4-demerol-1-carboxamide;

N-(2-chloro-4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}phenyl)-4-(methoxymethyl)piperidine-1-carboxamide;

N-[(5-chloro-6-{[(5r,8r)-2-oxo-1-ox-3-azaspiro[4.5]Dec-8-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(5s,8s)-2-oxo-1-ox-3-azaspiro[4.5]Dec-8-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-(2-chloro-4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}phenyl)-4-(morpholine-4-yl)piperidine-1-carboxamide;

N-[(5-chloro-6-{[TRANS-4-hydroxy-4-(methoxymethyl)cyclohexyl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[CIS-4-hydroxy-4-(g�proximity)cyclohexyl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[TRANS-4-hydroxy-4-(gidroximetil)cyclohexyl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

and their therapeutically acceptable salts, and metabolites.

In another aspect, the present invention provides compounds of formula (IV)

and their therapeutically acceptable salts, and metabolites, where A1B1, D1E1and Y1have the meanings given in this application for Formula (I); R100has the meaning specified for substituents on R26; n is 0, 1, 2 or 3; R101has the meaning specified for substituents on R30; p has the value 0, 1, 2, 3, 4, 5 or 6; R104has the meaning specified for substituents on R38; s is set to 0, 1, 2, 3, 4, 5 or 6; R103has the meaning specified for substituents on R58; and r is 0, 1, 2, 3, or 4.

In one embodiment of formula (IV), n, p, r, and s each have a value of 0.

In one embodiment of formula (IV), A1represents N. In another embodiment of formula (IV), A 1is C(A2). In another embodiment of formula (IV), A1is C(A2); and A2represents H, F, Cl, Br or I. In another embodiment of formula (IV), A1is C(A2); and A2represents H.

In one embodiment of formula (IV), B1is an R1, OR1, NHR1, NHC(O)R1, F, Cl, Br or I. In another embodiment of formula (IV), A1is C(A2); A2represents H; and B1represents NHR1. In another embodiment of formula (IV), A1is C(A2); A2represents H; and B1represents OR1. In another embodiment of formula (IV), A1is C(A2); A2represents H; and B1represents Cl. In another embodiment of formula (IV), A1is C(A2); A2represents H; and B1is an R1. In another embodiment of formula (IV), A1represents N; and B1represents NHR1. In another embodiment of formula (IV), A1represents N; and B1represents OR1. In another embodiment of formula (IV), A1is the FDS�th N; and B1represents Cl. In another embodiment of formula (IV), A1represents N; and B1is an R1.

In one embodiment of formula (IV), D1represents H or Cl. In another embodiment of formula (IV), A1is C(A2); A2represents H; B1represents NHR1; and D1represents H. In another embodiment of formula (IV), A1is C(A2); A2represents H; B1represents NHR1; and D1represents Cl. In another embodiment of formula (IV), A1is C(A2); A2represents H; B1represents OR1; and D1represents H. In another embodiment of formula (IV), A1is C(A2); A2represents H; B1represents Cl; and D1represents H. In another embodiment of formula (IV), A1is C(A2); A2represents H; B1is an R1; and D1represents H. In another embodiment of formula (IV), A1represents N; B1represents NHR1; and D1represents H. In another embodiment, the implementation�ing formula (IV), A1represents N; B1represents NHR1; and D1represents Cl. In another embodiment of formula (IV), A1represents N; B1represents OR1; and D1represents H. In another embodiment of formula (IV), A1represents N; B1represents Cl; and D1represents H. In another embodiment of formula (IV), A1represents N; B1is an R1; and D1represents H.

In one embodiment of formula (IV), E1represents H. In another embodiment of formula (IV), A1is C(A2); A2represents H; B1represents NHR1; D1represents H; and E1represents H. In another embodiment of formula (IV), A1is C(A2); A2represents H; B1represents NHR1; E1represents H; and D1represents Cl. In another embodiment of formula (IV), A1is C(A2); A2represents H; B1represents OR1; D1represents H; and E1represents H. In another embodiment of formula (IV), A1ameri� a C(A 2); A2represents H; B1represents Cl; D1represents H; and E1represents H. In another embodiment of formula (IV), A1is C(A2); A2represents H; B1is an R1; D1represents H; and E1represents H. In another embodiment of formula (IV), A1represents N; B1represents NHR1; D1represents H; and E1represents H. In another embodiment of formula (IV), A1represents N; B1represents NHR1; E1represents H; and D1represents Cl. In another embodiment of formula (IV), A1represents N; B1represents OR1; D1represents H; and E1represents H. In another embodiment of formula (IV), A1represents N; B1represents Cl; D1represents H; and E1represents H. In another embodiment of formula (IV), A1represents N; B1is an R1; D1represents H; and E1represents H.

In one embodiment of formula (IV), Y1represents H, CN, NO2, F, Cl, Br, I, CF317, OR17, SR17, SO2R17or C(O)NH2. In another embodiment of formula (IV), Y1represents H. In another embodiment of formula (IV), Y1represents CN. In another embodiment of formula (IV), Y1represents F, Cl, Br or I. In another embodiment of formula (IV), Y1is a CF3. In another embodiment of formula (IV), Y1represents SR17. In another embodiment of formula (IV), Y1represents OR17. In another embodiment of formula (IV), Y1is a NO2. In another embodiment of formula (IV), Y1is a SO2R17; where R17has the meaning specified in the present application. In another embodiment of formula (IV), Y1is a SO2R17; where R17represents alkyl. In another embodiment of formula (IV), Y1is an R17; where R17is alkynyl. In another embodiment of formula (IV), A1is C(A2); A2represents H; B1represents NHR1; D1represents H; E1represents H; and Y1is a NO2or SO2R17; �de R 17represents an alkyl or alkynyl. In another embodiment of formula (IV), A1is C(A2); A2represents H; B1represents NHR1; D1represents H; E1represents H; and Y1is a NO2. In another embodiment of formula (IV), A1is C(A2); A2represents H; B1represents NHR1; D1represents H; E1represents H; and Y1is a SO2R17; where R17represents alkyl, substituted with three F. In another embodiment of formula (IV), A1represents N; B1represents NHR1; D1represents H; E1represents H; and Y1is a NO2or SO2R17; where R17represents an alkyl or alkynyl. In another embodiment of formula (IV), A1represents N; B1represents NHR1; D1represents H; E1represents H; and Y1is a NO2. In another embodiment of formula (IV), A1represents N; B1represents NHR1; D1represents H; E1represents H; and Y1isone SO 2R17; where R17represents alkyl, substituted with three F.

In one embodiment of formula (IV), Y1and B1together with the atoms to which they are linked, represent a benzene. In another embodiment of formula (IV), Y1and B1together with the atoms to which they are linked, represent heteroaryl. In another embodiment of formula (IV), A1is C(A2); A2E1and D1independently selected from H; and Y1and B1together with the atoms to which they are linked, represent a benzene. In another embodiment of formula (IV), A1is C(A2); A2E1and D1independently selected from H; and Y1and B1together with the atoms to which they are linked, represent heteroaryl.

In one embodiment of formula (IV), R1is an R4or R5. In one embodiment of formula (IV), R1is an R4. In one embodiment of formula (IV), R1is an R5. In one embodiment of formula (IV), R1is an R4; and R4is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen. In one embodiment of formula (IV), R1represents Rsup> 4; and R4is cycloalkyl or heteroseksualci. In one embodiment of formula (IV), R1is an R4; and R4is cycloalkyl. In one embodiment of formula (IV), R1is an R4; and R4is heteroseksualci.

In one embodiment of formula (IV), R1is an R4; and R4is cycloalkyl; where R4is unsubstituted or substituted as defined in this application. In another embodiment of formula (IV), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is substituted as defined in this application. In another embodiment of formula (IV), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is substituted with R57or N(R57)2Deputy. In another embodiment of formula (IV), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57Deputy; and R57is an R60. In another embodiment of formula (IV), R1is an R4R 4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57Deputy; R57is an R60; and R60is heteroseksualci. In another embodiment of formula (IV), R1is an R4; R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57Deputy; R57is an R60; R60is heteroseksualci; where geteroseksualnoe ring is morpholinyl. In another embodiment of formula (IV), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring substituted N(R57)2Deputy. In another embodiment of formula (IV), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with N(R57)2Deputy. In another embodiment of formula (IV), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring substituted N( 57)2Deputy; R57is an R61; and R61represents alkyl, which is unsubstituted or substituted with R62Deputy. In another embodiment of formula (IV), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57Deputy; R57is an R61; and R61represents alkyl, which is unsubstituted or substituted with R62Deputy, R62is an R65; and R65is cycloalkyl. In another embodiment of formula (IV), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57Deputy; R57is an R61; and R61represents alkyl which is substituted by R62; R62is an R65; and R65represents cyclopropyl.

In one embodiment of formula (IV), R1is an R4; and R4is heteroseksualci; where R4is unsubstituted or substituted as defined in this application. In another embodiment, the implementation�ing formula (IV), R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring is substituted as defined in this application. In another embodiment of formula (IV), R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring is substituted with R57Deputy. In another embodiment of formula (IV), R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where geteroseksualnoe ring is substituted with R57Deputy; and R57is an R60or R61. In another embodiment of formula (IV), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring is substituted with R57Deputy; R57is an R60or R61; R60is heteroseksualci; and R61represents alkyl. In another embodiment of formula (IV), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring ameri� piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring is substituted with R57Deputy; R57is an R60; R60is heteroseksualci; where heteroseksualci is tetrahydropyranyl. In another embodiment of formula (IV), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring is substituted with R57Deputy; R57is an R61; R61represents alkyl; and the alkyl is methyl. In another embodiment of formula (IV), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted with C(O)OR57Deputy; R57is an R61; R61represents alkyl; and the alkyl is methyl.

In one embodiment of formula (IV), R1is an R5; and R5represents alkyl; which is unsubstituted or substituted. In one embodiment of formula (IV), R1is an R5; and R5is the FDS�th alkyl; which is unsubstituted or substituted with R7, OR7, OH, CN or F Deputy. In another embodiment of formula (IV), R1is an R5; and R5represents alkyl; which is substituted with R7, OR7, NHR7or N(R7)2Deputy.

In one embodiment of formula (IV), R7is an R8, R9, R10or R11which are unsubstituted or substituted as defined in this application. In another embodiment of formula (IV), R7is an R8which is unsubstituted or substituted as defined in this application. In another embodiment of formula (IV), R7is an R9which is unsubstituted or substituted as defined in this application. In another embodiment of formula (IV), R7is an R10which is unsubstituted or substituted as defined in this application. In another embodiment of formula (IV), R7is an R11which is unsubstituted or substituted as defined in this application.

In one embodiment of formula (IV), R8represents phenyl, which is unsubstituted or substituted as defined in this application.

In one embodiment, the OS�implementation of the formula (IV), R9is heteroaryl, which is unsubstituted or substituted as defined in this application. In another embodiment of formula (IV), R9is furanyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (IV), R9is furanyl; which is unsubstituted.

In one embodiment of formula (IV), R10is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen; which are unsubstituted or substituted as defined in this application. In another embodiment of formula (IV), R10is heteroseksualci; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (IV), R10is tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, dioxane, oxetanyl, piperidinyl or pyrrolidinyl; which are unsubstituted or substituted as defined in this application. In another embodiment of formula (IV), R10is tetrahydropyranyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (IV), R10is morpholinyl; which is unsubstituted or substituted, as defined in the present application. In another embodiment of formula (IV), R10is cycloalkyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (IV), R10is cycloalkyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (IV), R10represents cyclohexyl, cyclopropyl, cyclobutyl or bicyclo[2.2.1]heptenyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (IV), R10is heteroseksualci; which is fused with R10A; and R10Ais heteroaryl. In another embodiment of formula (IV), R10is a 5,6,7,8-tetrahydroimidazo[1,2-a]pyridinyl.

In one embodiment of formula (IV), R11represents alkyl, alkenyl or alkynyl; which are unsubstituted or substituted as defined in this application. In another embodiment of formula (IV), R11represents alkyl. In another embodiment of formula (IV), R11is methyl; which is unsubstituted or substituted as defined in this application. In another embodiment, the implemented�I of the formula (IV), R11represents alkyl; which is substituted as defined in this application. In another embodiment of formula (IV), R11represents alkyl; which is substituted with R12, OR12or CF3Deputy. In another embodiment of formula (IV), R11represents alkyl; which is substituted OR12Deputy; R12is an R16; and R16represents alkyl. In another embodiment of formula (IV), R11represents alkyl; which is substituted with CF3Deputy. In another embodiment of formula (IV), R11represents alkyl; which is substituted with R12Deputy, R12is an R14and R14is heteroaryl.

In one embodiment of formula (IV),

n, p, r, and s each have a value of 0;

A1represents N or C(A2);

A2represents H, F, Br, I or Cl;

B1is an R1, OR1, NHR1, NHC(O)R1, F, Br, I or Cl;

D1represents H, F, Br, I or Cl;

E1represents H; and

Y1represents H, CN, NO2,F, Cl, Br, I, CF3, R17, OR17, SR17, SO2R17or C(O)NH2; or

Y1and B1together with the atoms to which they are linked, represent �Wallpaper benzene, heteroaryl or heteroseksualci; and

A2, D1and E1independently selected from H;

R1is an R4or R5;

R4is cycloalkyl or heteroseksualci;

R5represents an alkyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R7, OR7, NHR7N(R7)2, CN, OH, F, Cl, Br or I;

R7is an R8, R9, R10or R11;

R8represents phenyl;

R9is heteroaryl;

R10is cycloalkyl, cycloalkenyl or geteroseksualen; each of which is neskondensirovannyh or fused with R10A, R10Ais heteroaryl;

R11represents alkyl each of which is unsubstituted or substituted with one or two or three independently selected substituents R12, OR12or CF3;

R12is an R14or R16;

R14is heteroaryl;

R16represents alkyl;

R17is an R21;

R21represents an alkyl or alkynyl, each of which is unsubstituted or substituted by one or two or three not�avisio selected substituents R 22, F, Cl, Br or I;

R22is an R25;

R25is heteroseksualci;

where the cyclic groups represented by Y1and B1together, R4, R8, R10, R10Aand R25that are independently unsubstituted, having additional substitution, substituted or further substituted by one or two or three or four or five independently selected substituents R57A, R57, OR57, SO2R57, C(O)R57, CO(O)R57, C(O)N(R57)2NH2, NHR57N(R57)2, NHC(O)R57, NHS(O)2R57, C(O)OH, OH, CN, (O), F, Cl, Br or I;

R57Ais spiralcell or spiroheterocyclic;

R57is an R58, R60or R61;

R58represents phenyl;

R60is cycloalkyl or heteroseksualci;

R61represents alkyl, which is unsubstituted or substituted with one or two or three independently selected substituents R62, OR62N(R62)2, C(O)OH, OH, CN, F, Cl, Br or I;

R62is an R65or R66;

R65is cycloalkyl or heteroseksualci;

R66represents alkyl, which is unsubstituted or substituted OR67Deputy;

R 67represents alkyl;

where the cyclic groups represented as R57A, R58and R60are unsubstituted or substituted with one or two or three or four independently selected substituents R68, (O), F, Cl, Br or I;

R68is an R71or R72;

R71is heteroseksualci; and

R72represents alkyl, which is unsubstituted or substituted with one or two F.

Another variant of implementation relates to compounds having the formula (IV), which represent

4-{4-[(4'-chloro-1,1'-biphenyl-2-yl)methyl]piperazine-1-yl}-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chloro-1,1'-biphenyl-2-yl)methyl]piperazine-1-yl}-N-({4-[(3-morpholine-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

and their therapeutically acceptable salts, and metabolites.

In another aspect, the present invention provides compounds of formula (V)

and their therapeutically acceptable salts, and metabolites,

where A1B1, D1E1and Y1have the meanings given in this application for Formula (I); R100has the meaning specified for substituents on R26; n is 0, 1, 2 or 3; R101 has the meaning defined for substituents on R30; p has the value 0, 1, 2, 3, 4, 5 or 6; R105has the meaning specified for substituents on R40; t is 0, 1, 2, 3 or 4; R103has the meaning specified for substituents on R58; and r is 0, 1, 2, 3, or 4.

In one embodiment of formula (V), n, p, r and t each have the value 0.

In one embodiment of formula (V), A1represents N. In another embodiment of formula (V), A1is C(A2). In another embodiment of formula (V), A1is C(A2); and A2represents H, F, Cl, Br or I. In another embodiment of formula (V), A1is C(A2); and A2represents H.

In one embodiment of formula (V), B1is an R1, OR1, NHR1, NHC(O)R1, F, Cl, Br or I. In another embodiment of formula (V), A1is C(A2); A2represents H; and B1represents NHR1. In another embodiment of formula (V), A1is C(A2); A2represents H; and B1represents OR1. In another embodiment of formula (V), A1is C(A2); A2represents H; and B1performance�ulation of a Cl. In another embodiment of formula (V), A1is C(A2); A2represents H; and B1is an R1. In another embodiment of formula (V), A1represents N; and B1represents NHR1. In another embodiment of formula (V), A1represents N; and B1represents OR1. In another embodiment of formula (V), A1represents N; and B1represents Cl. In another embodiment of formula (V), A1represents N; and B1is an R1.

In one embodiment of formula (V), D1represents H or Cl. In another embodiment of formula (V), A1is C(A2); A2represents H; B1represents NHR1; and D1represents H. In another embodiment of formula (V), A1is C(A2); A2represents H; B1represents NHR1; and D1represents Cl. In another embodiment of formula (V), A1is C(A2); A2represents H; B1represents OR1; and D1represents H. In another embodiment of formula (V), A1is C(A2 ); A2represents H; B1represents Cl; and D1represents H. In another embodiment of formula (V), A1is C(A2); A2represents H; B1is an R1; and D1represents H. In another embodiment of formula (V), A1represents N; B1represents NHR1; and D1represents H. In another embodiment of formula (V), A1represents N; B1represents NHR1; and D1represents Cl. In another embodiment of formula (V), A1represents N; B1represents OR1; and D1represents H. In another embodiment of formula (V), A1represents N; B1represents Cl; and D1represents H. In another embodiment of formula (V), A1represents N; B1is an R1; and D1represents H.

In one embodiment of formula (V), E1represents H. In another embodiment of formula (V), A1is C(A2); A2represents H; B1represents NHR1; D1represents H; and E1represents H. In another embodiment of osushestvleniya (V), A1is C(A2); A2represents H; B1represents NHR1; E1represents H; and D1represents Cl. In another embodiment of formula (V), A1is C(A2); A2represents H; B1represents OR1; D1represents H; and E1represents H. In another embodiment of formula (V), A1is C(A2); A2represents H; B1represents Cl; D1represents H; and E1represents H. In another embodiment of formula (V), A1is C(A2); A2represents H; B1is an R1; D1represents H; and E1represents H. In another embodiment of formula (V), A1represents N; B1represents NHR1; D1represents H; and E1represents H. In another embodiment of formula (V), A1represents N; B1represents NHR1; E1represents H; and D1represents Cl. In another embodiment of formula (V), A1represents N; B1represents OR1; D1represents H; and E1submitted�is H. In another embodiment of formula (V), A1represents N; B1represents Cl; D1represents H; and E1represents H. In another embodiment of formula (V), A1represents N; B1is an R1; D1represents H; and E1represents H.

In one embodiment of formula (V), Y1represents H, CN, NO2, F, Cl, Br, I, CF3, R17, OR17, SR17, SO2R17or C(O)NH2. In another embodiment of formula (V), Y1represents H. In another embodiment of formula (V), Y1represents CN. In another embodiment of formula (V), Y1represents F, Cl, Br or I. In another embodiment of formula (V), Y1is a CF3. In another embodiment of formula (V), Y1represents SR17. In another embodiment of formula (V), Y1represents OR17. In another embodiment of formula (V), Y1is a NO2. In another embodiment of formula (V), Y1is a SO2R17; where R17has the meaning specified in the present application. In another embodiment of formula (V), Y1is a SO2R17 ; where R17represents alkyl. In another embodiment of formula (V), Y1is an R17; where R17is alkynyl. In another embodiment of formula (V), A1is C(A2); A2represents H; B1represents NHR1; D1represents H; E1represents H; and Y1is a NO2or SO2R17; where R17represents an alkyl or alkynyl. In another embodiment of formula (V), A1is C(A2); A2represents H; B1represents NHR1; D1represents H; E1represents H; and Y1is a NO2. In another embodiment of formula (V), A1is C(A2); A2represents H; B1represents NHR1; D1represents H; E1represents H; and Y1is a SO2R17; where R17represents alkyl, substituted with three F. In another embodiment of formula (V), A1represents N; B1represents NHR1; D1represents H; E1represents H; and Y1is a NO2or SO2R17; where R17before�offers an alkyl or alkynyl. In another embodiment of formula (V), A1represents N; B1represents NHR1; D1represents H; E1represents H; and Y1is a NO2. In another embodiment of formula (V), A1represents N; B1represents NHR1; D1represents H; E1represents H; and Y1is a SO2R17; where R17represents alkyl, substituted with three F.

In one embodiment of formula (V), Y1and B1together with the atoms to which they are linked, represent a benzene. In another embodiment of formula (V), Y1and B1together with the atoms to which they are linked, represent heteroaryl. In another embodiment of formula (V), A1is C(A2); A2E1and D1independently selected from H; and Y1and B1together with the atoms to which they are linked, represent a benzene. In another embodiment of formula (V), A1is C(A2); A2E1and D1independently selected from H; and Y1and B1together with the atoms to which they are linked, represent heteroaryl.

In one embodiment of formula (V), R1is an R4or R5 . In one embodiment of formula (V), R1is an R4. In one embodiment of formula (V), R1is an R5. In one embodiment of formula (V), R1is an R4; and R4is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen. In one embodiment of formula (V), R1is an R4; and R4is cycloalkyl or heteroseksualci. In one embodiment of formula (V), R1is an R4; and R4is cycloalkyl. In one embodiment of formula (V), R1is an R4; and R4is heteroseksualci.

In one embodiment of formula (V), R1is an R4; and R4is cycloalkyl; where R4is unsubstituted or substituted as defined in this application. In another embodiment of formula (V), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is substituted as defined in this application. In another embodiment of formula (V), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring substituted� R 57or N(R57)2Deputy. In another embodiment of formula (V), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57Deputy; and R57is an R60. In another embodiment of formula (V), R1is an R4; R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57Deputy; R57is an R60; and R60is heteroseksualci. In another embodiment of formula (V), R1is an R4; R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57Deputy; R57is an R60; R60is heteroseksualci; where geteroseksualnoe ring is morpholinyl. In another embodiment of formula (V), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring substituted N(R57)2Deputy. In another embodiment of formula (V), R1is with�battle R 4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with N(R57)2Deputy. In another embodiment of formula (V), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with N(R57)2Deputy; R57is an R61; and R61represents alkyl, which is unsubstituted or substituted with R62Deputy. In another embodiment of formula (V), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57Deputy; R57is an R61; and R61represents alkyl, which is unsubstituted or substituted with R62Deputy; R62is an R65; and R65is cycloalkyl. In another embodiment of formula (V), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57Deputy; R57is with�battle R 61; and R61represents alkyl which is substituted by R62Deputy; R62is an R65; and R65represents cyclopropyl.

In one embodiment of formula (V), R1is an R4; and R4is heteroseksualci; where R4is unsubstituted or substituted as defined in this application. In another embodiment of formula (V), R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring is substituted as defined in this application. In another embodiment of formula (V), R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring is substituted with R57Deputy. In another embodiment of formula (V), R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where geteroseksualnoe ring is substituted with R57Deputy; and R57is an R60or R61. In another embodiment of formula (V), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is a �piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring is substituted with R57Deputy; R57is an R60or R61; R60is heteroseksualci; and R61represents alkyl. In another embodiment of formula (V), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring is substituted with R57Deputy; R57is an R60; R60is heteroseksualci; where heteroseksualci is tetrahydropyranyl. In another embodiment of formula (V), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring is substituted with R57Deputy; R57is an R61; R61represents alkyl; and the alkyl is methyl. In another embodiment of formula (V), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl�Noah ring substituted with C(O)OR 57Deputy; R57is an R61; R61represents alkyl; and the alkyl is methyl.

In one embodiment of formula (V), R1is an R5; and R5represents alkyl, which is unsubstituted or substituted. In one embodiment of formula (V), R1is an R5; and R5represents alkyl, which is unsubstituted or substituted with R7, OR7, OH, CN or F Deputy. In another embodiment of formula (V), R1is an R5; and R5represents alkyl which is substituted by R7, OR7, NHR7or N(R7)2Deputy.

In one embodiment of formula (V), R7is an R8, R9, R10or R11which are unsubstituted or substituted as defined in this application. In another embodiment of formula (V), R7is an R8which is unsubstituted or substituted as defined in this application. In another embodiment of formula (V), R7is an R9which is unsubstituted or substituted as defined in this application. In another embodiment of formula (V), R7is an R10that is n�substituted or substituted, as defined in the present application. In another embodiment of formula (V), R7is an R11which is unsubstituted or substituted as defined in this application.

In one embodiment of formula (V), R8represents phenyl, which is unsubstituted or substituted as defined in this application.

In one embodiment of formula (V), R9is heteroaryl, which is unsubstituted or substituted as defined in this application. In another embodiment of formula (V), R9is furanyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (V), R9is furanyl; which is unsubstituted.

In one embodiment of formula (V), R10is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen; which are unsubstituted or substituted as defined in this application. In another embodiment of formula (V), R10is heteroseksualci; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (V), R10is tetrahydrofuranyl, tetrahydropyranyl, morpholine�l, dioxane, oxetanyl, piperidinyl or pyrrolidinyl; which are unsubstituted or substituted as defined in this application. In another embodiment of formula (V), R10is tetrahydropyranyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (V), R10is morpholinyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (V), R10is cycloalkyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (V), R10is cycloalkyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (V), R10represents cyclohexyl, cyclopropyl, cyclobutyl or bicyclo[2.2.1]heptenyl; which are unsubstituted or substituted as defined in this application. In another embodiment of formula (V), R10is heteroseksualci which is fused with R10A; and R10Ais heteroaryl. In another embodiment of formula (V), R10is a 5,6,7,8-tetrahydroimidazo[1,2-a]pyridinyl.

In one embodiment �of sushestvennee of formula (V), R11represents alkyl, alkenyl or alkynyl, which are unsubstituted or substituted as defined in this application. In another embodiment of formula (V), R11represents alkyl. In another embodiment of formula (V), R11is methyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (V), R11represents alkyl; which is substituted as defined in this application. In another embodiment of formula (V), R11represents alkyl; which is substituted with R12, OR12or CF3Deputy. In another embodiment of formula (V), R11represents alkyl; which is substituted OR12Deputy; R12is an R16; and R16represents alkyl. In another embodiment of formula (V), R11represents alkyl; which is substituted with CF3Deputy. In another embodiment of formula (V), R11represents alkyl; which is substituted with R12Deputy; R12is an R14; and R14is heteroaryl.

In one embodiment of formula (V),

n, p, r and t each have a value of 0;

A1represents N or C(A2);

A2/sup> represents H, F, Br, I or Cl;

B1is an R1, OR1, NHR1, NHC(O)R1, F, Br, I or Cl;

D1represents H, F, Br, I or Cl;

E1represents H; and

Y1represents H, CN, NO2,F, Cl, Br, I, CF3, R17, OR17, SR17, SO2R17or C(O)NH2; or

Y1and B1together with the atoms to which they are linked, represent a benzene, heteroaryl or heteroseksualci; and

A2, D1and E1independently selected from H;

R1is an R4or R5;

R4is cycloalkyl or heteroseksualci;

R5represents an alkyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R7, OR7, NHR7N(R7)2, CN, OH, F, Cl, Br or I;

R7is an R8, R9, R10or R11;

R8represents phenyl;

R9is heteroaryl;

R10is cycloalkyl, cycloalkenyl or geteroseksualen; each of which is neskondensirovannyh or fused with R10A, R10Ais heteroaryl;

R11represents alkyl each of which is unsubstituted Il� substituted with one or two or three independently selected substituents R 12, OR12or CF3;

R12is an R14or R16;

R14is heteroaryl;

R16represents alkyl;

R17is an R21;

R21represents an alkyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R22, F, Cl, Br or I;

R22is an R25;

R25is heteroseksualci;

where the cyclic groups represented by Y1and B together, R4, R8, R10, R10Aand R25that are independently unsubstituted, having additional substitution, substituted or further substituted by one or two or three or four or five independently selected substituents R57A, R57, OR57, SO2R57, C(O)R57, CO(O)R57,C(O)N(R57)2NH2, NHR57N(R57)2, NHC(O)R57, NHS(O)2R57, C(O)OH, OH, CN, (O), F, Cl, Br or I;

R57Ais spiralcell or spiroheterocyclic;

R57is an R58, R60or R61;

R58represents phenyl;

R60is cycloalkyl or heteroseksualci;

R61represents alkyl, which is illegal�emenim or substituted with one or two or three independently selected substituents R 62, OR62N(R62)2, C(O)OH, OH, CN, F, Cl, Br or I;

R62is an R65or R66;

R65is cycloalkyl or heteroseksualci;

R66represents alkyl, which is unsubstituted or substituted OR67;

R67represents alkyl;

where the cyclic groups represented as R57A, R58and R60are unsubstituted or substituted with one or two or three or four independently selected substituents R68, (O), F, Cl, Br or I;

R68is an R71or R72;

R71is heteroseksualci; and

R72represents alkyl, which is unsubstituted or substituted with one or two F.

Another variant of implementation relates to a compound having the Formula (V), which is a

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(1,4-dioxane-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxane-2-ylethoxy)-3-nitrophenyl]su�hanil}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-{[4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-(trifluoromethyl)phenyl]sulfonyl}benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-({4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(1-demerol-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)Benza�ID;

CIS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-methylpiperazin-1-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

and its therapeutically acceptable salts, and metabolites.

In another aspect, the present invention provides compounds of formula (VI)

and their therapeutically acceptable salts, and metabolites,

where A1B1, D1E1and Y1have the meanings given in this application for Formula (I); R100has the meaning specified for substituents on R26; n is 0, 1, 2 or 3; R101has the meaning specified for substituents on R30; p has the value 0, 1, 2, 3, 4, 5 or 6; R102has the meaning specified for substituents on R40; q has a value of 0, 1, 2, 3, 4, 5 or 6; R103has the meaning specified for substituents on R58; and r is 0, 1, 2, 3, or 4.

In one embodiment of formula (VI n, p, r and q each have a value of 0.

In one embodiment of formula (VI), A1represents N. In another embodiment of formula (VI), A1is C(A2). In another embodiment of formula (VI), A1is C(A2); and A2represents H, F, Cl, Br or I. In another embodiment of formula (VI), A1is C(A2); and A2represents H.

In one embodiment of formula (VI), B1is an R1, OR1, NHR1, NHC(O)R1, F, Cl, Br or I. In another embodiment of formula (VI), A1is C(A2); A2represents H; and B1represents NHR1. In another embodiment of formula (VI), A1is C(A2); A2represents H; and B1represents OR1. In another embodiment of formula (VI), A1is C(A2); A2represents H; and B1represents Cl. In another embodiment of formula (VI), A1is C(A2); A2represents H; and B1is an R1. In another embodiment of formula (VI), A1represents N; and B1represents NHR1. In another embodiment, the implementation�tion of the formula (VI), A1represents N; and B1represents OR1. In another embodiment of formula (VI), A1represents N; and B1represents Cl. In another embodiment of formula (VI), A1represents N; and B1is an R1.

In one embodiment of formula (VI), D1is H or Cl. In another embodiment of formula (VI), A1is C(A2); A2represents H; B1represents NHR1; and D1represents H. In another embodiment of formula (VI), A1is C(A2); A2represents H; B1represents NHR1; and D1represents Cl. In another embodiment of formula (VI), A1is C(A2); A2represents H; B1represents OR1; and D1represents H. In another embodiment of formula (VI), A1is C(A2); A2represents H; B1represents Cl; and D1represents H. In another embodiment of formula (VI), A1is C(A2); A2represents H; B1is an R1; and D1represents H. In another embodiment of formula (VI), Asup> 1represents N; B1represents NHR1; and D1represents H. In another embodiment of formula (VI), A1represents N; B1represents NHR1; and D1represents Cl. In another embodiment of formula (VI), A1represents N; B1represents OR1; and D1represents H. In another embodiment of formula (VI), A1represents N; B1represents Cl; and D1represents H. In another embodiment of formula (VI), A1represents N; B1is an R1; and D1represents H.

In one embodiment of formula (VI), E1represents H. In another embodiment of formula (VI), A1is C(A2); A2represents H; B1represents NHR1; D1represents H; and E1represents H. In another embodiment of formula (VI), A1is C(A2); A2represents H; B1represents NHR1; E1represents H; and D1represents Cl. In another embodiment of formula (VI), A1is C(A2); A2represents H; B1is�Oh OR 1; D1represents H; and E1represents H. In another embodiment of formula (VI), A1is C(A2); A2represents H; B1represents Cl; D1represents H; and E1represents H. In another embodiment of formula (VI), A1is C(A2); A2represents H; B1is an R1; D1represents H; and E1represents H. In another embodiment of formula (VI), A1represents N; B1represents NHR1; D1represents H; and E1represents H. In another embodiment of formula (VI), A1represents N; B1represents NHR1; E1represents H; and D1represents Cl. In another embodiment of formula (VI), A1represents N; B1represents OR1; D1represents H; and E1represents H. In another embodiment of formula (VI), A1represents N; B1represents Cl; D1represents H; and E1represents H. In another embodiment of formula (VI), A1represents N; B1is an R1; D1isone H; and E1represents H.

In one embodiment of formula (VI), Y1represents H, CN, NO2, F, Cl, Br, I, CF3, R17, OR17, SR17, SO2R17or C(O)NH2. In another embodiment of formula (VI), Y1represents H. In another embodiment of formula (VI), Y1represents CN. In another embodiment of formula (VI), Y1represents F, Cl, Br or I. In another embodiment of formula (VI), Y1is a CF3. In another embodiment of formula (VI), Y1represents SR17. In another embodiment of formula (VI), Y1represents OR17. In another embodiment of formula (VI), Y1is a NO2. In another embodiment of formula (VI), Y1is a SO2R17; where R17has the meaning specified in the present application. In another embodiment of formula (VI), Y1is a SO2R17; where R17represents alkyl. In another embodiment of formula (VI), Y1is an R17; where R17is alkynyl. In another embodiment of formula (VI), A1is C(A2); A2represents H; B1isone NHR 1; D1represents H; E1represents H; and Y1is a NO2or SO2R17; where R17represents an alkyl or alkynyl. In another embodiment of formula (VI), A1is C(A2); A2represents H; B1represents NHR1; D1represents H; E1represents H; and Y1is a NO2. In another embodiment of formula (VI), A1is C(A2); A2represents H; B1represents NHR1; D1represents H; E1represents H; and Y1is a SO2R17; where R17represents alkyl, substituted with three F. In another embodiment of formula (VI), A1represents N; B1represents NHR1; D1represents H; E1represents H; and Y1is a NO2or SO2R17; where R17represents an alkyl or alkynyl. In another embodiment of formula (VI), A1represents N; B1represents NHR1; D1represents H; E1represents H; and Y1is a NO2. In another embodiment of formula (VI), A1presented�a splash zones N; B1represents NHR1; D1represents H; E1represents H; and Y1is a SO2R17; where R17represents alkyl, substituted with three F.

In one embodiment of formula (IV), Y1and B1together with the atoms to which they are linked, represent a benzene. In another embodiment of formula (IV), Y1and B1together with the atoms to which they are linked, represent heteroaryl. In another embodiment of formula (IV), A1is C(A2); A2E1and D1independently selected from H; and Y1and B1together with the atoms to which they are linked, represent a benzene. In another embodiment of formula (IV), A1is C(A2); A2E1and D1independently selected from H; and Y1and B1together with the atoms to which they are linked, represent heteroaryl.

In one embodiment of formula (VI), R1is an R4or R5. In one embodiment of formula (VI), R1is an R4. In one embodiment of formula (VI), R1is an R5. In one embodiment of formula (VI), R1is an R4; and R4is cyclea�Kil, cycloalkenyl, heteroseksualci or geteroseksualen. In one embodiment of formula (VI), R1is an R4; and R4is cycloalkyl or heteroseksualci. In one embodiment of formula (VI), R1is an R4; and R4is cycloalkyl. In one embodiment of formula (VI), R1is an R4; and R4is heteroseksualci.

In one embodiment of formula (VI), R1is an R4; and R4is cycloalkyl; where R4is unsubstituted or substituted as defined in this application. In another embodiment of formula (VI), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is substituted as defined in this application. In another embodiment of formula (VI), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is substituted with R57or N(R57)2. In another embodiment of formula (VI), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57; and R57before�provide an R 60. In another embodiment of formula (VI), R1is an R4; R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57; R57is an R60; and R60is heteroseksualci. In another embodiment of formula (VI), R1is an R4; R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57; R57is an R60; R60is heteroseksualci; where geteroseksualnoe ring is morpholinyl. In another embodiment of formula (VI), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring substituted N(R57)2. In another embodiment of formula (VI), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with N(R57)2Deputy. In another embodiment of formula (VI), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a �illogical; and where pirazinokarbazolovogo cyclohexyl ring is substituted with N(R57)2Deputy; R57is an R61; and R61represents alkyl, which is unsubstituted or substituted with R62Deputy. In another embodiment of formula (VI), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57Deputy; R57is an R61; and R61represents alkyl, which is unsubstituted or substituted with R62Deputy; R62is an R65; and R65is cycloalkyl. In another embodiment of formula (VI), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where pirazinokarbazolovogo cyclohexyl ring is substituted with R57taken together; R57is an R61; and R61represents alkyl which is substituted by R62Deputy; R62is an R65; and R65represents cyclopropyl.

In one embodiment of formula (VI), R1is an R4; and R4is heteroseksualci; where R4is unsubstituted or substituted, ka� defined in the present application. In another embodiment of formula (VI), R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring is substituted as defined in this application. In another embodiment of formula (VI), R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring is substituted with R57Deputy. In another embodiment of formula (VI), R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where geteroseksualnoe ring is substituted with R57Deputy; and R57is an R60or R61. In another embodiment of formula (VI), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring is substituted with R57Deputy; R57is an R60or R61; R60is heteroseksualci; and R61represents alkyl. In another embodiment of formula (VI), R1is an R4; R4is heteroseksualci; g�e geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring is substituted with R57Deputy; R57is an R60; R60is heteroseksualci; where heteroseksualci is tetrahydropyranyl. In another embodiment of formula (VI), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring is substituted with R57Deputy; R57is an R61; R61represents alkyl; and the alkyl is methyl. In another embodiment of formula (VI), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted with C(O)OR57Deputy; R57is an R61; R61represents alkyl; and the alkyl is methyl.

In one embodiment of formula (VI), R1is an R5; and R5represents alkyl, which is unsubstituted or substituted. In one embodiment of formula (VI), R1is an R5; and R5is the FDS�th alkyl, which is unsubstituted or substituted with R7, OR7, OH, CN or F Deputy. In another embodiment of formula (VI), R1is an R5; and R5represents alkyl which is substituted by R7, OR7, NHR7or N(R7)2Deputy.

In one embodiment of formula (VI), R7is an R8, R9, R10or R11; which are unsubstituted or substituted as defined in this application. In another embodiment of formula (VI), R7is an R8; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (VI), R7is an R9; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (VI), R7is an R10; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (VI), R7is an R11; which is unsubstituted or substituted as defined in this application.

In one embodiment of formula (VI), R8represents phenyl; which is unsubstituted or substituted as defined in this application.

In one embodiment, the OS�implementation of the formula (VI), R9is heteroaryl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (VI), R9is furanyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (VI), R9is furanyl; which is unsubstituted.

In one embodiment of formula (VI), R10is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen; which are unsubstituted or substituted as defined in this application. In another embodiment of formula (VI), R10is heteroseksualci; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (VI), R10is tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, dioxane, oxetanyl, piperidinyl or pyrrolidinyl; which are unsubstituted or substituted as defined in this application. In another embodiment of formula (VI), R10is tetrahydropyranyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (VI), R10is morpholinyl; which is unsubstituted or substituted, as defined in the present application. In another embodiment of formula (VI), R10is cycloalkyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (VI), R10is cycloalkyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (VI), R10represents cyclohexyl, cyclopropyl, cyclobutyl or bicyclo[2.2.1]heptenyl; which is unsubstituted or substituted as defined in this application. In another embodiment of formula (VI), R10is heteroseksualci; which is fused with R10A; and R10Ais heteroaryl. In another embodiment of formula (VI), R10is a 5,6,7,8-tetrahydroimidazo[1,2-a]pyridinyl.

In one embodiment of formula (VI), R11represents alkyl, alkenyl or alkynyl; which are unsubstituted or substituted as defined in this application. In another embodiment of formula (VI), R11represents alkyl. In another embodiment of formula (VI), R11is methyl; which is unsubstituted or substituted as defined in this application. In another embodiment, the implemented�I of the formula (VI), R11represents alkyl; which is substituted as defined in this application. In another embodiment of formula (VI), R11represents alkyl; which is substituted with R12, OR12or CF3Deputy. In another embodiment of formula (VI), R11represents alkyl; which is substituted OR12Deputy; R12is an R16; and R16represents alkyl. In another embodiment of formula (VI), R11represents alkyl; which is substituted with CF3Deputy. In another embodiment of formula (VI), R11represents alkyl; which is substituted with R12Deputy; R12is an R14; and R14is heteroaryl.

In one embodiment of formula (VI)

n, p, r and q each have a value of 0;

A1represents N or C(A2);

A2represents H, F, Br, I or Cl;

B1is an R1, OR1, NHR1, NHC(O)R1, F, Br, I or Cl;

D1represents H, F, Br, I or Cl;

E1represents H; and

Y1represents H, CN, NO2,F, Cl, Br, I, CF3, R17, OR17, SR17, SO2R17or C(O)NH2; or

Y1and B1together with the atoms to which they are linked, represent �Wallpaper benzene, heteroaryl or heteroseksualci; and

A2, D1and E1independently selected from H;

R1is an R4or R5;

R4is cycloalkyl or heteroseksualci;

R5represents an alkyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected substituents R7, OR7, NHR7N(R7)2, CN, OH, F, Cl, Br or I;

R7is an R8, R9, R10or R11;

R8represents phenyl;

R9is heteroaryl;

R10is cycloalkyl, cycloalkenyl or geteroseksualen; each of which is neskondensirovannyh or fused with R10A, R10Ais heteroaryl;

R11represents alkyl each of which is unsubstituted or substituted with one or two or three independently selected substituents R12, OR12or CF3;

R12is an R14or R16;

R14is heteroaryl;

R16represents alkyl;

R17is an R21;

R21represents an alkyl or alkynyl, each of which is unsubstituted or substituted by one or two or three not�avisio selected substituents R 22, F, Cl, Br or I;

R22is an R25;

R25is heteroseksualci;

where the cyclic groups represented by Y1and B1together, R4, R8, R10, R10Aand R25that are independently unsubstituted, having additional substitution, substituted or further substituted by one or two or three or four or five independently selected substituents R57A, R57, OR57, SO2R57, C(O)R57, CO(O)R57,C(O)N(R57)2NH2, NHR57N(R57)2, NHC(O)R57, NHS(O)2R57, C(O)OH, OH, CN, (O), F, Cl, Br or I;

R57Ais spiralcell or spiroheterocyclic;

R57is an R58, R60or R61;

R58represents phenyl;

R60is cycloalkyl or heteroseksualci;

R61represents alkyl, which is unsubstituted or substituted with one or two or three independently selected substituents R62, OR62N(R62)2, C(O)OH, OH, CN, F, Cl, Br or I;

R62is an R65or R66;

R65is cycloalkyl or heteroseksualci;

R66represents alkyl, which is unsubstituted or substituted OR67Deputy;

R 67represents alkyl;

where the cyclic groups represented as R57A, R58and R60are unsubstituted or substituted with one or two or three or four independently selected substituents R68, (O), F, Cl, Br or I;

R68is an R71or R72;

R71is heteroseksualci; and

R72represents alkyl, which is unsubstituted or substituted with one or two F.

Another variant of implementation relates to a compound having the Formula (VI), which is a

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide;

and their therapeutically acceptable salts, and metabolites.

Pharmaceutical compositions, combination therapies, methods of treatment and introduction

Another variant implementation includes pharmaceutical compositions in�Luchshie connection having the Formula (I), and excipient.

Another option implementation includes methods of treating cancer in a mammal, comprising administering to the mammal a therapeutically acceptable amount of the compounds having Formula (I).

Another option implementation includes methods of treating autoimmune diseases in a mammal, comprising administering to the mammal a therapeutically acceptable amount of the compounds having Formula (I).

Another variant of implementation relates to compositions for treating diseases during which anti-ipoptions Bcl-2 proteins are expressed, these compositions include excipient and a therapeutically effective amount of the compounds having Formula (I).

Another variant of implementation relates to methods of treating diseases in a patient during which is expressed anti-ipoptions Bcl-2 proteins, these methods include the introduction to the patient a therapeutically effective amount of the compounds having Formula (I).

Another variant of implementation relates to compositions for treating bladder cancer, brain cancer, breast cancer, cancer of the bone marrow, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular l�mpoma, lymphoid malignant diseases of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, lung cancer, prostate cancer, small cell lung cancer or cancer of the spleen, these compositions include excipient and a therapeutically effective amount of the compounds having Formula (I).

Another variant of implementation relates to methods of treating bladder cancer, brain cancer, breast cancer, cancer of the bone marrow, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignant diseases of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, lung cancer, prostate cancer, small cell lung cancer or cancer of the spleen in a patient, these methods include the introduction to the patient a therapeutically effective amount of the compounds having Formula (I).

Another variant of implementation relates to compositions for treating diseases during which is expressed anti-ipoptions Bcl-2 proteins, thus specified compositionlocal excipient and a therapeutically effective amount of the compounds having the Formula (I) and a therapeutically effective amount of one additional therapeutic agent or more additional therapeutic agents.

Another variant of implementation relates to methods of treating diseases in a patient during which is expressed anti-ipoptions Bcl-2 proteins, these methods include the introduction to the patient a therapeutically effective amount of the compounds having Formula (I) and a therapeutically effective amount of one additional therapeutic agent or more additional therapeutic agents.

Another variant of implementation relates to compositions for treating bladder cancer, brain cancer, breast cancer, cancer of the bone marrow, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignant diseases of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, lung cancer, prostate cancer, small cell lung cancer or cancer of the spleen, these compositions include excipient and a therapeutically effective amount of the compounds and�housego Formula (I), and a therapeutically effective amount of one additional therapeutic agent or more additional therapeutic agents.

Another variant of implementation relates to methods of treating bladder cancer, brain cancer, breast cancer, cancer of the bone marrow, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignant diseases of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, lung cancer, prostate cancer, small cell lung cancer or cancer of the spleen in a patient, these methods include the introduction to the patient a therapeutically effective amount of the compounds having Formula (I) and a therapeutically effective amount of one additional therapeutic agent or more additional therapeutic agents.

Metabolites of compounds having Formula (I), generated by in vitro or in vivo metabolic processes, may also be useful for treatment of diseases associated with anti-apoptosome Bcl-2 proteins.

Some of the precursor compounds, which can metabolize�to train in vitro or in vivo with the formation of compounds having the Formula (I) may also be useful for treatment of diseases associated with expression of anti-apofaticheski Bcl-2 proteins.

Compounds having Formula (I) may exist in the form of acid-additive salts, basic additive salts or zwitterions. Salts of the compounds obtained in the process of selection or after cleaning compounds. Acid-additive salts of compounds are those salts which are formed by interaction of the compounds with an acid. For example, acetate, adipate, alginate, bicarbonate, citrate, aspartanetary, benzoate, benzolsulfonat, bisulfate, butyrate, comparatie, camphorsulfonate, digluconate, formate, fumaric, glycerophosphate, glutamate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactobionate, lactate, maleate, mesitylenesulfonic, methansulfonate, naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, phosphate, picrate, propionate, succinate, tartrate, thiocyanate, trichloroacetate, triptoreline, para-toluensulfonate and undecanoate salt compounds are covered by the present invention. Basically additive salts of compounds are those salts which are formed in the cut�LTTE interactions of the compounds with hydroxide, carbonate or bicarbonate of cations such as lithium, sodium, potassium, calcium and magnesium.

Compounds having the formula (I) can be introduced, for example, buccal, ophthalmic, oral, osmotic, parenteral (intramuscular, intraperitoneal intrasternal, intravenous, subcutaneous), rectal, local, percutaneous, or through the vagina.

Therapeutically effective amounts of compounds having the Formula (I) depend on recipient, receiving treatment, disorder being treated and the severity of this disorder, from the compositions containing the compound, time of administration, route of administration, duration of treatment, activity of the compound, its rate of elimination from the body and from being used or not co-administration of another drug. The number of compounds of the present invention having the Formula (I) used for production of the composition is for daily administration to a patient in a single dose or in fractional doses is from about 0.03 to about 200 mg/kg of body weight. Single dose compositions contain these amounts or a combination of these pairs of numbers.

Compounds having the Formula (I) can be introduced with excipients or without excipient. Excipient include, for example, encapsulating substances or additives such as absorption accelerators, antioxidants, binders, buffers are substances of coatings, colorants, diluents, disintegrants, emulsifiers, volumetric fillers, fillers, fragrances, humectants, lubricants, perfumes, preservatives, propellants, release agents, sterilizing agents, sweeteners, solubilizers substances, wetting agents and mixtures thereof.

Excipients to obtain compositions comprising a compound having the Formula (I) is intended for oral administration in solid dosage form include, for example, agar, alginic acid, aluminum hydroxide, benzyl alcohol, benzyl benzoate, 1,3-butyleneglycol, carbomer, castor oil, cellulose, cellulose acetate, cocoa butter, corn starch, corn oil, cotton seeds, cross-povidone, diglycerides, ethanol, ethylcellulose, ethyl laurate, ethyloleate, esters of fatty acids, gelatin, oil of sprouts of seeds, glucose, glycerin, the peanut oil, hydroxypropyl methylcellulose, isopropanol, isotonic saline, lactose, magnesium hydroxide, magnesium stearate, malt, mannitol, monoglycerides, olive oil, peanut oil, califofnia salt, potato starch, povidone, propylene glycol, ringer's solution, Safarova oil, sesame oil, sodium salt of carboxymethyl cellulose, nativespace salt, sodium lauryl sulfate, sodium�sorbitol, soybean oil, stearic acid, fumarate, sucrose, surfactants, talc, tragakant, tetrahydrofurfuryl alcohol, triglycerides, water, and mixtures thereof. Excipients to obtain compositions comprising a compound having the Formula (I) intended for the introduction of ophthalmic or by oral, liquid dosage forms include, for example, 1,3-butyleneglycol, castor oil, corn oil, cotton seeds, ethanol, esters of fatty acids sorbitan, oil of sprouts of seeds, peanut oil, glycerol, isopropanol, olive oil, polyethylene glycols, propylene glycol, sesame oil, water and mixtures thereof. Excipients to obtain compositions comprising a compound having the Formula (I), which can be entered by osmotic include, for example, chlorofluorohydrocarbons, ethanol, water and mixtures thereof. Excipients to obtain compositions comprising a compound having the Formula (I), which can be administered parenterally include, for example, 1,3-butanediol, castor oil, corn oil, cotton seeds, dextrose, oil of sprouts of seeds, peanut oil, liposomes, oleic acid, olive oil, peanut oil, ringer's solution, Safarova oil, sesame oil, soybean oil, U. S. P. or isotonic sodium chloride solution, water and with their�art. Excipients to obtain compositions comprising a compound having the Formula (I), which can be entered by rectal or vaginal, and include, for example, cocoa butter, polyethylene glycol, wax and mixtures thereof.

Expected that compounds having Formula (I), are useful when used with alkylating agents, inhibitors of angiogenesis, antibodies, antimetabolites, antimitotic means, antiproliferative funds, antiviral agents, inhibitors of aurora kinase and other promoters of apoptosis (e.g., Bcl-xL, Bcl-w and Bfl-1) inhibitors, activators of the way receptors, apoptosis, inhibitors of the kinase Bcr-Abl, BiTE (Bi-specific T-cell comprising a mechanism) antibodies, conjugates antibody-drug, biological response modifiers, inhibitors of cyclin-dependent kinases, the cell cycle inhibitors, cyclooxygenase-2 inhibitors, DVDs, inhibitors of receptor homolog leukemia viral oncogene (ErbB2), inhibitors of growth factors, inhibitors of heat shock protein (HSP)-90, inhibitors discontiuation (HDAC), hormonal terapiya, immunological agents, inhibitors of inhibitors of apoptosis proteins (IAPS), intercalating antibiotics, kinase inhibitors, inhibitors of kinesin, Jak2 inhibitors, inhibitors of target of rapamycin in mammals, micron�, inhibitors of the mitogen-activated extracellular regulated signal kinase, multivalent binding proteins, non-steroidal anti-inflammatory drugs (NCPLS), inhibitors of poly ADP (adenosine diphosphate)-rabota polymerase (PARP), chemotherapeutic agents based on platinum, inhibitors of polo-like kinase (Plk) inhibitors phosphoinositide-3 kinase (PI3K), proteasome inhibitors, purine analogs, pyrimidine analogs, inhibitors tyrosinemia kinase receptors, the retinoid/deltoidea plant alkaloids, small inhibitory ribonucleic acids (siRNAs), topoisomerase inhibitors, inhibitors of ubicacin-ligase and the like, as well as in combination with one or more such funds.

BiTE antibodies represent a bi-specific antibodies that direct T-cells to attack cancer cells by simultaneous binding of these two cells. T-cells then attack machinewww cancer cell. Examples of BiTE antibodies include adecatumumab (Micromet MT201), blinatumomab (Micromet MT103) and the like. Without limitation by theory, one mechanism whereby T-cells trigger the apoptosis micheneau cancer cell represent the exocytosis of cytolytic granule components that weaken the induction of apoptosis by perforin, t�to and granzyme B. These data suggest that inhibition of Bcl-2 may enhance the cytotoxic effects induced T-cells when sighting the effects on cancer cells (V. R. Sutton, D. L. Vaux and J. A. Trapani, J. of Immunology 1997, 158 (12), 5783).

SiRNAs are molecules containing endogenous RNA bases or chemically modified nucleotides. Modifications do not eliminate cellular activity, but rather reported increased stability and/or increased cellular activity. Examples of chemical modifications include phosphorothioate group, 2'-deoxynucleotide, 2'-OCH3-containing ribonucleotides, 2'-F-ribonucleotides, 2'-methoxyethylamine, combinations thereof and the like. siRNAs can have different lengths (e.g., 10-200 BP) and patterns (e.g., “studs”, single/double stranded, loop, “nicks/gaps, erroneous pairing(reason)) and processinputs in the cells, allowing active gene salesin. Double-stranded siRNAs (ds) may contain the same number of nucleotides in each chain (blunt ends) or asymmetric (protruding)ends. The exposed end of 1-2 nucleotides can be present in sense and/or antisense chain, and also be present at the 5' and/or 3'ends of the chain. For example, it was shown that siRNAs targeting Mcl-1 increase the activity of ABT-263, (i.e., N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-EN-1-yl)methyl)Pipa�Azin-1-yl)benzoyl)-4-(((1R)-3-(morpholine-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzosulfimide) or ABT-737 (i.e., N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazine-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide) in several tumor cell lines (Tse et. al, Cancer Research 2008, 68(9), 3421 and specified in this document references).

Multivalent binding proteins are binding proteins comprising two or more binding sites of the antigen. Multivalent binding proteins are designed so that they contain three or more binding sites and, as a rule, are antibodies unnatural origin. The term “multivalent binding protein” means a binding protein capable of binding two or more related or unrelated targets. Binding proteins with two variable domain (DVD) are tetravalent or multivalent binding proteins comprising two or more binding sites of the antigen. These DVDs can be monospecifičeskoj (i.e., capable of binding one antigen) or polyspecific (i.e. capable of binding two or more antigens). DVD binding proteins comprising two DVD polypeptide heavy chains and two DVD light chain polypeptide is referred to as DVD Ig's. Each half DVD Ig polypeptide includes DVD heavy chain DVD polypeptide light chain and two binding site of the antigen. Each site concerned�neither includes the variable domain of the heavy chain and the variable domain light chain and a total of 6 CDR, involved in binding to the antigen, the binding site of the antigen.

Alkylating agents include altretamin, AMD-473, AP-5280, apaziquone, bendamustine, brostallicin, busulfan, carboquone, carmustine (BCNU), chlorambucil, CLORETAZINE®(laromustine, VNP 40101M), cyclophosphamide, dacarbazine, estramustine, fotemustine, glufosfamide, ifosfamide, KW-2170, lomustine (CCNU), mafosfamide, melphalan, metabolical, mitolactol, nimustine, nitrogen mustard N-oxide, ranimustine, temozolomide, thiotepa, TREANDA®(bendamustine), treosulfan, rotospeed and such.

Angiogenesis inhibitors include endothelial-specific inhibitors of tyrosine kinase receptor (Tie-2) inhibitors of the receptor of epidermal growth factor (EGFR) inhibitors of the receptor insulin-like growth factor-2 (IGFR-2) inhibitors, matrix metalloproteinase-2 (MMP-2) inhibitors, matrix metalloproteinase-9 (MMP-9) inhibitors of the receptor platelet-derived growth factor (PDGFR), the analogues of thrombospondin, inhibitors of tyrosine kinase receptors endothelial growth factor (VEGFR) and the like.

Antimetabolites include ALIMTA®(pemetrexed disodium, LY231514, MTA), 5-azacytidine, XELODA®(capecitabine), carmofur, LEUSTAT®(cladribine), Clofarabine, cytarabine, cytarabine ocfosfate, cytosine arabinoside, decitabine, deferoxamine, doxifluridine, eflornithine, EICAR (5-ethinyl-1-β-D-ribofuranoside�ol-4-carboxamide), enocitabine, ethnicities, fludarabine, 5-fluorouracil alone or in combination with leucovorin, GEMZAR®(gemcitabine), hydroxyurea, ALKERAN®(melphalan), mercaptopurine, 6-mercaptopurine ribozid, methotrexate, mycophenolic acid, nelarabine, nolatrexed, ocfosfate, political, pentostatin, raltitrexed, Ribavirin, triapine, trimetrexate, S-1, tianfuan, tegafur, TS-1, vidarabine, UFT and the like.

Antiviral agents include ritonavir, hydroxychloroquin and such.

Inhibitors of aurora kinase include ABT-348, AZD-1152, MLN-8054, VX-680, Aurora A-specific kinase inhibitors, Aurora B-specific inhibitors of kinases and kinase inhibitors pan - aurora and such.

Inhibitors of Bcl-2 protein include AT-101 ((-)gossypol), GENASENSE®(G3139 or oblimersen (Bcl-2-targeting antisense oligonucleotide)), IPI-194, IPI-565, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazine-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide) (ABT-737), N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-EN-1-yl)methyl)piperazine-1-yl)benzoyl)-4-(((1R)-3-(morpholine-4-yl)-1-((phenylsulfanyl)methyl)propyl)-amino)-3-((trifluoromethyl)sulfonyl)benzosulfimide (ABT-263), GX-070 (obatoclax) and the like.

Inhibitors of Bcr-Abl kinase include DASATINIB®(BMS-354825), GLEEVEC®(imatinib) and the like.

The CDK inhibitors include AZD-5438, BMI-1040, BMS-032, BMS-387, CVT-2584, flavoured�l, GPC-286199, MCS-5A, PD0332991, PHA-690509, seliciclib (CYC-202, R-roscovitine), ZK-304709 and the like.

The COX-2 inhibitors include ABT-963, ARCOXIA®(etoricoxib), BEXTRA®(valdecoxib), BMS347070, CELEBREX®(celecoxib), a COX-189 (lumiracoxib), CT-3, DERAMAXX®(deracoxib), JTE-522, 4-methyl-2-(3,4-dimethylphenyl)-1-(4-sulfamoyl-1H-pyrrol), MK-663 (etoricoxib), NS-398, parecoxib, RS-57067, SC-58125, SD-8381, SVT-2016, S-2474, T-614, VIOXX®(rofecoxib) and the like.

EGFR inhibitors include ABX-EGF, anti-EGFR of immunoliposome, EGF-vaccine, EMD-7200, ERBITUX®(cetuximab), HR3, IgA antibodies, IRESSA®(gefitinib), TARCEVA®(erlotinib or OSI-774), TP-38, EGFR fusion protein, TYKERB®(lapatinib) and the like.

Inhibitors of ErbB2 receptor include CP-724-714, CI-1033 (canertinib), HERCEPTIN®(trastuzumab), TYKERB®(lapatinib), OMNITARG®(2C4, pertuzumab), TAK-165, GW-572016 (inferni), GW-282974, EKB-569, PI-166, dHER2 (HER2 vaccine), APC-8024 (HER-2 vaccine), anti-HER/2neu bespecifically antibody, B7.her2IgG3, AS HER2 trifunctional bespecifically antibodies, mAB AR-209, mAB 2B-1 and the like.

Inhibitors discontiuation include depsipeptide, LAQ-824, MS-275, trioxin, suberoylanilide hydroxamic acid (SAHA), TSA, valproate acid and the like.

Inhibitors of HSP-90 include 17-AAG-nab, 17-AAG, CNF-101, CNF-1010, CNF-2024, 17-DMAG, geldanamycin, IPI-504, KOS-953, MYCOGRAB®(human recombinant antibody to HSP-90), NCS-683664, PU24FCl, PU-3, radicial, SNX-2112, STA-9090 VER49009 and such.

Inhibitors of inhibitors of apoptosis proteins include HGS1029, GDC-0145, GDC-0152, LCL-161, LBW-242 and the like.

Conjugates of the antibody-drug include anti-CD22-MC-MMAF, anti-CD22-MC-MMAE, anti-CD22-MCC-DM1, CR-011-vcMMAE, PSMA-ADC, MEDI-547, SGN-19Am SGN-35, SGN-75 and the like.

Activators of the way of the apoptosis receptor include TRAIL, antibodies or other means that are precisely aimed at TRAIL or a receptor of apoptosis (e.g., DR4 and DR5) such as Apomab, contumes, ETR2-ST01, GDC0145 (lexatumumab), HGS-1029, LBY-135, PRO-1762 and trastuzumab.

Inhibitors include kinesin Eg5 inhibitors, such as AZD4877, ARRY-520; CENPE inhibitors, such as GSK923295A, and the like.

Inhibitors of JAK-2 include CEP-701 (resourcelib), XL019 and INCB018424 and such.

The MEK inhibitors include ARRY-142886, ARRY-438162 PD-325901, PD-98059 and the like.

The mTOR inhibitors include AP-23573, CCI-779, everolimus, RAD-001, rapamycin, temsirolimus, ATP-competitive inhibitors of TORC1/TORC2, including PI-103, PP242, PP30, Torin 1 and the like.

Nonsteroidal anti-inflammatory drugs include AMIGESIC®(salsalate), DOLOBID®(diflunisal), MOTRIN®(ibuprofen), ORUDIS®(Ketoprofen), RELAFEN®(nabumetone), FELDENE®(piroxicam), ibuprofen cream ALEVE®(naproxen) NAPROSYN and®(naproxen), VOLTAREN®(diclofenac), INDOCIN®(indomethacin), CLINORIL®(sulindac), TOLECTIN®(tolmetin), LODINE®(etodolac), TORADOL®(Ketorolac), DAYPO ®(oxaprozin) and the like.

The PDGFR inhibitors include C-451, CP-673, CP-868596 and such.

Chemotherapeutic agents based on platinum include cisplatin, ELOXATIN®(oxaliplatin) heptaplatin, lobaplatin, nedaplatin, PARAPLATIN®(carboplatin), satraplatin, picoplatin and such.

Inhibitors of Polo-like kinases include BI-2536 and the like.

Inhibitors phosphoinositide-3 kinase (PI3K) include wortmannin, LY294002, XL-147, CAL-120, ONC-21, AEZS-127, ETP-45658, PX-866, GDC-0941, BGT226, BEZ235, XL765 and the like.

Analogs of thrombospondin include ABT-510, ABT-567, ABT-898, TSP-1 and similar.

The VEGFR inhibitors include AVASTIN®(bevacizumab), ABT-869, AEE-788, ANGIOZYME™ (a ribozyme that inhibits angiogenesis (Ribozyme Pharmaceuticals (Boulder, CO.) and Chiron, (Emeryville, CA)), axitinib (AG-13736), AZD-2171, CP-547,632, IM-862, MACUGEN (pegaptanib), NEXAVAR®(sorafenib, BAY43-9006), pazopanib (GW-786034), vatalanib (PTK-787, ZK-222584), SUTENT®(sunitinib, SU-11248), VEGF trap, ZACTIMA™ (vandetanib, ZD-6474) and the like.

Antibiotics include intercalating antibiotics aclarubicin, actinomycin D, amrubicin, annamycin, adriamycin, BLENOXANE®(bleomycin), daunorubicin, CAELYX®or MYOCET®(liposomal doxorubicin), elsamitrucin, epirotan, parboil, ZAVEDOS®(idarubicin), mitomycin C, nemorubicin, neocarzinostatin, peplomycin, pirarubicin, rebeccamycin, stimulater, streptozocin, VALSTAR®(valrubicin), sinostar�n and the like.

The topoisomerase inhibitors include aclarubicin, 9-aminocamptothecin, amonafide, amsacrine, bicategory, belotecan, BN-80915, CAMPTOSAR®(irinotecan hydrochloride), camptothecin, CARDIOXANE®(dexrazoxane), diflomotecan, edotecarin, ELLENCE®or PHARMORUBICIN®(epirubicin), etoposide, eksteen, 10-hydroxycamptothecin, gimatecan, lurtotecan, mitoxantrone, oracin, parabolin, pixantrone, rubitecan, sobuzoxane, SN-38, tafluprost, topotecan and the like.

Antibodies include AVASTIN®(bevacizumab), CD40-specific antibodies, chTNT-1/B, denosumab, ERBITUX®(cetuximab), HUMAX-CD4®(zanolimumab), IGF1R-specific antibodies, lintuzumab, PANOREX®(edrecolomab), RENCAREX®(WX G250), RITUXAN®(rituximab), ticilimumab, trastuzumab, CD20 antibodies types I and II and the like.

Hormonal therapies include ARIMIDEX®(anastrozole), AROMASIN®(exemestane), arzoxifene, CASODEX®(bikalutamid), CETROTIDE®(cetrorelix), degarelix, deslorelin, DESOPAN®(trilostane), dexamethasone, DROGENIL®(flutamide), EVISTA®(raloxifene), AFEMA™ (fadrozole), FARESTON®(toremifene), FASLODEX®(fulvestrant), FEMARA®(letrozole), formestane, glucocorticoids, HECTOROL®(doxercalciferol), RENAGEL®(sevelamer carbonate), lasofoxifene, leuprolide acetate, MEGACE®(megestrol), MIFEPREX®(mifepristone), NILANDRON� (nilutamid), NOLVADEX®(tamoxifen citrate), PLENAXIS™ (abarelix), prednisone, PROPECIA®(finasteride), elastan, SUPREFACT®(buserelin), TRELSTAR®(releasing factor, luteinizing hormone (LHRH)), VANTAS®(Histrelin implant), VETORYL®(trilostane or morestan), ZOLADEX®(forlin, goserelin) and the like.

Deltoids and retinoids include seocalcitol (EB1089, CB1093), lexicality (KH1060), phenetidine, PANRETIN®(alitretinoin), ATRAGEN®(liposomal tretinoin), TARGRETIN®(bexarotene), LGD-1550 and the like.

PARP inhibitors include ABT-888 (veliparib), olaparib, KU-59436, AZD-2281, AG-014699, BSI-201, BGP-15, INO-1001, ONO-2231 and the like.

Plant alkaloids include, but are not limited to, vincristine, vinblastine, vindesine, vinorelbine and the like.

The proteasome inhibitors include VELCADE®(bortezomib), MG, NPI-0052, PR-171 and the like.

Examples of immunological tools include interferons and other immunoassay funds. Interferons include interferon alpha, interferon alpha-2a, interferon alpha-2b, interferon beta, interferon gamma-1a, ACTIMMUNE®(interferon gamma-1b) or interferon gamma-n1, combinations thereof and the like. Other tools include ALFAFERONE®,(IFN-α), BAM-002 (oxidized glutathione), BEROMUN®(tasonermin), BEXXAR®(it), CAMPATH®(alemtuzumab), CTLA4 (cytotoxic limfotsity antigen 4),dacarbazine, denileukin, epratuzumab, GRANOCYTE®(lenograstim), lentinan, leukocyte alpha interferon, imiquimod, MDX-010 (anti-CTLA-4), vaccines against melanoma, mitooma, molgramostim, MYLOTARG™ (gemtuzumab ozogamicin), NEUPOGEN®(filgrastim), OncoVAC-CL, OVAREX®(oregovomab), pemtumomab (Y-muHMFG1), PROVENGE®(sipuleucel-T), sargramostim, sizofiran, teceleukin, THERACYS®(Bacillus Calmette-Guerin), ubenimex, VIRULIZIN®(immunotherapeutic agent, Lorus Pharmaceuticals), Z-100 (specific substance of Maruyama (SSM)), WF-10 (tetrachlorodecaoxide (TCDO)), PROLEUKIN®(aldesleukin), ZADAXIN®(thymalfasin), ZENAPAX®(impact), ZEVALIN®(90Y-Ibritumomab tiuxetan) and the like.

The biological response modifiers are tools that modify defense mechanisms of living organisms or biological responses such as survival, growth or differentiation of tissue cells, directing them to the acquisition of antitumor activity, and include baptisms, lentinan, sizofiran, picibanil PF-3512676 (CpG-8954), ubenimex and such.

Pyrimidine analogs include cytarabine (ara C or Arabinose C), cytosine arabinoside, doxifluridine, FLUDARA®(fludarabine), 5-FU (5-fluorouracil), floxuridine, GEMZAR®(gemcitabine), TOMUDEX®(raytraced), TROXATYL™ (triacetyluridine troxacitabine) and the like.

Purine analogs include LANVIS®(t�guanin) and PURI-NETHOL ®(mercaptopurine).

Antimitotic funds include metabolin, epothilone D (KOS-862), N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide, ixabepilone (BMS 247550), paclitaxel, TAXOTERE®(docetaxel), PNU100940 (109881), patupilone, XRP-9881 (larotaxel), vinflunine, ZK-EPO (synthetic epothilone) and the like.

Inhibitors ubicacin-include the ligase MDM2 inhibitors, such as nutlin, NEDD8 inhibitors, such as N4924 and such.

Compounds of the present invention can also be used as radiosensitisation that enhance the effectiveness of radiation therapy. Examples of radiation therapy include radiation therapy with external beam teletherapy, brachytherapy and radiation therapy using sealed and unsealed source, and the like.

Additionally, compounds having Formula (I), can be used in combination with other chemotherapeutic agents such as ABRAXANE™ (ABI-007), ABT-100 (inhibitor farnesyltransferase), ADVEXIN®(Ad5CMV-p53 vaccine), ALTOCOR®or MEVACOR®(lovastatin), AMPLIGEN®(poly I:poly C12U, a synthetic RNA), APTOSYN®(asialand), AREDIA®(pamidronate acid), Arglabin, L-asparaginase, atamestane (1-methyl-3,17-dione-androsta-1,4-diene), AVAGE®(tazarotene), AVE-8062 (derived combretastatin) BEC2 (mitooma), cachectin or cachexin (factor NEK�oz's tumor), canvaxin (vaccine), CEAVAC®(cancer vaccine), CELEUK®(Almonacid), CEPLENE®(histamine dihydrochloride), CERVARIX®(the vaccine against human papillomavirus (HPV), CHOP®(C: CYTOKCAN®(cyclophosphamide); H: ADRIAMYCIN®(hydroxydoxorubicin); O: Vincristine (ONCOVIN®); P: prednisone), CYPAT™ (ciproteron acetate), complestatin A4P, DAB(389)EGF (catalytic and translocation domains of diphtheria toxin fused via a His-Ala linker to human epidermal growth factor) or TransMID-107R™ (diphtheria toxins), dacarbazine, dactinomycin, 5,6-dimethylxanthene-4-acetic acid (DMXAA), eniluracil, EVIZON™ (squalamine lactate), DIMERICINE®(T4N5 liposome lotion), discodermolide, DX-8951f (eksteen mesilate), enzastaurin, EPO906 (epitalon B), GARDASIL®(quadrivalent recombinant vaccine against human papillomavirus (Types 6, 11, 16, 18)), GASTRIMMUNE®, GENASENSE®, GMK (ganglioside conjugate vaccine), GVAX®(a vaccine against prostate cancer), halofuginone, histrelin, hydroxyurea, ibandronova acid, IGN-101, IL-13-PE38, IL-13-PE38QQR (cintredekin besudotox), IL-13-pseudomonas exotoxin, interferon-α, interferon-γ, JUNOVAN™ or MEPACT™ (mifamurtide), lonafarnib, 5,10-methylentetrahydrofolate, miltefosin (hexadecylphosphocholine), NEOVASTAT®(AE-941), NEUTREXIN®(trimetrexate the glucuronate), NIPENT®(pentostatin), ONCONASE®(the enzyme ribonuclease), ONCOPHAGE®(vaccine for treatment of melanoma), ONCOVAX®(IL-2 Vaccine), ORATHECIN™ (rubitecan), OSIDEM®(cell a medicament based on antibodies), OVAREX®MAb (murine monoclonal antibody), paclitaxel, PANDIMEX™ (aglionby saponins of Panax ginseng, including 20(S)protopanaxadiol (aPPD) and 20(S) protopanaxatriol (aPPT)), panicum, PANVAC®-VF (ongoing clinical trial of cancer vaccine), pegaspargase, PEG Interferon-A, phenoxodiol, procarbazine, ropemaster, REMOVAB®(catumaxomab), REVLIMID®(lenalidomide), RSR13 (efaproxiral), SOMATULINE®LA (untreated), SORIATANE®(acitretin), STS (Streptomyces staurospores), talabostat (PT100), TARGRETIN®(bexarotene), TAXOPREXIN®(DHA-paclitaxel), TELCYTA®(canvasframe, TLK286), tesmilifene, TEMODAR®(temozolomide), tesmilifene, thalidomide, THERATOPE®(STn-KLH), thymitaq (2-amino-3,4-dihydro-6-methyl-4-oxo-5-(4-pyridylthio)hinzelin dihydrochloride), TNFERADE™ (adenovector: native DNA, containing the gene for tumor necrosis factor-α), TRACLEER®or ZAVESCA®(bosentan), tretinoin (retin-A), tetrandrine, TRISENOX®(arsenic trioxide), VIRULIZIN®, Ukrain (derivative of alkaloids from the greater celandine), vitaxin (anti-alpha against beta antibody), XCYTRIN®(motexafin gadolinium), XINLAY™ (atrasentan), XYOTAX™ (paclitaxel poliglumex), YNDELIS ®(trabectedin), ZD-6126, ZINECARD®the dexrazoksana), ZOMETA®(zoledronicaa acid), zorubicin and such.

Data

The definition of the utility of compounds having Formula (I) as binders to and inhibitors of anti-apofaticheski Bcl-2 proteins was carried out using analysis of resonant energy transfer fluorescence with a time resolution (TR-FRET). Tb-anti-GST antibody was purchased from the company Invitrogen (Catalog No. PV4216).

The synthesis of probe

All reagents used in the form as they were received from the supplier, unless otherwise noted. Reagents for peptide synthesis, including diisopropylethylamine (DIEA), dichloro methane (DCM), N-methylpyrrolidone (NMP), hexaflurophosphate 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium (HBTU), N-hydroxy-benzotriazole (HOBt) and piperidine were obtained from the company Applied Biosystems, Inc. (ABI), Foster City, CA, or from American Bioanalytical, Natick, MA. Pre-loaded 9-Fluorenylmethoxycarbonyl (Fmoc) amino acid cartridges (Fmoc-Ala-OH, Fmoc-Cys(Trt)-OH, Fmoc-Asp(tBu)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Phe-OH, Fmoc-Gly-OH, Fmoc-His(Trt)-OH, Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Met-OH, Fmoc-Asn(Trt)-OH, Fmoc-Pro-OH, Fmor-Gln(Trt)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Val-OH, Fmoc-Trp(Boc)-OH, Fmoc-Tyr(tBu)-OH) were obtained from ABI or Anaspec, San Jose, CA. The resin for peptide synthesis (Fmoc-Rink amide MBHA resin) and Fmoc-Lys(Mtt)-OH was obtained from the company Novabiochem, San Diego, CA. 6- ether in the form of a single isomer (6-FAM-NHS) was obtained from the company� Anaspec. Trifluoroacetic acid (TFA) was obtained from the company Oakwood Products, West Columbia, SC. Thioanisole, phenol, triisopropylsilane (TIS), 3,6-dioxa-1,8-octanedithiol (DODT) and isopropanol were obtained from the company Aldrich Chemical Co., Milwaukee, WI. Mass spectra obtained by laser desorption ionization using matrix (MALDI-MS) were recorded on Applied Biosystems Voyager DE-PRO MS). Mass-spectra were obtained using electrospray (ESI-MS) were recorded on Finnigan SSQ7000 (Finnigan Corp., San Jose, CA) as in the mode of positive and negative ions.

General procedure for solid-phase peptide synthesis (psycho-audio-linguistic)

Peptides were synthesized using a maximum of 250 µmol pre-loaded Wang resin/vessel on an ABI 433A peptide synthesizer using 250 μmol scale Fastmoc™ cycles of binding. Pre-load cartridges containing 1 mmol of standard Fmoc-amino acids, except for the provisions of the accession of the fluorophore, where 1 mmol Fmoc-Lys(Mtt)-OH was loaded into the cartridge, used with the monitoring feedback on the conductivity. N-terminal acetylation was carried out using 1 mmol of acetic acid in the cartridge in a standard binding conditions.

The removal of 4-Methyltetra (Mtt) from lysine

The resin from the synthesizer were washed three times using DCM and kept moist. 150 ml of 95:4:1 dichloromethane:triisopropylsilane:triflorum�usnei acid was passed through the resin for 30 minutes. The mixture became dark yellow, then the color changed to pale yellow. 100 ml of DMF was passed through the layer for 15 minutes. The resin was then washed three times using DMF and filtered. Ninhydrin tests showed a strong signal for the primary amine.

Tagging resin 6-carboxyfluorescein-NHS (6-FAM-NHS)

The resin was treated with 2 equivalents of 6-FAM-NHS in 1% DIEA/DMF and stirred or shaken at ambient temperature overnight. After that, the resin was drained, washed three times using DMF, three times with 1× DCM and 1× methanol) and dried with getting an orange resin, which according to ninhydrin analysis was negative.

General procedure for cleavage and removal of the protection associated with the resin peptide

Peptides were tsalala from the resin by shaking for 3 hours at ambient temperature to cleave the cocktail consisting of 80% TFA, 5% water, 5% thioanisole, 5% phenol and 2.5% TIS and 2.5% EDT (1 ml/0.1 g resin). The resin was removed by filtration and washing twice using TFA. TFA was evaporated from the filtrate and the product was precipitated with simple ether (10 ml/0.1 g resin), was isolated by centrifugation, washed two times with simple ether (10 ml/0.1 g resin) and dried to obtain the crude peptide.

General procedure for purification of peptides

The crude peptides were purified on a Gilson system for preparative HPLC with ICP�Lovanium analysis programs offer® (Gilson, Inc., Middleton, WI) on a column with radial compression, comprising two 25× 100 mm segment with padding Delta-Pak™ C18 15 μm particles with a pore size of 100 Å and suirable one way of using the gradient described below. One to two milliliters of crude peptide solution (10 mg/ml in 90% DMSO/water) was purified in the calculation of the input sample. The peaks containing the product(s) from each experiment were pooled and liofilizirovanny. All cycles of preparative purification was performed at a speed of 20 ml/min using as allentow buffer A is 0.1% TFA-water and buffer B: acetonitrile.

General procedure for analytical HPLC

Analytical HPLC was performed on a series system, a Hewlett-Packard 1200 detector diode matrix and a fluorescence detector Hewlett-Packard 1046A using HPLC 3D ChemStation version A. 03.04 (Hewlett-Packard Company. Palo Alto, CA) 4.6× 250 mm YMC column with gasket ODS-AQ 5 µm particles with a pore size of 120 Å and suirable one way of using the gradient described below, after pre-equilibration to initial conditions for 7 minutes. Eluent was a buffer A is 0.1% TFA-water and buffer B: acetonitrile. The flow rate for all gradients was 1 ml/min.

F-Bak: Peptide probe Acetyl-(SEQ ID NO: 1)GQVGRQLAIIGDK(6-FAM)-(SEQ ID NO: 2)INR-NH2

Fmoc-Rink amide MBHA resin was extended using the General procedure of peptide synthesis obtained with�eat associated with the protected peptide resin (1,020 g). Mtt group was removed, labeled with 6-FAM-NHS and carried out the cleavage and removal of protection, as described above in this application, to obtain the crude product as an orange solid (0,37 g). This product was purified using RP-HPLC. Fractions of the main peak was tested by the method of analytical RP-HPLC and pure fractions were isolated and liofilizirovanny, the main peak gave specified in the header connection (0,0802 g) as a yellow solid; MALDI-MS m/z = 2137,1 [(M+H)+].

Alternative synthesis of peptide probe F-Bak: Acetyl-(SEQ ID NO: 1)GQVGRQLAIIGDK(6-FAM)-(SEQ ID NO:2)INR-NH2

Assembly of the protected peptide was carried out using 0.25 mmol Fmoc-Rink amide MBHA resin (Novabiochem) on an automatic peptide synthesizer Applied Biosystems 433A using cycles of binding Fastmoc™ using pre-loaded cartridges with 1 mmol amino acid, except for the fluorescein(6-FAM)-labeled lysine, where the cartridge was weighed 1 mmol Fmoc-Lys(4-medicrity). N-terminal acetyl group was included by loading 1 mmol of acetic acid in the cartridge and binding, as described above in the present application. Selective removal of 4-methyltricyclo groups was carried out using a solution of 95:4:1 DCM:TIS:TFA (V/V/V) was passed through the resin for 15 minutes, followed by quenching a stream of dimethylformamide. Individual isomers� 6-carboxyfluorescein-NHS was subjected to interaction with a lysine side chain in 1% DIEA in DMF and the completion of the reaction was confirmed using a ninhydrin analysis. The peptide was tsalala from the resin and remove the protection of the side chains by treatment with a mixture 80:5:5:5:2,5:2,5 TFA/water/phenol/thioanisole/triisopropylsilane: 3,6-dioxa-1,8-octanedithiol (about/about/about/about/about/about) and the crude peptide was isolated by precipitation with diethyl ether. The crude peptide was purified by reversed-phase high-performance liquid chromatography and its purity and identity was confirmed by analytical reversed-phase high-performance liquid chromatography and laser desorption mass spectrometry using a matrix (m/z = 2137,1 ((M+H)+)).

Analysis of resonant energy transfer fluorescence with a time resolution (TR-FRET)

Performed serial dilutions of representative compounds in dimethylsulfoxide (DMSO), from 50 microns (2× initial concentration; 10% DMSO) and 10 ál was transferred into a 384-well plate. Then 10 µl of a mixture of a protein/probe/antibody was added to each well at final concentrations listed in Table 1. The sample was then mixed on a shaking device for 1 minute and incubated for 3 hours at room temperature. For each analysis, each analytical tablet included the probe/antibody and protein/probe/antibody as negative and positive controls, respectively. Fluorescence was measured on the device is in the Envision (Perkin Elmer) using the filter DL�HN of the excitation wave 340/35 nm filters and the wavelength of emission 520/525 (F-Bak peptide) and 495/510 nm (Tb-labeled anti-Histidine antibody). Dissociation constants (Ki) are presented in Table 2 below and were determined using the equation of Wang (Wang Z.-X., An Exact Mathematical Expression For Describing Competitive Binding Of Two Different Ligands To A Protein Molecule. FEBS Lett. 1995, 360:111-4).

Table 1
Protein, probe and antibody used for TR-FRET analysis
ProteinProbeProtein (nm)Probe (nm)AntibodyAntibody (nm)
GST-Bcl-2F-Bak Peptide Probe
Acetyl-(SEQ ID NO: 1 GQVGRQLAIIGDK(6-FAM) SEQ ID NO: 2 INR-amide)
1100Tb-anti-GST1
6-FAM = 6-carboxyfluorescein.; Tb = terbium; GST = glutathione S-transferase

The sample was then mixed on a shaking device for 1 minute and incubated for 3 hours at room temperature. For each analysis, each analytical tablet included the probe/antibody and protein/probe/antibody as negative and positive controls, respectively. Fluorescence was measured on the device is in the Envision (Perkin Elmer) using Phil�tra wavelength excitation 340/35 nm filters and the wavelength of emission 520/525 (F-Bak peptide) and 495/510 nm (Tb-labeled anti-Histidine antibody).

The inhibition constants (Kifor compounds in accordance with the present invention are presented below in Table 2. When Kithe connection is represented as “<” (less than) a certain numerical value, it means that the value of the affinity of binding (e.g., for Bcl-2) is less than the detection limit used in the analysis. The inhibition constants were determined using the equation of Wang ((Wang Z.-X., An Exact Mathematical Expression For Describing Competitive Binding Of Two Different Ligands To A Protein Molecule. FEBS Lett. 1995, 360:111-4).

5
Table 2
TR-FRET analysis of binding of Bcl-2, Ki(μm)
Example No.KiExample No.Ki
10,000225203<0,000010
2<0,000010204<0,000010
30,000013205<0,000010
4<0,0000102060,000036
<0,0000102070,00003
60,0000182080,000104
70,00492209<0,000010
80,0001532100,000011
9<0,0000102110,000058
10<0,0000102120,0001330
110,000016213<0,000010
12<0,000010214<0,000010
13<0,000010215<0,000010
140,002798216<0,000010
15 <0,000010217<0,000010
160,0002192180,000013
170,000092190,001192
180,0000172200,000988
190,0002262210,000049
200,0001812220,000938
210,0009122230,000053
220,000291224<0,000010
230,0000832250,000196
24<0,0000102260,000139
25<0,000010227/td> <0,000010
260,0000112280,026761
270,0001342290,002109

28<0,0000102300,000031
29<0,0000102310,000770
30<0,0000102320,001631
31<0,0000102330,001654
32<0,0000102340,000115
33<0,0000102350,000023
340,000012360,000033
35<0,000010 2370,000024
360,000017238<0,000010
37<0,0000102390,000026
380,0003240<0,000010
390,000012241<0,000010
40<0,0000102420,000057
41<0,0000102430,000546
420,0004392440,000281
430,0000122450,000015
44<0,0000102460,000144
45<0,000010247460,0009352480,000029
47<0,0000102500,000412
48<0,0000102510,000571
490,000074252<0,000010
500,0000212530,000052
51<0,000010254<0,000010
520,000114255<0,000010
53<0,000010256<0,000010
540,0020712570,000052
55<0,000010258<0,000010
560,000037259<0,000010
570,0000632600,000016
58<0,0000102610,000134
590,000203262<0,000010
60<0,0000102630,000156
610,0000912640,000036

62<0,000010265<0,000010
63<0,000010266<0,000010
64<0,0000102670,000035
65<0,000010268<0,000010
66<0,0000102690,000016
67<0,000010270<0,000010
680,0000122710,000039
690,0011572720,000031
700,0039642730,000035
710,000012740,000040
72<0,000010275<0,000010
73<0,000010276<0,000010
740,000029277<0,000010
75<0,0000102780,000252
760,0001962790,000035
770,0002132800,000071
78<0,0000102810,000145
79<0,000010282<0,000010
80<0,000010283<0,000010
81<0,0000102840,000024
820,000328285<0,000010
830,000071286<0,000010
840,0001232870,000081
850,0003912880,000251
86 0,0004982890,000090
870,000618290<0,000010
880,000672291<0,000010
890,0000732920,000190
900,0000132930,000093
910,0004872940,000046
920,000128295<0,000010
930,0034612960,000512
940,0006782970,000174
950,000014298<0,000010

96 0,0000142990,000039
970,0000173000,001627
98<0,0000103010,002065
990,0002333020,000332
100<0,0000103030,000044
1010,000021304Nd
1020,0000943050,000033
103<0,0000103060,002067
1040,0000163070,000130
105<0,0000103080,000141
1060,000895309 0,000023
1070,0000353100,000165
108<0,000010311<0,000010
1090,000127312<0,000010
1100,0005573130,001102
111<0,0000103140,000042
112<0,0000103150,000052
113<0,0000103160,000601
114<0,000010317<0,000010
115<0,000010318<0,000010
116<0,000010319 <0,000010
117<0,000010320<0,000010
118<0,000010321<0,000010
119<0,000010322<0,000010
120<0,0000103230,000104
121<0,000010324<0,000010
122<0,000010325<0,000010
123<0,000010326<0,000010
124<0,000010327<0,000010
125<0,000010328<0,000010
126<0,000010329 0,000030
127<0,000010330<0,000010
128<0,0000103310,001086
1290,0000023320,000621

0,000023/tr>
130<0,0000103330,000511
131<0,0000103340,000572
132<0,0000103350,000150
133<0,0000103360,000198
134<0,000010337<0,000010
135<0,0000103380,000013
136<0,0000100,000036
137<0,000010340<0,000010
138<0,000010341<0,000010
139<0,000010342<0,000010
140<0,000010343<0,000010
141<0,000010344<0,000010
1420,00013345<0,000010
143<0,0000103460,000042
144<0,0000103470,000013
145<0,0000103480,000034
146<0,000010349
147<0,000010350<0,000010
148<0,000010351<0,000010
149<0,0000103520,000014
150<0,000010353<0,000010
1510,0000173540,000010
152<0,0000103550,000014
153<0,0000103560,000039
154<0,000010357<0,000010
1550,000059358<0,000010
156<0,000010359<0,000010
157<0,000010360<0,000010
158<0,000010361<0,000010
159<0,0000103620,000016
160<0,0000103630,000017
161<0,000010364<0,000010
162<0,000010365<0,000010
163<0,0000103660,000024

164<0,000010367Nd
165<0,000010368Nd
166<0,000010369 <0,000010
167<0,0000103700,000285
168<0,000010371<0,0000010
1690,000021372Nd
1700,000022373<0,0000010
171<0,000010374<0,0000010
172<0,0000103750,00010999
173<0,000010376<0,0000010
174<0,000010377<0,0000010
1750,000119378<0,0000010
1760,000023379 <0,000010
1770,000111380<0,000010
1780,000076381<0,000010
179<0,000010382<0,000010
180<0,000010383<0,000010
1810,0000173840,000704
1820,000068385<0,000010
183<0,000010386<0,000010
184<0,000010387<0,000010
1850,0000223880,000812
1860,0000473890,000774
1870.00008 inch390<0,000010
188<0,000010391<0,000010
1890,0000183920,000171
1900,0000263930,000263
191<0,0000103940,000132
192<0,0000103950,000257
193<0,0000103960,000014
194<0,0000103970,000041
195<0,0000103980,000149
196<0,000010399<0,000010
197<0,0000104000,000031

198<0,000010401<0,000010
199<0,000010402<0,000010
200<0,000010403<0,000010
2010,000014404<0,000010
202<0,000010
nd = not determined

The inhibition constant (Ki) represents the dissociation constant of the complex enzyme-inhibitor or complex protein/small molecule, a small molecule inhibits binding of one protein to another protein or peptide. Thus, a high value of Kiindicates low affinity binding, while a low value of Kiindicates the high affinity of the binding.

Table 2 shows the inhibition constants d�I inhibition of Bak BH3 peptide to probe Bcl-2 protein and shows what compounds according to the present invention possess high affinity binding against anti-apofaticheski Bcl-2 protein. It is therefore expected that the compounds may be useful in treating diseases during which is expressed anti-apoptosi Bcl-2 protein.

Analysis of cell viability RS4;11

Cell line acute lymphoblastic leukemia (ALL) RS4;11 was used as a primary cell line of human rights to assess cellular activity funds, selective in relation to Bcl-2, in vitro and their efficacy in vivo. Previous studies have shown on the example of BH3 profiling, mitochondrial analysis, which classifies blockade characteristic adoptioncom way that RS4;11 cells are highly dependent on BCL-2 for survival and are sensitive to ABT-737 inhibitor family members Bcl-2 (Blood, 2008, Vol. 111, 2300-2309). The prevalence of Bcl-2 in complex with proapoptotic BH3 protein Bim in RS4;11 suggests that these cells are "premirovanii" or more susceptible to cell death through antagonism antiepilepticheskogo of Bcl-2 protein from which they are dependent for survival.

RS4;11 cells were cultured in RPMI-1640 supplemented with 2 mm L-glutamine, 10% FBS, 1 mm sodium pyruvate, 2 mm HEPES, 1% penicillin/streptomycin (Invitrogen), 4.5 g/l glucose, and maintained at 37°C in atmosphere of 5% CO2. For testing�ing cellular activity of the compounds in vitro cells were treated at a density of 50000 cells per well in 96-well microtiter tablets in the presence of 10% human serum for 48 hours in a humidified chamber with 5% CO2. The performance of cellular cytotoxicity, EC50was determined using CellTiter Glo (Promega) according to the manufacturer's recommendations. The values of EC50was defined as the percentage of viable cells after treatment as compared to untreated control cells.

207
Table 3
The values of EC50for RS4;11 (μm)
Example No.EC50Example No.EC50
10,7122030,02208
20,7832040,16475
30,01422050,01059
40,018542060,05291
50,012410,00376
60,034872080,12121
70,1922090,0045

0,0015528
80,1582100,06022
90,014762110,3073
100,052022120,01283
110,013932130,0060976
120,034712140,0043751
130,02322150,00056038
143,89472160,68263
150,01276217
161,20982180,0072907
170,475219>1
180,086220>1
19Of 0.4652210,094771
200,191222>1
210,0622230,18208
220,0852240,013887
230,0452250,56001
240,009832260,1178
250,0072270,0073566
26 0,05888228>1
270,33237229>1
280,04192300,052821
290,020472310,52301
300,01529232>1
310,01565233>1
320,081472340,13532
330,007112350,03232
340,007482360,04292
350,291472370,05316
360,18137238
370,001182390,023699
383,50922400,017266
390,019742410,11377
400,099742420,22275
410,058012430,80718

420,534122440,79378
430,272082450,083614
440,053092460,40218
450,009922470,092976
46>52480,099588
470,03265250>1
480,003332510,91782
490,351612520,003475
500,312642530,049586
510,023082540,019908
520,199642550,009004
530,066742560,017997
541,91582570,026002
550,01322580,00055345
560,086542590,00038795
57 0,426112600,0054323
58>52610,18366
590,72152620,016346
600,05948263>1
610,183372640,68866
620,025062650,0071718
630,007512660,0072924
64A 0.000252670,06944
65A 0.000252680,048792
660,018932690,0072346
670,04954270680,108462710,43657
691,72432720,84006
70>52730,20925
710,091652740,21418
720,007512750,14303
730,023692760,0035006
740,0572770,0081845
750,015092780,79393

760,511312790,22492
770,761962800,4593
780,012522810,65371
790,06492820,032187
800,068632830,013096
810,048142840,16213
820,683832850,057413
830,1972860,034464
840,1582870,59312
851,952880,39042
861,022890,6687
871,182900,10663
880,47 2910,016079
890,064462920,88938
900,062992930,28715
910,182962940,12525
920,080892950,014803
93>52960,76869
941,69462970,59157
950,029542980,070305
960,043562990,067981
970,055573000,76334
980,0229301&g; 1
991,39233020,38106
1000,136663030,04776
1010,29913040,29755
1020,621783050,032539
1030,039173060,55348
1040,071253070,12767
1050,053573080,257
1060,826393090,052421
1070,06117310>1
1080,024073110,035835
109 0,183393120,016178

1100,53638313>1
1110,014513140,66006
1120,020633150,21027
1130,00136316>1
1140,010783170,013313
1150,011843180,011566
1160,028533190,0044972
1170,01823200,050974
1180,012943210,0188
119 0,011383220,012367
1200,001473230,71689
1210,059723240,0045254
1220,001853250,012319
1230,003333260,023133
1240,212243270,0027224
1250,008383280,0098808
1260,053593290,42369
1270,009753300,0097843
1280,005893310,92638
1290,01484332 0,45738
1300,010593330,46292
1310,01266334>1
1320,022093350,26951
1330,031863360,35134
1340,002513370,001759
1350,002373380,003399
1360,002963390,45016
1370,012723400,05646
1380,001523410,031652
1390,016813420,050891
140 0,012753430,12664
1410,020443440,0066616
1420,345313450,0092536
1430,019143460,19003

1440,02123470,018849
1450,0043480,050263
1460,019163490,023086
1470,026183500,0058378
1480,009383510,0020618
1490,013473520,0011961
150 0,051033530,0050512
1510,033723540,053231
1520,020373550,018771
1530,017233560,026623
1540,026473570,013235
1550,594213580,0038131
1560,008053590,0059243
1570,010863600,0098968
1580,017933610,00053755
1590,011793620,031726
1600,08363363 0,02643
1610,034653640,011244
1620,012973650,0030168
1630,004323660,016548
1640,01476367nd
1650,0051368nd
1660,011853690,0079974
1670,00093370nd
1680,088673710,007165
1690,07626372nd
1700,12515373nd
171 0,052723740,015475
1720,020533750,56013
1730,005163760,008765
1740,126213770,002377
175>13780,006764
1760,133533790,019371
1770,159363800,13375

1780,202343810,0014055
1790,042733820,026976
180Of 0.01183830,012436
181 0,10612384>1
1820,12343850,13251
1830,017533860,0083796
1840,023233870,91091
1850,02747388>1
1860,064433890,73345
1870,214943900,0050612
1880,016383910,008412
1890,14397392>1
1900,55068393>1
1910,00691394 0,46138
1920,00241395>1
1930,000763960,084052
1940,008193970,11285
1950,002073980,54754
1960,001723990,12748
197Of 0.01254000,064041
1980,036194010,026563
1990,005064020,010064
2000,010994030,034024
2010,59132404>1
202 0,0438
nd = not determined

Table 3 shows the utility of compounds having Formula I, for functional inhibition of anti-apofaticheski Bcl-2 protein in the cellular context. The cell line RS4;11 acute lymphoblastic leukemia (ALL), as was shown in the example of BH3 profiling, mitochondrial analysis, which classifies blockade characteristic adoptioncom the way, is heavily dependent on BCl-2 for survival and is sensitive to ABT-737 inhibitor family members Bcl-2 (Blood, 2008, Vol. 111, 2300-2309). The ability of compounds to kill RS4;11 cells is a direct indicator of the ability of compounds to inhibit the function of anti-apofaticheski Bcl-2 protein. Compounds of formula I are highly effective as a means of killing RS4;11 cells, as demonstrated by the low EC50values.

Compounds disclosed in the patent application U.S. No. 12/631404 entitled “BCL-2-SELECTIVE APOPTOSIS-INDUCING AGANTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES”, filed on 4 December 2009, may be useful to treat various types of cancer and autoimmune diseases, due to their activity against Bcl-2 family proteins, and more specifically Bcl-2. These compounds bind with Bcl-2 with high affinity in the FRET analysis, opisan�m 12/631404. The introduction of one or more such compounds into cells dependent on Bcl-2 family proteins Bcl-2 for survival, such as the cell line RS4:11 B-cell human leukemia, results in apoptosis, also known as programmed cell death. A quantitative index of apoptosis induced by administration of the compounds are presented as EC50 value in the analysis of cell viability, which involves measuring the number of surviving cells after the introduction of the connection.

TABLE 4 presents some compounds (described below in Examples 19, 20, 23, 92, and described in more detail in 12/631404, the disclosure of which is incorporated in this application by reference) with different substituents described in the definitions of R, X and Y above. As can be seen from Table 4, these compounds show a trend of increasing binding affinity (Kiin relation to Bcl-2 with increasing levels of apoptosis or cell death in Bcl-2-dependent tumor cell line RS4;11. Based on this, the authors of the present invention expect that connection even with a greater affinity in relation to Bcl-2 than those compounds that are shown in Table 4, show a similar trend, potentially causing even higher levels of apoptosis when introduced into cells dependent on Bcl-2 for survival.

Table 4
Selected compounds in the Patent application U.S. No. 12/631404
ExampleRXYBcl-2 FRET
Ki(μm)RS4;11 EC50
(μm)(23)CO0,0000830,045(92)CC0,0001280,081

(20)CC0,0001810,191
(19)CC0,000226Of 0.465

To this end, the binding affinity and cellular activity of the compounds�s in accordance with the present invention were compared with structurally similar indole compounds. In particular, the compounds of the present invention, in which nitrogen is in a particular position in heteroarenes, condensed heteroaryl ring, compared with the corresponding indole compounds, these latter compounds there is no specific nitrogen substitution included in the compounds of the present invention.

As can be seen in Table 5, the compounds of the present invention containing the specific nitrogen substitution (i.e. compounds of Examples 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 15, 16 and 17, where Z = N), really achieve relatively higher levels of apoptosis when introduced into cells that depend on Bcl-2 for survival, and have high affinity against Bcl-2 compared with the corresponding structural analogues, have no such specific nitrogen substitution (i.e. compounds of Examples 87, 88, 89, 90, 91, 19, 20, 21, 92, 22, 23, 93 and 94, respectively, where Z = C, described in 9696USL2, the disclosure of which is incorporated in this application by reference).

In particular, the seventh count of Table 5 compares the binding affinity of the compounds of the present invention (the compound that a certain specified substituents in the top row in each pair of rows which are separated by blank lines) with the corresponding compounds lacking about�icanoe nitrogen substitution. In each comparison compounds disclosed in the present application (top row in each pair of rows which are separated by blank lines), contact Bcl-2 with greater affinity to Bcl-2 than the corresponding analogs (bottom row in each pair of rows which are separated by blank lines).

In addition, column 8 of Table 5 compares the quantitative index of apoptosis in Bcl-2-dependent RS4;11 cell line achieved using the compounds of the present invention (again, the connection defined by the specified substituents in the top row in each pair of rows which are separated by blank lines), with the rate achieved using the compounds of Examples 87, 88, 89, 90, 91, 19, 20, 21, 92, 22, 23, 93 and 94, where Z = C. comparison of the compounds of the present invention (top line in each pair of rows which are separated by blank lines) reach higher values of apoptosis in Bcl-2-dependent RS4;11 cells than the corresponding analogs (bottom row in each pair of rows which are separated by blank lines).

The increased binding affinity of the compounds of the present invention in comparison with the corresponding ranges from 2.7 x to more than 100x, and increased activity in RS4;11 cells is from 1.65 x increase to more than 10x magnification.

As detailed description�about below specific substitution of a carbon atom by a nitrogen atom leads to an unexpected increase in the affinity of binding to antiapoptosis Bcl-2 and increased activity in the analysis of cell viability to evaluate apoptosis in Bcl-2-dependent cell lines.

The present invention therefore includes a number of compounds that exhibit unexpected properties in terms of their binding to anti-apoptosis Bcl-2 protein and inhibiting its activity, to a much greater extent than their counterparts.

Table 5
A direct comparison of the compounds of the present invention with the relevant counterparts

More specifically, the compounds of the present invention have a picture of substitution, represented in the diagram below.

Other compounds that contain isomeric ring systems relative to those shown above, such as a ring system containing a nitrogen atom adjacent to the oxidized carbon in the ring, as shown below, have the disadvantage of the instability.

In particular, it was discovered by the authors of the present invention obtain the following compounds. Intermediate structure F, which immediately precedes the final product unstable compounds, were obtained in accordance with the path shown below. All intermediate compounds A-F were stable and could be isolated using methods known to experts in this field.

Intermediate compound F, represented in the diagram above, was subjected to interaction with the intermediate connection of G using the standard binding conditions, which are known to specialists in this field. The reaction mixture was analyzed using HPLC/MS to monitor the formation of a peak corresponding to compound H. Although this peak was formed within a few hours after start of the reaction shown below, the peak gradually disappeared in the course of processing and chromatography, until its complete disappearance. The lack of stability in the implicit�aguinaga compounds derived from the provisions of nitrogen in the condensed ring system, described above. This provision, which is adjacent to the oxygen-containing carbon in 5-substituted-1H-imidazo[2,3-c]pyridine ring system, are presented below and described above, makes the connection H is unstable.

It is expected that the compound containing a condensed 5-substituted-1H-imidazo[3,2-b]pyridine ring system, presented below, will also be unstable because the position of the nitrogen is adjacent to the oxygen-containing carbon in the ring.

Therefore, compounds with 5-substituted-1H-imidazo[2,3-b]pyridine are preferred in comparison with the isomeric compounds.

It is expected that, because compounds having Formula (I) bind to Bcl-2, they can also be useful as a binder with anti-apoptosome proteins having close structural homology to Bcl-2, such as, for example, anti-ipoptions Bcl-XL, Bcl-w, Mcl-1 and Bfl-1/A1 proteins.

The involvement of Bcl-2 proteins in bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignant disease of T-cell or B-cell origin, melanoma, mi�logeny leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer, cancer of the spleen, and the like are described in co-owned PCT application US 2004/36770, published as WO 2005/049593, and PCT US 2004/037911, published as WO 2005/049594.

The involvement of Bcl-2 proteins in immune and autoimmune diseases is described in Current Allergy and Asthma Reports 2003, 3, 378-384; British Journal of Haematology 2000, 110(3), 584-90; Blood 2000, 95(4), 1283-92; and New England Journal of Medicine 2004, 351(14), 1409-1418.

The involvement of Bcl-2 proteins in arthritis are disclosed in co-owned provisional patent application U.S. serial No. 60/988479.

The involvement of Bcl-2 proteins in graft rejection, bone marrow disclosed in jointly owned patent application U.S. serial No. 11/941196.

Overexpression of Bcl-2 proteins correlates with resistance to chimiotherapie, clinical outcome, disease progression, overall prognosis or a combination of these factors in different types of cancer and disorders of the immune system. Cancer includes, but is not limited to, hematologic and solid tumor types such as acoustic neuroma, acute leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia (monocytic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, mielomonocitarnyi and promyelocytes�s) acute t-cell leukemia, basal cell carcinoma, carcinoma of bile duct cancer, bladder cancer, brain cancer, breast cancer (including estrogen receptor-positive breast cancer), bronchogenic carcinoma, Burkitt lymphoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic miliitary (granulocytic) leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, deproliferation changes (dysplasia and metaplasia), embryonal carcinoma, endometrial cancer, endothelioma, ependyma, epithelial carcinoma, erythroleucus, esophageal cancer, estrogen receptor - positive breast cancer, essential thrombocythemia, Ewing tumor, fibrosarcoma, gastrochaena, paradisevalley testicular cancer, gestational trophoblastic disease, glioblastoma, head and neck cancer, heavy chain disease, hemangioblastoma, hepatoma, hepatocellular cancer, hormone insensitive prostate cancer, leiomyosarcoma, liposarcoma, lung cancer (including small cell lung cancer and non-small cell lung cancer), lymphangiectasia-sarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma (lymphoma, including diff�EIT large-B-cell lymphoma, follicular lymphoma, Hodgkin's lymphoma and non-Hodgkins lymphoma), malignant diseases and hyperproliferative disorders of the bladder, breast, colon, lung, ovaries, pancreas, prostate, skin and uterus, lymphoid malignant disease of T-cell or B-cell origin, leukemia, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinomas, papillary carcinoma, peripheral T-cell lymphoma, pinealoma, polycythemia Vera, prostate cancer (including hormone-insensitive (refractory) prostate cancer), rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous gland carcinoma, seminoma, skin cancer, small-cell lung carcinoma, solid tumors (carcinomas and sarcomas), stomach cancer, squamocellular carcinoma, sinovioma, carcinoma of the perspiration glands, testicular cancer (including paradisevalley testicular cancer), thyroid cancer, waldenstrom's macroglobulinemia, testicular tumors, uterine cancer, Wilms ' tumor and the like./p>

It is also expected that compounds having Formula (I), will inhibit the growth of cells expressing Bcl-2 proteins, which originate from a pediatric cancer or tumor, including the embryonic rhabdomyosarcoma, pediatric acute lymphoblastic leukemia, pediatric acute myelogenous leukemia, pediatric alveolar rhabdomyosarcoma, pediatric anaplastic ependymoma, pediatric anaplastic large cell lymphoma, pediatric anaplastic medulloblastoma, pediatric atypical teratoid/Rathenow tumor of the Central nervous system, pediatric biphetamine acute leukemia, pediatric Burkitt's lymphoma, pediatric cancers of the family of Ewing tumors such as primitive neuroectodermal tumors, pediatric diffuse anaplastic Wilms tumor, pediatric Wilms tumor with favorable histology, pediatric glioblastoma, pediatric medulloblastoma, pediatric neuroblastoma originating in pediatric neuroblastoma myelocytomatosis, pediatric pre-B-cell cancers (such as leukemia), pediatric pleasecome, pediatric Rathenow kidney tumor, pediatric rhabdomyosarcoma and pediatric T-cell cancers such as �of infoma and skin cancer, and such.

Autoimmune disorders include acquired immunodeficiency syndrome (AIDS), autoimmune lymphoproliferative syndrome, hemolytic anemia, inflammatory diseases, and thrombocytopenia, acute or chronic immune disease associated with organ transplantation, Addison's disease, allergic diseases, alopecia, alopecia alopecia, atheromatous disease/arteriosclerosis, atherosclerosis, arthritis (including osteoarthritis, juvenile chronic arthritis, septic arthritis, Lyme arthritis, psoriatic arthritis and reactive arthritis), autoimmune bullous disease, abetalipoproteinemia, diseases associated with acquired immunodeficiency, acute immune disease associated with organ transplantation, acquired acrocyanosis, acute and chronic parasitic or infectious processes, acute pancreatitis, acute renal failure, acute rheumatic fever, acute transverse myelitis, adenocarcinomas, transmitted by air, ectopic beats, (acute) respiratory distress syndrome, adult, complex, AIDS-dementia, alcoholic cirrhosis caused by alcohol liver damage caused by alcohol hepatitis, allergic conjunctivitis, allergic contact dermatitis, allergic rhinitis, allergies and asthma, rejection allot�of spuntata, alpha-l - antitrypsin deficit, Alzheimer's disease, amyotrophic lateral sclerosis, anemia, angina, associated with ankylosing spondylitis pulmonary disease, degeneration of anterior horn cells of the spinal cord, antibody-mediated cytotoxicity, antiphospholipid syndrome, anti-receptor allergic reactions, aortic aneurysm and peripheral vascular disease, aortic dissection, arterial hypertension, arteriosclerosis, arteriovenous fistula, arthropathy, asthenia, asthma, ataxia, atopic Allergy, atrial fibrillation (or congestive proximally), atrial flutter, atrioventricular blockade, atrophic autoimmune hypothyroidism, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune hepatitis type 1 (classical autoimmune or lipoid hepatitis), autoimmune-mediated hypoglycemia, autoimmune neutropenia, autoimmune thrombocytopenia, autoimmune thyroid disease, B-cell lymphoma, bone graft rejection, graft rejection, bone marrow (BMT), obliterative bronchiolitis, blockade branching beam, burns, cachexia, cardiac arrhythmias, the syndrome is a temporary heart failure, cardiac tumors, cardiomyopathy, inflammatory response to cardiopulmonary bypass, rejection cartilage tra�of spuntata, cerebellum-cortical degeneration, cerebellar disorders, chaotic or multifocal tachycardia fibrillation associated with chemioterapia disorders, chlamydia, homeostatic, chronic alcoholism, chronic active hepatitis, chronic fatigue syndrome, chronic immune disease associated with organ transplantation, chronic eosinophilic pneumonia, chronic inflammatory pathologies, chronic candidiasis, affecting the skin and mucous membranes, chronic obstructive pulmonary disease (COPD), chronic salicylate intoxication, variable unclassifiable immunodeficiency (variable unclassified hypogammaglobulinemia), conjunctivitis, associated with connective tissue disease, interstitial lung disease, contact dermatitis, Coombs-positive hemolytic anemia, pulmonary heart disease Creutzfeldt-Jakob disease, cryptogenic autoimmune hepatitis, cryptogenic fibrosing alveolitis, culture negative sepsis, cystic fibrosis, associated with cytokine therapy disorders, Crohn's disease, dementia pugilistica, demyelinizing of the disease, Dengue hemorrhagic fever, dermatitis, scleroderma, skin disorders associated with dermatomyositis/polymyositis lung disease, diabetes, diabetic ar�erosclerosis disease diabetes mellitus, diffuse disease with Lewy bodies, dilated cardiomyopathy, advanced congestive cardiomyopathy, discoid lupus erythematosus, disorders of the basal ganglia, disseminated intravascular coagulation, down's syndrome in middle age, drug-induced interstitial lung disease, drug-induced hepatitis, drug-induced movement disorders caused by drugs which block CNS dopamine receptors, drug sensitivity, eczema, encephalomyelitis, endocarditis, endocrinopathy, enteropathic synovitis, epiglottitis, an infection caused by the Epstein-Barr, erythromelalgia, extrapyramidal and cerebellar disorders, familial hematopoietically lymphohistiocytic, the rejection, fetal thymus implant, inherited Friedreich's ataxia, functional peripheral arterial disorders, female infertility, fibrosis, fibrotic lung disease caused by the fungal infection sepsis, gas gangrene, gastric ulcer, giant cell arteri, glomerular nephritis, glomerulonephritis syndrome Goodpasture, goitrous autoimmune hypothyroidism (Hashimoto's disease), gouty arthritis, graft rejection of any organ or tissue, disease “Tr�nsplant-versus-host gram-negative sepsis, gram positive sepsis, granulomas that are caused by intracellular organisms, streptococcal infection group B (GBS), Grave's disease associated with pulmonary hemosiderosis disease, volatitlity leukemia, the disease of Hallervorden-Spitze, Hashimoto's thyroiditis, hay fever, rejection of a heart transplant, hemachromatosis, hematopoietic malignant diseases (leukemia and lymphoma), hemolytic anemia, hemolytic uremic syndrome/thrombolytic thrombocytopenic purple, hemorrhage, hemorrhagic purple Schonlein purpura-Henoch, Hepatitis A, Hepatitis B, Hepatitis C, HIV infection/HIV neuropathy, Hodgkin's disease, hypoparathyroidism, Huntington's chorea, hyperkinetic movement disorders, allergic reactions, allergic pneumonitis, hyperthyroidism, hypokinetic movement disorders, evaluation of the hypothalamic-pituitary-adrenal, idiopathic Addison's disease, idiopathic leukopenia, idiopathic pulmonary fibrosis, idiopathic thrombocytopenia, idiosyncratic liver disease, infantile spinal muscular atrophy, infectious diseases, inflammation of the aorta, inflammatory bowel disease, insulin-dependent diabetes mellitus, interstitial pneumonitis, iridocyclitis/uveitis/retrobulbar� neuritis, ischemic-reperfusion lesion, ischemic stroke, juvenile pernicious anaemia, juvenile rheumatoid arthritis, juvenile spinal muscular atrophy, Kaposi's sarcoma, Kawasaki's disease, transplant rejection of kidney, Legionnaires ' disease, Leishmania, leprosy, lesions of the corticospinal system disease, associated with linear IgA, lipidemia, graft rejection liver, Lyme disease, lymphedema, lymphocytic infiltrative lung disease, malaria, male infertility idiopathic or NOS, malignant histiocytosis, malignant melanoma, meningitis, meningococcemia, microscopic vasculitis of the kidneys, migrainebuy headache, mitochondrial Multisystem disorder, mixed connective tissue disease, lung disease associated with mixed connective tissue disease, the monoclonal gammopathy, multiple myeloma, degeneration of multiple systems (Menzel Dieren-Thomas Shi-Drager and Machado-Joseph), millionsi encephalitis/Royal Free disease, myasthenia gravis, microscopic vasculitis of the kidneys, intracellular mycobacterium avium, mycobacterium tuberculosis, myelodysplastic syndrome, myocardial infarction, ischemic disorders of the myocardium, nasopharyngeal carcinoma, neonatal chronic lung disease, nephritis, nephrosis, nephrotic�cue syndrome, neurodegenerative diseases, neurogenic I muscular atrophy, neitropeniceskih fever, non-alcoholic steatohepatitis, occlusion of the abdominal aorta and its branches, occlusive arterial disorders, rejection of organ transplant, orchitis/epididymitis, orchitis/vasectomy reverse procedure, organomegaly, osteoarthritis, osteoporosis, insufficient ovarian function, graft rejection, pancreatic cancer, parasitic diseases, parathyroid transplant rejection and cancer, Parkinson's disease, an inflammatory disease of the renal pelvis, pemphigus vulgaris, litwinow pemphigus, pemphigoid, chronic rhinitis, pericardial disease, peripheral atherosclerotic disease, peripheral vascular disorders, peritonitis, pernicious anemia, phacogenic uveitis, pneumonia caused by pneumocystis carinii, pneumonia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes syndrome), post perfusion syndrome, post-injection syndrome, post-MI cardiotoniceski syndrome, postinfectious interstitial lung disease, premature ovarian failure, primary biliary cirrhosis, primary sclerosing hepatitis, primary myxoedema, primary pulmonary hypertension, primary sklerosiruuschem� cholangitis, primary vasculitis, progressive supranuclear palsy, psoriasis, psoriasis type 1, psoriasis type 2, psoriatic arthropathy, pulmonary hypertension being secondary to connective tissue disease, pulmonary manifestation of polyarteritis polyarteritis, post-inflammatory interstitial lung disease, radiation fibrosis, radiation therapy, phenomenon and Raynaud's disease, Raynaud's disease, adult refsum disease, tachycardia with regular short QRS, Reiter's disease, renal disease NOS, renovascular hypertension, reperfusion lesion, restrictive cardiomyopathy associated with rheumatoid arthritis interstitial lung disease, rheumatoid spondylitis, sarcoidosis, Schmidt's syndrome, scleroderma, senile chorea, senile dementia type Taurus Lewy, sepsis syndrome, septic shock, erotically arthropathies, shock, sickle cell anemia, associated with Sjogren's syndrome pulmonary disease, Sjogren's syndrome, rejection of skin allograft, skin changes syndrome, graft rejection of the small intestine, autoimmune reaction of sperm, multiple sclerosis (all subtypes), spinal ataxia, spenomegaly degeneration, spondyloarthropathy, sporadic polyglandular deficiency type I sporadic polyglandular deficiency type II, still's disease, streptoc�kovy myositis, stroke, structural lesions of the cerebellum, subacute sclerosing panencephalitis, simpaticheskuyu ophthalmia, syncope, syphilis of the cardiovascular system, systemic anaphylaxis, systemic inflammatory response syndrome, systemic juvenile rheumatoid arthritis, systemic lupus erythematosus associated with systemic lupus erythematosus lung disease, systemic sclerosis associated with systemic sclerosis interstitial lung disease, T-cell or FAB ALL, Takayasu disease/arteret, telangiectasia, Th2 type and Th1 type mediated diseases, obliterating thromboangiitis, thrombocytopenia, thyroiditis, toxicity, toxic shock syndrome, transplants, trauma/hemorrhage, autoimmune hepatitis type 2 (hepatitis with anti-LKM antibody), type B insulin resistance with acanthosis nigricans, Hyper allergic reactions type III, Hyper allergic reactions type IV associated with ulcerative colitis arthropathy, ulcerative colitis, unstable angina, uremia, urosepsis, urticaria, uveitis, valvular heart, varicose veins, vasculitis, masculine diffuse lung disease, venous diseases, venous thrombosis, ventricular fibrillation, vitiligo, acute liver disease, viral and fungal infections, vital encephalitis/aseptic meningitis, vital-associiruemyi hemophagocytosis Sindh�Ohm, the Wegener's granulomatosis syndrome Wernicke-Korsakov, Wilson's disease, rejection of xenotransplanted any organ or tissue, yersinia and salmonella-associated arthropathy and the like.

Diagram and description of experiments

The following abbreviations have the following meaning. ADDP means 1,1'-(azodicarbon)dipiperidino; AD-mix-β means a mixture of (DHQD)2PHAL, K3Fe(CN)6, K2CO3and K2SO4; 9-BBN means 9-borabicyclo(3,3,1)nonane; Boc means tert-butoxycarbonyl; (DHQD)2PHAL means hydrogenizing 1,4-phthalazinedione ether; DBU means 1,8-diazabicyclo[5,4,0]undec-7-ene; DIBAL means diisobutylaluminium; DIEA means diisopropylethylamine; DMAP means N,N-dimethylaminopyridine; DMF means N,N-dimethylformamide; dmpe means 1,2-bis(dimethylphosphino)ethane; DMSO means dimethylsulfoxide; dppb means 1,4-bis(diphenylphosphino)-butane; dppe means 1,2-bis(diphenylphosphino)ethane; dppf means 1,1'-bis(diphenylphosphino)ferrocene; dppm means 1,1-bis(diphenylphosphino)methane; EDAC·HCl means hydrochloride 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide; Fmoc means fluorenylmethoxycarbonyl; HATU refers to hexaflurophosphate O-(7-asobancaria-1-yl)-N,N'n'n'-tetramethylurea; HMPA means of hexamethylphosphoramide; IPA means isopropyl alcohol; MP-BH3means the macroporous trimetilammoniietilakrilata-cyanoborohydride; TEA means three�tiemin; TFA means trifluoroacetic acid; THF means tetrahydrofuran; NCS means N-chlorosuccinimide; NMM means N-methylmorpholine; NMP means N-methylpyrrolidine; PPh3means triphenylphosphine.

The following schemes are presented to provide what is considered the most useful and easy to understand description of procedures and conceptual aspects of the present invention. Compounds of the present invention can be obtained using the methods of chemical synthesis, examples of which are provided in the present application. It should be clear that the order of steps in the methods may vary, that you can use other reagents, solvents and reaction conditions than those specifically stated that vulnerable groups can be protected and can realize the removal of their protection, as appropriate.

Scheme 1

Compounds of the formula (4) can be obtained as shown in Scheme 1, and can be used as described in Scheme 8, to obtain the compounds of formula (I) which are representative of compounds of the present invention. Compounds of formula (1), where R represents alkyl, can be converted into compounds of formula (2) with Z3L1MgX1where X1is a halide, in a solvent such as, but not limited to�as this, ether or tetrahydrofuran. Compounds of the formula (3) can be obtained from compounds of formula (2) using strong bases such as NaH, and R57X2where X2is a halide and R57has the meaning specified in the present application. Compounds of the formula (3), and aqueous NaOH or LiOH, to give compounds of the formula (4).

Scheme 2

As shown in Scheme 2, compounds of formula (5) can be subjected to interaction with compounds of the formula (6) and a reducing agent with obtaining the compounds of formula (7). Examples of reducing agents include sodium borohydride, cyanoborohydride, sodium , cyanoborohydride polymer carrier and the like. The reaction is typically carried out in a solvent such as, but not limited to, methanol, tetrahydrofuran and dichloro methane or mixtures thereof. Compounds of the formula (8) can be obtained from compounds of formula (7) as described in Scheme 1, and can be used as described in Scheme 8, to obtain the compounds of formula (I).

Figure 3

Compounds of the formula (9) in their interaction with the compound of Formula (10), where X is a halide or triflic, and a base to give a compound of formula (11). Bases that are useful in this reaction include triethylamine, diisopropylethylamine and the like. �couplers of the formula (13), where Y has the meaning specified in the present application for Deputy in the Z3, can be obtained from compounds of formula (11) and compounds of formula (12) using the conditions of the binding according to the method of Suzuki, known to specialists in this area and easily accessible from the literature. Compounds of formula (14) can be obtained from compounds of formula (13) as described in Scheme 1, and can be used as described in Scheme 8, to obtain the compound of formula (I).

Scheme 4

As shown in Scheme 4, compounds of formula (17) can be obtained from compounds of formula (15) and compounds of formula (16), where R represents alkyl, and R38has the meaning specified in the present application, using conditions binding by the method of Suzuki, known to specialists in this area and easily accessible from the literature. Compounds of formula (17) can be restored to the compounds of formula (18) using a reducing agent such as LiAlH4, in a solvent such as, but not limited to, diethyl ether or THF. Compounds of formula (19) can be obtained from compounds of formula (18) using periodinane Dess-Martin or oxidation conditions according to the method Swarna known to specialists in this area and easily accessible from the literature. Compounds of formula (19) monopoint interaction with the compound of formula (5) and a reducing agent with obtaining the compounds of formula (20). Examples of reducing agents include sodium borohydride, cyanoborohydride, sodium, cyanoborohydride polymer carrier and the like. The reaction is typically carried out in a solvent such as, but not limited to, methanol, tetrahydrofuran, 1,2-dichloroethane and dichloro methane or mixtures thereof. Compounds of formula (21) can be obtained from compounds of formula (20) as described in Scheme 1, and can be used as described in Scheme 8, to obtain the compound of formula (I).

Scheme 5

As shown in Scheme 5, compounds of formula (22), where Rrepresents alkyl, can be converted into compounds of formula (23) by reacting first, where X1represents Cl, Br, I or CF3SO3-, and compounds of formula R41-OH and a catalyst, with or without a first base. Examples of catalysts include complex triftormetilfullerenov of copper(I) with toluene, PdCl2, Pd(OAc)2and Pd2(dba)3. Examples of first bases include triethylamine, N,N-diisopropylethylamine, Cs2CO3, Na2CO3, K3PO4and mixtures thereof.

Compounds of formula (22) can also be converted into compounds of formula (23) by reacting first when X1represents Cl, F or NO2and compounds of formula R41-OH first base. Examples of first bases include�t triethylamine, N,N-diisopropylethylamine, Cs2CO3, Na2CO3, K3PO4and mixtures thereof.

Scheme 6

Compounds of formula (18) can be subjected to interaction with methylchloride and a base such as, but not limited to, triethylamine, followed by interaction with N-tert-butoxycarbonylamino with obtaining the compounds of formula (24). Compounds of formula (25) can be obtained by reacting compounds of formula (24) with triethylsilane and trifluoroacetic acid. Compounds of formula (25) can be subjected to interaction with compounds of the formula (26) and HK2PO4obtaining compounds of formula (27) in a solvent such as, but not limited to, dimethyl sulfoxide. Compounds of formula (28) can be obtained from compounds of formula (27) as described in Scheme 1, and can be used as described in Scheme 8, to obtain the compounds of formula (I).

Scheme 7

As shown in Scheme 7, compounds of formula (1) can be subjected to interaction with a suitable triphenylphosphonium formulas (29) and a base such as, but not limited to, sodium hydride or n-butyllithium, to yield compounds of formula (30). The reaction is typically carried out in a solvent such as THF or DMSO. Compounds of formula (31) can be obtained from compounds of formula (30) as described in Scheme 1, and they can be used as described in Scheme 8, to obtain the compounds of formula (I).

Scheme 8

As shown in Scheme 8, compounds of formula (32), which can be obtained as described in the present application, can be converted into compounds of formula (33) by reacting first with ammonia. Compounds of formula (33) can be converted into compounds of formula (I) by reacting the first and compounds of the formula(4), (8), (14), (21), (28), (31) or (38) and a bonding agent, with or without a first base. Examples of the binder agent include hydrochloride 1-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide, 1,1'-carbonyldiimidazole and hexaflurophosphate the benzotriazole-1-yl-exitapplication. Examples of first bases include triethylamine, N,N-diisopropylethylamine, 4-(dimethylamino)pyridine, and mixtures thereof.

Scheme 9

Compounds of formula (33), obtained as described in Scheme 8, can also be converted into compounds of formula (I) by reacting the first and the compounds of formula (34) and first base. Examples of first bases include, but are not limited to, sodium hydride, triethylamine, N,N-diisopropylethylamine, 4-(dimethylamino)pyridine, and mixtures thereof.

Scheme 10

As shown in Scheme 10, compounds of formula (35), where L is a bond,alkyl, O, S, S(O), S(O)2NH, etc., can be subjected to interaction with compounds of the formula (36), to obtain compounds of formula (37). The reaction is typically carried out at elevated temperatures in a solvent such as, but not limited to, dimethylsulfoxide, and may require the use of a base, such as, but not limited to, potassium phosphate, potassium carbonate and the like. Compounds of formula (38) can be obtained from compounds of formula (37) as described in Scheme 1, and can be used as described in Scheme 8, to obtain the compounds of formula (I).

Scheme 11

Compounds of formula (39), where Y has the meaning specified in the present application for Deputy in the Z3, can be obtained from compounds of formula (39A), where X is a halide or triflic, and Y-B(OH)2using conditions binding by the method of Suzuki, known to specialists in this area and easily accessible from the literature. Compounds of formula (39) can be subjected to interaction with tert-butylpiperazine-1-carboxylate and a reducing agent, such as triacetoxyborohydride sodium, to obtain compounds of formula (40). The reaction is typically carried out in a solvent such as, but not limited to, methylene chloride. Compounds of formula (41) can be obtained from compounds of formula (40) by C�istia last with R 57X, where X represents a halide, and NaH in a solvent such as N,N-dimethylformamide, and then the resulting material can be treated with triethylsilane and trifluoroacetic acid in dichloromethane. Compounds of formula (41) can be used as described in Scheme 10, where L1-Z3defined in the Formula (41).

Scheme 12

As shown in figure 12, the substituted piperazine-2-ones, wherein R57represents alkyl, can be subjected to interaction with compounds of the formula (6) and a reducing agent, such as triacetoxyborohydride sodium in dichloromethane to yield compounds of formula (42). Compounds of formula (42) can be restored to the compounds of formula (43) using a reducing agent such as, but not limited to, alumoweld lithium, in a solvent such as, but not limited to, tetrahydrofuran. Compounds of formula (43) can be used as described in Scheme 10, where L1-Z3defined in the Formula (43).

The following examples are presented to provide what is considered the most useful and easy to understand description of procedures and conceptual aspects of the present invention. Presented compounds are named using ACD/ChemSketch Version 5.06 (05 June 2001, Advanced Chemistry Development Inc., Toronto, Ontario), ACD/ChemSketch Version 12.01 (13 May 2009), Advanced Chemistry Development Inc., Toronto, Ontario) ChemDraw® Ver. 9.0.5 (CambridgeSoft, Cambridge, MA). Intermediate compounds were named using ChemDraw® Ver. 9.0.5 (CambridgeSoft, Cambridge, MA).

EXAMPLE 1

4-{4-[(4'-chloro-1,1'-biphenyl-2-yl)methyl]piperazine-1-yl}-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 1A

tert-butyl 4-((4'-chlorobiphenyl-2-yl)methyl)piperazine-1-carboxylate

4'-Chlorobiphenyl-2-carboxaldehyde (4.1 g), tert-butyl piperazine-1-carboxylate (to 4.23 g) and triacetoxyborohydride sodium (5,61 g) in CH2Cl2(60 ml) was stirred for 24 hours. The reaction was quenched with methanol and poured into ether. The solution was washed with water and saturated brine, concentrated and chromatographically on silica gel using 2-25% ethyl acetate/hexane.

EXAMPLE 1B

1-((4'-chlorobiphenyl-2-yl)methyl)piperazine

The compound of Example 1A (3.0 g) and triethylsilane (1 ml) was stirred in CH2Cl2(30 ml) and trifluoroacetic acid (30 ml) for 2 hours and the reaction mixture was concentrated and then carried out the absorption of the mixture in ether and concentrated again. Carried out the absorption of substances obtained in dichloro methane (200 ml) and a solution of NaHCO3(100 ml) and the layers were separated. The organic layer was dried over Na2SO4and condensible with obtaining specified in the header connection.

EXAMPLE 1C

tert-butyl 4-(4-((4'-chlorobiphenyl-2-yl)�ethyl)piperazine-1-yl)-2-perbenzoate

Tert-butyl 4-bromo-2-perbenzoate (14.0 g), the compound of Example 1B (16,05 g), Pd2(dba)3(Tris(dibenzylideneacetone)dipalladium(0))(1.40 g), 2-(di-tert-butylphosphino)biphenyl (1,82 g) and K3PO4(16,2 g) was stirred in 1,2-dimethoxyethane (300 ml) at 80°C for 24 hours. The reaction mixture was cooled and concentrated. The crude product was chromatographically on silica gel using 10-20% ethyl acetate/hexane.

EXAMPLE 1D

tert-butyl 2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazine-1-yl)benzoate

1H-Imidazo[2,3-B]pyridin-5-ol (167 mg), the compound of Example 1C (500 mg) and Cs2CO3(508 mg) was stirred in dimethylsulfoxide (5 ml) at 130°C for 24 hours. The mixture was cooled, diluted with ethyl acetate, washed three times with water and saturated brine and dried (Na2SO4), filtered and concentrated. The crude product was chromatographically on silica gel using 25% ethyl acetate/hexane.

EXAMPLE 1E

2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazine-1-yl)benzoic acid

The compound of Example 1D (200 mg) and triethylsilane (1 ml) was stirred in dichloromethane (15 ml) and trifluoroacetic acid (15 ml) for 1 hour. The mixture was concentrated, was carried out by absorption of the mixture in ethyl acetate, washed twice NaH2PO4and saturated brine and dried� (Na 2SO4), filtered and concentrated.

EXAMPLE 1F

3-nitro-4-((tetrahydro-2H-Piran-4-yl)methylamino)benzolsulfonat

4-Fluoro-3-nitrobenzenesulfonamide (2.18 g), 1-(tetrahydropyran-4-yl)methylamine (1.14 g) and triethylamine (1 g) was stirred in tetrahydrofuran (30 ml) in 24 hours. The solution was diluted with ethyl acetate, washed with a solution of NaH2PO4and saturated brine and dried (Na2SO4), filtered and concentrated. The product was obtained by grinding into powder from ethyl acetate.

EXAMPLE 1G

4-{4-[(4'-chloro-1,1'-biphenyl-2-yl)methyl]piperazine-1-yl}-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

The compound of Example 1E (115 mg), the compound of Example 1F (67 mg), hydrochloride 1-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide (82 mg) and 4-dimethylaminopyridine (26 mg) was stirred in CH2Cl2(3 ml) for 24 hours. The reaction mixture was cooled and chromatographically on silica gel using 0-5% methanol/ethyl acetate.1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,48 (lat.s, 1H), of 8.34 (lat.s, 1H), 8,31 (m, 1H), 7,90 (d, 1H), 7,68 (m, 1H), 7,58 (m, 2H), of 7.46 (m, 4H), 7,35 (m, 2H), 7,21 (DD, 1H), 6,76 (m, 4H), 6,28 (m, 2H), 3,02 (m, 2H), 2,89 (m, 4H), 2,80 (m, 4H), is 2.40 (m, 3H), 1,59 (m, 2H), 1,25 (m, 4H), 0.87 (m, 2H).

EXAMPLE 2

4-{4-[(4'-chloro-1,1'-biphenyl-2-yl)methyl]piperazine-1-yl}-N-({4-[(3-morpholine-4-ylpropyl)amino]-3-nitrophenyl}sulfone�)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 2A

4-(3-morpholinopropan)-3-nitrobenzenesulfonamide

The compound of this Example was obtained by using 3-(N-morpholinyl)-Propylamine instead of 1-(tetrahydropyran-4-yl)methylamine in Example 1F.

EXAMPLE 2B

4-{4-[(4'-chloro-1,1'-biphenyl-2-yl)methyl]piperazine-1-yl}-N-({4-[(3-morpholine-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

The compound of this Example was obtained by using the compound of Example 2A instead of the compound of Example 1F in Example 1G.1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,60 (lat.s, 1H), at 8.60 (m, 1H), 8,43 (d, 1H), 7,94 (d, 1H), of 7.64 (m, 2H), 7,54 (d, 1H), 7,45 (m, 4H), to 7.33 (m, 2H), 7.23 percent (DD, 1H), of 6.96 (d, 1H), of 6.85 (m, 2H), 6.32 per (d, 1H), of 6.26 (d, 1H), 3,60 (m, 4H), 3,10 (m, 4H), 3,05 (m, 10H), is 2.40 (m, 2H), 2,33 (m, 2H), of 1.77 (m, 2H).

EXAMPLE 3

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 3A

methyl 4,4-dimethyl-2-(triftormetilfullerenov)cyclohex-1-enecarboxylate

To the suspension washed with hexane NaH (17 g) in dichloromethane (700 ml) was added 5,5-dimethyl-2-methoxycarbonylamino (38.5 g) dropwise at 0°C. After stirring for 30 minutes the mixture was cooled to -78°C was added trifluoroacetic anhydride (40 ml). The reaction mixture was warmed to room temperature and was stirred for 24 �aces. The organic layer was washed with saturated brine, dried (Na2SO4), filtered and concentrated to give the product.

EXAMPLE 3B

methyl 2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enecarboxylate

The compound of Example 3A (62,15 g), 4-Chlorfenvinphos acid (32,24 g), CsF (64 g) and tetrakis(triphenylphosphine)palladium(0) (2 g) in 2:1 mixture dimethoxyethane/methanol (600 ml) was heated to 70°C for 24 hours. The mixture was concentrated. Was added a simple ether (4× 200 ml) and the mixture was filtered. The combined ethereal solution was concentrated to give the product.

EXAMPLE 3C

(2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methanol

To a mixture of LiBH4(13 g), compounds of Example 3B (53,8 g) and simple ether (400 ml) was added methanol (25 ml) slowly through a syringe. The mixture was stirred at room temperature for 24 hours. The reaction was quenched with 1N HCl solution under cooling with ice. The mixture was diluted with water and was extracted with simple ether (3× 100 ml). The extracts were dried (Na2SO4), filtered and concentrated. The crude product was chromatographically on silica gel using 0-30% ethyl acetate/hexane.

EXAMPLE 3D

tert-butyl 4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-carboxylate

Methylchloride (7.5 ml) was added via a syringe to the compound of Example 3C (to 29.3 g) and triethylamine (30 ml) in CH2Cl2(500 ml) at 0°C � the mixture was stirred for 1 minute. Was added N-tert-butoxycarbonylmethyl (25 g) and the mixture stirred at room temperature for 24 hours. The suspension was washed with saturated brine, dried, (Na2SO4), filtered and concentrated. The crude product was chromatographically on silica gel using 10-20% ethyl acetate/hexane.

EXAMPLE 3E

1-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine

The compound of Example 3D (1 g) was stirred in dichloromethane (10 ml), trifluoroacetic acid (10 ml) and triethylsilane (1 ml) for 1 hour. The mixture was concentrated, was carried out by absorption in a mixture of dichloromethane (100 ml) and saturated aqueous solution of Na2CO3(20 ml) and stirred for 10 minutes. The layers were separated and the organic layer was dried over Na2SO4, filtered and concentrated to give the product.

EXAMPLE 3F

5-bromo-1-(triisopropylsilyl)-1H-imidazo[2,3-b]pyridin

To a mixture of 5-bromo-1H-imidazo[2,3-b]pyridine(15,4 g) in tetrahydrofuran (250 ml) was added a solution of 1M hexamethyldisilazide lithium in tetrahydrofuran (86 ml) and after 10 minutes was added TIPS-Cl (triisopropylsilane) (18,2 ml). The mixture was stirred at room temperature for 24 hours. The reaction mixture was diluted simple ether and the resulting solution was washed twice with water. The extracts were dried (Na2SO4), filtered and concentri�up. The crude product was chromatographically on silica gel using 10% ethyl acetate/hexane.

EXAMPLE 3G

1-(triisopropylsilyl)-1H-imidazo[2,3-b]pyridin-5-ol

To a mixture of compound of Example 3FWith 24.3 g) in tetrahydrofuran (500 ml) at -78°C was added 2.5 M BuLi (30,3 ml). After 2 minutes add trimethylboron (11,5 ml) and the mixture was allowed to warm to room temperature for 1 hour. The reaction mixture was poured into ice water, extracted three times with ethyl acetate and the combined extracts were washed with saturated brine and concentrated. The crude product was taken for absorption in tetrahydrofuran (200 ml) at 0°C was added 1M NaOH (69 ml), followed by the addition of 30% solution of H2O2(Of 8.43 ml) and the solution was stirred for 1 hour. Added Na2S2O3(10 g) and the pH was adjusted to 4-5 using concentrated HCl and solid NaH2PO4. The solution was extracted twice with ethyl acetate and the combined extracts were washed with saturated brine, dried (Na2SO4), filtered and concentrated. The crude product was chromatographically on silica gel using 5-25% ethyl acetate/hexane.

EXAMPLE 3H

methyl 2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-4-perbenzoate

The joint compound of Example 3G(8.5 g), methyl 2,4-differentat (7,05 g) and K3PO4(9,32 g) in diglyme (40 ml) at 115°C re�shivali within 24 hours. The reaction mixture was cooled, diluted with simple ether (600 ml) and washed twice with water and saturated brine and concentrated. The crude product was chromatographically on silica gel using 2% to 50% ethyl acetate/hexane.

EXAMPLE 3I

methyl 2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)benzoate

The joint compound of Example 3H(1.55 g), compound of Example 3E (2.42 g) and HK2PO4(1.42 g) in dimethylsulfoxide (20 ml) at 135°C was stirred for 24 hours. The reaction mixture was cooled, diluted with simple ether (400 ml) and washed 3× with a solution of 1M NaOH and saturated brine and concentrated. The crude product was chromatographically on silica gel using 10-50% ethyl acetate/hexane.

EXAMPLE 3J

2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)benzoic acid

The compound of Example 3I(200 mg) in dioxane (10 ml) and 1M NaOH (6 ml) at 50°C was stirred for 24 hours. The reaction mixture was cooled, was added to a solution of NaH2PO4and extracted three times with ethyl acetate. The combined extracts were washed with saturated brine and concentrated to give the pure product.

EXAMPLE 3K

tert-butyl 1-(tetrahydro-2H-Piran-4-yl)piperidine-4-ylcarbamate

Tert-BU�Il piperidine-4-ylcarbamate (45,00 g, 225 mmol) and dihydro-2H-Piran-4(3H)-he (24,74 g, 247 mmol) was added to dichloro methane (1000 ml). Added triacetoxyborohydride sodium (61,90 g, 292 mmol) and the solution stirred at room temperature for 16 hours. The solution was extracted using 1M sodium hydroxide and dried over anhydrous sodium sulfate. The solution was filtered and concentrated and was purified column flash chromatography on silica gel using 10% methanol (in dichloromethane), increasing to 20% methanol (in dichloromethane).

EXAMPLE 3L

the dihydrochloride of 1-(tetrahydro-2H-Piran-4-yl)piperidine-4-amine

A solution of compound of Example 3K (52,57 g, 185 mmol) in dichloromethane (900 ml) was treated with 4M aqueous solution of HCl (462 ml) and the solution was intensively stirred at room temperature for 16 hours. The solvent was removed under vacuum to obtain the crude product in the form dihydrochloride salt, which was used without further purification.

EXAMPLE 3M

3-nitro-4-(1-(tetrahydro-2H-Piran-4-yl)piperidine-4-ylamino)benzolsulfonat

The compound of Example 3L (of 22.12 g, 86 mmol) was added to 1,4-dioxane (300 ml) and water (43 ml). Was added triethylamine (43,6 ml, 31.6 g, 313 mmol) and the mixture was stirred at room temperature until complete dissolution of the compound of Example 3L. Was added 4-chloro-3-nitrobenzenesulfonamide and the mixture was heated at 90°C for 16 hours. The mixture was cooled�Lee and the solvent was removed under vacuum. Was added 10% solution of methanol (in dichloromethane) and the solution was intensively stirred at room temperature to obtain a finely dispersed suspension. The solids were isolated by vacuum filtration and washed with dichloromethane to obtain the pure product.

EXAMPLE 3N

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

The compound of this Example was obtained by using the compound of Example 3J instead of the compound of Example 1E and using the compound of Example 3M instead of the compound of Example 1F in Example 1G.1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,65 (lat.s, 1H), 8,53 (lat.s, 1H), 8,18 (m, 1H), 8,00 (lat.s, 1H), 7,63 (m, 1H), 7,49 (m, 3H), 7,34 (d, 2H), 7,12 (m, 1H), to 7.04 (d, 2H), to 6.67 (DD, 1H), 6,37 (d, 1H), of 6.20 (d, 1H), 3,95 (m, 2H), 3,05 (m, 10H), 2,73 (m, 4H), 2,17 (m, 10H), 1,95 (m, 2H), 1,80 (m, 2H), 1,63 (m, 2H), 1,39 (t, 2H), 0,93 (c, 6H).

EXAMPLE 4

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-demerol-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 4A

4-(1-demerol-4-ylamino)-3-nitrobenzenesulfonamide

The compound of this Example was obtained by using 4-amino-N-methylpiperidine instead of 1-(tetrahydropyran-4-yl)methylamine in Example 1F.

EXAMPLE 4B

4-(4-{[2-(4-chlorophenyl)-4,4-DIMET�cyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-demerol-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

The compound of this Example was obtained by using the compound of Example 3J instead of the compound of Example 1E and using the compound of Example 4A instead of the compound of Example 1F in Example 1G.1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,65 (lat.s, 1H), 8,55 (lat.s, 1H), 8,17 (m, 1H), 8,02 (d, 1H), a 7.85 (DD, 1H), 7,51 (m, 3H), 7,35 (m, 2H), 7,18 (DD, 1H), 7,05 (d, 2H), 6,68 (DD, 1H), 6,38 (d, 1H), of 6.20 (d, 1H), 3,90 (m, 1H), 3,09 (m, 8H), 2,77 (m, 2H), 2,05-of 2.30 (m, 10H), 1,95 (c, 3H), of 1.39 (t, 2H), 1,24 (m, 2H), 0,93 (c, 6H).

EXAMPLE 5

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 5A

3-nitro-4-((tetrahydro-2H-Piran-4-yl)methylamino)benzolsulfonat

A mixture of 4-fluoro-3-nitrobenzenesulfonamide (2.18 g), 1-(tetrahydropyran-4-yl)methylamine (1.14 g) and triethylamine (1 g) in tetrahydrofuran (30 ml) was stirred overnight, neutralized using concentrated HCl and concentrated. The residue was suspended in ethyl acetate and precipitated particles were collected, washed with water and dried with obtaining specified in the header connection.

EXAMPLE 5B

methyl 4,4-dimethyl-2-(triftormetilfullerenov)cyclohex-1-enecarboxylate

To the suspension washed with hexane NaH (17 g) in dichloromethane (700 ml) was added 5,5-dimethyl-2-methoxycarbonylamino (38.5 g) dropwise at 0°C. After stirring within 30 minutes, the mixture was cooled to -78°C was added trifluoroacetic anhydride (40 ml). The reaction mixture was warmed to room temperature and was stirred for 24 hours. The organic layer was washed with saturated brine, dried (Na2SO4), filtered and concentrated to give the product.

EXAMPLE 5C

methyl 2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enecarboxylate

The compound of Example 5B (62,15 g), 4-Chlorfenvinphos acid (32,24 g), CsF (64 g) and tetrakis(triphenylphosphine)palladium(0) (2 g) in 2:1 mixture dimethoxyethane/methanol (600 ml) was heated to 70°C for 24 hours. The mixture was concentrated. Was added a simple ether (4× 200 ml) and the mixture was filtered. The combined ethereal solution was concentrated to give the product.

EXAMPLE 5D

(2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methanol

To a mixture of LiBH4(13 g), compounds of Example 5C (53,8 g) and simple ether (400 ml), was added methanol (25 ml) slowly through a syringe. The mixture was stirred at room temperature for 24 hours. The reaction was quenched with 1N HCl solution under cooling with ice. The mixture was diluted with water and was extracted with simple ether (3× 100 ml). The extracts were dried (Na2SO4), filtered and concentrated. The crude product was chromatographically on silica gel using 0-30% ethyl acetate/hexane.

EXAMPLE 5E

tert-butyl 4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-carboxylate

Methylchloride (7.5 ml) was added via� a syringe to the compound of Example 5D (to 29.3 g) and triethylamine (30 ml) in CH 2Cl2(500 ml) at 0°C and the mixture was stirred for 1 minute. Was added N-tert-butoxycarbonylmethyl (25 g) and the mixture stirred at room temperature for 24 hours. The suspension was washed with saturated brine, dried (Na2SO4), filtered and concentrated. The crude product was chromatographically on silica gel using 10-20% ethyl acetate/hexane.

EXAMPLE 5F

1-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine

The compound of Example 5E (200 mg) and triethylsilane (1 ml) was stirred in dichloromethane (15 ml) and trifluoroacetic acid (15 ml) for 1 hour. The mixture was concentrated, was carried out by absorption of the mixture in ethyl acetate, washed twice NaH2PO4and saturated brine and dried (Na2SO4), filtered and concentrated.

EXAMPLE 5G

5-bromo-1-(triisopropylsilyl)-1H-imidazo[2,3-b]pyridin

To a mixture of 5-bromo-1H-imidazo[2,3-b]pyridine(15,4 g) in tetrahydrofuran (250 ml) was added 1M hexamethyldisilazide lithium in tetrahydrofuran (86 ml) and after 10 minutes was added TIPS-Cl (triisopropylsilane) (18,2 ml). The mixture was stirred at room temperature for 24 hours. The reaction mixture was diluted simple ether and the resulting solution was washed twice with water. The extracts were dried (Na2SO4), filtered and concentrated. The crude was productconfiguration on silica gel using 10% ethyl acetate/hexane.

EXAMPLE 5H

1-(triisopropylsilyl)-1H-imidazo[2,3-b]pyridin-5-ol

To a mixture of compound of Example 5GWith 24.3 g) in tetrahydrofuran (500 ml) at -78°C was added 2.5 M BuLi (30,3 ml). After 2 minutes add trimethylboron (11,5 ml) and the mixture was allowed to warm to room temperature for 1 hour. The reaction mixture was poured into ice water, extracted three times with ethyl acetate and the combined extracts were washed with saturated brine and concentrated. The crude product was taken for absorption in tetrahydrofuran (200 ml) at 0°C was added 1M NaOH (69 ml), followed by the addition of 30% H2O2(Of 8.43 ml) and the solution was stirred for 1 hour. Added Na2S2O3(10 g) and the pH was adjusted to 4-5 using concentrated HCl and solid NaH2PO4. The solution was extracted twice with ethyl acetate and the combined extracts were washed with saturated brine, dried (Na2SO4), filtered and concentrated. The crude product was chromatographically on silica gel using 5-25% ethyl acetate/hexane.

EXAMPLE 5I

methyl 2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-4-perbenzoate

The joint compound of Example 5H(8.5 g), methyl 2,4-differentat (7,05 g) and K3PO4(9,32 g) in diglyme (40 ml) at 115°C was stirred for 24 hours. The reaction mixture was cooled, diluted with simple ether (600 ml) and washed with two �Aza with water and saturated brine and concentrated. The crude product was chromatographically on silica gel using 2% to 50% ethyl acetate/hexane.

EXAMPLE 5J

methyl 2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)benzoate

The joint compound of Example 5I (1.55 g), compound of Example 5F (2.42 g) and HK2PO4(1.42 g) in dimethylsulfoxide (20 ml) at 135°C was stirred for 24 hours. The reaction mixture was cooled, diluted with simple ether (400 ml) and washed 3× with a solution of 1M NaOH and saturated brine and concentrated. The crude product was chromatographically on silica gel using 10-50% ethyl acetate/hexane.

EXAMPLE 5K

2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)benzoic acid

The compound of Example 5J (200 mg) in dioxane (10 ml) and 1M NaOH (6 ml) at 50°C was stirred for 24 hours. The reaction mixture was cooled, was added to a solution of NaH2PO4and extracted three times with ethyl acetate. The combined extracts were washed with saturated brine and concentrated to give the pure product.

EXAMPLE 5L

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

The compound of Example 5K (3,39 g), the compound of Example 5A(1.87 g), hydrochloride of 1-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide (2,39 g) and 4-dimethylaminopyridine (1,09 g) was stirred in CH2Cl2(40 ml) for 24 hours. The reaction mixture was cooled and chromatographically on silica gel using 25-100% ethyl acetate/hexane, then 10% methanol/ethyl acetate with 1% acetic acid to give product (1.62 g, 32%) as a white solid.1H NMR (300 MHz, dimethylsulfoxide-d6) 11,65 (lat.s, 1H), 8,55 (lat.s, 1H), 8,04 (d, 1H), to 7.89 (DD, 1H), 7,51 (m, 3H), of 7.33 (d, 2H), was 7.08 (m, 1H), to 7.04 (d, 2H), 6,68 (DD, 1H), 6,39 (d, 1H), 6,19 (d, 1H), 3,84 (m, 1H), 3,30 (m, 4H), of 3.07 (m, 4H), 2,73 (m, 2H), 2,18 (m, 6H), 1,95 (m, 2H), 1,61 (DD, 2H), 1,38 (m, 2H), 1,24 (m, 4H), 0,92 (c, 6H).

EXAMPLE 6

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methylpiperazin-1-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 6A

4-(4-methylpiperazin-1 ylamino)-3-nitrobenzenesulfonamide

In a 50 ml round bottom flask was loaded with 4-chloro-3-nitrobenzenesulfonamide (1 g, to 4.23 mmol) of the dihydrochloride of 4-methylpiperazin-1-amine (1 g, 5,32 mmol) and N1N1N2N2-tetramethylene-1,2-diamine (3 ml, 20,01 mmol) in dioxane (10 ml). The reaction mixture was boiled with reflux for 12 hours. Thereafter, the reaction mixture was cooled to room temperature, the salt was filtered through a Buchner funnel and the solvent was removed in vacuum. Untreated �the product was introduced into a column with silica gel (Analogix, SF65-200 g) and was purified by using for elution 0-5% methanol in dichloromethane.

EXAMPLE 6B

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methylpiperazin-1-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

The compound of this Example was obtained by using the compound of Example 3J instead of the compound of Example 1E and using the compound of Example 6A instead of the compound of Example 1F in Example 1G.1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,65 (lat.s, 1H), 9,09 (lat.s, 1H), of 8.47 (d, 1H), 8,24 (DD, 1H), 7,99 (d, 1H), 7,50 (m, 4H), 7,34 (d, 2H), to 7.04 (d, 2H), only 6.64 (DD, 1H), 6.35 mm (d, 1H), of 6.20 (d, 1H), of 3.04 (m, 4H), 2,89 (m, 4H), 2,73 (m, 2H), 2,34 (c, 3H), 2,17 (m, 6H), 1,95 (lat.s, 2H), 1,38 (t, 2H), of 1.05 (m, 4H), 0,93 (c, 6H).

EXAMPLE 7

2-(9H-carbazole-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-demerol-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide

EXAMPLE 7A

ethyl 2-(9H-carbazole-4-yloxy)-4-perbenzoate

The compound of this Example was obtained by using ethyl 2,4-differentat instead of methyl 2,4-differentat and using 4-hydroxycarbazole instead of the compound of Example 3G in Example 3H.

EXAMPLE 7B

ethyl 2-(9H-carbazole-4-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)benzoate

The compound of this Example was obtained by using the compound of Example 7A instead of connecting to the Tonic�as in Example 3H 3I.

EXAMPLE 7C

2-(9H-carbazole-4-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)benzoic acid

The compound of this Example was obtained by using the compound of Example 7B instead of the compound of Example 3I in Example 3J, except that in this example, after completion of the reaction was added water and 2n HCl solution to bring the pH to 2 and the HCl salt of the product was extracted using CHCl3/CH3OH.

EXAMPLE 7D

2-(9H-carbazole-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-demerol-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide

The compound of this Example was obtained by using the compound of Example 7C instead of the compound of Example 1E and using the compound of Example 4A instead of the compound of Example 1F in Example 1G, except that in this example, the purification was performed using preparative HPLC using a C18 column, 250×50 mm, 10 μm, and suirable using a gradient of 20-100% CH3CN vs. Of 0.1% trifluoroacetic acid in water, receiving the product in the form bestreplicawatches salt.1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,82 (lat.s, 1H), 11,40 (c, 1H), 9,70, 9,40 (both very wide.with just 2H), 8,40 (d, 1H), 8,10 (lat.d, 1H), 7,90 (lat.d, 1H), 7,72 (DD, 1H), 7,60 (d, 1H), of 7.48 (d, 1H), 7,38 (m, 3H), 7,22 (m, 2H), 7,07 (m, 4H), 6,78 (DD, 1H), gold 6.43 (DD, 1H), 6,19 (c, 1H), 3,97 (m, 1H), 3,80 (m, 2H), 3,60, 3,30, 3,10, all 2,80 wide.m, total 11H), 2,20, 2,10, 2,00 (all wide.m, total 8H), 1,78 (m, 2H), of 1.42 (m, 2H), 1,25 (m, 2H), 0,92 (c, 6H).

EXAMPLE 8

2-(9H-carbazole-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3-pyrrolidin-1-ylpropyl)amino]phenyl}sulfonyl)benzamide

EXAMPLE 8A

3-nitro-4-(3-(pyrrolidin-1-yl)propylamino)benzolsulfonat

The compound of this Example was obtained by using 3-(pyrrolidin-1-yl)propan-1-amine instead of 1-(tetrahydropyran-4-yl)methylamine in Example 1F.

EXAMPLE 8B

2-(9H-carbazole-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3-pyrrolidin-1-ylpropyl)amino]phenyl}sulfonyl)benzamide

The compound of this Example was obtained by using the compound of Example 7C instead of the compound of Example 1E and using the compound of Example 8A instead of the compound of Example 1F in Example 1G, except that in this example, the purification was performed using preparative HPLC using a C18 column, 250×50 mm, 10 μm, and suirable using a gradient of 20-100% CH3CN vs. Of 0.1% trifluoroacetic acid in water, receiving the product in the form bestreplicawatches salt.1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,80 (lat.s, 1H), 11,42 (c, 1H), 9,50, 9,25 (both very wide.with just 2H), 8,58 (lat.t, 1H), 8,43 (d, 1H), 7,91 (d, 1H), 7,72 (DD, 1H), 7,60 (d, 1H), 7,50 (d, 1H), 7,38 (m, 3H), 7.23 percent (m, 2H), 7,07 (m, 3H), 6,93 (d, 1H), 6,78 (DD, 1H), 6,44 (DD, 1H), 6,1 (c, 1H), 3,70, 3,60, 3,20, 3,00 (all the Shire.m, total 18H), 2,18 (lat.m, 2H), 2,00-180 (modulated, 8H), of 1.42 (m, 2H), 0,92 (c, 6H).

EXAMPLE 9

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 9A

TRANS-tert-butyl 4-morpholinosydnonimine

A solution of tert-butyl-4-aminocyclohexanecarboxylic (20,32 g, 95 mmol), bis(2-bromacil)new ether (14,30 ml, 114 mmol) and triethylamine (33,0 ml, 237 mmol) in N,N-dimethylformamide (200 ml) was stirred for 16 hours at 70°C. the Reaction mixture was cooled to room temperature, concentrated and the product was extracted with ethyl acetate. The organic layer was washed with sodium carbonate solution (15% aq.), dried and concentrated. The product was used for next step without purification.

EXAMPLE 9B

dihydrochloride TRANS-4-morpholinosydnonimine

To a solution of TRANS-tert-butyl-4-morpholinosydnonimine (19.2 g, of 67.5 mmol) in dichloromethane (100 ml) was added HCl (100 ml, 400 mmol) (4M in dioxane) and the reaction mixture was stirred for 16 hours at room temperature. The reaction mixture was diluted simple ether and the solid salt was filtered and dried in a kiln.

EXAMPLE 9C

TRANS-4-(4-morpholinosydnonimine)-3-nitrobenzenesulfonamide

A solution of dihydrochloride of TRANS-4-Mohali�of acycloguanosine (5 g, 19,44 mmol), 4-fluoro-3-nitrobenzenesulfonamide (4,32 g, 19,63 mmol) and triethylamine (20 ml, 143 mmol) in tetrahydrofuran (60 ml) was stirred for 16 hours at room temperature. The solid product was filtered, washed with tetrahydrofuran, simple ether, dichloromethane (3×) and dried in vacuum.

EXAMPLE 9D

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

The compound of this Example was obtained by using the compound of Example 3J instead of the compound of Example 1E and using the compound of Example 9C instead of the compound of Example 1F in Example 1G.1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,61 (lat.s, 1H), 8,49 (lat.s, 1H), 8,12 (m, 1H), 7,99 (lat.s, 1H), 7,71 (m, 1H), 7,50 (m, 3H), 7,35 (d, 2H), to 7.04 (d, 2H), 7,01 (m, 1H), 6,65 (DD, 1H), 6,36 (d, 1H), 6,21 (d, 1H), 3,60 (m, 4H), of 3.04 (m, 4H), 2,73 (m, 2H), of 2.57 (m, 2H), 2,42 (m, 1H), 2,18 (m, 6H), of 2.05 (m, 2H), 1,95 (m, 2H), 1,90 (m, 2H), 1,38 (m, 6H), of 1.15 (m, 3H), of 0.92 (c, 6H).

EXAMPLE 10

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-methoxyethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 10A

4-(2-methoxyethylamine)-3-nitrobenzenesulfonamide

The compound of this Example was obtained by using 2-methoxyethylamine instead of 1-(tetrahydropyran-4-yl)methylamine in Example 1F.

PR�MEASURES 10B

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-methoxyethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

The compound of this Example was obtained by using the compound of Example 3J instead of the compound of Example 1E and using the compound of Example 10A instead of the compound of Example 1F in Example 1G.1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,65 (lat.s, 1H), 8,58-8,49 (m, 1H), 8,55 (d, 1H), 8,03 (d, 1H), 7,79 (m, 1H), 7,49 (m, 3H), 7,34 (m, 2H), 7,06 (m, 1H), to 7.04 (d, 2H), 6,68 (DD, 1H), 6,38 (m, 1H), of 6.20 (d, 1H), 3,61-3,51 (m, 4H), and 3.31 (c, 3H), Of 3.07 (m, 4H), to 2.74 (m, 2H), 2,17 (m, 6H), 1,95 (lat.s, 2H), 1,38 (t, 2H), 0,92 (c, 6H).

EXAMPLE 11

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 11A

(S)-3-nitro-4-((tetrahydro-2H-Piran-3-yl)methylamino)benzolsulfonat and

(R)-3-nitro-4-((tetrahydro-2H-Piran-3-yl)methylamino)benzolsulfonat

The compound of this Example was obtained by using (tetrahydro-2H-Piran-3-yl)methanamine instead of 1-(tetrahydropyran-4-yl)methylamine in Example 1F.

EXAMPLE 11B

(S)-3-nitro-4-((tetrahydro-2H-Piran-3-yl)methylamino)benzolsulfonat

The racemic mixture of Example 11A were separated using chiral SFC column AD (21mm V. D. ×250 mm in length) using a gradient of 10-30% 0.1% diethylamine methanol in CO within 15 minutes (oven temperature: 40°C; flow rate: 40 ml/min) with obtaining specified in the header connection.

EXAMPLE 11C

(R)-3-nitro-4-((tetrahydro-2H-Piran-3-yl)methylamino)benzolsulfonat

The racemic mixture of Example 11A were separated using chiral SFC column AD (21mm V. D. ×250 mm in length) using a gradient of 10-30% 0.1% diethylamine methanol in CO2within 15 minutes (oven temperature: 40°C; flow rate: 40 ml/min) with obtaining specified in the header connection.

EXAMPLE 11D

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

To a mixture of compound of Example 3J (59,8 mg, 0,105 mmol), compound of Example 11B (33 mg, 0,105 mmol) and N,N-dimethylpyridin-4-amine (38.4 mg, 0,314 mmol) in dichloromethane (5 ml) was added hydrochloride 1-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide (24,07 mg, 0,13 mmol). The reaction mixture was stirred at room temperature overnight and concentrated. The residue was purified using obremenitve HPLC on a C18 column using a gradient of 40-60% acetonitrile/0,1% trifluoroacetic acid in water with obtaining specified in the header connection in the form of triptoreline salt. Salt of trifluoroacetic acid was dissolved in dichloromethane (6 ml) and washed with 50% aqueous p�the target NaHCO 3. The organic layer was dried over anhydrous Na2SO4and concentrated to obtain specified in the header connection.1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,68 (c, 1H), 11,40 (lat.c, 1H), 8,53-8,58 (m, 2H), 8,04 (d, 1H), 7,80 (DD, 1H), 7,47-7,54 (m, 3H), 7,34 (d, 2H), 7,02-to 7.09 (m, 3H), to 6.67 (DD, 1H), 6,39 (DD, 1H), 6,19 (d, 1H), 3,79 (DD, 1H), 3,69-3,73 (m, 1H), 3,22-3,37 (m, 3H), 3,16-3,21 (m, 1H), of 3.07 (c, 4H), to 2.74 (c, 2H), 2,09-of 2.24 (m, 6H), 1,95 (c, 2H), 1,86-of 1.93 (m, 1H), 1,79-of 1.85 (m, 1H), 1,58-of 1.64 (m, 1H), 1,42-is 1.51 (m, 1H), 1,38 (t, 2H), 1,25-1,34 (m, 1H), 0,92 (c, 6H).

EXAMPLE 12

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxane-2-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 12A

4-((1,4-dioxane-2-yl)methoxy)-3-nitrobenzenesulfonamide

(1,4-Dioxane-2-yl)methanol (380 mg, up 3.22 mmol) in tetrahydrofuran (30 ml) was treated with a solution of sodium hydride (60%) (245 mg, 6,13 mmol) at room temperature for 30 minutes. The reaction mixture was cooled in an ice bath was added 4-fluoro-3-nitrobenzenesulfonamide (675 mg, 3,06 mmol). The resulting mixture was stirred at room temperature for 2 hours and added another portion of sodium hydride (60%) (245 mg, 6,13 mmol). The reaction mixture was stirred overnight and quenched with ice water (3 ml). The cloudy mixture was filtered and the filtrate concentrated. The residue was ground into powder with methanol to obtain specified in the header connection.

P�EMER 12B

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxane-2-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound obtained as described in Example 11D, using the compound of Example 12A instead of the compound of Example 11B.1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,67 (c, 1H), 11,42 (lat.s, 1H), of 8.34 (c, 1H), 8,03 (d, 2H), of 7.48-to 7.55 (m, 3H), 7,41 (d, 1H), 7,35 (d, 2H), to 7.04 (d, 2H), to 6.67 (DD, 1H), 6,39 (DD, 1H), 6,21 (d, 1H), 4,20-to 4.28 (m, 2H), 3,85-of 3.91 (m, 1H), 3,82 (DD, 1H), 3,74-of 3.78 (m, 1H), 3,59-of 3.69 (m, 2H), 3,41-3,51 (m, 2H), 3,05-3,17 (m, 4H), 2,83 (lat.s, 2H), 2,27 (lat.s, 4H), of 2.15 (c, 2H), 1,96 (c, 2H), 1,39 (t, 2H), 0,93 (c, 6H).

EXAMPLE 13

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3R)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound obtained as described in Example 11D, using the compound of Example 11C instead of the compound of Example 11B. Proton NMR spectra of the compounds of Example 13 and the compound of Example 11D are identical.1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,68 (c, 1H), 11,40 (lat.s, 1H), 8,53-8,58 (m, 2H), 8,04 (d, 1H), 7,80 (DD, 1H), 7,47-7,54 (m, 3H), 7,34 (d, 2H), 7,02-to 7.09 (m, 3H), to 6.67 (DD, 1H), 6,39 (DD, 1H), 6,19 (d, 1H), 3,79 (DD, 1H), 3,69-3,73 (m, 1H), 3,22-3,37 (m, 3H), 3,16-3,21 (m, 1H), of 3.07 (c, 4H), to 2.74 (c, 2H), 2,09-of 2.24 (m, 6H), 1,95 (c, 2H), 1,86-of 1.93 (m, 1H), 1,79-of 1.85 (m, 1H), 1,58-of 1.64 (m, 1H), 1,42-is 1.51 (m, 1H), 1,38 (t, 2H), 1,25-1,34 (m, 1H), 0,92 (c, 6H).

WHEN�EP 14

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-(2-naphthylmethyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound obtained as described in Example 11D, using naphthalene-2-sulfonamide (47 mg, 0,227 mmol) instead of compound of Example 11B.1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,82 (c, 1H), 11,69 (c, 1H), 8,51 (c, 1H), 8,08 (d, 1H), with 8.05 (d, 1H), 7,97 (DD, 2H), 7,82 (DD, 1H), 7,66-7,71 (m, 1H), 7,63 (t, 1H), 7,54 (d, 1H), 7,47-7,52 (m, 2H), 7,34 (d, 2H), to 7.04 (d, 2H), Of 6.65 (DD, 1H), 6,39 (DD, 1H), 6.18 of (c, 1H), of 3.04 (c, 4H), 2,72 (c, 2H), 2,10-of 2.20 (m, 6H), 1,95 (c, 2H), 1,38 (t, 2H), 0,92 (c, 6H).

EXAMPLE 15

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 15A

methyl 6,6-dimethyl-4-exoterica-2H-Piran-3-carboxylate

To the suspension washed with hexane NaH (0,72 g, 60% in mineral oil) in tetrahydrofuran (30 ml) was added a solution of 2,2-dimethylbicyclo-2H-Piran-4(3H)-she (2.0 g) in tetrahydrofuran (20 ml). The suspension was stirred at room temperature for 30 minutes. Dimethylcarbonate (6,31 ml) was added dropwise via syringe. The mixture was heated to boiling temperature with reflux for 4 hours. LC/MS analysis showed the expected product as the main product. The mixture was acidified with using 5% HCl and was extracted with dichloromethane (100 ml× 3) and washed with water, saturated brine and dried over Na2SO4. After evaporation the crude product was charged to a column and suirable 10% solution of ethyl acetate in hexane to give product.

EXAMPLE 15B

methyl 6,6-dimethyl-4-(triftormetilfullerenov)-5,6-dihydro-2H-Piran-3-carboxylate

To the cooled (0°C) stirred suspension of NaH (0,983 g, 60% in mineral oil) in a simple ether (50 ml) was added the compound of Example 15A (3.2 g). The mixture was stirred at 0°C for 30 minutes before adding Tf2O (4,2 ml). The mixture was then stirred at room temperature over night. The mixture was diluted simple ether (200 ml) and washed with 5% HCl solution, water and saturated brine. After drying over Na2SO4and evaporation of the solvent was obtained the crude product, which was used for next step without further purification.

EXAMPLE 15C

methyl 4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-carboxylate

To the solution of compound of Example 15B (2,88 g), 4-Chlorfenvinphos acid (1.88 g) and Pd(Ph3P)4(0,578 g) in toluene (40 ml) and ethanol (10 ml) was added a 2n solution of Na2CO3(10 ml). The mixture was stirred at the temperature of reflux during the night. The mixture was diluted simple ether (300 ml) and washed with water, saturated brine and dried over Na2SO4. After my�pairing of the solvent, the residue was loaded into a column and suirable a solution of 3% ethyl acetate in hexane to give product.

EXAMPLE 15D

(4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl)methanol

To the solution of compound of Example 15C (1.6 g) in a simple ether (20 ml) was added LiAlH4(1.2 g). The mixture was stirred for 4 hours. The mixture was carefully acidified with using 5% HCl and was extracted with ethyl acetate (100 ml ×3) and washed with water, saturated brine and dried over Na2SO4. After concentration the crude product was charged to a column and suirable using 10% ethyl acetate in hexane to give product.

EXAMPLE 15E

4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-carbaldehyde

To a solution of oxalicacid (1.1 g) in dichloromethane (30 ml) at -78°C was added dimethyl sulfoxide (6,12 ml). The mixture was stirred at the same temperature for 30 minutes and then was added a solution of compound of Example 15D (1.2 g) in dichloromethane (10 ml). The mixture was stirred at -78°C for 2 hours before addition of triethylamine (10 ml). The mixture was stirred overnight and the temperature was allowed to rise to room temperature. The mixture was diluted simple ether (300 ml) and washed with water, saturated brine and dried over Na2SO4. Concentration of the solvent and column purification (5% ethyl acetate in hexane) gave the product.

EXAMPLE 15F

methyl 2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-4-(piperazine-1-yl)benzoate

The joint compound of Example 3H (20.5 g) and piperazine (37,0 g) in dimethylsulfoxide (200 ml) was heated to 110°C for 24 hours and the mixture was allowed to cool to room temperature. The mixture was poured into water (1 l), extracted three times with dichloromethane and the combined extracts were washed 2× with water and saturated brine and was filtered and concentrated to give the pure product.

EXAMPLE 15G

methyl 2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl)methyl)piperazine-1-yl)benzoate

To the solution of compound of Example 15E (100 mg) and the compound of Example 15F (177 mg) in dichloromethane (10 ml) was added triacetoxyborohydride sodium (154 mg). The mixture was stirred over night. The mixture was diluted with ethyl acetate (200 ml) and washed with 2% NaOH, water and saturated brine. After drying over Na2SO4the mixture was filtered and the solvent evaporated under vacuum. The residue was loaded into a column and suirable using 30% ethyl acetate in hexane to obtain the pure product.

EXAMPLE 15H

2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl)methyl)piperazine-1-yl)benzoic acid

To the solution of compound of Example 15G (254 mg) in tetrahydrofuran (4 ml), methanol (2 ml) and water (2 ml) was added LiOH H2O (126 mg). The mixture was stirred over night. The mixture is then neutralized using 5% HCl and once�alali ethyl acetate (200 ml). After washing with saturated brine, the mixture was dried over Na2SO4. Filtration and evaporation of the solvent gave the product.

EXAMPLE 15I

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound obtained as described in Example 1G, substituting the compound of Example 1E, the compound of Example N.1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,68 (lat.s, 1H), 11,42 (c, 1H), at 8.60 (m, 1H), to 8.57 (d, 1H), with 8.05 (d, 1H), 7,80 (DD, 1H), of 7.48-7,54 (m, 3H), 7,38 (d, 2H), 7,12 (m, 3H), 6,68 (DD, 1H), 6,40 (DD, 1H), of 6.20 (c, 1H), 4,11 (c, 2H), 3,85 (m, 2H), 3,27 (m, 6H), of 3.07 (m, 2H), 2,84 (m, 2H), 2,14 (m, 5H), 1,92 (m, 1H), of 1.42 (m, 2H), 1,24 (m, 2H), 1,10 (c, 6H).

EXAMPLE 16

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-methoxyethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 16A

4-(2-methoxyethylamine)-3-(triftormetilfullerenov)benzolsulfonat

A solution of 4-fluoro-3-(triftormetilfullerenov)benzosulfimide (1,536 g, 5 mmol), 2-methoxyethylamine (0,376 g, 5 mmol) and triethylamine (1,939 g, 15 mmol) in anhydrous tetrahydrofuran (30 ml) was heated at 55°C for 3 hours. The solution was diluted with ethyl acetate, washed with water and saturated brine and dried (Na2SO4), filtered and the filter�at concentrated. The crude substance was used in the next stage without additional purification.

EXAMPLE 16B

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-methoxyethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

The compound of this Example was obtained by using the compound of Example 3J instead of the compound of Example 1E and using the compound of Example 16A instead of the compound of Example 1F in Example 1G.1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11,67 (lat.s, 1H), to 8.14 (m, 1H), 8,03 (d, 1H), 7,91 (d, 1H), 7,50 (m, 3H), 7,34 (d, 2H), of 7.19 (c, 1H), to 7.04 (m, 3H), to 6.67 (DD, 1H), 6,39 (m, 1H), 6,19 (d, 1H), 3,51 (m, 4H), or 3.28 (c, 3H), 3,06 (m, 4H), to 2.75 (m, 2H), 2,17 (m, 6H), 1,95 (m, 2H), 1,39 (t, 2H), 0,93 (c, 6H).

EXAMPLE 17

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-({4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide

EXAMPLE 17A

4-((tetrahydro-2H-Piran-4-yl)methylamino)-3-(triftormetilfullerenov)benzolsulfonat

The compound of this Example was obtained by using 1-(tetrahydropyran-4-yl)methylamine instead of 2-methoxyethylamine in Example 16A.

EXAMPLE 17B

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)-N-({4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)�ansamed

The compound of this Example was obtained by using the compound of Example 3J instead of the compound of Example 1E and using the compound of Example 17A instead of the compound of Example 1F in Example 1G.,1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11,70 (lat.s, 1H), 8,15 (m, 1H), 8,04 (d, 1H), 7,92 (d, 1H), 7,51 (m, 3H), 7,34 (d, 2H), of 7.19 (c, 1H), 7,05 (m, 3H), 6,68 (DD, 1H), 6,40 (m, 1H), 6.18 of (d, 1H), 3,85 (m, 2H), 3,25 (m, 4H), of 3.07 (m, 4H), 2,77 (m, 2H), 2,17 (m, 6H), 1,95 (m, 2H), of 1.84 (m, 1H), 1,54 (m, 2H), 1,39 (t, 2H), 1,24 (m, 2H), 0,93 (c, 6H).

EXAMPLE 18

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide

EXAMPLE 18A

methyl 2-(1H-indol-5-yloxy)-4-perbenzoate

A mixture of 5-hydroxyindole(8.5 g), methyl 2,4-differentat (7,05 g) and K3PO4(9,32 g) in diglyme (40 ml) at 115°C was stirred for 24 hours. The reaction mixture was cooled, diluted with simple ether (600 ml) and washed twice with water and saturated brine and concentrated. The crude product was chromatographically on silica gel using 2% to 50% ethyl acetate/hexane.

EXAMPLE 18B

methyl 2-(1H-indol-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)benzoate

The joint compound of Example 18A(1.7 g), compounds of Example 3E (1.8 g) and HK2PO4(1.21 g) in dimethylsulfoxide (20 ml) at 135°C was stirred for 24 hours. �actionnow the mixture was cooled, was diluted with simple ether (400 ml) and washed 3× with a solution of 1M NaOH and saturated brine and concentrated. The crude product was chromatographically on silica gel using 10-50% ethyl acetate/hexane.

EXAMPLE 18C

2-(1H-indol-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)benzoic acid

The compound of Example 18B(200 mg) in dioxane (10 ml) and 1M NaOH (6 ml) at 50°C was stirred for 24 hours. The reaction mixture was cooled, was added to a solution of NaH2PO4and extracted three times with ethyl acetate. The combined extracts were washed with saturated brine and concentrated to give the pure product.

EXAMPLE 18D

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide

Specified in the title compound obtained as described in Example 11D, replacing the compound of Example 3J compound of Example 18C and replacing the compound of Example 11B compound of Example 1F.1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,18 (c, 2H), 8,59-8,64 (m, 2H), 7,80 (DD, 1H), 7,52 (d, 1H), 7,39-of 7.42 (m, 2H), to 7.33 (d, 2H), made 7.16 interest (d, 1H), 7,10 (d,1H), 7,03 (d, 2H), 6,8 (DD, 1H), 6,65 (DD, 1H), 6,40 (s, 1H), 6,14 (d, 1H), 3,85 (DD, 2H), 3,24-of 3.32 (m, 4H), 3,03 (c, 3H), 2,73 (c, 2H), 2,12-2,17 (m, 5H), 1,68-1,94 (m, 3H), of 1.61 (d, 2H), 1,37 (t, 2H), 1,24-of 1.27 (m, 2H), 0,92 (c, 6H).

EXAMPLE 19

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-d�methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-indol-5-yloxy)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)benzamide

Specified in the title compound obtained as described in Example 11D, replacing the compound of Example 11B compound of Example 9B and substituting the compound of Example 3J compound of Example 18C.1H NMR (500 MHz, pyridine-d5) δ 12,29 (c, 1H), 9,29 (d, J=2.1 Hz, 1H), 8,37 (d, J=7,6 Hz, 1H), 8,32 (DD, J=9,3, 2,3 Hz, 1H), 8,18 (d, J=8,8 Hz, 1H), 7,52-EUR 7.57 (m, 2H), 7,39-7,47 (m, 3H), 7,10 (DD, J=8,7, and 2.3 Hz, 1H), 7,05-was 7.08 (m, 2H), 6,90 (d, J=9,5 Hz, 1H), 6,74 (DD, J=9,0, 2,3 Hz, 1H), 6,59-6,63 (m, 1H), 6,55 (d, J=2.4 Hz, 1H), and 3.72 and 3.78 (m, 4H), 3,33-of 3.43 (m, 1H), 2,99-3,09 (m, 4H), 2,76 (c, 2H), 2,46-of 2.54 (m, 4H), 2,16-to 2.29 (m, 3H), Of 2.09 to 2.14 (m, 4H), of 2.05 (d, J=11,9 Hz, 2H), of 1.97 (d, J=1,8 Hz, 2H), to 1.87 (d, J=11,6 Hz, 2H), 1,19-of 1.42 (m, 6H), 0,93 (c, 6H).

EXAMPLE 20

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-indol-5-yloxy)-N-({4-[(2-methoxyethyl)amino]-3-nitrophenyl}sulfonyl)benzamide

Specified in the title compound obtained as described in Example 11D, replacing the compound of Example 11B compound of Example 10A and substituting the compound of Example 3J compound of Example 18C.1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11,20 (lat.s, 1H) 11,15 (c, 1H) 8,59 (m, 2H) 7,81 (DD, 1H) 7,50 (d, 1H) of 7.36 (m, 4H) was 7.08 (m, 4H) of 6.85 (DD, 1H) 6,65 (DD, 1H) 6,38 (m, 1H) 6,14 (m, 1H) 3,58 (m, 4H) 3,30 (c, 3H) 3,03 (m, 4H) 2,73 (c, 2H) 2,15 (m, 6H) 1,96 (c, 2H) 1,38 (t, 2H) 0,92 (c, 6H).

EXAMPLE 21

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-indol-5-yloxy)-N-[(3-nitro-4-{[(3S)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]benzamide

Specified in the title compound obtained as described � Example 11D, replacing the compound of Example 3J compound of Example 18C.1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11,17 (c, 2H), 8,53-8,65 (m, 2H), 7,80 (d, 1H), 7,51 (d, 1H), 7,38-7,44 (m, 2H), to 7.33 (d, 2H), 7,15 (c, 1H), 7,02-to 7.09 (m, 3H), about 6,82-at 6.92 (m, 1H), 6,65 (d, 1H), 6,39 (c, 1H), 6,14 (c, 1H), 3,68-3,82 (m, 2H), 3,22-of 3.32 (m, 2H), 3,13-up 3.22 (m, 1H), 3,03 (c, 4H), 2,72 (c, 2H), 2,09-of 2.23 (m, 6H), 1,78-of 1.98 (m, 4H), 1.56 to of 1.66 (m, 1H), 1,43-is 1.51 (m, 1H), 1,37 (t, 2H), 1,22-1,33 (m, 1H), 0,92 (c, 6H).

EXAMPLE 22

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-indol-5-yloxy)-N-[(3-nitro-4-{[(3R)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]benzamide

Specified in the title compound obtained as described in Example 11D, using the compound of Example 11C instead of the compound of Example 11B and using the compound of Example 18C instead of the compound of Example 3J.1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11,17 (c, 2H), 8,53-8,65 (m, 2H), 7,80 (d, 1H), 7,51 (d, 1H), 7,38-7,44 (m, 2H), to 7.33 (d, 2H), 7,15 (c, 1H), 7,02-to 7.09 (m, 3H), about 6,82-at 6.92 (m, 1H), 6,65 (d, 1H), 6,39 (c, 1H), 6,14 (c, 1H), 3,68-3,82 (m, 2H), 3,22-of 3.32 (m, 2H), 3,13-up 3.22 (m, 1H), 3,03 (c, 4H), 2,72 (c, 2H), 2,09-of 2.23 (m, 6H), 1,78-of 1.98 (m, 4H), 1.56 to of 1.66 (m, 1H), 1,43-is 1.51 (m, 1H), 1,37 (t, 2H), 1,22-1,33 (m, 1H), 0,92 (c, 6H).

EXAMPLE 23

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-2-(1H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide

EXAMPLE 23A

methyl 2-(1H-indol-5-yloxy)-4-(piperazine-1-yl)benzoate

Specified in the title compound obtained as described in Example 15F, Deputy�the average of the compound of Example 3H compound of Example 18A.

EXAMPLE 23B

methyl 2-(1H-indol-5-yloxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl)methyl)piperazine-1-yl)benzoate

Specified in the title compound obtained as described in Example 15G, replacing the compound of Example 15F compound of Example 23A.

EXAMPLE 23C

2-(1H-indol-5-yloxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl)methyl)piperazine-1-yl)benzoic acid

Specified in the title compound obtained as described in Example 15H, replacing the compound of Example 15G compound of Example 23B.

EXAMPLE 23D

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-2-(1H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide

Specified in the title compound obtained as described in Example 11D, replacing the compound of Example 11B compound of Example 1F, and substituting the compound of Example 3J compound of Example 23C.1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11,20 (lat.s, 1H), 11,17 (c, 1H), 8,63 (t, 1H), 8,59 (d, 1H), 7,79 (DD, 1H), 7,51 (d, 1H), of 7.36 (m, 3H), 7,13 (m, 2H), 6,86 (DD, 1H), 6,66 (DD, 1H), 6,39 (c, 1H), 6,15 (d, 1H), 4,10 (c, 2H), 3,85 (m, 3H), 3,50 (m, 2H), 3,42 (m, 2H), 3,24 (m, 4H), 3,02 (m, 4H), 2,82 (m, 2H), 2,16 (m, 2H), 1.61 of (m, 3H), 1,25 (m, 4H), of 1.17 (c, 6H).

EXAMPLE 24

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 24A

3-nitro-4-((tet�ahydro-2H-Piran-4-yl)methoxy)benzolsulfonat

(Tetrahydro-2H-Piran-4-yl)methanol (2.0 g) in tetrahydrofuran (20 ml) was treated with 60% NaH (1,377 g). The solution was stirred for 20 minutes at room temperature. To this solution was added 4-fluoro-3-nitrobenzenesulfonamide (2.84 g) in portions. The reaction mixture was stirred for 2 hours. The mixture was poured into water, neutralized with 10% HCl solution and was extracted with ethyl acetate three times. The combined organic layers were washed with saturated brine, dried over MgSO4, filtered and concentrated. The residue was purified column flash chromatography on silica gel using for the elution of 20-60% ethyl acetate in hexane.

EXAMPLE 24B

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by using the compound of Example 24A instead of the compound of Example 11B in Example 11D.1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,67 (c, 1H), of 8.33 (c, 1H), 8,00-8,02 (m, 2H), 7,50-7,53 (m, 3H), 7,34-of 7.36 (m, 3H), to 7.04 (d, 2H), to 6.67 (DD, 1H), 6,38 (d, 1H), 6,21 (c, 1H), 4,06 (d, 2H), 3,88 (DD, 2H), is 3.08 (c, 4H), 2,80 (c, 2H), 2,25 (c, 4H), of 2.15 (c, 2H), 1,96 (c, 2H), 1,63-of 1.66 (m, 2H), 1,52-of 1.55 (m, 1H), 1,33-of 1.40 (m, 4H), 0,92 (c, 6H).

EXAMPLE 25

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1,4-dioxane-2-ylmethyl)amino]-3-nitrophenyl}su�honil)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 25A

4-((1,4-dioxane-2-yl)methylamino)-3-nitrobenzenesulfonamide

Specified in the title compound obtained as described in Example 1F using (1,4-dioxane-2-yl)methanamine instead (tetrahydropyran-4-yl)methanamine.

EXAMPLE 25B

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1,4-dioxane-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound obtained as described in Example 11D, using the compound of Example 25A instead of the compound of Example 11B.1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,66 (c, 1H), 11,38 (c, 1H), 8,53-8,59 (m, 2H), 8,03 (d, 1H), 7,81 (DD, 1H), of 7.46-7,54 (m, 3H), 7,34 (d, 2H), to 7.09 (d, 1H), to 7.04 (d, 2H), 6,68 (DD, 1H), 6,38 (DD, 1H), 6,19 (d, 1H), 3,75-3,86 (m, 3H), 3,58-3,68 (m, 2H), 3.45 points-3,52 (m, 2H), 3,35-of 3.43 (m, 2H), of 3.07 (c, 4H), to 2.75 (c, 2H), 2,17 (d, 6H), 1,95 (c, 2H), 1,38 (t, 2H), 0,92 (c, 6H).

EXAMPLE 26

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(2,2,2-trifluoroethyl)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 26A

3-nitro-4-(2,2,2-triptoreline)benzolsulfonat

Specified in the title compound was obtained by using 2,2,2-triptoreline instead (tetrahydropyran-4-yl)methylamine in Example 1F.

EXAMPLE 26B

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(2,2,2-trifluoroethyl)amino]phenyl}sulfonyl)2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by using the compound of Example 26A instead of the compound of Example 11B in Example 11D.1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,48 (c, 1H), 8,40 (m, 2H), 7,90 (d, 1H), 7,71 (DD, 1H), members, 7.59 (d, 1H), 7,40 (t, 1H), 7,34 (d, 2H), 7,25 (d, 1H), 7,06 (m, 3H), 6,61 (DD, 1H), of 6.26 (m, 2H), 4,32 (m, 2H), 3,00 (m, 4H), 2,73 (c, 2H), 2,19 (m, 6H), to 1.96 (c, 2H), 1,39 (t, 2H), 0,93 (c, 6H).

EXAMPLE 27

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3,3,3-cryptochromes)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 27A

3-nitro-4-(3,3,3-triphosphopyridine)benzolsulfonat

Specified in the title compound was obtained by using 3,3,3-cryptochrome-1-amine instead of (tetrahydropyran-4-yl)methylamine in Example 1F.

EXAMPLE 27B

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3,3,3-cryptochromes)amino]phenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by using the compound of Example 27A instead of the compound of Example 11B in Example 11D.1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,47 (c, 1H), 8,37 (d, 1H), 8,29 (m, 1H), to 7.89 (d, 1H), 7,61 (m, 2H), 7,39 (t, 1H), 7,35 (d, 2H), 7,22 (d, 1H), 7,05 (d, 2H), 6.75 in (d, 1H), 6,62 (DD, 1H), 6,27 (m, 2H) and 3.59 (q, 2H), 3,00 (m, 4H), 2,73 (c, 2H), 2,66 (m, 2H), 2,18 (m, 6H), to 1.96 (c, 2H), 1,39 (t, 2H), of 0.93 (m, 6H).

EXAMPLE 28

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methylpiperazin-1-yl)-N-({4-[(2S)-1,4-dioxane-2-ylethoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 28A

(S)-4-((1,4-dioxane-2-yl)methoxy)-3-nitrobenzenesulfonamide

The racemic mixture of Example 12A were separated on chiral SFC AD column with obtaining specified in the header connection.

EXAMPLE 28B

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2S)-1,4-dioxane-2-ylethoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound obtained as described in Example 11D, using the compound of Example 28A instead of the compound of Example 11B.1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,67 (c, 2H), 8,35 (c, 1H), 8,03 (d, 2H), of 7.48-EUR 7.57 (m, 3H), of 7.42 (d, 1H), 7,35 (d, 2H), 7,05 (d, 2H), 6,68 (DD, 1H), 6,39 (DD, 1H), 6,21 (c, 1H), 4,19-4,30 (m, 2H), 3,85-3,92 (m, 1H), 3,73-3,85 (m, 2H), 3,58-3,70 (m, 2H), 3,40-3,52 (m, 2H), 3,10 (c, 4H), 2,85 (c, 2H), 2,18-2,39 (m, 3H), of 2.15 (c, 2H), 1,96 (c, 2H), 1,39 (t, 2H), 0,93 (c, 6H).

EXAMPLE 29

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 29A

CIS-4-((4-methoxycyclohexyl)methylamino)-3-nitrobenzenesulfonamide

4-Fluoro-3-nitrobenzenesulfonamide (1,098 g) and the compound of Example 34A (1 g) in tetrahydrofuran (20 ml) was treated with N,N-diisopropylethylamine (0,871 ml) over night. The reaction mixture was concentrated and the residue was purified by reversed-phase chromatography, was suirable using 40-55% acetonitrile containing 0.1% trifluoroacetic acid water for 25 minutes with obtaining the CIS isomer of the compound of Example 29A and the TRANS isomer of the compound of Example 34B.

EXAMPLE 29B

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound obtained as described in Example 11D, using the compound of Example 29A instead of the compound of Example 11B.1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,69 (c, 1H), 11,36 (c, 1H), 8,53-8,63 (m, 2H), 8,04 (d, 1H), 7,79 (DD, 1H), 7,47-7,56 (m, 3H), 7,34 (d, 2H), 7,00-7,12 (m, 3H), 6,68 (DD, 1H), 6,39 (DD, 1H), 6,19 (d, 1H), 3,37 (c, 1H), 3,26 (t, 2H), 3,20 (c, 3H), of 3.07 (c, 4H), to 2.75 (c, 2H), 2,17 (d, 6H), 1,95 (c, 2H), is 1.81 (DD, 2H), 1,64-of 1.74 (m, 1H), 1,48 (DD, 2H), 1,23-of 1.42 (m, 6H), 0,92 (c, 6H).

EXAMPLE 30

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2R)-1,4-dioxane-2-ylethoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 30A

(R)-4-((1,4-dioxane-2-yl)methoxy)-3-nitrobenzenesulfonamide

The racemic mixture of Example 12A were separated on chiral SFC AD column with obtaining specified in the header connection.

EXAMPLE 30B

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2R)-1,4-dioxane-2-ylethoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound obtained as described in Example 11D, using the compound of Example 30A instead of the compound of Example 11B.1H NMR (500 MHz, dimethylsulfoxide-d6 ) δ 11,67 (c, 2H), 8,35 (c, 1H), 8,03 (d, 2H), of 7.48-EUR 7.57 (m, 3H), of 7.42 (d, 1H), 7,35 (d, 2H), 7,05 (d, 2H), 6,68 (DD, 1H), 6,39 (DD, 1H), 6,21 (c, 1H), 4,19-4,30 (m, 2H), 3,85-3,92 (m, 1H), 3,73-3,85 (m, 2H), 3,58-3,70 (m, 2H), 3,40-3,52 (m, 2H), 3,10 (c, 4H), 2,85 (c, 2H), 2,18-2,39 (m, 3H), of 2.15 (c, 2H), 1,96 (c, 2H), 1,39 (t, 2H), 0,93 (c, 6H).

EXAMPLE 31

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(1,4-dioxane-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound obtained as described in Example 1G, substituting the compound of Example 1E and compound of Example 1F compound of Example 15H and compound of Example 25A, respectively.1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,66 (c, 1H), 11,46 (m, 1H), 8,54 (m, 2H), to 8.45 (m, 1H), 8,03 (d, 1H), 7,83 (m, 2H), 7,50 (m, 3H), 7,34 (m, 3H), 7,12 (m, 2H), 6,68 (DD, 1H), 6,38 (DD, 1H), of 6.20 (d, 1H), 4,11 (c, 2H), 3,79 (m, 4H), 3,51 (m, 6H), 3,05 (m, 4H), 2,17 (m, 3H), of 1.17 (c, 6H).

EXAMPLE 32

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxane-2-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound obtained as described in Example 1G, substituting the compound of Example 1E and compound of Example 1F compound of Example 15H and compound of Example 12A, respectively.1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,67 (c, 1H), 8,37 (d, 1H), 8,03 (m, 2H), 7,50 (m, 3H), value of 7, 37 (d, 2H), 7,13 (d, 2H), 6,68 (DD, 1H), 6,40 (DD, 1H), of 6.20 (d, 1H), 4,25 (m, 2H), 4,12 (c, 2H), 3,84 (m, 3H), 3,63 (m, 2H), 3.45 points (m, 2H), 3,06 (m, 4H) 2,86 (m, 2H), 2,24 (m, 6H), of 1.20 (m, 6H).

EXAMPLE 33

TRANS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound obtained as described in Example 1G, substituting the compound of Example 1E and compound of Example 1F compound of Example 15H and compound of Example 9C, respectively.1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,63 (c, 1H), 8,51 (d, 1H), 8,15 (d, 1H), 8,01 (d, 1H), 7,76 (DD, 1H), of 7.48 (m, 3H), 7,38 (d, 2H), 7,13 (d, 2H), 7,06 (d, 1H), 6,66 (DD, 1H), 6,36 (DD, 1H), 6,21 (d, 1H), 4,11 (c, 2H), 3,63 (m, 5H), 3,05 (m, 4H), 2,83 (c, 2H), 2,64 (m, 4H), 2,17 (m, 6H), of 2.05 (m, 2H), 1.91 a (c, 2H), 1,43 (m, 6H), 1,17 (m, 6H).

EXAMPLE 34

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 34A

(4-methoxycyclohexyl)methanamine

(4-Methoxyphenyl)methanamine (1 g, 1,29 mmol) in ethanol (10 ml) was treated with 5% Rh-Al2O3(And 99.8 mg, 0,048 mmol) in the atmosphere of H2(500 f/inch2(To 35.15 kg/cm2)) at 50°C for 16 hours. Added additional amount of 5% Rh-Al2O3(0.4 g). The resulting mixture was stirred in the atmosphere of H2(500 f/inch2(To 35.15 kg/cm2)) at 60°C for 2 hours. The insoluble substance was filtered and the filtrate concentration of�Aravali to provide a mixture of CIS and TRANS product in the form of oil, which was used for next step without further purification.

EXAMPLE 34B

TRANS-4-((4-methoxycyclohexyl)methylamino)-3-nitrobenzenesulfonamide

4-Fluoro-3-nitrobenzenesulfonamide (1,098 g) and the compound of Example 34A (1 g) in tetrahydrofuran (20 ml) was treated with N,N-diisopropylethylamine (0,871 ml) over night. The reaction mixture was concentrated and the residue was purified by reversed-phase chromatography and suirable using 40-55% in acetonitrile containing 0.1% trifluoroacetic acid water for 25 minutes.

EXAMPLE 34C

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound obtained as described in Example 11D, using the compound of Example 34B instead of the compound of Example 11B.1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,69 (c, 1H), 11.37 per (c, 1H), 8,52 is 8.62 (m, 2H), 8,04 (d, 1H), 7,79 (DD, 1H), 7,47-to 7.55 (m, 3H), 7,34 (d, 2H), 7,02-to 7.09 (m, 3H), 6,68 (DD, 1H), 6,39 (DD, 1H), 6,19 (d, 1H), 3,21-3,27 (m, 5H), 3,02-of 3.12 (m, 5H), of 2.75 (c, 2H), measuring 2.20 (c, 4H), 2,14 (c, 2H), 1.93 and-2,04 (m, 4H), to 1.79 (d, 2H), 1,55-1,65 (m, 1H), 1,38 (t, 2H), 0,97-of 1.12 (m, 4H), 0,92 (c, 6H).

EXAMPLE 35

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the header� connection is received, as described in Example 1G, substituting the compound of Example 1E and compound of Example 1F compound of Example 15H and compound of Example 36C, respectively.1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,65 (c, 1H), 8,78 (c, 1H), 8,58 (c, 1H), 8,00 (d, 1H), 7,51 (m, 3H), 7,38 (d, 2H), 7,14 (d, 2H), 6,68 (DD, 1H), 6,37 (DD, 1H), 6,23 (d, 1H), 4,31 (d, 2H), 4,13 (c, 2H), 3,88 (DD, 2H), 3,11 (m, 5H), 2,16 (m, 6H), 1,65 (m, 2H), 1,35 (m, 2H), 1,19 (c, 6H).

EXAMPLE 36

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 36A

5-Bromo-6-chloropyridin-3-sulphonylchloride (8.2 g) in methanol (20 ml) was cooled to 0°C. To this solution was added 7n solution of NH3in methanol (80 ml). The reaction mixture was stirred over night. The solvent was removed at low temperature and the residue was distributed between ethyl acetate and water. The aqueous layer was extracted with ethyl acetate three times. The combined organic layers were washed with saturated brine, dried (MgSO4), filtered and concentrated. The solid is purified column flash chromatography on silica gel using 20-100% ethyl acetate in hexane, obtaining specified in the header connection.

EXAMPLE 36B

Specified in the title compound was obtained by using the compound of Example 36A instead of 4-fluoro-3-nitrobenzenesulfonamide� in Example 24A.

EXAMPLE 36C

The joint compound of Example 36B (0,702 g), dilantine (0,129 g) and tetrakis(triphenylphosphine)palladium(0) (0,231 g) in N,N-dimethylformamide (2 ml) was degassed, cyclically changing the atmosphere of vacuum/nitrogen three times. The reaction mixture was heated at 120°C for 3 hours. After cooling, the mixture was poured into water and was extracted with ethyl acetate three times. The combined organic layers were washed with saturated brine, dried over MgSO4, filtered and concentrated. The residue was purified column flash chromatography on silica gel using for the elution of 20%-60% ethyl acetate in hexane, obtaining specified in the header connection.

EXAMPLE 36D

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by using the compound of Example 36C instead of the compound of Example 11B in Example 11D.1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,56 (c, 1H), 8.66 roubles (c, 1H), 8,44 (c, 1H), 7,94 (d, 1H), 7,55 (d, 1H), 7,44 (t, 1H), 7,34-7,35 (m, 3H), to 7.04 (d, 2H), of 6.65 (DD, 1H), 6.32 per (c, 1H), for 6.24 (c, 1H), to 4.26 (d, 2H), 3,86 (DD, 2H), 3,10 (c, 4H), to 2.75 (c, 2H), 2,31-of 2.35 (m, 2H), 2,01-2,05 (m, 1H), 2,15 (c, 2H), 1,96 (c, 2H), 1,63-of 1.66 (m, 2H), 1,33-of 1.40 (m, 4H), 0,92 (c, 6H).

EXAMPLE 37

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-imidazo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 37A

1,6-dioxaspiro[2.5]octane-2-carbonitrile

The mixture tetrahydropyran-4-she (10 ml) and chloroacetonitrile (6.4 ml) in tert-butanol (10 ml) was stirred for 10 minutes. To this solution was added a solution of tert-butoxide potassium (12,11 g) in 200 ml of tert-butanol at room temperature for 40 minutes. The reaction mixture was stirred for 16 hours, diluted with water and quenched slowly with 1 n HCl solution. The solvent was partially removed on a rotary evaporator. The mixture then was extracted with simple ether (5× 200 ml). The combined extracts were washed with saturated br